Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors

Abstract

Disclosed are novel multi-functional hematopoietic receptor agonist proteins, DNAs which encode the multi-functional hematopoietic receptor agonists proteins, methods of making the multi-functional hematopoietic receptor agonists proteins and methods of using the multi-functional hematopoietic receptor agonists proteins.

Description

FIELD OF THE INVENTION

The present invention relates to multi-functional hematopoietic receptor agonists.

BACKGROUND OF THE INVENTION

Colony stimulating factors (CSFs) which stimulate the differentiation and/or proliferation of bone marrow cells have generated much interest because of their therapeutic potential for restoring depressed levels of hematopoietic stem cell-derived cells. CSFs in both human and murine systems have been identified and distinguished according to their activities. For example, granulocyte-CSF (G-CSF) and macrophage-CSF (M-CSF) stimulate the in vitro formation of neutrophilic granulocyte and macrophage colonies, respectively, while GM-CSF and interleukin-3 (IL-3) have broader activities and stimulate the formation of both macrophage, neutrophilic and eosinophilic granulocyte colonies. IL-3 also stimulates the formation of mast, megakaryocyte and pure and mixed erythroid colonies.

U.S. Pat. No. 4,877,729 and U.S. Pat. No. 4,959,455 disclose human IL-3 and gibbon IL-3 cDNAs and the protein sequences for which they code. The hIL-3 disclosed has serine rather than proline at position 8 in the protein sequence.

International Patent Application (PCT) WO 88/00598 discloses gibbon- and human-like IL-3. The hIL-3 contains a Ser.sup.8 ->Pro.sup.8 replacement. Suggestions are made to replace Cys by Ser, thereby breaking the disulfide bridge, and to replace one or more amino acids at the glycosylation sites.

U.S. Pat. No. 4,810,643 discloses the DNA sequence encoding human G-CSF.

WO 91/02754 discloses a fusion protein comprised of GM-CSF and IL-3 which has increased biological activity compared to GM-CSF or IL-3 alone. Also disclosed are nonglycosylated IL-3 and GM-CSF analog proteins as components of the multi-functional hematopoietic receptor agonist.

WO 92/04455 discloses fusion proteins composed of IL-3 fused to a lymphokine selected from the group consisting of IL-3, IL-6, IL-7, IL-9, IL-11, EPO and G-CSF.

WO 95/21197 and WO 95/21254 disclose fusion proteins capable of broad multi-functional hematopoietic properties.

GB 2,285,446 relates to the c-mpl ligand (thrombopoietin) and various forms of thrombopoietin which are shown to influence the replication, differentiation and maturation of megakaryocytes and megakaryocytes progenitors which may be used for the treatment of thrombocytopenia.

EP 675,201 A1 relates to the c-mpl ligand (Megakaryocyte growth and development factor (MGDF), allelic variations of c-mpl ligand and c-mpl ligand attached to water soluble polymers such as polyethylene glycol.

WO 95/21920 provides the murine and human c-mpl ligand and polypeptide fragments thereof. The proteins are useful for in vivo and ex vivo therapy for stimulating platelet production.

Rearrangement of Protein Sequences

In evolution, rearrangements of DNA sequences serve an important role in generating a diversity of protein structure and function. Gene duplication and exon shuffling provide an important mechanism to rapidly generate diversity and thereby provide organisms with a competitive advantage, especially since the basal mutation rate is low (Doolittle, Protein Science 1: 191-200, 1992).

The development of recombinant DNA methods has made it possible to study the effects of sequence transposition on protein folding, structure and function. The approach used in creating new sequences resembles that of naturally occurring pairs of proteins that are related by linear reorganization of their amino acid sequences (Cunningham, et al., Proc. Natl. Acad. Sci. U.S.A. 76: 3218-3222, 1979; Teather & Erfle, J. Bacteriol. 172: 3837-3841, 1990; Schimming et al., Eur. J. Biochem. 204: 13-19, 1992; Yamiuchi and Minamikawa, FEBS Lett. 260: 127-130, 1991; MacGregor et al., FEBS Lett. 378: 263-266). The first in vitro application of this type of rearrangement to proteins was described by Goldenberg and Creighton (J. Mol. Biol. 165: 407-413, 1983). A new N-terminus is selected at an internal site (breakpoint) of the original sequence, the new sequence having the same order of amino acids as the original from the breakpoint until it reaches an amino acid that is at or near the original C-terminus. At this point the new sequence is joined, either directly or through an additional portion of sequence (linker), to an amino acid that is at or near the original N-terminus, and the new sequence continues with the same sequence as the original until it reaches a point that is at or near the amino acid that was N-terminal to the breakpoint site of the original sequence, this residue forming the new C-terminus of the chain.

This approach has been applied to proteins which range in size from 58 to 462 amino acids (Goldenberg & Creighton, J. Mol. Biol. 165: 407-413, 1983; Li & Coffino, Mol. Cell. Biol. 13: 2377-2383, 1993). The proteins examined have represented a broad range of structural classes, including proteins that contain predominantly .alpha.-helix (interleukin-4; Kreitman et al., Cytokine 7: 311-318, 1995), .beta.-sheet (interleukin-1; Horlick et al., Protein Eng. 5: 427-431, 1992), or mixtures of the two (yeast phosphoribosyl anthranilate isomerase; Luger et al., Science 243: 206-210, 1989). Broad categories of protein function are represented in these sequence reorganization studies:

Enzymes T4 lysozyme Zhang et al., Biochemistry 32: 12311-12318, 1993; Zhang et al., Nature Struct. Biol. 1: 434-438 (1995) dihydrofolate reductase Buchwalder et al., Biochemistry 31: 1621-1630, 1994; Protasova et al., Prot. Eng. 7: 1373-1377, 1995) ribonuclease T1 Mullins et al., J. Am. Chem. Soc. 116: 5529-5533, 1994; Garrett et al., Protein Science 5: 204-211, 1996) Bacillus .beta.-glucanse Hahn et al., Proc. Natl. Acad. Sci. U.S.A. 91: 10417-10421, 1994) aspartate transcarbamoylase Yang & Schachman, Proc. Natl. Acad. Sci. U.S.A. 90: 11980-11984, 1993) phosphoribosyl anthranilate isomerase Luger et al., Science 243: 206-210 (1989; Luger et al., Prot. Eng. 3: 249-258, 1990) pepsin/pepsinogen Lin et al., Protein Science 4: 159-166, 1995) glyceraldehyde-3-phosphate dehydrogenase Vignais et al., Protein Science 4: 994-1000, 1995) ornithine decarboxylase Li & Coffino, Mol. Cell. Biol. 13: 2377-2383, 1993) yeast phosphoglycerate dehydrogenase Ritco-Vonsovici et al., Biochemistry 34: 16543-16551, 1995) Enzyme Inhibitor basic pancreatic trypsin inhibitor Goldenberg & Creighton, J. Mol. Biol. 165: 407-413, 1983) Cytokines interleukin-1.beta. Horlick et al., Protein Eng. 5: 427-431, 1992) interleukin-4 Kreitman et al., Cytokine 7: 311-318, 1995) Tyrosine Kinase Recognition Domain .alpha.-spectrin SH3 domain Viguera, et al., J. Mol. Biol. 247: 670-681, 1995) Transmembrane Protein omp A Koebnik & Kramer, J. Mol. Biol. 250: 617-626, 1995) Chimeric Protein interleukin-4-Pseudomonas exotoxin Kreitman et al., Proc. Natl. Acad. Sci. U.S.A. 91: 6889-6893, 1994).

The results of these studies have been highly variable. In many cases substantially lower activity, solubility or thermodynamic stability were observed (E. coli dihydrofolate reductase, aspartate transcarbamoylase, phosphoribosyl anthranilate isomerase, glyceraldehyde-3-phosphate dehydrogenase, ornithine decarboxylase, omp A, yeast phosphoglycerate dehydrogenase). In other cases, the sequence rearranged protein appeared to have many nearly identical properties as its natural counterpart (basic pancreatic trypsin inhibitor, T4 lysozyme, ribonuclease T1, Bacillus .beta.-glucanase, interleukin-1.beta., .alpha.-spectrin SH3 domain, pepsinogen, interleukin-4). In exceptional cases, an unexpected improvement over some properties of the natural sequence was observed, e.g., the solubility and refolding rate for rearranged .alpha.-spectrin SH3 domain sequences, and the receptor affinity and anti-tumor activity of transposed interleukin-4-Pseudomonas exotoxin fusion molecule (Kreitman et al., Proc. Natl. Acad. Sci. U.S.A. 91: 6889-6893, 1994; Kreitman et al., Cancer Res. 55: 3357-3363, 1995).

The primary motivation for these types of studies has been to study the role of short-range and long-range interactions in protein folding and stability. Sequence rearrangements of this type convert a subset of interactions that are long-range in the original sequence into short-range interactions in the new sequence, and vice versa. The fact that many of these sequence rearrangements are able to attain a conformation with at least some activity is persuasive evidence that protein folding occurs by multiple folding pathways (Viguera, et al., J. Mol. Biol. 247: 670-681, 1995). In the case of the SH3 domain of a-spectrin, choosing new termini at locations that corresponded to .beta.-hairpin turns resulted in proteins with slightly less stability, but which were nevertheless able to fold.

The positions of the internal breakpoints used in the studies cited here are found exclusively on the surface of proteins, and are distributed throughout the linear sequence without any obvious bias towards the ends or the middle (the variation in the relative distance from the original N-terminus to the breakpoint is ca. 10 to 80% of the total sequence length). The linkers connecting the original N- and C-termini in these studies have ranged from 0 to 9 residues. In one case (Yang & Schachman, Proc. Natl. Acad. Sci. U.S.A. 90: 11980-11984, 1993), a portion of sequence has been deleted from the original C-terminal segment, and the connection made from the truncated C-terminus to the original N-terminus. Flexible hydrophilic residues such as Gly and Ser are frequently used in the linkers. Viguera, et al. (J. Mol. Biol. 247: 670-681, 1995) compared joining the original N- and C-termini with 3- or 4-residue linkers; the 3-residue linker was less thermodynamically stable. Protasova et al. (Protein Eng. 7: 1373-1377, 1994) used 3- or 5-residue linkers in connecting the original N-termini of E. coli dihydrofolate reductase; only the 3-residue linker produced protein in good yield.

SUMMARY OF THE INVENTION

Novel hematopoietic proteins of this invention are represented by the formulas:

R.sub.1 -L.sub.1 -R.sub.2, R.sub.2 -L.sub.1 -R.sub.1, R.sub.1 -R.sub.2, or R.sub.2 -R.sub.1

wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of;

(I) A polypeptide comprising; a modified human G-CSF amino acid sequence of the formula:

1 10Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu Pro Gln Ser Xaa 20Leu Leu Xaa Xaa Xaa Glu Gln Val Xaa Lys Xaa Gln Gly Xaa Gly 30 40Ala Xaa Leu Gln Glu Xaa Leu Xaa Ala Thr Tyr Lys Leu Xaa Xaa 50Xaa Glu Xaa Xaa Val Xaa Xaa Gly His Ser Xaa Gly Ile Pro Trp 60 70Ala Pro Leu Ser Ser Xaa Pro Ser Xaa Ala Leu Xaa Leu Ala Gly 80Xaa Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu 90 100Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu 110Xaa Thr Leu Gln Xaa Asp Val Ala Asp Phe Ala Xaa Thr Ile Trp 120 130Gln Gln Met Glu Xaa Xaa Gly Met Ala Pro Ala Leu Gln Pro Thr 140Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Xaa Gln Xaa Xaa Ala 150 160Gly Gly Val Leu Val Ala Ser Xaa Leu Gln Xaa Phe Leu Xaa Xaa 170Ser Tyr Arg Val Leu Xaa Xaa Leu Ala Gln Pro (SEQ ID NO:1) wherein Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly; Xaa at position 2 is Pro or Leu; Xaa at position 3 is Leu, Arg, Tyr or Ser; Xaa at position 13 is Phe, Ser, His, Thr or Pro; Xaa at position 16 is Lys, Pro, Ser, Thr or His; Xaa at position 17 is Cys, Ser, Gly, Ala, Ile, Tyr or Arg; Xaa at position 18 is Leu, Thr, Pro, His, Ile or Cys; Xaa at position 22 is Arg, Tyr, Ser, Thr or Ala; Xaa at position 24 is Ile, Pro, Tyr or Leu; Xaa at position 27 is Asp, or Gly; Xaa at position 30 is Ala, Ile, Leu or Gly; Xaa at position 34 is Lys or Ser; Xaa at position 36 is Cys or Ser; Xaa at position 42 is Cys or Ser; Xaa at position 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys, or Leu; Xaa at position 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gln, or Thr; Xaa at position 46 is Glu, Arg, Phe, Arg, Ile or Ala; Xaa at position 47 is Leu or Thr; Xaa at position 49 is Leu, Phe, Arg or Ser; Xaa at position 50 is Leu, Ile, His, Pro or Tyr; Xaa at position 54 is Leu or His; Xaa at position 64 is Cys or Ser; Xaa at position 67 is Gln, Lys, Leu or Cys; Xaa at position 70 is Gln, Pro, Leu, Arg or Ser; Xaa at position 74 is Cys or Ser; Xaa at position 104 is Asp, Gly or Val; Xaa at position 108 is Leu, Ala, Val, Arg, Trp, Gln or Gly; Xaa at position 115 is Thr, His, Leu or Ala; Xaa at position 120 is Gln, Gly, Arg, Lys or His Xaa at position 123 is Glu, Arg, Phe or Thr Xaa at position 144 is Phe, His, Arg, Pro, Leu, Gln or Glu; Xaa at position 146 is Arg or Gln; Xaa at position 147 is Arg or Gln; Xaa at position 156 is His, Gly or Ser; Xaa at position 159 is Ser, Arg, Thr, Tyr, Val or Gly; Xaa at position 162 is Glu, Leu, Gly or Trp; Xaa at position 163 is Val, Gly, Arg or Ala; Xaa at position 169 is Arg, Ser, Leu, Arg or Cys; Xaa at position 170 is His, Arg or Ser; wherein optionally 1-11 amino acids from the N-terminus and 1-5 from the C-terminus can be deleted; and wherein the N-terminus is joined to the C-terminus directly or through a linker capable of joining the N-terminus to the C-terminus and having new C- and N-termini at amino acids; ______________________________________39-40 63-64 124-12540-41 125-12641-42 126-12742-43 128-12943-44 128-12945-46 129-13048-49 130-13149-50 131-13252-53 132-13353-54 133-13454-55 134-13555-56 135-13656-57 136-13757-58 137-13858-59 138-13959-60 139-14060-61 140-14161-62 141-142 or 142-143;______________________________________

(II) A polypeptide comprising; a modified hIL-3 amino acid sequence of the formula:

Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn1 5 10 15Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 80 85 90Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 95 100 105Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 110 115 120Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe 125 130 (SEQ ID NO:2); wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg; Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln; Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys; Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala; Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa at position 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg; Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu; Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala; Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp; Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp; Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val; Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys; Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln; Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu; Xaa at position 33 is Pro, Leu, Gln, Ala, Thr, or Glu; Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met; Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln, or Val; Xaa at position 36 is Asp, Leu, or Val; Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile; Xaa at position 38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg; Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro; Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met or Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly; Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His; Xaa at position 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp; Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr; Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met; Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu; Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly; Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys; Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg; Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr; Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser; Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile; Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val; Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys; Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser; Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser; Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His; Xaa at position 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His; Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu; Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala; Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp; Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg; Xaa at position 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala; Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu; Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp; Xaa at position 77 is Ile, Ser, Arg, Thr, or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys; Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val; Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val; Xaa at position 85 is Leu, Asn, Val, or Gln; Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys; Xaa at position 87 is Leu, Ser, Trp, or Gly; Xaa at position 88 is Ala, Lys, Arg, Val, or Trp; Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser; Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met; Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His; Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu; Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg; Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro; Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile, or Tyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr; Xaa at position 97 is Ile, Val, Lys, Ala, or Asn; Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro; Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe, or His; Xaa at position 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln; Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position 103 is Asp, or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, or Gly; Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His; Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro; Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro; Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, or Trp; Xaa at position 111 is Leu, Ile, Arg, Asp, or Met; Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe; Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn; Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met; Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile; Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gln; Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly; Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu; wherein optionally from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from 0 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; and wherein the N-terminus is joined to the C-terminus directly or through a linker (L.sub.2) capable of joining the N-terminus to the C-terminus and having new C- and N-termini at amino acids; ______________________________________26-27 49-50 83-8427-28 84-8528-29 85-8629-30 86-8730-31 87-8831-32 88-8932-33 89-9033-34 90-9134-35 91-9235-36 92-9336-37 97-9837-38 98-9938-39 99-10039-40 100-10140-41 101-10241-42 102-103 or 103-104;______________________________________ or

(III) A polypeptide comprising; a modified human c-mpl ligand amino acid sequence of the formula:

SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer1 5 10 15HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro20 25 30 35ValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu 40 45 50 55ThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla 60 65 70 75AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly 80 85 90 95GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnXaaXaaXaa 100 105 110XaaGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHis115 120 125 130LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal 135 140 145 150ArgArgAlaProProThrThrAlaValProSerArgThrSerLeuValLeuThrLeu 155 160 165 170AsnGluLeuProAsnArgThrSerGlyLeuLeuGluThrAsnPheThrAlaSerAla 175 180 185 190ArgThrThrGlySerGlyLeuLeuLysTrpGlnGlnGlyPheArgAlaLysIlePro 195 200 205GlyLeuLeuAsnGlnThrSerArgSerLeuAspGlnIleProGlyTyrLeuAsnArg210 215 220 225IleHisGluLeuLeuAsnGlyThrArgGlyLeuPheProGlyProSerArgArgThr 230 235 240 245LeuGlyAlaProAspIleSerSerGlyThrSerAspThrGlySerLeuProProAsn 250 255 260 265LeuGlnProGlyTyrSerProSerProThrHisProProThrGlyGlnTyrThrLeu 270 275 280 285PheProLeuProProThrLeuProThrProValValGlnLeuHisProLeuLeuPro 290 295 300AspProSerAlaProThrProThrProThrSerProLeuLeuAsnThrSerTyrThr305 310 315 320HisSerGlnAsnLeuSerGlnGluGly (SEQ ID NO:3) 325 330 332153 wherein; Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe, Trp, or Met; Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met; Xaa at position 114 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met; Xaa at position 115 is deleted or Gln, Gly, Ser, Thr, Tyr, or Asn; and wherein the N-terminus is joined to the C-terminus directly or through a linker (L.sub.2) capable of joining the N-terminus to the C-terminus and having new C- and N-termini at amino acids; ______________________________________26-27 51-52 108-10927-28 109-11028-29 110-11129-30 111-11230-31 112-11332-33 113-11433-34 114-11534-35 115-11636-37 116-11737-38 117-11838-39 118-11940-41 119-12041-42 120-12142-43 121-12243-44 122-12344-45 123-12446-47 124-12547-48 125-12648-49 126-12750-51 or 127-128;______________________________________ or

(IV) A polypeptide comprising; a modified hIL-3 amino acid sequence of the formula:

Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn1 5 10 15Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 80 85 90Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 95 100 105Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 110 115 120Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe 125 130 (SEQ ID NO:2) wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg; Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln; Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys; Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala; Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa at position 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg; Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu; Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala; Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp; Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp; Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val; Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys; Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln; Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu; Xaa at position 33 is Pro, Leu, Gln, Ala, Thr, or Glu; Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met; Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln, or Val; Xaa at position 36 is Asp, Leu, or Val; Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile; Xaa at position 38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg; Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro; Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met or Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly; Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His; Xaa at position 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp; Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr; Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu; Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly; Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys; Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg; Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr; Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser; Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile; Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val; Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys; Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser; Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser; Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His; Xaa at position 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His; Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu; Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala; Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp; Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg; Xaa at position 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala; Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu; Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp; Xaa at position 77 is Ile, Ser, Arg, Thr, or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys; Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val; Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val; Xaa at position 85 is Leu, Asn, Val, or Gln; Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys; Xaa at position 87 is Leu, Ser, Trp, or Gly; Xaa at position 88 is Ala, Lys, Arg, Val, or Trp; Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser; Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met; Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His; Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu; Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg; Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro; Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile, or Tyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr; Xaa at position 97 is Ile, Val, Lys, Ala, or Asn; Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro; Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe, or His; Xaa at position 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln; Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position 103 is Asp, or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, or Gly; Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His; Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro; Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro; Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, or Trp; Xaa at position 111 is Leu, Ile, Arg, Asp, or Met; Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe; Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn; Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met; Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile; Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gln; Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly; Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu; wherein optionally from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; or

(V) a colony stimulating factor;

and wherein L.sub.1 is a linker capable of linking R.sub.1 to R.sub.2 ;

with the proviso that at least R.sub.1 or R.sub.2 is selected from the polypeptide of formula (I) , (II), or (III); and

said hematopoietic protein can optionally be immediately preceded by (methionine.sup.-1), (alanine.sup.-1) or (methionine.sup.-2, alanine.sup.-1).

The more preferred breakpoints at which new C-terminus and N-terminus can be made in the polypeptide (I) above are; 38-39, 39-40, 40-41, 41-42, 48-49, 53-54, 54-55, 55-56, 56-57, 57-58, 58-59, 59-60, 60-61, 61-62, 62-63, 64-65, 65-66, 66-67, 67-68, 68-69, 69-70, 96-97, 125-126, 126-127, 127-128, 128-129, 129-130, 130-131, 131-132, 132-133, 133-134, 134-135, 135-136, 136-137, 137-138, 138-139, 139-140, 140-141 and 141-142.

The most preferred breakpoints at which new C-terminus and N-terminus can be made in the polypeptide (I) above are; 38-39, 48-49, 96-97, 125-126, 132-133 and 141-142.

The more preferred breakpoints at which new C-terminus and N-terminus can be made in the polypeptide (II) above are; 28-29, 29-30, 30-31, 31-32, 32-33, 33-34, 34-35, 35-36, 36-37, 37-38, 38-39, 39-40, 66-67, 67-68, 68-69, 69-70, 70-71, 84-85, 85-86, 86-87, 87-88, 88-89, 89-90, 90-91, 98-99, 99-100, 100-101 and 101-102.

The most preferred breakpoints at which new C-terminus and N-terminus can be made in the polypeptide (II) above are; 34-35, 69-70 and 90-91.

The more preferred breakpoints at which new C-terminus and N-terminus can be made in the polypeptide (III) above or the amino acid sequence of (SEQ ID NO:256) are; 80-81, 81-82, 82-83, 83-84, 84-85, 85-86, 86-87, 108-109, 109-110, 110-111, 111-112, 112-113, 113-114, 114-115, 115-116, 116-117, 117-118, 118-119, 119-120, 120-121, 121-122, 122-123, 123-124, 124-125, 125-126 and 126-127.

The most preferred breakpoints at which new C-terminus and N-terminus can be made in the polypeptide (III) above or the amino acid sequence of (SEQ ID NO:256) are; 81-82, 108-109, 115-116, 119-120, 122-123 and 125-126.

The invention is also intended to include multifunctional receptor agonists which comprises a sequence rearranged c-mpl receptor agonist in which the cysteine at position 7 and/or 151 are substituted with another amino acid. Preferably, the substitution at position 7 and 151 is Ser, Ala, Gly, His, Asn, Asp, Thr, Phe or Thr. More preferably, the substitution at position 7 and 151 is Ser, Ala, Gly, His or Asn.

The multifunctional receptor agonist of the present invention can also be represented by the following formula:

(T.sup.1)a-(L.sup.1)b-X.sup.1 -(L)c-X.sup.2 -(L.sup.2)d-(T.sup.2)e X.sup.1 -(L)c-X.sup.2 -(L)-Y.sup.1 -(L)c-Y.sup.2 in which: X.sup.1 is a peptide comprising an amino acid sequence corresponding to the sequence of residues n+1 through J of the original protein having amino acids residues numbered sequentially 1 through J with an amino terminus at residue 1; L is an optional linker; X.sup.2 is a peptide comprising an amino acid sequence of residues 1 through n of the original protein;

Y.sup.1 is a peptide comprising an amino acid sequence corresponding to the sequence of residues n=1 through K of the original protein having amino acids residues numbered sequentially 1 through K with an amino terminus at residue 1;

Y.sup.2 is a peptide comprising an amino acid sequence of residues 1 through n of the original protein; L.sup.1 and L.sup.2 are optional peptide spacers: n is an integer ranging from 1 to J-1; b, c, and d are each independently 0 or 1; a and e are either 0 or 1, provided that both a and e cannot both be 0; and T.sup.1 and T.sup.2 are proteins.

Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the multi-functional hematopoietic receptor agonists, related microbial expression systems, and processes for making the multi-functional hematopoietic receptor agonists. The invention also relates to pharmaceutical compositions containing the multi-functional hematopoietic receptor agonists, and methods for using the multi-functional hematopoietic receptor agonists.

In addition to the use of the multi-functional hematopoietic receptor agonists of the present invention in vivo, it is envisioned that in vitro uses would include the ability to stimulate bone marrow and blood cell activation and growth before infusion into patients.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 schematically illustrates the sequence rearrangement of a protein. The N-terminus (N) and the C-terminus (C) of the native protein are joined through a linker, or joined directly. The protein is opened at a breakpoint creating a new N-terminus (new N) and a new C-terminus (new-C) resulting in a protein with a new linear amino acid sequence. A rearranged molecule may be synthesized de novo as linear molecule and not go through the steps of joining the original N-terminus and the C-terminus and opening of the protein at the breakpoint.

FIG. 2 shows a schematic of Method I, for creating new proteins in which the original N-terminus and C-terminus of the native protein are joined with a linker and different N-terminus and C-terminus of the protein are created. In the example shown the sequence rearrangement results in a new gene encoding a protein with a new N-terminus created at amino acid 97 of the original protein, the original C-terminus (a.a. 174) joined to the amino acid 11 (a.a. 1-10 are deleted) through a linker region and a new C-terminus created at amino acid 96 of the original sequence.

FIG. 3 shows a schematic of Method II, for creating new proteins in which the original N-terminus and C-terminus of the native protein are joined without a linker and different N-terminus and C-terminus of the protein are created. In the example shown the sequence rearrangement results in a new gene encoding a protein with a new N-terminus created at amino acid 97 of the original protein, the original C-terminus (a.a. 174) joined to the original N-terminus and a new C-terminus created at amino acid 96 of the original sequence.

FIG. 4 shows a schematic of Method III, for creating new proteins in which the original N-terminus and C-terminus of the native protein are joined with a linker and different N-terminus and C-terminus of the protein are created. In the example shown the sequence rearrangement results in a new gene encoding a protein with a new N-terminus created at amino acid 97 of the original protein, the original C-terminus (a.a. 174) joined to amino acid 1 through a linker region and a new C-terminus created at amino acid 96 of the original sequence.

DETAILED DESCRIPTION OF THE INVENTION

The present invention encompasses multi-functional hematopoietic receptor agonists formed from covalently linked polypeptides, each of which may act through a different and specific cell receptor to initiate complementary biological activities. Hematopoiesis requires a complex series of cellular events in which stem cells generate continuously into large populations of maturing cells in all major lineages. There are currently at least 20 known regulators with hematopoietic proliferative activity. Most of these proliferative regulators can only stimulate one or another type of colony formation in vitro, the precise pattern of colony formation stimulated by each regulator is quite distinctive. No two regulators stimulate exactly the same pattern of colony formation, as evaluated by colony numbers or, more importantly, by the lineage and maturation pattern of the cells making up the developing colonies. Proliferative responses can most readily be analyzed in simplified in vitro culture systems. Three quite different parameters can be distinguished: alteration in colony size, alteration in colony numbers and cell lineage. Two or more factors may act on the progenitor cell, inducing the formation of larger number of progeny thereby increasing the colony size. Two or more factors may allow increased number of progenitor cells to proliferate either because distinct subsets of progenitors cells exist that respond exclusively to one factor or because some progenitors require stimulation by two or more factors before being able to respond. Activation of additional receptors on a cell by the use of two or more factors is likely to enhance the mitotic signal because of coalescence of initially differing signal pathways into a common final pathway reaching the nucleus (Metcalf, Nature 339: 27, 1989). Other mechanisms could explain synergy. For example, if one signaling pathway is limited by an intermediate activation of an additional signaling pathway which is caused by a second factor, then this may result in a super additive response. In some cases, activation of one receptor type can induce an enhanced expression of other receptors (Metcalf, Blood 82: 3515-3523, 1993). Two or more factors may result in a different pattern of cell lineages than from a single factor. The use of multi-functional hematopoietic receptor agonists may have a potential clinical advantage resulting from a proliferative response that is not possible by any single factor.

The receptors of hematopoietic and other growth factors can be grouped into two distinct families of related proteins: (1) tyrosine kinase receptors, including those for epidermal growth factor, M-CSF (Sherr, Blood 75: 1, 1990) and SCF (Yarden et al., EMBO J. 6: 3341, 1987): and (2) hematopoietic receptors, not containing a tyrosine kinase domain, but exhibiting obvious homology in their extracellular domain (Bazan, PNAS USA 87: 6934-6938, 1990). Included in this latter group are erythropoietin (EPO) (D'Andrea et al., Cell 57: 277, 1989), GM-CSF (Gearing et al., EMBO J. 8: 3667, 1989), IL-3 (Kitamura et al., Cell 66: 1165, 1991), G-CSF (Fukunaga et al., J. Bio. Chem. 265: 14008-15, 1990), IL-4 (Harada et al., PNAS USA 87: 857, 1990), IL-5 (Takaki et al., EMBO J. 9: 4367, 1990), IL-6 (Yamasaki et al., Science 241: 825, 1988), IL-7 (Goodwin et al., Cell 60: 941-51, 1990), LIF (Gearing et al., EMBO J. 10: 2839, 1991) and IL-2 (Cosman et al., Mol-Immunol. 23: 935-94, 1986). Most of the latter group of receptors exists in a high-affinity form as heterodimers. After ligand binding, the specific .alpha.-chains become associated with at least one other receptor chain (.beta.-chain, .gamma.-chain). Many of these factors share a common receptor subunit. The .alpha.-chains for GM-CSF, IL-3 and IL-5 share the same .beta.-chain (Kitamura et al., Cell 66: 1165, 1991), Takaki et al., EMBO J. 10: 2833-8, 1991) and receptor complexes for IL-6, LIF and IL-11 share a common .beta.-chain (gp130) (Taga et al., Cell 58: 573-81, 1989; Gearing et al., Science 255: 1434-7, 1992). The receptor complexes of IL-2, IL-4, IL-7, IL-9 and IL-15 share a common .gamma.-chain (Kondo et al., Science 262: 1874, 1993; Russell et al., Science 266: 1042-1045, 1993; Noguchi et al., Science 262: 1877, 1993; Giri et al., EMBO J. 13: 2822-2830, 1994).

The use of a multiply acting hematopoietic factor may also have a potential advantage by reducing the demands placed on factor-producing cells and their induction systems. If there are limitations in the ability of a cell to produce a factor, then by lowering the required concentrations of each of the factors, and using them in combination may usefully reduce demands on the factor-producing cells. The use of a multiply acting hematopoietic factor may lower the amount of the factors that would be needed, probably reducing the likelihood of adverse side-effects.

Novel compounds of this invention are represented by a formula selected from the group consisting of:

R.sub.1 -L.sub.1 -R.sub.2, R.sub.2 -L.sub.1 -R.sub.1, R.sub.1 -R.sub.2, and R.sub.2 -R.sub.1

Where R.sub.1 and R2 are as defined above. R.sub.2 is preferably a colony stimulating factor with a different but complementary activity than R.sub.1. By complementary activity is meant activity which enhances or changes the response to another cell modulator. The R.sub.1 polypeptide is joined either directly or through a linker segment to the R.sub.2 polypeptide. The term "directly" defines multi-functional hematopoietic receptor agonists in which the polypeptides are joined without a peptide linker. Thus L.sub.1 represents a chemical bond or polypeptide segment to which both R.sub.1 and R.sub.2 are joined in frame, most commonly L.sub.1 is a linear peptide to which R.sub.1 and R.sub.2 are joined by amide bonds linking the carboxy terminus of R.sub.1 to the amino terminus of L.sub.1 and carboxy terminus of L.sub.1 to the amino terminus of R.sub.2. By "joined in frame" is meant that there is no translation termination or disruption between the reading frames of the DNA encoding R.sub.1 and R.sub.2.

A non-exclusive list of other growth factors, i.e. colony stimulating factors (CSFs), are cytokines, lymphokines, interleukins, hematopoietic growth factors which can be joined to (I), (II) or (III) include GM-CSF, G-CSF, c-mpl ligand (also known as TPO or MGDF), M-CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-3, IL-5, IL 6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, LIF, flt3 ligand, human growth hormone, and stem cell factor (SCF) also known as steel factor or c-kit ligand. Additionally, this invention encompasses the use of modified R.sub.1 or R.sub.2 molecules or mutated or modified DNA sequences encoding these R.sub.1 or R.sub.2 molecules. The present invention also includes multi-functional hematopoietic receptor agonists in which R.sub.1 or R.sub.2 is an hIL-3 variant, c-mpl ligand variant, or G-CSF variant. A "hIL-3 variant" is defined as a hIL-3 molecule which has amino acid substitutions and/or portions of hIL-3 deleted as disclosed in WO 94/12638, WO 94/12639 and WO 95/00646, as well as other variants known in the art. A "c-mpl ligand variant" is defined an c-mpl ligand molecule which has amino acid substitutions and/or portions of c-mpl ligand deleted, disclosed in U.S. application Ser. No. 08/383,035 as well as other variants known in the art. A "G-CSF variant" is defined an G-CSF molecule which has amino acid substitutions and/or portions of G-CSF deleted, as disclosed herein, as well as other variants known in the art.

The linking group (Li) is generally a polypeptide of between 1 and 500 amino acids in length. The linkers joining the two molecules are preferably designed to (1) allow the two molecules to fold and act independently of each other, (2) not have a propensity for developing an ordered secondary structure which could interfere with the functional domains of the two proteins, (3) have minimal hydrophobic characteristics which could interact with the functional protein domains and (4) provide steric separation of R.sub.1 and R.sub.2 such that R.sub.1 and R.sub.2 could interact simultaneously with their corresponding receptors on a single cell. Typically surface amino acids in flexible protein regions include Gly, Asn and Ser. Virtually any permutation of amino acid sequences containing Gly, Asn and Ser would be expected to satisfy the above criteria for a linker sequence. Other neutral amino acids, such as Thr and Ala, may also be used in the linker sequence. Additional amino acids may also be included in the linkers due to the addition of unique restriction sites in the linker sequence to facilitate construction of the multi-functional hematopoietic receptor agonists.

Preferred L.sub.1 linkers of the present invention include sequences selected from the group of formulas: (Gly.sup.3 Ser).sup.n (SEQ ID NO:4), (Gly.sup.4 Ser).sup.n (SEQ ID NO:5), (Gly.sup.5 Ser).sup.n (SEQ ID NO:6), (Gly.sup.n Ser).sup.n (SEQ ID NO:7) or (AlaGlySer).sup.n (SEQ ID NO:8).

One example of a highly-flexible linker is the glycine and serine-rich spacer region present within the pIII protein of the filamentous bacteriophages, e.g. bacteriophages M13 or fd (Schaller et al., PNAS USA 72: 737-741, 1975). This region provides a long, flexible spacer region between two domains of the pIII surface protein. The spacer region consists of the amino acid sequence:

GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGluGlyGlyGlySerGluGlyGlyGlySerGluGlyGlyGlySerGluGlyGlyGlySerGlyGlyGlySer (SEQ ID NO:9).

The present invention also includes linkers in which an endopeptidase recognition sequence is included. Such a cleavage site may be valuable to separate the individual components of the multi-functional hematopoietic receptor agonist to determine if they are properly folded and active in vitro. Examples of various endopeptidases include, but are not limited to, plasmin, enterokinase, kallikrein, urokinase, tissue plasminogen activator, clostripain, chymosin, collagenase, Russell's viper venom protease, postproline cleavage enzyme, V8 protease, Thrombin and factor Xa.

Peptide linker segments from the hinge region of heavy chain immunoglobulins IgG, IgA, IgM, IgD or IgE provide an angular relationship between the attached polypeptides. Especially useful are those hinge regions where the cysteines are replaced with serines. Preferred linkers of the present invention include sequences derived from murine IgG gamma 2b hinge region in which the cysteines have been changed to serines. These linkers may also include an endopeptidase cleavage site. Examples of such linkers include the following sequences:

IleSerGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerPro (SEQ ID NO:10) and IleGluGlyArgIleSerGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerPro (SEQ ID NO:11).

The present invention is, however, not limited by the form, size or number of linker sequences employed and the only requirement of the linker is that functionally it does not interfere with the folding and function of the individual molecules of the multi-functional hematopoietic receptor agonist.

One aspect of the invention includes multi-functional hematopoietic receptor agonists which comprise a sequence rearranged c-mpl receptor agonist in which the cysteine(s) at position 7 and 151 of c-mpl ligand, have been substituted with another amino acid. Kaushansky et al. (Blood 86: 255a Abstract 1008, 1995) teaches that all four of the cysteines at positions 7, 29, 85, and 151 are required for bioactivity. The presence of cysteines in a protein can cause problems in processing when the protein is being produced recombinantly in a bacterial host. Microbially produced cysteine-containing proteins may tend to form multimers which greatly complicate purification of the protein product. Several additional purification steps, such as reduction and reoxidation of the recombinant protein may be required to obtain the protein in the proper confirmation. Removal of one of the cysteine residues, with concurrent replacement by a chemically equivalent neutral amino acid, would be desirable, in order to simplify the isolation and purification of the molecule. However, the successful removal of cysteines from biologically active molecules is unpredictable, in that the tertiary structure in the absence of the normally formed disulfide bridges, can be substantially altered. A molecule in which a pair of cysteines at positions 7 and 151 are substituted with another amino acid may have one or more advantages including, but not limited to: 1) increased folding efficiency of the heterologously expressed protein; 2) elimination of mispaired disulfides, 3) use of milder refold conditions (ie. Guanidine vs. Urea); 4) increased purification yields, 5) increased protein solubility; and 6) increased protein stability.

Determination of the Linker L.sub.2

The length of the amino acid sequence of the linker L.sub.2 to be used in R.sub.1 and/or R.sub.2 can be selected empirically or with guidance from structural information, or by using a combination of the two approaches.

When no structural information is available, a small series of linkers can be prepared for testing using a design whose length is varied in order to span a range from 0 to 50 .ANG. and whose sequence is chosen in order to be consistent with surface exposure (hydrophilicity, Hopp & Woods, Mol. Immunol. 20: 483-489, 1983), Kyte & Doolittle, J. Mol. Biol. 157: 105-132; solvent exposed surface area, Lee & Richards, J. Mol. Biol. 55: 379-400, 1971) and the ability to adopt the necessary conformation with out deranging the conformation of R.sup.1 or R.sup.2 (conformationally flexible; Karplus & Schulz, Naturwissenschaften 72: 212-213, 1985). Assuming an average of translation of 2.0 to 3.8 .ANG. per residue, this would mean the length to test would be between 0 to 30 residues, with 0 to 15 residues being the preferred range. Exemplary of such an empirical series would be to construct linkers using a cassette sequence such as Gly-Gly-Gly-Ser (SEQ ID NO:12) repeated n times, where n is 1, 2, 3 or 4. Those skilled in the art will recognize that there are many such sequences that vary in length or composition that can serve as linkers with the primary consideration being that they be neither excessively long nor short (cf., Sandhu, Critical Rev. Biotech. 12: 437-462, 1992); if they are too long, entropy effects will likely destabilize the three-dimensional fold, and may also make folding kinetically impractical, and if they are too short, they will likely destabilize the molecule because of torsional or steric strain.

Those skilled in the analysis of protein structural information will recognize that using the distance between the chain ends, defined as the distance between the c-alpha carbons, can be used to define the length of the sequence to be used, or at least to limit the number of possibilities that must be tested in an empirical selection of linkers. They will also recognize that it is sometimes the case that the positions of the ends of the polypeptide chain are ill-defined in structural models derived from x-ray diffraction or nuclear magnetic resonance spectroscopy data, and that when true, this situation will therefore need to be taken into account in order to properly estimate the length of the linker required. From those residues whose positions are well defined are selected two residues that are close in sequence to the chain ends, and the distance between their c-alpha carbons is used to calculate an approximate length for a linker between them. Using the calculated length as a guide, linkers with a range of number of residues (calculated using 2 to 3.8 .ANG. per residue) are then selected. These linkers may be composed of the original sequence, shortened or lengthened as necessary, and when lengthened the additional residues may be chosen to be flexible and hydrophilic as described above; or optionally the original sequence may be substituted for using a series of linkers, one example being the Gly-Gly-Gly-Ser (SEQ ID NO:12) cassette approach mentioned above; or optionally a combination of the original sequence and new sequence having the appropriate total length may be used.

Determination of the Amino and Carboxyl Termini of R.sub.1 and R.sub.2

Sequences of R.sub.1 and R.sub.2 capable of folding to biologically active states can be prepared by appropriate selection of the beginning (amino terminus) and ending (carboxyl terminus) positions from within the original polypeptide chain while using the linker sequence L.sub.2 as described above. Amino and carboxyl termini are selected from within a common stretch of sequence, referred to as a breakpoint region, using the guidelines described below. A novel amino acid sequence is thus generated by selecting amino and carboxyl termini from within the same breakpoint region. In many cases the selection of the new termini will be such that the original position of the carboxyl terminus immediately preceded that of the amino terminus. However, those skilled in the art will recognize that selections of termini anywhere within the region may function, and that these will effectively lead to either deletions or additions to the amino or carboxyl portions of the new sequence.

It is a central tenet of molecular biology that the primary amino acid sequence of a protein dictates folding to the three-dimensional structure necessary for expression of its biological function. Methods are known to those skilled in the art to obtain and interpret three-dimensional structural information using x-ray diffraction of single protein crystals or nuclear magnetic resonance spectroscopy of protein solutions. Examples of structural information that are relevant to the identification of breakpoint regions include the location and type of protein secondary structure (alpha and 3-10 helices, parallel and anti-parallel beta sheets, chain reversals and turns, and loops; Kabsch & Sander, Biopolymers 22: 2577-2637, 1983), the degree of solvent exposure of amino acid residues, the extent and type of interactions of residues with one another (Chothia, Ann. Rev. Biochem. 53: 537-572, 1984) and the static and dynamic distribution of conformations along the polypeptide chain (Alber & Mathews, Methods Enzymol. 154: 511-533, 1987). In some cases additional information is known about solvent exposure of residues; one example is a site of post-translational attachment of carbohydrate which is necessarily on the surface of the protein. When experimental structural information is not available, or is not feasible to obtain, methods are also available to analyze the primary amino acid sequence in order to make predictions of protein tertiary and secondary structure, solvent accessibility and the occurrence of turns and loops. Biochemical methods are also sometimes applicable for empirically determining surface exposure when direct structural methods are not feasible; for example, using the identification of sites of chain scission following limited proteolysis in order to infer surface exposure (Gentile & Salvatore, Eur. J. Biochem. 218: 603-621, 1993) Thus using either the experimentally derived structural information or predictive methods (e.g., Srinivisan & Rose Proteins: Struct., Funct. & Genetics, 22: 81-99, 1995) the parental amino acid sequence is inspected to classify regions according to whether or not they are integral to the maintenance of secondary and tertiary structure. The occurrence of sequences within regions that are known to be involved in periodic secondary structure (alpha and 3-10 helices, parallel and anti-parallel beta sheets) are regions that should be avoided. Similarly, regions of amino acid sequence that are observed or predicted to have a low degree of solvent exposure are more likely to be part of the so-called hydrophobic core of the protein and should also be avoided for selection of amino and carboxyl termini. In contrast, those regions that are known or predicted to be in surface turns or loops, and especially those regions that are known not to be required for biological activity, are the preferred sites for location of the extremes of the polypeptide chain. Continuous stretches of amino acid sequence that are preferred based on the above criteria are referred to as a breakpoint region.

Non-covalent Multifunctional hematopoietic growth factors

An alternative method for connecting two hematopoietic growth factors is by means of a non-covalent interaction. Such complexed proteins can be described by one of the formulae:

R.sub.1 -C.sub.1 +R.sub.2 -C.sub.2 ; or C.sub.1 -R.sub.1 +C.sub.2 -R.sub.2 ; C.sub.1 -R.sub.1 +R.sub.2 -C.sub.2 ; or C.sub.1 -R.sub.1 +R.sub.2 -C.sub.2.

R.sub.1 and R.sub.2 are as is defined above. Domains C.sub.1 and C.sub.2 are either identical or non-identical chemical structures, typically proteinaceous, which can form a non-covalent, specific association. Complexes between C.sub.1 and C.sub.2 result in a one-to-one stoichiometric relationship between R.sub.1 and R.sub.2 for each complex. Examples of domains which associate are "leucine zipper" domains of transcription factors, dimerization domains of bacterial transcription repressors and immunoglobulin constant domains. Covalent bonds link R.sub.1 and C.sub.1, and R.sub.2 and C.sub.2, respectively. As indicated in the formulae, the domains C.sub.1 and C.sub.2 can be present either at the N-terminus or C-terminus of their corresponding hematopoietic growth factor (R). These multimerization domains (C.sub.1 and C.sub.2) include those derived from the bZIP family of proteins (Abel et al., Nature 341: 24-25, 1989; Landshulz et al., Science 240: 1759-1764, 1988; Pu et al., Nuc. Acid Res. 21: 4348-4355, 1993; Kozarides et al., Nature 336: 646-651, 1988), as well as multimerization domains of the helix-loop-helix family of proteins (Abel et al., Nature 341: 24-25, 1989; Murre et al., Cell 56: 777-783, 1989; Tapscott et al., Science 242: 405-411, 1988; Fisher et al., Genes & Dev. 5: 2342-2352, 1991). Preferred multi-functional hematopoietic receptor agonists of the present invention include colony stimulating factors dimerized by virtue of their incorporation as translational multi-functional hematopoietic receptor agonists with the leucine zipper dimerization domains of the bZIP family proteins Fos and Jun. The leucine zipper domain of Jun is capable of interacting with identical domains. On the other hand, the leucine zipper domain of Fos interacts with the Jun leucine zipper domain, but does not interact with other Fos leucine zipper domains. Mixtures of Fos and Jun predominantly result in formation of Fos-Jun heterodimers. Consequently, when joined to colony stimulating factors, the Jun domain can be used to direct the formation of either homo- or heterodimers. Preferential formation of heterodimers can be achieved if one of the colony stimulating factor partners is engineered to possess the Jun leucine zipper domain while the other is engineered to possess the Fos zipper.

Additional peptide sequences may also be added to facilitate purification or identification of multi-functional hematopoietic receptor agonist proteins (e.g., poly-His). A highly antigenic peptide may also be added that would enable rapid assay and facile purification of the multi-functional hematopoietic receptor agonist protein by a specific monoclonal antibody.

"Mutant amino acid sequence," "mutant protein", "variant protein", "mutein", or "mutant polypeptide" refers to a polypeptide having an amino acid sequence which varies from a native sequence due to amino acid deletions, substitutions, or both, or is encoded by a nucleotide sequence intentionally made variant from a native sequence. "Native sequence" refers to an amino acid or nucleic acid sequence which is identical to a wild-type or native form of a gene or protein.

Hematopoietic growth factors can be characterized by their ability to stimulate colony formation by human hematopoietic progenitor cells. The colonies formed include erythroid, granulocyte, megakaryocyte, granulocytic macrophages and mixtures thereof. Many of the hematopoietic growth factors have demonstrated the ability to restore bone marrow function and peripheral blood cell populations to therapeutically beneficial levels in studies performed initially in primates and subsequently in humans. Many or all of these biological activities of hematopoietic growth factors involve signal transduction and high affinity receptor binding. Multi-functional hematopoietic receptor agonists of the present invention may exhibit useful properties such as having similar or greater biological activity when compared to a single factor or by having improved half-life or decreased adverse side effects, or a combination of these properties.

Multi-functional hematopoietic receptor agonists which have little or no agonist activity maybe useful as antagonists, as antigens for the production of antibodies for use in immunology or immunotherapy, as genetic probes or as intermediates used to construct other useful hIL-3 muteins.

Biological activity of the multi-functional hematopoietic receptor agonist proteins of the present invention can be determined by DNA synthesis in factor-dependent cell lines or by counting the colony forming units in an in vitro bone marrow assay.

The multi-functional hematopoietic receptor agonists of the present invention may have an improved therapeutic profile as compared to single acting hematopoietic agonists. For example, some multi-functional hematopoietic receptor agonists of the present invention may have a similar or more potent growth factor activity relative to other hematopoietic agonists without having a similar or corresponding increase in side-effects.

The present invention also includes the DNA sequences which code for the multi-functional hematopoietic receptor agonist proteins, DNA sequences which are substantially similar and perform substantially the same function, and DNA sequences which differ from the DNAs encoding the multi-functional hematopoietic receptor agonists of the invention only due to the degeneracy of the genetic code. Also included in the present invention are the oligonucleotide intermediates used to construct the mutant DNAs and the polypeptides coded for by these oligonucleotides.

Genetic engineering techniques now standard in the art (U.S. Pat. No. 4,935,233 and Sambrook et al., "Molecular Cloning A Laboratory Manual", Cold Spring Harbor Laboratory, 1989) may be used in the construction of the DNA sequences of the present invention. One such method is cassette mutagenesis (Wells et al., Gene 34: 315-323, 1985) in which a portion of the coding sequence in a plasmid is replaced with synthetic oligonucleotides that encode the desired amino acid substitutions in a portion of the gene between two restriction sites.

Pairs of complementary synthetic oligonucleotides encoding the desired gene can be made and annealed to each other. The DNA sequence of the oligonucleotide would encode sequence for amino acids of desired gene with the exception of those substituted and/or deleted from the sequence.

Plasmid DNA can be treated with the chosen restriction endonucleases then ligated to the annealed oligonucleotides. The ligated mixtures can be used to transform competent JM101 cells to resistance to an appropriate antibiotic. Single colonies can be picked and the plasmid DNA examined by restriction analysis and/or DNA sequencing to identify plasmids with the desired genes.

Cloning of the DNA sequences of the novel multifunctional hematopoietic agonists wherein at least one of the with the DNA sequence of the other colony stimulating factor may be accomplished by the use of intermediate vectors. Alternatively one gene can be cloned directly into a vector containing the other gene. Linkers and adapters can be used for joining the DNA sequences, as well as replacing lost sequences, where a restriction site was internal to the region of interest. Thus genetic material (DNA) encoding one polypeptide, peptide linker, and the other polypeptide is inserted into a suitable expression vector which is used to transform bacteria, yeast, insect cells or mammalian cells. The transformed organism is grown and the protein isolated by standard techniques. The resulting product is therefore a new protein which has a colony stimulating factor joined by a linker region to a second colony stimulating factor.

Another aspect of the present invention provides plasmid DNA vectors for use in the expression of these novel multi-functional hematopoietic receptor agonists. These vectors contain the novel DNA sequences described above which code for the novel polypeptides of the invention. Appropriate vectors which can transform microorganisms capable of expressing the multi-functional hematopoietic receptor agonists include expression vectors comprising nucleotide sequences coding for the multi-functional hematopoietic receptor agonists joined to transcriptional and translational regulatory sequences which are selected according to the host cells used.

Vectors incorporating modified sequences as described above are included in the present invention and are useful in the production of the multi-functional hematopoietic receptor agonist polypeptides. The vector employed in the method also contains selected regulatory sequences in operative association with the DNA coding sequences of the invention and which are capable of directing the replication and expression thereof in selected host cells.

As another aspect of the present invention, there is provided a method for producing the novel multi-functional hematopoietic receptor agonists. The method of the present invention involves culturing suitable cells or cell line, which has been transformed with a vector containing a DNA sequence coding for expression of a novel multi-functional hematopoietic receptor agonist. Suitable cells or cell lines may be bacterial cells. For example, the various strains of E. coli are well-known as host cells in the field of biotechnology. Examples of such strains include E. coli strains JM101 (Yanish-Perron et al. Gene 33: 103-119, 1985) and MON105 (Obukowicz et al., Applied Environmental Microbiology 58: 1511-1523, 1992). Also included in the present invention is the expression of the multi-functional hematopoietic receptor agonist protein utilizing a chromosomal expression vector for E. coli based on the bacteriophage Mu (Weinberg et al., Gene 126: 25-33, 1993). Various strains of B. subtilis may also be employed in this method. Many strains of yeast cells known to those skilled in the art are also available as host cells for expression of the polypeptides of the present invention. When expressed in the E. coli cytoplasm, the gene encoding the multi-functional hematopoietic receptor agonists of the present invention may also be constructed such that at the 5' end of the gene codons are added to encode Met.sup.-2 -Ala.sup.-1 - or Met.sup.-1 at the N-terminus of the protein. The N termini of proteins made in the cytoplasm of E. coli are affected by post-translational processing by methionine aminopeptidase (Ben Bassat et al., J. Bac. 169: 751-757, 1987) and possibly by other peptidases so that upon expression the methionine is cleaved off the N-terminus. The multi-functional hematopoietic receptor agonists of the present invention may include multi-functional hematopoietic receptor agonist polypeptides having Met.sup.-1, Ala.sup.-1 or Met.sup.-2 -Ala.sup.-1 at the N-terminus. These mutant multi-functional hematopoietic receptor agonists may also be expressed in E. coli by fusing a secretion signal peptide to the N-terminus. This signal peptide is cleaved from the polypeptide as part of the secretion process.

Also suitable for use in the present invention are mammalian cells, such as Chinese hamster ovary cells (CHO). General methods for expression of foreign genes in mammalian cells are reviewed in Kaufman, R. J., 1987) Genetic Engineering, Principles and Methods, Vol. 9, J. K. Setlow, editor, Plenum Press, New York. An expression vector is constructed in which a strong promoter capable of functioning in mammalian cells drives transcription of a eukaryotic secretion signal peptide coding region, which is translationally joined to the coding region for the multi-functional hematopoietic receptor agonist. For example, plasmids such as pcDNA I/Neo, pRc/RSV, and pRc/CMV (obtained from Invitrogen Corp., San Diego, Calif.) can be used. The eukaryotic secretion signal peptide coding region can be from the gene itself or it can be from another secreted mammalian protein (Bayne, M. L. et al., Proc. Natl. Acad. Sci. USA 84: 2638-2642, 1987). After construction of the vector containing the gene, the vector DNA is transfected into mammalian cells. Such cells can be, for example, the COS7, HeLa, BHK, CHO, or mouse L lines. The cells can be cultured, for example, in DMEM media (JRH Scientific). The polypeptide secreted into the media can be recovered by standard biochemical approaches following transient expression for 24-72 hours after transfection of the cells or after establishment of stable cell lines following selection for antibiotic resistance. The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. See, e.g., Gething and Sambrook, Nature, 293: 620-625, 1981), or alternatively, Kaufman et al, Mol. Cell. Biol., 5 (7): 1750-1759, 1985) or Howley et al., U.S. Pat. No. 4,419,446. Another suitable mammalian cell line is the monkey COS-1 cell line. A similarly useful mammalian cell line is the CV-1 cell line.

Where desired, insect cells may be utilized as host cells in the method of the present invention. See, e.g., Miller et al., Genetic Engineering, 8: 277-298 (Plenum Press 1986) and references cited therein. In addition, general methods for expression of foreign genes in insect cells using Baculovirus vectors are described in: Summers, M. D. and Smith, G. E., 1987)--A manual of methods for Baculovirus vectors and insect cell culture procedures, Texas Agricultural Experiment Station Bulletin No. 1555. An expression vector is constructed comprising a Baculovirus transfer vector, in which a strong Baculovirus promoter (such as the polyhedron promoter) drives transcription of a eukaryotic secretion signal peptide coding region, which is translationally joined to the coding region for the multi-functional hematopoietic receptor agonist polypeptide. For example, the plasmid pVL1392 (obtained from Invitrogen Corp., San Diego, Calif.) can be used. After construction of the vector carrying the gene encoding the multi-functional hematopoietic receptor agonist polypeptide, two micrograms of this DNA is co-transfected with one microgram of Baculovirus DNA (see Summers & Smith, 1987) into insect cells, strain SF9. Pure recombinant Baculovirus carrying the multi-functional hematopoietic receptor agonist is used to infect cells cultured, for example, in Excell 401 serum-free medium (JRH Biosciences, Lenexa, Kans.). The multi-functional hematopoietic receptor agonist secreted into the medium can be recovered by standard biochemical approaches. Supernatants from mammalian or insect cells expressing the multi-functional hematopoietic receptor agonist protein can be first concentrated using any of a number of commercial concentration units.

The multi-functional hematopoietic receptor agonists of the present invention may be useful in the treatment of diseases characterized by decreased levels of either myeloid, erythroid, lymphoid, or megakaryocyte cells of the hematopoietic system or combinations thereof. In addition, they may be used to activate mature myeloid and/or lymphoid cells. Among conditions susceptible to treatment with the polypeptides of the present invention is leukopenia, a reduction in the number of circulating leukocytes (white cells) in the peripheral blood. Leukopenia may be induced by exposure to certain viruses or to radiation. It is often a side effect of various forms of cancer therapy, e.g., exposure to chemotherapeutic drugs, radiation and of infection or hemorrhage. Therapeutic treatment of leukopenia with these multi-functional hematopoietic receptor agonists of the present invention may avoid undesirable side effects caused by treatment with presently available drugs.

The multi-functional hematopoietic receptor agonists of the present invention may be useful in the treatment of neutropenia and, for example, in the treatment of such conditions as aplastic anemia, cyclic neutropenia, idiopathic neutropenia, Chediak-Higashi syndrome, systemic lupus erythematosus (SLE), leukemia, myelodysplastic syndrome and myelofibrosis.

The multi-functional hematopoietic receptor agonist of the present invention may be useful in the treatment or prevention of thrombocytopenia. Currently the only therapy for thrombocytopenia is platelet transfusion which are costly and carry the significant risks of infection (HIV, HBV) and alloimmunization. The multi-functional hematopoietic receptor agonist may alleviate or diminish the need for platelet transfusion. Severe thrombocytopenia may result from genetic defects such as Fanconi's Anemia, Wiscott-Aldrich, or May Hegglin syndromes. Acquired. thrombocytopenia may result from auto- or allo-antibodies as in Immune Thrombocytopenia Purpura, Systemic Lupus Erythromatosis, hemolytic anemia, or fetal maternal incompatibility. In addition, splenomegaly, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, infection or prosthetic heart valves may result in thrombocytopenia. Severe thrombocytopenia may also result from chemotherapy and/or radiation therapy or cancer. Thrombocytopenia may also result from marrow invasion by carcinoma, lymphoma, leukemia or fibrosis.

The multi-functional hematopoietic receptor agonists of the present invention may be useful in the mobilization of hematopoietic progenitors and stem cells in peripheral blood. Peripheral blood derived progenitors have been shown to be effective in reconstituting patients in the setting of autologous marrow transplantation. Hematopoietic growth factors including G-CSF and GM-CSF have been shown to enhance the number of circulating progenitors and stem cells in the peripheral blood. This has simplified the procedure for peripheral stem cell collection and dramatically decreased the cost of the procedure by decreasing the number of pheresis required. The multi-functional hematopoietic receptor agonist may be useful in mobilization of stem cells and further enhance the efficacy of peripheral stem cell transplantation.

The multi-functional hematopoietic receptor agonists of the present invention may also be useful in the ex vivo expansion of hematopoietic progenitors and stem cells. Colony stimulating factors (CSFs), such as hIL-3, have been administered alone, co-administered with other CSFs, or in combination with bone marrow transplants subsequent to high dose chemotherapy to treat the neutropenia and thrombocytopenia which are often the result of such treatment. However the period of severe neutropenia and thrombocytopenia may not be totally eliminated. The myeloid lineage, which is comprised of monocytes (macrophages), granulocytes (including neutrophils) and megakaryocytes, is critical in preventing infections and bleeding which can be life-threatening. Neutropenia and thrombocytopenia may also be the result of disease, genetic disorders, drugs, toxins, radiation and many therapeutic treatments such as conventional oncology therapy.

Bone marrow transplants have been used to treat this patient population. However, several problems are associated with the use of bone marrow to reconstitute a compromised hematopoietic system including: 1) the number of stem cells in bone marrow, spleen, or peripheral blood is limited, 2) Graft Versus Host Disease, 3) graft rejection and 4) possible contamination with tumor cells. Stem cells make up a very small percentage of the nucleated cells in the bone marrow, spleen and peripheral blood. It is clear that a dose response exists such that a greater number of stem cells will enhance hematopoietic recovery. Therefore, the in vitro expansion of stem cells should enhance hematopoietic recovery and patient survival. Bone marrow from an allogeneic donor has been used to provide bone marrow for transplant. However, Graft Versus Host Disease and graft rejection limit bone marrow transplantation even in recipients with HLA-matched sibling donors. An alternative to allogeneic bone marrow transplants is autologous bone marrow transplants. In autologous bone marrow transplants, some of the patient's own marrow is harvested prior to myeloablative therapy, e.g. high dose chemotherapy, and is transplanted back into the patient afterwards. Autologous transplants eliminate the risk of Graft Versus Host Disease and graft rejection. However, autologous bone marrow transplants still present problems in terms of the limited number of stems cells in the marrow and possible contamination with tumor cells. The limited number of stem cells may be overcome by ex-vivo expansion of the stem cells. In addition, stem cells can be specifically isolated, based on the presence of specific surface antigens such as CD34+ in order to decrease tumor cell contamination of the marrow graft.

The following patents contain further details on separating stem cells, CD34+ cells, culturing the cells with hematopoietic factors, the use of the cells for the treatment of patients with hematopoietic disorders and the use of hematopoietic factors for cell expansion and gene therapy.

U.S. Pat. No. 5,061,620 relates to compositions comprising human hematopoietic stem cells provided by separating the stem cells from dedicated cells.

U.S. Pat. No. 5,199,942 describes a method for autologous hematopoietic cell transplantation comprising: (1) obtaining hematopoietic progenitor cells from a patient; (2) ex-vivo expansion of cells with a growth factor selected from the group consisting of IL-3, flt3 ligand, c-kit ligand, GM-CSF, IL-1, GM-CSF/IL-3 fusion protein and combinations thereof; (3) administering cellular preparation to a patient.

U.S. Pat. No. 5,240,856 relates to a cell separator that includes an apparatus for automatically controlling the cell separation process.

WO 91/16116 describes devices and methods for selectively isolating and separating target cells from a mixture of cells.

WO 91/18972 describes methods for in vitro culturing of bone marrow, by incubating suspension of bone marrow cells, using a hollow fiber bioreactor.

WO 92/18615 relates to a process for maintaining and expanding bone marrow cells, in a culture medium containing specific mixtures of cytokines, for use in transplants.

WO 93/08268 describes a method for selectively expanding stem cells, comprising the steps of (a) separating CD34+ stem cells from other cells and (b) incubating the separated cells in a selective medium, such that the stem cells are selectively expanded.

WO 93/18136 describes a process for in vitro support of mammalian cells derived from peripheral blood.

WO 93/18648 relates to a composition comprising human neutrophil precursor cells with a high content of myeloblasts and promyelocytes for treating genetic or acquired neutropenia.

WO 94/08039 describes a method of enrichment for human hematopoietic stem cells by selection for cells which express c-kit protein.

WO 94/11493 describes a stem cell population that are CD34+ and small in size, which are isolated using a counterflow elutriation method.

WO 94/27698 relates to a method combining immunoaffinity separation and continuous flow centrifugal separation for the selective separation of a nucleated heterogeneous cell population from a heterogeneous cell mixture.

WO 94/25848 describes a cell separation apparatus for collection and manipulation of target cells.

The long term culturing of highly enriched CD34+ precursors of hematopoietic progenitor cells from human bone marrow in cultures containing IL-1a, IL-3, IL-6 or GM-CSF is discussed in Brandt et al J. Clin. Invest. 86: 932-941, 1990).

One aspect of the present invention provides a method for selective ex-vivo expansion of stem cells. The term "stem cell" refers to the totipotent hematopoietic stem cells as well as early precursors and progenitor cells which can be isolated from bone marrow, spleen or peripheral blood. The term "expansion" refers to the differentiation and proliferation of the cells. The present invention provides a method for selective ex-vivo expansion of stem cells, comprising the steps of: (a) separating stem cells from other cells, (b) culturing said separated stem cells with a selective media which contains multi-functional hematopoietic receptor agonist protein(s) and (c) harvesting said stems cells. Stem cells, as well as committed progenitor cells destined to become neutrophils, erythrocytes, platelets, etc. may be distinguished from most other cells by the presence or absence of particular progenitor marker antigens, such as D34, that are present on the surface of these cells nd/or by morphological characteristics. The phenotype for a highly enriched human stem cell fraction is reported as CD34+, Thy-1+ and lin-, but it is to be understood that the present invention is not limited to the expansion of this stem cell population. The CD34+ enriched human stem cell fraction can be separated by a number of reported methods, including affinity columns or beads, magnetic beads or flow cytometry using antibodies directed to surface antigens such as the CD34+. Further, physical separation methods such as counterflow elutriation may be used to enrich hematopoietic progenitors. The CD34+ progenitors are heterogeneous, and may be divided into several sub-populations characterized by the presence or absence of co-expression of different lineage associated cell surface associated molecules. The most immature progenitor cells do not express any known lineage associated markers, such as HLA-DR or CD38, but they may express CD90(thy-1). Other surface antigens such as CD33, CD38, CD41, CD71, HLA-DR or c-kit can also be used to selectively isolate hematopoietic progenitors. The separated cells can be incubated in selected medium in a culture flask, sterile bag or in hollow fibers. Various colony stimulating factors may be utilized in order to selectively expand cells. Representative factors that have been utilized for ex-vivo expansion of bone marrow include, c-kit ligand, IL-3, G-CSF, GM-CSF, IL-1, IL-6, IL-11, flt-3 ligand or combinations thereof. The proliferation of the stem cells can be monitored by enumerating the number of stem cells and other cells, by standard techniques (e.g. hemacytometer, CFU, LTCIC) or by flow cytometry prior and subsequent to incubation.

Several methods for ex-vivo expansion of stem cells have been reported utilizing a number of selection methods and expansion using various colony stimulating factors including c-kit ligand (Brandt et al., Blood 83: 1507-1514 [1994], McKenna et al., Blood 86: 3413-3420 [1995]), IL-3 (Brandt et al., Blood 83: 1507-1514 [1994], Sato et al., Blood 82: 3600-3609 [1993]), G-CSF (Sato et al., Blood 82: 3600-3609 [1993]), GM-CSF (Sato et al., Blood 82: 3600-3609 [1993]), IL-1 (Muench et al., Blood 81: 3463-3473 [1993]), IL-6 (Sato et al., Blood 82: 3600-3609 [1993]), IL-11 (Lemoli et al., Exp. Hem. 21: 1668-1672 [1993], Sato et al., Blood 82: 3600-3609 [1993]), flt-3 ligand (McKenna et al., Blood 86: 3413 3420 [1995]) and/or combinations thereof (Brandt et al., Blood 83: 1507 1514 [1994], Haylock et al., Blood 80: 1405-1412 [1992], Koller et al., Biotechnology 11: 358-363 [1993], (Lemoli et al., Exp. Hem. 21: 1668-1672 [1993]), McKenna et al., Blood 86: 3413-3420 [1995], Muench et al., Blood 81: 3463-3473 [1993], Patchen et al., Biotherapy 7: 13-26 [1994], Sato et al., Blood 82: 3600-3609 [1993], Smith et al., Exp. Hem. 21: 870-877 [1993], Steen et al., Stem Cells 12: 214-224 [1994], Tsujino et al., Exp. Hem. 21: 1379-1386 [1993]). Among the individual colony stimulating factors, hIL-3 has been shown to be one of the most potent in expanding peripheral blood CD34+ cells (Sato et al., Blood 82: 3600-3609 [1993], Kobayashi et al., Blood 73: 1836-1841 [1989]). However, no single factor has been shown to be as effective as the combination of multiple factors. The present invention provides methods for ex vivo expansion that utilize multi-functional hematopoietic receptor agonists that are more effective than a single factor alone.

Another aspect of the invention provides methods of sustaining and/or expanding hematopoietic precursor cells which includes inoculating the cells into a culture vessel which contains a culture medium that has been conditioned by exposure to a stromal cell line such as HS-5 (WO 96/02662, Roecklein and Torok-Strob, Blood 85: 997-1105, 1995) that has been supplemented with a multi-functional hematopoietic receptor agonist of the present invention.

Another projected clinical use of growth factors has been in the in vitro activation of hematopoietic progenitors and stem cells for gene therapy. Due to the long life-span of hematopoietic progenitor cells and the distribution of their daughter cells throughout the entire body, hematopoietic progenitor cells are good candidates for ex vivo gene transfection. In order to have the gene of interest incorporated into the genome of the hematopoietic progenitor or stem cell one needs to stimulate cell division and DNA replication. Hematopoietic stem cells cycle at a very low frequency which means that growth factors may be useful to promote gene transduction and thereby enhance the clinical prospects for gene therapy. Potential applications of gene therapy (review Crystal, Science 270: 404-410 [1995]) include; 1) the treatment of many congenital metabolic disorders and immunodeficiencies (Kay and Woo, Trends Genet. 10: 253-257 [1994]), 2) neurological disorders (Friedmann, Trends Genet. 10: 210-214 [1994]), 3) cancer (Culver and Blaese, Trends Genet. 10: 174-178 [1994]) and 4) infectious diseases (Gilboa and Smith, Trends Genet. 10: 139-144 [1994]).

There are a variety of methods, known to those with skill in the art, for introducing genetic material into a host cell. A number of vectors, both viral and non-viral have been developed for transferring therapeutic genes into primary cells. Viral based vectors include; 1) replication deficient recombinant retrovirus (Boris-Lawrie and Temin, Curr. Opin. Genet. Dev. 3: 102-109 [1993], Boris-Lawrie and Temin, Annal. New York Acad. Sci. 716: 59-71 [1994], Miller, Current Top. Microbiol. Immunol. 158: 1-24 [1992]) and replication-deficient recombinant adenovirus (Berkner, BioTechniques 6: 616-629 [1988], Berkner, Current Top. Microbiol. Immunol. 158: 39-66 [1992], Brody and Crystal, Annal. New York Acad. Sci. 716: 90-103 [1994]). Non-viral based vectors include protein/DNA complexes (Cristiano et al., PNAS USA. 90: 2122-2126 [1993], Curiel et al., PNAS USA 88: 8850-8854 [1991], Curiel, Annal. New York Acad. Sci. 716: 36-58 [1994]), electroporation and liposome mediated delivery such as cationic liposomes (Farhood et al., Annal. New York Acad. Sci. 716: 23-35 [1994]).

The present invention provides an improvement to the existing methods of expanding hematopoietic cells, which new genetic material has been introduced, in that it provides methods utilizing multi-functional hematopoietic receptor agonist proteins that have improved biological activity, including an activity not seen by any single colony stimulation factor.

Many drugs may cause bone marrow suppression or hematopoietic deficiencies. Examples of such drugs are AZT, DDI, alkylating agents and anti-metabolites used in chemotherapy, antibiotics such as chloramphenicol, penicillin, gancyclovir, daunomycin and sulfa drugs, phenothiazones, tranquilizers such as meprobamate, analgesics such as aminopyrine and dipyrone, anti-convulsants such as phenytoin or carbamazepine, antithyroids such as propylthiouracil and methimazole and diuretics. The multi-functional hematopoietic receptor agonists of the present invention may be useful in preventing or treating the bone marrow suppression or hematopoietic deficiencies which often occur in patients treated with these drugs.

Hematopoietic deficiencies may also occur as a result of viral, microbial or parasitic infections and as a result of treatment for renal disease or renal failure, e.g., dialysis. The multi-functional hematopoietic receptor agonists of the present invention may be useful in treating such hematopoietic deficiencies.

The treatment of hematopoietic deficiency may include administration of a pharmaceutical composition containing the multi-functional hematopoietic receptor agonists to a patient. The multi-functional hematopoietic receptor agonists of the present invention may also be useful for the activation and amplification of hematopoietic precursor cells by treating these cells in vitro with the multi-functional hematopoietic receptor agonist proteins of the present invention prior to injecting the cells into a patient.

Various immunodeficiencies, e.g., in T and/or B lymphocytes, or immune disorders, e.g., rheumatoid arthritis, may also be beneficially affected by treatment with the multi-functional hematopoietic receptor agonists of the present invention. Immunodeficiencies may be the result of viral infections, e.g., HTLVI, HTLVII, HTLVIII, severe exposure to radiation, cancer therapy or the result of other medical treatment. The multi-functional hematopoietic receptor agonists of the present invention may also be employed, alone or in combination with other colony stimulating factors, in the treatment of other blood cell deficiencies, including thrombocytopenia (platelet deficiency), or anemia. Other uses for these novel polypeptides are the in vivo and ex vivo treatment of patients recovering from bone marrow transplants, and in the development of monoclonal and polyclonal antibodies generated by standard methods for diagnostic or therapeutic use.

Other aspects of the present invention are methods and therapeutic compositions for treating the conditions referred to above. Such compositions comprise a therapeutically effective amount of one or more of the multi-functional hematopoietic receptor agonists of the present invention in a mixture with a pharmaceutically acceptable carrier. This composition can be administered either parenterally, intravenously or subcutaneously. When administered, the therapeutic composition for use in this invention is preferably in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such a parenterally acceptable protein solution, having due regard to pH, isotonicity, stability and the like, is within the skill of the art.

The dosage regimen involved in a method for treating the above-described conditions will be determined by the attending physician considering various factors which modify the action of drugs, e.g., the condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. Generally, a daily regimen may be in the range of 0.2-150 .mu.g/kg of multi-functional hematopoietic receptor agonist protein per kilogram of body weight. Dosages would be adjusted relative to the activity of a given multi-functional hematopoietic receptor agonist protein and it would not be unreasonable to note that dosage regimens may include doses as low as 0.1 microgram and as high as 1 milligram per kilogram of body weight per day. In addition, there may exist specific circumstances where dosages of multi-functional hematopoietic receptor agonist would be adjusted higher or lower than the range of 0.2-150 micrograms per kilogram of body weight. These include co-administration with other colony stimulating factors or IL-3 variants or growth factors; co-administration with chemotherapeutic drugs and/or radiation; the use of glycosylated multi-functional hematopoietic receptor agonist protein; and various patient-related issues mentioned earlier in this section. As indicated above, the therapeutic method and compositions may also include co-administration with other human factors. A non-exclusive list of other appropriate colony stimulating factors (CSFs), cytokines, lymphokines, hematopoietic growth factors and interleukins for simultaneous or serial co-administration with the polypeptides of the present invention includes GM-CSF, G-CSF, c-mpl ligand (also known as TPO or MGDF), M-CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-3, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, LIF, flt3 ligand, and eosinophil differentiation factor, stem cell factor (SCF) also known as steel factor or c-kit ligand, or combinations thereof. The dosage recited above would be adjusted to compensate for such additional components in the therapeutic composition. Progress of the treated patient can be monitored by periodic assessment of the hematological profile, e.g., differential cell count and the like.

Materials and Methods

Unless noted otherwise, all specialty chemicals were obtained from Sigma, Co. (St. Louis, Mo.). Restriction endonucleases and T4 DNA ligase were obtained from New England Biolabs (Beverly, Mass.) or Boehringer Mannheim (Indianapolis, Ind.).

Transformation of E. coli strains

E. coli strains, such as DH5.alpha..TM. (Life Technologies, Gaithersburg, Md.) and TG1 (Amersham Corp., Arlington Heights, Ill.) are used for transformation of ligation reactions and are the source of plasmid DNA for transfecting mammalian cells. E. coli strains, such as JM101 (Yanisch-Perron, et al., Gene, 33: 103-119, 1985) and MON105 (Obukowicz, et al., Appl. and Envir. Micr., 58: 1511-1523, 1992) can be used for expressing the multi-functional hematopoietic receptor agonist of the present invention in the cytoplasm or periplasmic space.

MON105 ATCC#55204: F-, lambda-,IN(rrnD, rrE)1, rpoD+, rpoH358 DH5.alpha..TM.: F-, phi80dlacZdeltaM15, delta(lacZYA-argF)U169, deoR, recA1, endA1, hsdR17(rk-,mk+), phoA, supE44lamda-, thi-1, gyrA96, relA1 TG1: delta(lac-pro), supE, thi-1, hsdD5/F'(traD36, proA+B+, lacIq, lacZdeltaM15) JM101 ATCC#33876: delta (pro lac), supE, thi, F'(traD36, proA+B+, lacIq, lacZdeltaM15)

DH5.alpha..TM. Subcloning efficiency cells are purchased as competent cells and are ready for transformation using the manufacturer's protocol, while both E. coli strains TG1 and MON105 are rendered competent to take up DNA using a CaCl.sub.2 method. Typically, 20 to 50 mL of cells are grown in LB medium (1% bacto-tryptone, 0.5% bacto-yeast extract, 150 mM NaCl) to a density of approximately 1.0 optical density unit at 600 nanometers (OD600) as measured by a Baush & Lomb Spectronic spectrophotometer (Rochester, N.Y.). The cells are collected by centrifugation and resuspended in one-fifth culture volume of CaCl.sub.2 solution (50 mM CaCl.sub.2, 10 mM Tris-Cl, pH7.4) and are held at 4.degree. C. for 30 minutes. The cells are again collected by centrifugation and resuspended in one-tenth culture volume of CaCl.sub.2 solution. Ligated DNA is added to 0.2 mL of these cells, and the samples are held at 4.degree. C. for 30-60 minutes. The samples are shifted to 42.degree. C. for two minutes and 1.0 mL of LB is added prior to shaking the samples at 37.degree. C. for one hour. Cells from these samples are spread on plates (LB medium plus 1.5% bacto-agar) containing either ampicillin (100 micrograms/mL, ug/mL) when selecting for ampicillin-resistant transformants, or spectinomycin (75 ug/mL) when selecting for spectinomycin-resistant transformants. The plates are incubated overnight at 37.degree. C. Colonies are picked and inoculated into LB plus appropriate antibiotic (100 ug/mL ampicillin or 75 ug/mL spectinomycin) and are grown at 37.degree. C. while shaking.

Methods for creation of genes with new N-terminus/C-terminus Method I. Creation of genes with new N-terminus/C-terminus which contain a linker region (L.sub.2).

Genes with new N-terminus/C-terminus which contain a linker region (L.sub.2) separating the original C-terminus and N-terminus can be made essentially following the method described in L. S. Mullins, et al J. Am. Chem. Soc. 116, 5529-5533, 1994). Multiple steps of polymerase chain reaction (PCR) amplifications are used to rearrange the DNA sequence encoding the primary amino acid sequence of the protein. The steps are illustrated in FIG. 2.

In the first step, the first primer set ("new start" and "linker start") is used to create and amplify, from the original gene sequence, the DNA fragment ("Fragment Start") that contains the sequence encoding the new N-terminal portion of the new protein followed by the linker (L.sub.2) that connects the C-terminal and N-terminal ends of the original protein. In the second step, the second primer set ("new stop" and "linker stop") is used to create and amplify, from the original gene sequence, the DNA fragment ("Fragment Stop") that encodes the same linker as used above, followed by the new C-terminal portion of the new protein. The "new start" and "new stop" primers are designed to include the appropriate restriction sites which allow cloning of the new gene into expression plasmids. Typical PCR conditions are one cycle 95.degree. C. melting for two minutes; 25 cycles 94.degree. C. denaturation for one minute, 50.degree. C. annealing for one minute and 72.degree. C. extension for one minute; plus one cycle 72.degree. C. extension for seven minutes. A Perkin Elmer GeneAmp PCR Core Reagents kit is used. A 100 ul reaction contains 100 pmole of each primer and one ug of template DNA; and 1.times. PCR buffer, 200 uM dGTP, 200 uM DATP, 200 uM dTTP, 200 uM dCTP, 2.5 units AmpliTaq DNA polymerase and 2 mM MgCl2. PCR reactions are performed in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, Conn.).

"Fragment Start" and "Fragment Stop", which have complementary sequence in the linker region and the coding sequence for the two amino acids on both sides of the linker, are joined together in a third PCR step to make the full-length gene encoding the new protein. The DNA fragments "Fragment Start" and "Fragment Stop" are resolved on a 1% TAE gel, stained with ethidium bromide and isolated using a Qiaex Gel Extraction kit (Qiagen). These fragments are combined in equimolar quantities, heated at 70.degree. C. for ten minutes and slow cooled to allow annealing through their shared sequence in "linker start" and "linker stop". In the third PCR step, primers "new start" and "new stop" are added to the annealed fragments to create and amplify the full-length new N-terminus/C-terminus gene. Typical PCR conditions are one cycle 95.degree. C. melting for two minutes; 25 cycles 94.degree. C. denaturation for one minute, 60.degree. C. annealing for one minute and 72.degree. C. extension for one minute; plus one cycle 72.degree. C. extension for seven minutes. A Perkin Elmer GeneAmp PCR Core Reagents kit is used. A 100 ul reaction contains 100 pmole of each primer and approximately 0.5 ug of DNA; and 1.times. PCR buffer, 200 uM dGTP, 200 uM dATP, 200 uM dTTP, 200 uM dCTP, 2.5 units AmpliTaq DNA polymerase and 2 mM MgCl2. PCR reactions are purified using a Wizard PCR Preps kit (Promega).

Method II. Creation of genes with new N-terminus/C-terminus without a linker region.

New N-terminus/C-terminus genes without a linker joining the original N-terminus and C-terminus can be made using two steps of PCR amplification and a blunt end ligation. The steps are illustrated in FIG. 3. In the first step, the primer set ("new start" and "P-bl start") is used to create and amplify, from the original gene sequence, the DNA fragment ("Fragment Start") that contains the sequence encoding the new N-terminal portion of the new protein. In the second step, the primer set ("new stop" and "P-bl stop") is used to create and amplify, from gene sequence, the DNA fragment ("Fragment Stop") that contains the sequence encoding the new C-terminal portion of the new protein. The "new start" and "new stop" primers are designed to include appropriate restriction sites which allow cloning of the new gene into expression vectors. Typical PCR conditions are one cycle 95.degree. C. melting for two minutes; 25 cycles 94.degree. C. denaturation for one minute, 50.degree. C. annealing for 45 seconds and 72.degree. C. extension for 45 seconds. Deep Vent polymerase (New England Biolabs) is used to reduce the occurrence of overhangs in conditions recommended by the manufacturer. The "P-bl start" and "P-bl stop" primers are phosphorylated at the 5' end to aid in the subsequent blunt end ligation of "Fragment Start" and "Fragment Stop" to each other. A 100 ul reaction contained 150 pmole of each primer and one ug of template DNA; and 1.times. Vent buffer (New England Biolabs), 300 uM dGTP, 300 uM DATP, 300 uM dTTP, 300 uM dCTP, and 1 unit Deep Vent polymerase. PCR reactions are performed in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, Conn.). PCR reaction products are purified using a Wizard PCR Preps kit (Promega).

The primers are designed to include appropriate restriction sites which allow for the cloning of the new gene into expression vectors. Typically "Fragment Start" is designed to create NcoI restriction site, and "Fragment Stop" is designed to create a HindIII restriction site. Restriction digest reactions are purified using a Magic DNA Clean-up System kit (Promega). Fragments Start and Stop are resolved on a 1% TAE gel, stained with ethidium bromide and isolated using a Qiaex Gel Extraction kit (Qiagen). These fragments are combined with and annealed to the ends of the .about.3800 base pair NcoI/HindIII vector fragment of pMON3934 by heating at 50.degree. C. for ten minutes and allowed to slow cool. The three fragments are ligated together using T4 DNA ligase (Boehringer Mannheim). The result is a plasmid containing the full-length new N-terminus/C-terminus gene. A portion of the ligation reaction is used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, Md.). Plasmid DNA is purified and sequence confirmed as below.

Method III. Creation of new N-terminus/C-terminus genes by tandem-duplication method

New N-terminus/C-terminus genes can be made based on the method described in R. A. Horlick, et al Protein Eng. 5: 427-431, 1992). Polymerase chain reaction (PCR) amplification of the new N-terminus/C-terminus genes is performed using a tandemly duplicated template DNA. The steps are illustrated in FIG. 3.

The tandemly-duplicated template DNA is created by cloning and contains two copies of the gene separated by DNA sequence encoding a linker connecting the original C- and N-terminal ends of the two copies of the gene. Specific primer sets are used to create and amplify a full-length new N terminus/C-terminus gene from the tandemly-duplicated template DNA. These primers are designed to include appropriate restriction sites which allow for the cloning of the new gene into expression vectors. Typical PCR conditions are one cycle 95.degree. C. melting for two minutes; 25 cycles 94.degree. C. denaturation for one minute, 50.degree. C. annealing for one minute and 72.degree. C. extension for one minute; plus one cycle 72.degree. C. extension for seven minutes. A Perkin Elmer GeneAmp PCR Core Reagents kit (Perkin Elmer Corporation, Norwalk, Conn.) is used. A 100 ul reaction contains 100 pmole of each primer and one ug of template DNA; and 1.times. PCR buffer, 200 uM dGTP, 200 uM DATP, 200 uM dTTP, 200 uM dCTP, 2.5 units AmpliTaq DNA polymerase and 2 mM MgCl.sub.2. PCR reactions are performed in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, Conn.). PCR reactions are purified using a Wizard PCR Preps kit (Promega).

Cloning of new N-terminus/C-terminus genes into multi-functional receptor agonist expression vectors

The new N-terminus/C-terminus gene is digested with restriction endonucleases to create ends that are compatible to insertion into an expression vector containing another colony stimulating factor gene. This expression vector is likewise digested with restriction endonucleases to form compatible ends. After purification, the gene and the vector DNAs are combined and ligated using T4 DNA ligase. A portion of the ligation reaction is used to transform E. coli. Plasmid DNA is purified and sequenced to confirm the correct insert. The correct clones are grown for protein expression.

DNA isolation and characterization

Plasmid DNA can be isolated by a number of different methods and using commercially available kits known to those skilled in the art. A few such methods are shown herein. Plasmid DNA is isolated using the Promega Wizard.TM. Miniprep kit (Madison, Wis.), the Qiagen QIAwell Plasmid isolation kits (Chatsworth, Calif.) or Qiagen Plasmid Midi kit. These kits follow the same general procedure for plasmid DNA isolation. Briefly, cells are pelleted by centrifugation (5000.times.g), plasmid DNA released with sequential NaOH/acid treatment, and cellular debris is removed by centrifugation (10000.times.g). The supernatant (containing the plasmid DNA) is loaded onto a column containing a DNA-binding resin, the column is washed, and plasmid DNA eluted with TE. After screening for the colonies with the plasmid of interest, the E. coli cells are inoculated into 50-100 mls of LB plus appropriate antibiotic for overnight growth at 37.degree. C. in an air incubator while shaking. The purified plasmid DNA is used for DNA sequencing, further restriction enzyme digestion, additional subcloning of DNA fragments and transfection into mammalian, E. coli or other cells.

Sequence confirmation

Purified plasmid DNA is resuspended in dH.sub.2 O and quantitated by measuring the absorbance at 260/280 nm in a Bausch and Lomb Spectronic 601 UV spectrometer. DNA samples are sequenced using ABI PRISM.TM. DyeDeoxy.TM. terminator sequencing chemistry (Applied Biosystems Division of Perkin Elmer Corporation, Lincoln City, Calif.) kits (Part Number 401388 or 402078) according to the manufacturers suggested protocol usually modified by the addition of 5% DMSO to the sequencing mixture. Sequencing reactions are performed in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, Conn.) following the recommended amplification conditions. Samples are purified to remove excess dye terminators with Centri-Sep.TM. spin columns (Princeton Separations, Adelphia, N.J.) and lyophilized. Fluorescent dye labeled sequencing reactions are resuspended in deionized formamide, and sequenced on denaturing 4.75% polyacrylamide-8M urea gels using an ABI Model 373A automated DNA sequencer. Overlapping DNA sequence fragments are analyzed and assembled into master DNA contigs using Sequencher v2.1 DNA analysis software (Gene Codes Corporation, Ann Arbor, Mich.).

Expression of multi-functional receptor agonists in mammalian cells Mammalian Cell Transfection/Production of Conditioned Media

The BHK-21 cell line can be obtained from the ATCC (Rockville, Md.). The cells are cultured in Dulbecco's modified Eagle media (DMEM/high-glucose), supplemented to 2 mM (mM) L-glutamine and 10% fetal bovine serum (FBS). This formulation is designated BHK growth media. Selective media is BHK growth media supplemented with 453 units/mL hygromycin B (Calbiochem, San Diego, Calif.). The BHK-21 cell line was previously stably transfected with the HSV transactivating protein VP16, which transactivates the IE110 promoter found on the plasmid pMON3359 (See Hippenmeyer et al., Bio/Technology, pp.1037-1041, 1993). The VP16 protein drives expression of genes inserted behind the IE110 promoter. BHK-21 cells expressing the transactivating protein VP16 are designated BHK-VP16. The plasmid pMON1118 (See Highkin et al., Poultry Sci., 70: 970-981, 1991) expresses the hygromycin resistance gene from the SV40 promoter. A similar plasmid is available from ATCC, pSV2-hph.

BHK-VP16 cells are seeded into a 60 millimeter (mm) tissue culture dish at 3.times.10.sup.5 cells per dish 24 hours prior to transfection. Cells are transfected for 16 hours in 3 mL of "OPTIMEM".TM. (Gibco-BRL, Gaithersburg, Md.) containing 10 ug of plasmid DNA containing the gene of interest, 3 ug hygromycin resistance plasmid, pMON1118, and 80 ug of Gibco-BRL "LIPOFECTAMINE".TM. per dish. The media is subsequently aspirated and replaced with 3 mL of growth media. At 48 hours post-transfection, media from each dish is collected and assayed for activity (transient conditioned media). The cells are removed from the dish by trypsin-EDTA, diluted 1:10 and transferred to 100 mm tissue culture dishes containing 10 mL of selective media. After approximately 7 days in selective media, resistant cells grow into colonies several millimeters in diameter. The colonies are removed from the dish with filter paper (cut to approximately the same size as the colonies and soaked in trypsin/EDTA) and transferred to individual wells of a 24 well plate containing 1 mL of selective media. After the clones are grown to confluence, the conditioned media is re-assayed, and positive clones are expanded into growth media.

Expression of multi-functional receptor agonists in E. coli

E. coli strain MON105 or JM101 harboring the plasmid of interest are grown at 37.degree. C. in M9 plus casamino acids medium with shaking in a air incubator Model G25 from New Brunswick Scientific (Edison, N.J.). Growth is monitored at OD600 until it reaches a value of 1.0 at which time Nalidixic acid (10 milligrams/mL) in 0.1 N NaOH is added to a final concentration of 50 .mu.g/mL. The cultures are then shaken at 37.degree. C. for three to four additional hours. A high degree of aeration is maintained throughout culture period in order to achieve maximal production of the desired gene product. The cells are examined under a light microscope for the presence of inclusion bodies (IB). One mL aliquots of the culture are removed for analysis of protein content by boiling the pelleted cells, treating them with reducing buffer and electrophoresis via SDS-PAGE (see Maniatis et al. Molecular Cloning: A Laboratory Manual, 1982). The culture is centrifuged (5000.times.g) to pellet the cells.

Inclusion Body preparation, Extraction, Refolding, Dialysis, DEAE Chromatography, and Characterization of the multi-functional hematopoietic receptor agonists which accumulate as inclusion bodies in E. coli Isolation of Inclusion Bodies

The cell pellet from a 330 mL E. coli culture is resuspended in 15 mL of sonication buffer (10 mM 2-amino-2-(hydroxymethyl) 1,3-propanediol hydrochloride (Tris-HCl), pH 8.0+1 mM ethylenediaminetetraacetic acid (EDTA). These resuspended cells are sonicated using the microtip probe of a Sonicator Cell Disruptor (Model W-375, Heat Systems-Ultrasonics, Inc., Farmingdale, N.Y.). Three rounds of sonication in sonication buffer followed by centrifugation are employed to disrupt the cells and wash the inclusion bodies (IB). The first round of sonication is a 3 minute burst followed by a 1 minute burst, and the final two rounds of sonication are for 1 minute each.

Extraction and refolding of proteins from inclusion body pellets

Following the final centrifugation step, the IB pellet is resuspended in 10 mL of 50 mM Tris-HCl, pH 9.5, 8 M urea and 5 mM dithiothreitol (DTT) and stirred at room temperature for approximately 45 minutes to allow for denaturation of the expressed protein.

The extraction solution is transferred to a beaker containing 70 mL of 5 mM Tris-HCl, pH 9.5 and 2.3 M urea and gently stirred while exposed to air at 4.degree. C. for 18 to 48 hours to allow the proteins to refold. Refolding is monitored by analysis on a Vydac (Hesperia, Calif.) C18 reversed phase high pressure liquid chromatography (RP-HPLC) column (0.46.times.25 cm). A linear gradient of 40% to 65% acetonitrile, containing 0.1% trifluoroacetic acid (TFA), is employed to monitor the refold. This gradient is developed over 30 minutes at a flow rate of 1.5 mL per minute. Denatured proteins generally elute later in the gradient than the refolded proteins.

Purification

Following the refold, contaminating E. coli proteins are removed by acid precipitation. The pH of the refold solution is titrated to between pH 5.0 and pH 5.2 using 15% (v/v) acetic acid (HOAc). This solution is stirred at 4.degree. C. for 2 hours and then centrifuged for 20 minutes at 12,000.times.g to pellet any insoluble protein.

The supernatant from the acid precipitation step is dialyzed using a Spectra/Por 3 membrane with a molecular weight cut off (MWCO) of 3,500 daltons. The dialysis is against 2 changes of 4 liters (a 50-fold excess) of 10 mM Tris-HCl, pH 8.0 for a total of 18 hours. Dialysis lowers the sample conductivity and removes urea prior to DEAE chromatography. The sample is then centrifuged (20 minutes at 12,000.times.g) to pellet any insoluble protein following dialysis.

A Bio-Rad Bio-Scale DEAE2 column (7.times.52 mm) is used for ion exchange chromatography. The column is equilibrated in a buffer containing 10 mM Tris-HCl, pH 8.0, and a 0-to-500 mM sodium chloride (NaCl) gradient, in equilibration buffer, over 45 column volumes is used to elute the protein. A flow rate of 1.0 mL per minute is used throughout the run. Column fractions (2.0 mL per fraction) are collected across the gradient and analyzed by RP HPLC on a Vydac (Hesperia, Calif.) C18 column (0.46.times.25 cm). A linear gradient of 40% to 65% acetonitrile, containing 0.1% trifluoroacetic acid (TFA), is employed. This gradient is developed over 30 minutes at a flow rate of 1.5 mL per minute. Pooled fractions are then dialyzed against 2 changes of 4 liters (50-to-500-fold excess) of 10 mM ammonium acetate (NH4Ac), pH 4.0 for a total of 18 hours. Dialysis is performed using a Spectra/Por 3 membrane with a MWCO of 3,500 daltons. Finally, the sample is sterile filtered using a 0.22 .mu.m syringe filter (.mu.Star LB syringe filter, Costar, Cambridge, Mass.), and stored at 4.degree. C.

In some cases the folded proteins can be affinity purified using affinity reagents such as mAbs or receptor subunits attached to a suitable matrix. Alternatively, (or in addition) purification can be accomplished using any of a variety of chromatographic methods such as: ion exchange, gel filtration or hydrophobic chromatography or reversed phase HPLC.

These and other protein purification methods are described in detail in Methods in Enzymology, Volume 182 `Guide to Protein Purification` edited by Murray Deutscher, Academic Press, San Diego, Calif. (1990).

Protein Characterization

The purified protein is analyzed by RP-HPLC, electrospray mass spectrometry, and SDS-PAGE. The protein quantitation is done by amino acid composition, RP-HPLC, and Bradford protein determination. In some cases tryptic peptide mapping is performed in conjunction with electrospray mass spectrometry to confirm the identity of the protein.

AML Proliferation Assay for Bioactive Human Interleukin-3

The factor-dependent cell line AML 193 was obtained from the American Type Culture Collection (ATCC, Rockville, Md.). This cell line, established from a patient with acute myelogenous leukemia, is a growth factor dependent cell line which displayed enhanced growth in GM-CSF supplemented medium (Lange, B., et al., Blood 70: 192, 1987; Valtieri, M., et al., J. Immunol. 138: 4042, 1987). The ability of AML 193 cells to proliferate in the presence of human IL-3 has also been documented. (Santoli, D., et al., J. Immunol. 139: 348, 1987). A cell line variant was used, AML 193 1.3, which was adapted for long term growth in IL-3 by washing out the growth factors and starving the cytokine dependent AML 193 cells for growth factors for 24 hours. The cells are then replated at 1.times.10.sup.5 cells/well in a 24 well plate in media containing 100 U/mL IL-3. It took approximately 2 months for the cells to grow rapidly in IL-3. These cells are maintained as AML 193 1.3 thereafter by supplementing tissue culture medium (see below) with human IL-3.

AML 193 1.3 cells are washed 6 times in cold Hanks balanced salt solution (HBSS, Gibco, Grand Island, N.Y.) by centrifuging cell suspensions at 250.times.g for 10 minutes followed by decantation of the supernatant. Pelleted cells are resuspended in HBSS and the procedure is repeated until six wash cycles are completed. Cells washed six times by this procedure are resuspended in tissue culture medium at a density ranging from 2.times.10.sup.5 to 5.times.10.sup.5 viable cells/mL. This medium is prepared by supplementing Iscove's modified Dulbecco's Medium (IMDM, Hazelton, Lenexa, Kans.) with albumin, transferrin, lipids and 2-mercaptoethanol. Bovine albumin (Boehringer-Mannheim, Indianapolis, Ind.) is added at 500 .mu.g/mL; human transferrin (Boehringer-Mannheim, Indianapolis, Ind.) is added at 100 .mu.g/mL; soybean lipid (Boehringer-Mannheim, Indianapolis, Ind.) is added at 50 .mu.g/mL; and 2-mercaptoethanol (Sigma, St. Louis, Mo.) is added at 5.times.10.sup.-5 M.

Serial dilutions of human interleukin-3 or multi-functional hematopoietic receptor agonist proteins are made in triplicate series in tissue culture medium supplemented as stated above in 96 well Costar 3596 tissue culture plates. Each well contained 50 .mu.l of medium containing interleukin-3 or multi-functional hematopoietic receptor agonist proteins once serial dilutions are completed. Control wells contained tissue culture medium alone (negative control). AML 193 1.3 cell suspensions prepared as above are added to each well by pipetting 50 .mu.l (2.5.times.10.sup.4 cells) into each well. Tissue culture plates are incubated at 37.degree. C. with 5% CO.sub.2 in humidified air for 3 days. On day 3, 0.5 .mu.Ci .sup.3 H-thymidine (2 Ci/mM, New England Nuclear, Boston, Mass.) is added in 50 .mu.l of tissue culture medium. Cultures are incubated at 37.degree. C. with 5% CO.sub.2 in humidified air for 18-24 hours. Cellular DNA is harvested onto glass filter mats (Pharmacia LKB, Gaithersburg, Md.) using a TOMTEC cell harvester (TOMTEC, Orange, Conn.) which utilized a water wash cycle followed by a 70% ethanol wash cycle. Filter mats are allowed to air dry and then placed into sample bags to which scintillation fluid (Scintiverse II, Fisher Scientific, St. Louis, Mo. or BetaPlate Scintillation Fluid, Pharmacia LKB, Gaithersburg, Md.) is added. Beta emissions of samples from individual tissue culture wells are counted in a LKB BetaPlate model 1205 scintillation counter (Pharmacia LKB, Gaithersburg, Md.) and data is expressed as counts per minute of .sup.3 H-thymidine incorporated into cells from each tissue culture well. Activity of each human interleukin-3 preparation or multi-functional hematopoietic receptor agonist protein preparation is quantitated by measuring cell proliferation (.sup.3 H-thymidine incorporation) induced by graded concentrations of interleukin-3 or multi-functional hematopoietic receptor agonist. Typically, concentration ranges from 0.05 pM-10.sup.5 pM are quantitated in these assays. Activity is determined by measuring the dose of interleukin-3 or multi-functional hematopoietic receptor agonist protein which provides 50% of maximal proliferation (EC.sub.50 =0.5.times.(maximum average counts per minute of .sup.3 H-thymidine incorporated per well among triplicate cultures of all concentrations of interleukin-3 tested--background proliferation measured by .sup.3 H-thymidine incorporation observed in triplicate cultures lacking interleukin-3). This EC.sub.50 value is also equivalent to 1 unit of bioactivity. Every assay is performed with native interleukin-3 as a reference standard so that relative activity levels could be assigned.

Typically, the multi-functional hematopoietic receptor agonist proteins were tested in a concentration range of 2000 pM to 0.06 pM titrated in serial 2 fold dilutions.

Activity for each sample was determined by the concentration which gave 50% of the maximal response by fitting a four-parameter logistic model to the data. It was observed that the upper plateau (maximal response) for the sample and the standard with which it was compared did not differ. Therefore relative potency calculation for each sample was determined from EC.sub.50 estimations for the sample and the standard as indicated above. AML 193.1.3 cells proliferate in response to hIL-3, hGM-CSF and hG-CSF. Therefore the following additional assays were performed for some samples to demonstrate that the G-CSF receptor agonist portion of the multi-functional hematopoietic receptor agonist proteins was active. The proliferation assay was performed with the multi-functional hematopoietic receptor agonist plus and minus neutralizing monoclonal antibodies to the hIL-3 receptor agonist portion. In addition, a fusion molecule with the factor Xa cleavage site was cleaved then purified and the halves of the molecule were assayed for proliferative activity. These experiments showed that both components of the multi-functional hematopoietic receptor agonist proteins were active.

TF1 c-mpl ligand dependent proliferation assay

The c-mpl ligand proliferative activity can be assayed using a subclone of the pluripotential human cell line TF1 (Kitamura et al., J. Cell Physiol 140: 323-334. [1989]). TF1 cells are maintained in h-IL3 (100 U/mL). To establish a sub-clone responsive to c-mpl ligand, cells are maintained in passage media containing 10% supernatant from BHK cells transfected with the gene expressing the 1-153 form of c-mpl ligand (pMON26448). Most of the cells die, but a subset of cells survive. After dilution cloning, a c-mpl ligand responsive clone is selected, and these cells are split into passage media to a density of 0.3.times.10.sup.6 cells/mL the day prior to assay set-up. Passage media for these cells is the following: RPMI 1640 (Gibco), 10% FBS (Harlan, Lot #91206), 10% c-mpl ligand supernatant from transfected BHK cells, 1 mM sodium pyruvate (Gibco), 2 mM glutamine (Gibco), and 100 ug/mL penicillin-streptomycin (Gibco). The next day, cells are harvested and washed twice in RPMI or IMDM media with a final wash in the ATL, or assay media. ATL medium consists of the following: IMDM (Gibco), 500 ug/mL of bovine serum albumin, 100 ug/mL of human transferrin, 50 ug/mL soybean lipids, 4.times.10-8M beta-mercaptoethanol and 2 mL of A9909 (Sigma, antibiotic solution) per 1000 mL of ATL. Cells are diluted in assay media to a final density of 0.25.times.10.sup.6 cells/mL in a 96-well low evaporation plate (Costar) to a final volume of 50 ul. Transient supernatants (conditioned media) from transfected clones are added at a volume of 50 ul as duplicate samples at a final concentration of 50% and diluted three-fold to a final dilution of 1.8%. Triplicate samples of a dose curve of IL-3 variant pMON13288 starting at 1 ng/mL and diluted using three-fold dilutions to 0.0014 ng/mL is included as a positive control. Plates are incubated at 5% CO.sub.2 and 37.degree. C. At day six of culture, the plate is pulsed with 0.5 Ci of 3H/well (NEN) in a volume of 20 ul/well and allowed to incubate at 5% CO.sub.2 and 37.degree. C. for four hours. The plate is harvested and counted on a Betaplate counter.

Other in vitro cell based proliferation assays

Other in vitro cell based assays, known to those skilled in the art, may also be useful to determine the activity of the multi-functional hematopoietic receptor agonists depending on the factors that comprise the molecule in a similar manner as described in the AML 193.1.3 cell proliferation assay. The following are examples of other useful assays.

TF1 proliferation assay: TF1 is a pluripotential human cell line (Kitamura et al., J. Cell Physiol 140: 323-334. [1989]) that responds to hIL-3.

32D proliferation assay: 32D is a murine IL-3 dependent cell line which does not respond to human IL-3 but does respond to human G-CSF which is not species restricted.

Baf/3 proliferation assay: Baf/3 is a murine IL-3 dependent cell line which does not respond to human IL-3 or human c-mpl ligand but does respond to human G-CSF which is not species restricted.

T1165 proliferation assay: T1165 cells are a IL-6 dependent murine cell line (Nordan et al., 1986) which respond to IL-6 and IL-11.

Human Plasma Clot meg-CSF Assay: Used to assay megakaryocyte colony formation activity (Mazur et al., 1981).

Transfected cell lines

Cell lines such as the murine Baf/3 cell line can be transfected with a colony stimulating factor receptor, such as the human G-CSF receptor or human c-mpl receptor, which the cell line does not have. These transfected cell lines can be used to determine the activity of the ligand for which the receptor has been transfected into the cell line.

One such transfected Baf/3 cell line was made by cloning the cDNA encoding c-mpl from a library made from a c-mpl responsive cell line and cloned into the multiple cloning site of the plasmid pcDNA3 (Invitrogen, San Diego Calif.). Baf/3 cells were transfected with the plasmid via electroporation. The cells were grown under G418 selection in the presence of mouse IL-3 in Wehi conditioned media. Clones were established through limited dilution.

In a similar manner the human G-CSF receptor can be transfected into the Baf/3 cell line and used to determine the bioactivity of the multi-functional hematopoietic receptor agoinsts.

Analysis of c-mpl ligand proliferative activity

Methods

1. Bone marrow proliferation assay

a. CD34+ Cell Purification

Bone marrow aspirates (15-20 mL) were obtained from normal allogeneic marrow donors after informed consent. Cells were diluted 1:3 in phosphate buffered saline (PBS, Gibco-BRL), 30 mL were layered over 15 mL Histopaque-1077 (Sigma) and centrifuged for 30 minutes at 300 RCF. The mononuclear interface layer was collected and washed in PBS. CD34+ cells were enriched from the mononuclear cell preparation using an affinity column per manufacturers instructions (CellPro, Inc, Bothell Wash.). After enrichment, the purity of CD34+ cells was 70% on average as determined by using flow cytometric analysis using anti-CD34 monoclonal antibody conjugated to fluorescein and anti-CD38 conjugated to phycoerythrin (Becton Dickinson, San Jose Calif.).

Cells were resuspended at 40,000 cells/mL in X-Vivo 10 media (Bio-Whittaker, Walkersville, Md.) and 1 mL was plated in 12-well tissue culture plates (Costar). The growth factor rhIL-3 was added at 100 ng/mL (pMON5873) was added to some wells. hIL3 variants were used at 10 ng/mL to 100 ng/mL. Conditioned media from BHK cells transfected with plasmid encoding c-mpl ligand or multi-functional hematopoietic receptor agonists were tested by addition of 100 .mu.l of supernatant added to 1 mL cultures (approximately a 10% dilution). Cells were incubated at 37.degree. C. for 8-14 days at 5% CO.sub.2 in a 37.degree. C. humidified incubator.

b. Cell Harvest and Analysis

At the end of the culture period a total cell count was obtained for each condition. For fluorescence analysis and ploidy determination cells were washed in megakaryocyte buffer (MK buffer, 13.6 mM sodium citrate, 1 mM theophylline, 2.2 .mu.m PGE1, 11 mM glucose, 3% w/v BSA, in PBS, pH 7.4,) (Tomer et al., Blood 70: 1735-1742, 1987) resuspended in 500 .mu.l of MK buffer containing anti-CD41a FITC antibody (1:200, AMAC, Westbrook, Me.) and washed in MK buffer. For DNA analysis cells were permeablized in MK buffer containing 0.5% Tween 20 (Fisher, Fair Lawn N.J.) for 20 min. on ice followed by fixation in 0.5% Tween-20 and 1% paraformaldehyde (Fisher Chemical) for 30 minutes followed by incubation in propidium iodide (Calbiochem , La Jolla Calif.) (50 .mu.g/mL) with RNA-ase (400 U/mL) in 55% v/v MK buffer (200 mOsm) for 1-2 hours on ice. Cells were analyzed on a FACScan or Vantage flow cytometer (Becton Dickinson, San Jose, Calif.). Green fluorescence (CD41a-FITC) was collected along with linear and log signals for red fluorescence (PI) to determine DNA ploidy. All cells were collected to determine the percent of cells that were CD41+. Data analysis was performed using software by LYSIS (Becton Dickinson, San Jose, Calif.). Percent of cells expressing the CD41 antigen was obtained from flow cytometry analysis (Percent). Absolute (Abs) number of CD41+ cells/mL was calculated by: (Abs)=(Cell Count)*(Percent)/100.

2. Megakaryocyte fibrin clot assay

CD34+ enriched population were isolated as described above. Cells were suspended at 25,000 cells/mL with or without cytokine(s) in a media consisting of a base Iscoves IMDM media supplemented with 0.3% BSA, 0.4 mg/mL apo-transferrin, 6.67 .mu.M FeCl.sub.2, 25 .mu.g/mL CaCl.sub.2, 25 .mu.g/mL L-asparagine, 500 .mu.g/mL .epsilon.-amino-n-caproic acid and penicillin/streptomycin. Prior to plating into 35 mm plates, thrombin was added (0.25 Units/mL) to initiate clot formation. Cells were incubated at 37.degree. C. for 13 days at 5% CO.sub.2 in a 37.degree. C. humidified incubator.

At the end of the culture period plates were fixed with methanol:acetone (1:3), air dried and stored at -200.degree. C. until staining. A peroxidase immunocytochemistry staining procedure was used (Zymed, Histostain-SP. San Francisco, Calif.) using a cocktail of primary monoclonal antibodies consisting of anti-CD41a, CD42 and CD61. Colonies were counted after staining and classified as negative, CFU-MK (small colonies, 1-2 foci and less that approx. 25 cells), BFU-MK (large, multi-foci colonies with >25 cells) or mixed colonies (mixture of both positive and negative cells.

Methylcellulose Assay

This assay reflects the ability of colony stimulating factors to stimulate normal bone marrow cells to produce different types of hematopoietic colonies in vitro (Bradley et al., Aust. Exp Biol. Sci. 44: 287-300, 1966), Pluznik et al., J. Cell Comp. Physio 66: 319-324, 1965).

Methods

Approximately 30 mL of fresh, normal, healthy bone marrow aspirate are obtained from individuals following informed consent. Under sterile conditions samples are diluted 1:5 with a 1.times. PBS (#14040.059 Life Technologies, Gaithersburg, Md.) solution in a 50 mL conical tube (#25339-50 Corning, Corning Md.). Ficoll (Histopaque 1077 Sigma H-8889) is layered under the diluted sample and centrifuged, 300.times.g for 30 min. The mononuclear cell band is removed and washed two times in 1.times. PBS and once with 1% BSA PBS (CellPro Co., Bothel, Wash.). Mononuclear cells are counted and CD34+ cells are selected using the Ceprate LC (CD34) Kit (CellPro Co., Bothel, Wash.) column. This fractionation is performed since all stem and progenitor cells within the bone marrow display CD34 surface antigen.

Cultures are set up in triplicate with a final volume of 1.0 mL in a 35.times.10 mm petri dish (Nunc#174926). Culture medium is purchased from Terry Fox Labs. (HCC-4230 medium (Terry Fox Labs, Vancouver, B.C., Canada) and erythropoietin (Amgen, Thousand Oaks, Calif.) is added to the culture media. 3,000-10,000 CD34+ cells are added per dish. Recombinant IL-3, purified from mammalian cells or E. coli, and multi-functional hematopoietic receptor agonist proteins, in conditioned media from transfected mammalian cells or purified from conditioned media from transfected mammalian cells or E. coli, are added to give final concentrations ranging from 0.001 nM to 10 nM. Recombinant hIL-3, GM-CSF, c-mpl ligand and multi-functional hematopoietic receptor agonist are supplied in house. G-CSF (Neupogen) is from Amgen (Thousand Oaks Calf.). Cultures are resuspended using a 3 cc syringe and 1.0 mL is dispensed per dish. Control (baseline response) cultures received no colony stimulating factors. Positive control cultures received conditioned media (PHA stimulated human cells: Terry Fox Lab. H2400). Cultures are incubated at 37.degree. C., 5% CO.sub.2 in humidified air. Hematopoietic colonies which are defined as greater than 50 cells are counted on the day of peak response (days 10-11) using a Nikon inverted phase microscope with a 40.times. objective combination. Groups of cells containing fewer than 50 cells are referred to as clusters. Alternatively colonies can be identified by spreading the colonies on a slide and stained or they can be picked, resuspended and spun onto cytospin slides for staining.

Human Cord Blood Hemopoietic Growth Factor Assays

Bone marrow cells are traditionally used for in vitro assays of hematopoietic colony stimulating factor (CSF) activity. However, human bone marrow is not always available, and there is considerable variability between donors. Umbilical cord blood is comparable to bone marrow as a source of hematopoietic stem cells and progenitors (Broxmeyer et al., PNAS USA 89: 4109-113, 1992; Mayani et al., Blood 81: 3252-3258, 1993). In contrast to bone marrow, cord blood is more readily available on a regular basis. There is also a potential to reduce assay variability by pooling cells obtained fresh from several donors, or to create a bank of cryopreserved cells for this purpose. By modifying the culture conditions, and/or analyzing for lineage specific markers, it is be possible to assay specifically for granulocyte/macrophage colonies (CFU-GM), for megakaryocyte CSF activity, or for high proliferative potential colony forming cell (HPP-CFC) activity.

Methods

Mononuclear cells (MNC) are isolated from cord blood within 24 hr. of collection, using a standard density gradient (1.077 g/mL Histopaque). Cord blood MNC have been further enriched for stem cells and progenitors by several procedures, including immunomagnetic selection for CD14-, CD34+ cells; panning for SBA-, CD34+ fraction using coated flasks from Applied Immune Science (Santa Clara, Calif.); and CD34+ selection using a CellPro (Bothell, Wash.) avidin column. Either freshly isolated or cryopreserved CD34+ cell enriched fractions are used for the assay. Duplicate cultures for each serial dilution of sample (concentration range from 1 pM to 1204 pM) are #prepared with 1.times.104 cells in 1 ml of 0.9% methycellulose containing medium without additional growth factors (Methocult H4230 from Stem Cell Technologies, Vancouver, BC.). In some experiments, Methocult H4330 containing erythropoietin (EPO) was used instead of Methocult H4230, or Stem Cell Factor (SCF), 50 ng/mL (Biosource International, Camarillo, Calif.) was added. After culturing for 7-9 days, colonies containing >30 cells are counted. In order to rule out subjective bias in scoring, assays are scored blind.

Additional details about recombinant DNA methods which may be used to create the variants, express them in bacteria, mammalian cells or insect cells, purification and refold of the desired proteins and assays for determining the bioactivity of the proteins may be found in co-filed Applications WO 95/00646, WO 94/12639, WO 94/12638, WO 95/20976, WO 95/21197, WO 95/20977, WO 95/21254 and US 08/383,035 which are hereby incorporated by reference in their entirety.

Further details known to those skilled in the art may be found in T. Maniatis, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, 1982) and references cited therein, incorporated herein by reference; and in J. Sambrook, et al., Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory, 1989) and references cited therein, incorporated herein by reference.

TABLE 1__________________________________________________________________________OLIGONUCLEOTIDES__________________________________________________________________________c-mplNcoI ACGTCCATGGCNTCNCCNGCNCCNCCTGCTTGTGCACTCCGAGTC (SEQ ID NO:13)N = A, C, G or TEcompl ATGCACGAATTCCCTGACGCAGAGGGTGGA (SEQ ID NO:14)c-mplHindIII TGACAAGCTTACCTGACGCAGAGGGTGGACCCT (SEQ ID NO:15)4L-5' AATTCGGCAA (SEQ ID NO:16)4L-3' CATGTTGCCG (SEQ ID NO:17)5L-5' AATTCGGCGGCAA (SEQ ID NO:18)5L-3' CATGTTGCCGCCG (SEQ ID NO:19)8L-5' AATTCGGCGGCAACGGCGGCAA (SEQ ID NO:20)8L-3' CATGTTGCCGCCGTTGCCGCCG (SEQ TDNO:21)31-5' CGATCCATGGAGGTTCACCCTTTGCCT (SEQ ID NO:22)31-3' GATCAAGCTTATGGGCACTGGCTCAGTCT (SEQ ID NO:23)35-5' CGATACATGTTGCCTACACCTGTCCTG (SEQ ID NO:24)35-3' GATCAAGCTTAAGGGTGAACCTCTGGGCA (SEQ ID NO:25)39-5' CGATCCATGGTCCTGCTGCCTGCTGTG (SEQ ID NO:26)39-3' GATCAAGCTTAAGGTGTAGGCAAAGGGTG (SEQ ID NO:27)43-5' CGATCCATGGCTGTGGACTTTAGCTTGGGA (SEQ ID NO:28)43-3' GATCAAGCTTAAGGCAGCAGGACAGGTGT (SEQ ID NO:29)45-5' CGATCCATGGACTTTAGCTTGGGAGAA (SEQ ID NO:30)45-3' GATCAAGCTTACACAGCAGGCAGCAGGAC (SEQ ID NO:31)49-5' CGATCCATGGGAGAATGGAAAACCCAG (SEQ ID NO:32)49-3' GATCAAGCTTACAAGCTAAAGTCCACAGC (SEQ ID NO:33)82-5' CGATCCATGGGACCCACTTGCCTCTCA (SEQ ID NO:34)82-3' GATCAAGCTTACAGTTGTCCCCGTGCTGC (SEQ ID NO:35)109-5' CAGTCCATGGGAACCCAGCTTCCTCCA (SEQ ID NO: 36)109-3' GATCAAGCTTAAAGGAGGCTCTGCAGGGC (SEQ ID NO:37)116-5' CGATCCATGGGCAGGACCACAGCTCAC (SEQ ID NO:38)116-3' GATCAAGCTTACTGTGGAGGAAGCTGGGTT (SEQ ID NO: 39)120-5' CGATCCATGGCTCACAAGGATCCCAATGCC (SEQ ID NO:40)120-3' GATCAAGCTTATGTGGTCCTGCCCTGTGG (SEQ ID NO:41)123-5' CGATCCATGGATCCCAATGCCATCTTCCTG (SEQ ID NO:42)123-3' GATCAAGCTTACTTGTGAGCTGTGGTCCT (SEQ ID NO:43)126-5' CGATCCATGGCCATCTTCCTGAGCTTCCAA (SEQ ID NO:44)126-3' GATCAAGCTTAATTGGGATCCTTGTGAGCTGT (SEQ ID NO:45)SYNNOXA1.REQ AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC TCC (SEQ ID NO:46)SYNNOXA2.REQ CCGGGGAGCC TCCACCGCCC TCTACGTACT GTTGAGCCTG CGCGTTCTCC AAGGTTTTCA GATAGAAGGT CAGTTTACGA CGG (SEQ ID NO:47)L1syn.for GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTAACTGCTC TATAATGAT (SEQ ID NO:48)L1syn.rev CGATCATTAT AGAGCAGTTA GAGCCACCAC CCTGTTGTTC CTGCGCTTGC TCAAGG (SEQ ID NO:49)L3syn.for GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTGGCGGTGG CAGCGGCGGC GGTTCTAACT GCTCTATAAT GAT (SEQ ID NO:50)L3syn.rev CGATCATTAT AGAGCAGTTA GAACCGCCGC CGCTGCCACC GCCAGAGCCA CCACCCTGTT GTTCCTGCGC TTGCTCAAGG (SEQ ID NO:51)35start.seq GATCGACCAT GGCTCTGGAC CCGAACAACC TC (SEQ ID NO:52)34rev.seq CTCGATTACG TACAAAGGTG CAGGTGGT (SEQ ID NO:53)70start.seq GATCGACCAT GGCTAATGCA TCAGGTATTG AG (SEQ ID NO:54)69rev.seq CTCGATTACG TATTCTAAGT TCTTGACA (SEQ ID NO:55)91start.seq GATCGACCAT GGCTGCACCC TCTCGACATC CA (SEQ ID NO:56)90rev.seq CTCGATTACG TAGGCCGTGG CAGAGGGC (SEQ ID NO:57)101start.seq GATCGACCAT GGCTGCAGGT GACTGGCAAG AA (SEQ ID NO:58)100rev.seq CTCGATTACG TACTTGATGA TGATTGGA (SEQ ID NO:59)L-11start.seq GCTCTGAGAG CCGCCAGAGC CGCCAGAGGG CTGCGCAAGG TGGCGTAGAA CGCG (SEQ ID NO:60)L-11stop.seq CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAG (SEQ ID NO:61)P-b1start.seq GGGCTGCGCA AGGTGGCG (SEQ ID NO:62)P-b1stop.seq ACACCATTGG GCCCTGCCAG C (SEQ ID NO:63)39start.seq GATCGACCAT GGCTTACAAG CTGTGCCACC CC (SEQ ID NO:64)38stop.Seq CGATCGAAGC TTATTAGGTG GCACACAGCT TCTCCT (SEQ ID NO:65)97start.seq GATCGACCAT GGCTCCCGAG TTGGGTCCCA CC (SEQ ID NO:66)96stop.Seq CGATCGAAGC TTATTAGGAT ATCCCTTCCA GGGCCT (SEQ ID NO:67)126start.seq GATCGACCAT GGCTATGGCC CCTGCCCTGC AG (SEQ ID NO:68)125stop.Seq CGATCGAAGC TTATTATCCC AGTTCTTCCA TCTGCT (SEQ ID NO:69)133start.seq GATCGACCAT GGCTACCCAG GGTGCCATGC CG (SEQ ID NO:70)132stop.seq CGATCGAAGC TTATTAGGGC TGCAGGGCAG GGGCCA (SEQ ID NO:71)142start.seq GATCGACCAT GGCTTCTGCT TTCCAGCGCC GG (SEQ ID NO:72)141stop.Seq CGATCGAAGC TTATTAGGCG AAGGCCGGCA TGGCAC (SEQ ID NO:73)GLYXA1 GTAGAGGGCG GTGGAGGCTC C (SEQ ID NO:74)GLYXA2 CCGGGGAGCC TCCACCGCCC TCTAC (SEQ ID NO:75)1GGGSfor TTCTACGCCA CCTTGCGCAG CCCGGCGGCG GCTCTGACAT GTCTACACCA TTG (SEQ ID NO:76)1GGGSrev CAATGGTGTA GACATGTCAG AGCCGCCGCC GGGCTGCGCA AGGTGGCGTA GAA (SEQ ID NO:77)Synnoxa1.req AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC TCC (SEQ ID NO:240)Synnoxa2.req CCGGGGAGCC TCCACCGCCC TCTACGTACT GTTGAGCCTG CGCGTTCTCC AAGGTTTTCA GATAGAAGGT CAGTTTACGA CGG (SEQ ID NO:241)__________________________________________________________________________ TABLE 2__________________________________________________________________________GENE SEQUENCES__________________________________________________________________________pMON30304GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGT (SEQ ID NO:78)pMON26458TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTC(SEQ ID NO:79)pMON28548TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG(SEQ ID NO:80)pMON28500TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG(SEQ ID NO:81)pMON28501TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG (SEQ ID NO:82)pMON28502TCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG (SEQ ID NO:83)Syntan11 CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA51 GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC101 TCTATCCTGA TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT151 AAGGGCTGTC AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC201 GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC CTCTCGACAT251 CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AAAAACTGAC301 GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT351 CTAACTGCTC TATAATGATC GATGAAATTA TACATCACTT AAAGAGACCA401 CCTGCACCTT TGCTGGACCC GAACAACCTC AATGACGAAG ACGTCTCTAT451 CCTGATGGAC CGAAACCTTC GACTTCCAAA CCTGGAGAGC TTCGTAAGGG501 CTGTCAAGAA CTTAGAAAAT GCATCAGGTA TTGAGGCAAT TCTTCGTAAT551 CTCCAACCAT GTCTGCCCTC TGCCACGGCC GCACCCTCTC GACATCCAAT601 CATCATCAAG GCAGGTGACT GGCAAGAATT CCGGGAAAAA CTGACGTTCT651 ATCTGGTTAC CCTTGAGCAA GCGCAGGAAC AACAGTAC (SEQ ID NO:84)Syntan31 CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA51 GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC101 TCTATCCTGA TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT151 AAGGGCTGTC AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC201 GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC CTCTCGACAT251 CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AAAAACTGAC301 GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT351 CTGGCGGTGG CAGCGGCGGC GGTTCTAACT GCTCTATAAT GATCGATGAA401 ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA451 CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC501 CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA551 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC601 GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG651 AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG701 GAACAACAGT AC (SEQ ID NO:85)pMON311041 ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT51 GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA101 AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA151 CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT201 CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG251 TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TAACTGCTCT301 ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTT351 GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT401 CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC451 ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG501 GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT551 CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC601 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG651 CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC701 ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT751 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG801 CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG851 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC901 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT951 GGCCCCTGCC CTGCAGCCCT AATAA (SEQ ID NO:86)pMON311051 ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG51 TCTGCCCTCT GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG101 CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTA TCTGGTTACC151 CTTGAGCAAG CGCAGGAACA ACAGGGTGGT GGCTCTAACT GCTCTATAAT201 GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG251 ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC301 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA351 ATACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT401 CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC451 ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG501 GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT551 CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC601 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG651 CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC701 ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT751 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG801 CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG851 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC901 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT951 GGCCCCTGCC CTGCAGCCCT AATAA (SEQ ID NO:87)pMON311061 ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA51 AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC101 AGGAACAACA GGGTGGTGGC TCTAACTGCT CTATAATGAT CGATGAAATT151 ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT201 CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA251 ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT301 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC351 CTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT401 CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC451 ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG501 GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT551 CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC601 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG651 CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC701 ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT751 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG801 CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG851 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC901 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT951 GGCCCCTGCC CTGCAGCCCT AATAA (SEQ ID NO:88)pMON311071 ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT51 GGTTACCCTT GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTAACTGCT101 CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT151 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA201 CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA251 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA301 TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA351 GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT401 CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC451 ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG501 GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT551 CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC601 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG651 CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC701 ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT751 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG801 CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG851 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC901 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT951 GGCCCCTGCC CTGCAGCCCT AATAA (SEQ ID NO:89)pMON311081 ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT51 GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA101 AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA151 CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT201 CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG251 TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TGGCGGTGGC301 AGCGGCGGCG GTTCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA351 CTTAAAGAGA CCACCTGCAC CTTTGTACGT AGAGGGCGGT GGAGGCTCCC401 CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT451 AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC501 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC551 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG601 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT651 AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC701 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA751 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC801 CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT851 ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC901 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG951 GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA (SEQ ID NO:90)pMON311091 ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG51 TCTGCCCTCT GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG101 CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTA TCTGGTTACC151 CTTGAGCAAG CGCAGGAACA ACAGGGTGGT GGCTCTGGCG GTGGCAGCGG201 CGGCGGTTCT AACTGCTCTA TAATGATCGA TGAAATTATA CATCACTTAA251 AGAGACCACC TGCACCTTTG CTGGACCCGA ACAACCTCAA TGACGAAGAC301 GTCTCTATCC TGATGGACCG AAACCTTCGA CTTCCAAACC TGGAGAGCTT351 CGTAAGGGCT GTCAAGAACT TAGAATACGT AGAGGGCGGT GGAGGCTCCC401 CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT451 AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC501 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC551 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG601 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT651 AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC701 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA751 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC801 CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT851 ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC901 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG951 GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA (SEQ ID NO:91)pMON311101 ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA51 AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC101 AGGAACAACA GGGTGGTGGC TCTGGCGGTG GCAGCGGCGG CGGTTCTAAC151 TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGC201 ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA251 TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT AAGGGCTGTC301 AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC GTAATCTCCA351 ACCATGTCTG CCCTCTGCCA CGGCCTACGT AGAGGGCGGT GGAGGCTCCC401 CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT451 AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC501 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC551 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG601 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT651 AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC701 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA751 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC801 CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT851 ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC901 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG951 GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA (SEQ ID NO:92)pMON311111 ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT51 GGTTACCCTT GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTGGCGGTG101 GCAGCGGCGG CGGTTCTAAC TGCTCTATAA TGATCGATGA AATTATACAT151 CACTTAAAGA GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA201 CGAAGACGTC TCTATCCTGA TGGACCGAAA CCTTCGACTT CCAAACCTGG251 AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCATC AGGTATTGAG301 GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC351 CTCTCGACAT CCAATCATCA TCAAGTACGT AGAGGGCGGT GGAGGCTCCC401 CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT451 AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC501 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC551 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG601 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT651 AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC701 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA751 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC801 CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT851 ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC901 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG951 GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA (SEQ ID NO:93)pMON131821 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT401 ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC451 ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC501 AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC551 TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA601 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA651 AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG701 CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC751 CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC801 GCAGCCCTCT GGCGGCTCTG GCGGCTCTCA GAGCTTCCTG CTCAAGTCTT851 TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG901 CTGTGTGCCA CCTAATAA (SEQ ID NO:94)pMON131831 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTACAAG451 CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC501 CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT551 GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG601 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA651 GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC701 TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC751 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT801 GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC851 CCTCTGGCGG CTCTGGCGGC TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG901 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG951 TGCCACCTAA TAA (SEQ ID NO:95)pMON131841 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC401 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT451 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT501 GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC551 GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG601 TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG GCTCTGGCGG651 CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA AAGATCCAGG701 GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CAAGCTGTGC751 CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC801 TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA851 GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG901 GAAGGGATAT CCTAATAA (SEQ ID NO:96)pMON131851 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCCCGAG451 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC501 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC551 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA601 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA651 CCGCGTTCTA CGCCACCTTG CGCAGCCCTC TGGCGGCTCT GGCGGCTCTC701 AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT751 GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC801 CGAGGAGCTG GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC851 TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA901 CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG951 GATATCCTAA TAA (SEQ ID NO:97)pMON131861 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA401 TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTCT451 GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG501 CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCTCTG551 GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG601 AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC651 CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG701 GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG751 GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCT801 CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA851 CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG901 GAAGAACTGG GATAATAA (SEQ ID NO:98)pMON131871 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTATGGCC451 CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT501 CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC551 TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CTCTGGCGGC601 TCTGGCGGCT CTCAGAGCTT CCTGCTCAAG TCTTTAGAGC AAGTGAGAAA651 GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT GCCACCTACA701 AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATC751 CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG801 CTGCTTGAGC CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC851 AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTT GGACACACTG901 CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA951 ACTGGGATAA TAA (SEQ ID NO:99)pMON131881 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA401 CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA451 GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG501 CGTTCTACGC CACCTTGCGC AGCCCTCTGG CGGCTCTGGC GGCTCTCAGA551 GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GAAAGATCCA GGGCGATGGC601 GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA651 GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA701 GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC751 CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT801 ATCCCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG851 ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT901 GCCCTGCAGC CCTAATAA (SEQ ID NO:100)pMON131891 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC551 TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC601 CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC651 GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC701 TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC751 TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG801 CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC851 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT901 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT951 GCAGCCCTAA TAA (SEQ ID NO:101)pMON131901 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT401 CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG451 AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTC501 TGGCGGCTCT GGCGGCTCTC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG551 TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC601 ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT651 GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC701 TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CTACCAGGGG751 CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CCACCTTGGA801 CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCATC TGGCAGCAGA851 TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG901 CCGGCCTTCG CCTAATAA (SEQ ID NO:102)pMON131911 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTCTGCT451 TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT501 CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG551 GCTCTGGCGG CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA601 AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA651 CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA701 TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA751 GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT801 GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GGGTCCCACC TTGGACACAC851 TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GCAGATGGAA901 GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC951 CTTCGCCTAA TAA (SEQ ID NO:103)pMON131921 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT401 ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC451 ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC501 AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC551 TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA601 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA651 AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG701 CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC751 CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC801 GCAGCCCACA CCATTGGGCC CTGCCAGCTC CCTGCCCCAG AGCTTCCTGC851 TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC901 CAGGAGAAGC TGTGTGCCAC CTAATAA (SEQ ID NO:104)pMON131931 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTACAAG451 CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC501 CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT551 GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG601 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA651 GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC701 TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC751 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT801 GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC851 CCACACCATT GGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG901 TCTTTAGAGC AAGTGAGAAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA951 GAAGCTGTGT GCCACCTAAT AA (SEQ ID NO:105)pMON251901 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC401 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT451 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT501 GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC551 GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG601 TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCACACCAT TGGGCCCTGC651 CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA701 AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC751 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT801 CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG851 GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG901 CAGGCCCTGG AAGGGATATC CTAATAA (SEQ ID NO:106)pMON251911 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCCCGAG451 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC501 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC551 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA601 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA651 CCGCGTTCTA CGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT701 CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GAGAAAGATC751 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT801 GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT851 GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC901 TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGCTCCTGCAGGC951 CCTGGAAGGG ATATCCTAAT AA (SEQ ID NO:107)pMON131941 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA401 TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTCT451 GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG501 CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCACAC551 CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA601 GAGCAAGTGA GAAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT651 GTGTGCCACC TAqAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC701 ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC751 CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA801 CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA851 CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG901 CAGCAGATGG AAGAACTGGG ATAATAA (SEQ ID NO:108)pMON131951 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTATGGCC451 CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT501 CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC551 TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CACACCATTG601 GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA651 AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG701 CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT751 CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA801 GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG851 GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTTG901 GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA951 GATGGAAGAA CTGGGATAAT AA (SEQ ID NO:109)pMON131961 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA401 CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA451 GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG501 CGTTCTACGC CACCTTGCGC AGCCCACACC ATTGGGCCCT GCCAGCTCCC551 TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG AAAGATCCAG601 GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG651 CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG701 CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG751 AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT801 GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA CTGCAGCTGG851 ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA901 ATGGCCCCTG CCCTGCAGCC CTAATAA (SEQ ID NO:110)pMON131971 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC551 TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC601 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA651 TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC701 CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC751 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA801 ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG851 GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC901 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC951 CCCTGCCCTG CAGCCCTAAT AA (SEQ ID NO:111)pMON131981 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT401 CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG451 AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCAC501 ACCATTGGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT551 TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG601 CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG651 ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG701 CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC751 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC801 CACCTTGGAC ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT851 GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCACCCAG901 GGTGCCATGC CGGCCTTCGC CTAATAA (SEQ ID NO:112)pMON131991 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTCTGCT451 TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT501 CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCACACCAT551 TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG601 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG651 TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT701 CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG751 CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA801 GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT851 TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG901 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC951 CATGCCGGCC TTCGCCTAAT AA (SEQ ID NO:113)pMON311121 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA51 GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG101 ATATCCTAAT GGACAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC151 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA201 AAATCTCCTG CCATGTCTGC CGCTAGCCAC GGCCGCACCC ACGCGACATC251 CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC301 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC551 TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC601 CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC651 GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC701 TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC751 TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG801 CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC851 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT901 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT951 GCAGCCCTAA TAA (SEQ ID NO:114)pMON311131 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA51 GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG101 ATATCCTGAT GGAAAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC151 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA201 AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC ACGCGACATC251 CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC301 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC551 TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC601 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA651 TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC701 CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC751 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA801 ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG851 GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC901 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC951 CCCTGCCCTG CAGCCCTAAT AA (SEQ ID NO:115)pMON311141 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA51 GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG101 ATATCCTGAT GGAAAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC151 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA201 AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC ACGCGACATC251 CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC301 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC551 TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC601 CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC651 GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC701 TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC751 TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG801 CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC851 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT901 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT951 GCAGCCCTAA TAA (SEQ ID NO:116)pMON311151 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA51 GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG101 ATATCCTAAT GGACAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC151 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA201 AAATCTCCTG CCATGTCTGC CGCTAGCCAC GGCCGCACCC ACGCGACATC251 CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC301 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC551 TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC601 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA651 TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC701 CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC751 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA801 ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG851 GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC901 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC951 CCCTGCCCTG CAGCCCTAAT AA (SEQ ID NO:117)pMON28505GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCA (SEQ ID NO:118)pMON28506GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCT (SEQ ID NO:119)pMON28507GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCT (SEQ ID NO:120)pMON28508GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT (SEQ ID NO:121)pMON28509GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTG (SEQ ID NO:122)pMON28510GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAACTCCAAACATGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGACCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGTTG (SEQ ID NO:123)pMON28511GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG (SEQ ID NO:124)pMON28512GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT (SEQ ID NO:125)pMON28513GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAG (SEQ ID NO:126)pMON28514GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACA (SEQ ID NO:127)pMON28515GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAG (SEQ ID NO:128)pMON28516GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT (SEQ ID NO:129)pMON28519GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCA (SEQ ID NO:130)pMON28520GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCT (SEQ ID NO:131)pMON28521GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCT (SEQ ID NO:132)pMON28522GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT (SEQ ID NO:133)pMON28523GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTG (SEQ ID NO:134)pMON28524GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTG (SEQ ID NO:135)pMON28525GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG (SEQ ID NO:136)pMON28526GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT (SEQ ID NO:137)pMON28527GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAG (SEQ ID NO:138)pMON28528GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACA (SEQ ID NO:139)pMON28529GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAG (SEQ ID NO:140)pMON28530GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT (SEQ ID NO:141)pMON28533GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGCATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGTAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCA (SEQ ID NO:142)pMON28534GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCT (SEQ IDNO:143)pMON28535GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCT (SEQ IDNO:144)pMON28536GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT(SEQ ID NO:145)pMON28537GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTG(SEQ ID NO:146)pMON28538GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTG(SEQ ID NO:147)pMON28539GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG(SEQ ID NO:148)pMON28540GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT(SEQ ID NO:149)pMON28541GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGqAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAG(SEQ ID NO:150)pMON28542GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACA(SEQ ID NO:151)pMON28543GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAG(SEQ ID NO:152)pMON28544GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT(SEQ ID NO:153)pMON28545GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGGGCAGGACCACAGCTCACAAG (SEQ ID NO:154)pMON159811 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTTACAAG451 CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC501 CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT551 GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG601 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA651 GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC701 TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC751 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT801 GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC851 CCGGCGGCGG CTCTGACATG GCTACACCAT TAGGCCCTGC CAGCTCCCTG901 CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGGA AGATCCAGGG951 CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAA TAA; (SEQ ID NO:155)pMON159821 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTCCCGAG451 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC501 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC551 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA601 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA651 CCGCGTTCTA CGCCACCTTG CGCAGCCCqG CGGCGGCTCT GACATGGCTA701 CACCATTAGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT751 TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA801 GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG851 GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG901 GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT951 CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCTAA TAA; (SEQ ID NO:156)pMON159651 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTTCTGCT451 TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT501 CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCGGCGGCG551 GCTCTGACAT GGCTACACCA TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC601 TTCCTGCTCA AGTCTTTAGA GCAAGTGAGG AAGATCCAGG GCGATGGCGC651 AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG701 AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC751 TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA801 TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT851 CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CGTCGCCGAC901 TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC951 CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTAA TAA (SEQ ID NO:157)pMON159661 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTATGGCC451 CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT501 CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC551 TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CGGCGGCGGC601 TCTGACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT651 CCTGCTCAAG TCTTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG701 CGCTCCAGGA GAAGCTGTGT GCCACCTACA AGCTGTGCCA CCCCGAGGAG751 CTGGTGCTGC TCGGACACTC TCTGGGCATC CCCTGGGCTC CCCTGAGCTC801 CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA851 GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AGGGATATCC901 CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT951 TGCCACCACC ATCTGGCAGC AGATGGAAGA ACTGGGATAA TAA (SEQ ID NO:158)pMON159671 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTACCCAG451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC551 TACGCCACCT TGCGCAGCCC GGCGGCGGCT CTGACATGGC TACACCATTA601 GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA651 AGTGAGGAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG701 CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT751 CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA801 GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG851 GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTTG901 GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA951 GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCTAA TAA (SEQ ID NO:159)pMON159601 ATGGCTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT51 CAAGTCTTTA GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC101 AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG151 CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC201 CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC251 TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG301 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC351 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC401 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA451 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA501 CCGCGTTCTA CGCCACCTTG CGCAGCCCGG CGGCGGCTCT GACATGGCTA551 CACCATTGGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT601 TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA651 GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG701 GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG751 GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT801 CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC851 CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCATC901 TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA1001 TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT1051 CTACGCCACC TTGCGCAGCC CTGATAA (SEQ ID NO:160)PM0N32132TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG(SEQ ID NO:249)PMON32133TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG (SEQ ID NO:250)pMON32134TCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG(SEQ ID NO:251)Pmon131811 CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG51 AGACCACCTG CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT101 CTCTATCCTG ATGGATCGAA ACCTTCGACT TCCAAACCTG GAGAGCTTCG151 TAAGGGCTGT CAAGAACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT201 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA251 TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA301 CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GTACGTAgag351 ggcggtggag gctcCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA401 CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGTAAGGTA451 CCGCATGCAA GCTT (SEQ ID NO:257)Pmon13180.Seg1 CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG51 AGACCACCTG CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT101 CTCTATCCTG ATGGATCGAA ACCTTCGACT TCCAAACCTG GAGAGCTTCG151 TAAGGGCTGT CAAGAACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT201 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA251 TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA301 CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GTACGTAgag351 ggcggtggag gctcCCCGGG TGGTGGTTCT GGCGGCGGCT CCAACATGTA401 AGGTACCGCA TGCAAGCTT (SEQ ID NO:258)pmon16017.seq1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTTAGGC451 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT501 GAGGAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA551 CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG601 GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT651 GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC701 TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC751 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT801 GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC851 CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT901 AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT951 TGCGCAGCCC GACATGGCTA CACCA (SEQ ID NO:259)pmon16018.seq1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCAGAGC451 TTCCTGCTCA AGTCTTTAGA GCAAGTGAGG AAGATCCAGG GCGATGGCGC501 AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG551 AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC601 TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA651 TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT701 CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CGTCGCCGAC751 TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC801 CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC851 GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG901 GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCGACA TGGCTACACC951 ATTAGGCCCT GCCAGCTCCC TGCCC (SEQ ID NO:260)pmon16019.seq1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTTCCTG451 CTCAAGTCTT TAGAGCAAGT GAGGAAGATC CAGGGCGATG GCGCAGCGCT501 CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG551 TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC601 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG651 CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG701 AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGC CGACTTTGCC751 ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA801 GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG851 CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG901 TACCGCGTTC TACGCCACCT TGCGCAGCCC GACATGGCTA CACCATTAGG951 CCCTGCCAGC TCCCTGCCCC AGAGC (SEQ ID NO:261)pmon16020.seq1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTGAGCAA451 GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC501 CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC551 TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG601 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG651 GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG701 ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG751 ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT801 GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG851 CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC901 CTTGCGCAGC CCGACATGGC TACACCATTA GGCCCTGCCA GCTCCCTGCC951 CCAGAGCTTC CTGCTCAAGT CTTTA (SEQ ID NO:262)pmon16021.seq1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCTGCTC451 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA501 GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC551 TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT601 CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT651 CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC701 AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG751 GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT801 TCTACGCCAC CTTGCGCAGC CCGACATGGC TACACCATTA GGCCCTGCCA851 GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AGTGAGGAAG901 ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA951 GCTGTGCCAC CCCGAGGAGC TGGTG (SEQ ID NO:263)pmon16022.seq1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCCCCTG451 AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT501 CCATAGCGGC CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA551 TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCT GGACGTCGCC601 GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCC651 TGCCCTGCAG CCCACCCAGG GTGCCATGCC GGCCTTCGCC TCTGCTTTCC701 AGCGCCGGGC AGGAGGGGTC CTGGTTGCTA GCCATCTGCA GAGCTTCCTG751 GAGGTGTCGT ACCGCGTTCT ACGCCACCTT GCGCAGCCCG ACATGGCTAC801 ACCATTAGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT851 TAGAGCAAGT GAGGAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG901 CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG951 ACACTCTCTG GGCATCCCCT GGGCT (SEQ ID NO:264)pmon16023.seq1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCAGGCC451 CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA501 CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA551 CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG601 CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG651 TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC701 TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA751 CGCCACCTTG CGCAGCCCGA CATGGCTACA CCATTAGGCC CTGCCAGCTC801 CCTGCCCCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC851 AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CTACAAGCTG901 TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG951 GGCTCCCCTG AGCTCCTGCC CCAGC (SEQ ID NO:265)pmon16024.seq1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCTGCAG451 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG501 GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG551 ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG601 ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT651 GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG701 CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC751 CTTGCGCAGC CCGACATGGC TACACCATTA GGCCCTGCCA GCTCCCTGCC801 CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AGTGAGGAAG ATCCAGGGCG851 ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC901 CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC951 CCTGAGCTCC TGCCCCAGCC AGGCC (SEQ ID NO:266)pmon16025.seq1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCTGGCA451 GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT501 GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GGGTCCCACC TTGGACACAC551 TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GCAGATGGAA601 GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC651 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC701 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG751 CAGCCCGACA TGGCTACACC ATTAGGCCCT GCCAGCTCCC TGCCCCAGAG801 CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG GAAGATCCAG GGCGATGGCG851 CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CCACCCCGAG901 GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG951 CTCCTGCCCC AGCCAGGCCC TGCAG (SEQ ID NO:267)pmon16026.seq1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTGAACTG451 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC501 CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC551 AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT TGCGCAGCCC601 GACATGGCTA CACCATTAGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT651 GCTCAAGTCT TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC701 TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG751 GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG801 CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG851 GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCCCC901 GAGTTGGGTC CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC951 CACCACCATC TGGCAGCAGA TGGAA (SEQ ID NO:268)pmon16027.seq1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTGGAATG451 GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC ATGCCGGCCT TCGCCTCTGC501 TTTCCAGCGC CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT CTGCAGAGCT551 TCCTGGAGGT GTCGTACCGC GTTCTACGCC ACCTTGCGCA GCCCGACATG601 GCTACACCAT TAGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA651 GTCTTTAGAG CAAGTGAGGA AGATCCAGGG CGATGGCGCA GCGCTCCAGG701 AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG751 CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG801 CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT851 TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG901 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC951 CATCTGGCAG CAGATGGAAG AACTG (SEQ ID NO:269)pmon16028.seq1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTAGCTTC451 CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCGACATGGC501 TACACCATTA GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT551 CTTTAGAGCA AGTGAGGAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG601 AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT651 CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC701 AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTC751 CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG801 TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA851 TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCACC901 CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC GGGCAGGAGG951 GGTCCTGGTT GCTAGCCATC TGCAG (SEQ ID NO:270)1 ATGGCTGGAC CCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACA51 GGTCCGTCTC CTCCTTGGGG CCCTGCAGAG CCTCCTTGGA ACCCAGCTTC101 CTCCACAGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CATCTTCCTG151 AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG201 AGGGTCCACC CTCGCCGTCA GGGAATTCGG CGGCAACATG GCGTCTCCGG251 CGCCGCCTGC TGCTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC301 CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC351 TACACCTGTC CTGCTGCCTG CTGTGGACTT TAGCTTGGGA GAATGGAAAA401 CCCAGATGGA GGAGACCAAG GCACAGGACA TTCTGGGAGC AGTGACCCTT451 CTGCTGGAGG GAGTGATGGC AGCACGGGGA CAACTG (SEQ ID NO:286)1 ATGGCTGGCA GGACCACAGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG51 CTTCCAACAC CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG101 GGTCCACCCT CGCCGTCAGG GAATTCGGCG GCAACATGGC GTCTCCGGCG151 CCGCCTGCTG CTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA201 TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA251 CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGA ATGGAAAACC301 CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT351 GCTGGAGGGA GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT401 CATCCCTCCT GGGGCAGCTT TCTGGACAGG TCCGTCTCCT CCTTGGGGCC451 CTGCAGAGCC TCCTTGGAAC CCAGCTTCCT CCACAG (SEQ ID NO:287)__________________________________________________________________________ TABLE 3__________________________________________________________________________PROTEIN SEQUENCES__________________________________________________________________________pMON26458pepSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe(SEQ ID NO:161)pMON28548pepSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg (SEQ ID NO:162)pMON28500SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg (SEQ ID NO:163)pMON28501SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg (SEQ ID NO:164)pMON28502SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg(SEQ ID NO:165)13182.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu CysHis Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile ProTrp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu AlaGly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln GlyLeu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro ThrLeu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr IleTrp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln ProThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly GlySer Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu CysAla Thr (SEQ ID NO:166)13183.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Tyr Lys Leu CysHis Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile ProTrp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu AlaGly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln GlyLeu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro ThrLeu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr IleTrp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln ProThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly GlySer Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu CysAla Thr (SEQ ID NO:167)13184.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu GlyPro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala ThrThr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala LeuGln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser PheLeu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro SerGly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu GluGln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu LysLeu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val LeuLeu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser CysPro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu HisSer Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu GlyIle Ser (SEQ ID NO:168)13185.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu GlyPro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala ThrThr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala LeuGln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser PheLeu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro SerGly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu GluGln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu LysLeu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val LeuLeu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser CysPro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu HisSer Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu GlyIle Ser (SEQ ID NO:169)13186.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala Pro AlaLeu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala PheGln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln SerPhe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln ProSer Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser LeuGlu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln GluLys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu ValLeu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser SerCys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln LeuHis Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu GluGly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln LeuAsp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu GluLeu Gly (SEQ ID NO:170)13187.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro AlaLeu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala PheGln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln SerPhe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln ProSer Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser LeuGlu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln GluLys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu ValLeu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser SerCys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln LeuHis Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu GluGly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln LeuAsp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu GluLeu Gly (SEQ ID NO:171)13188.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gln Gly AlaMet Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly ValLeu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr ArgVal Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly SerGln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile GlnGly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr LysLeu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu GlyIle Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu GlnLeu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu TyrGln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu GlyPro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala ThrThr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala LeuGln Pro (SEQ ID NO:172)13189.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly AlaMet Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly ValLeu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr ArgVal Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly SerGln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile GlnGly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr LysLeu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu GlyIle Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu GlnLeu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu TyrGln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu GlyPro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala ThrThr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala LeuGln Pro (SEQ ID NO:173)13190.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser PheLeu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro SerGly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu GluGln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu LysLeu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val LeuLeu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser CysPro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu HisSer Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu GlyIle Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu AspVal Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu LeuGly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro AlaPhe Ala (SEQ ID NO:174)13191.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser PheLeu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro SerGly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu GluGln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu LysLeu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val LeuLeu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser CysPro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu HisSer Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu GlyIle Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu AspVal Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu LeuGly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro AlaPhe Ala (SEQ ID NO:175)13192.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu CysHis Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile ProTrp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu AlaGly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln GlyLeu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro ThrLeu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr IleTrp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln ProThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr Pro LeuGly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser LeuGlu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln GluLys Leu Cys Ala Thr (SEQ ID NO:176)13193.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Tyr Lys Leu CysHis Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile ProTrp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu AlaGly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln GlyLeu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro ThrLeu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr IleTrp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln ProThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr Pro LeuGly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser LeuGlu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln GluLys Leu Cys Ala Thr (SEQ ID NO:177)25190.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu GlyPro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala ThrThr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala LeuGln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser PheLeu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro ThrPro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu LysSer Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala LeuGln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu GluLeu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro LeuSer Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu SerGln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln AlaLeu Glu Gly Ile Ser (SEQ ID NO:178)pMON25191.PepAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu GlyPro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala ThrThr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala LeuGln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser PheLeu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro ThrPro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu LysSer Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala LeuGln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu GluLeu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro LeuSer Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu SerGln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln AlaLeu Glu Gly Ile Ser (SEQ ID NO:179)13194.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala Pro AlaLeu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala PheGln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln SerPhe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln ProThr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu LeuLys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala AlaLeu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro GluGlu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala ProLeu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys LeuSer Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu GlnAla Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp ThrLeu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln GlnMet Glu Glu Leu Gly (SEQ ID NO:180)13195.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro AlaLeu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala PheGln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln SerPhe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln ProThr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu LeuLys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala AlaLeu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro GluGlu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala ProLeu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys LeuSer Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu GlnAla Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp ThrLeu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln GlnMet Glu Glu Leu Gly (SEQ ID NO:181)13196.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gln Gly AlaMet Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly ValLeu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr ArgVal Leu Arg His Leu Ala Gln Pro Thr Pro Leu Gly Pro Ala SerSer Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val ArgLys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys AlaThr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly HisSer Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser GlnAla Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly LeuPhe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser ProGlu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala AspPhe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met AlaPro Ala Leu Gln Pro (SEQ ID NO:182)13197.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly AlaMet Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly ValLeu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr ArgVal Leu Arg His Leu Ala Gln Pro Thr Pro Leu Gly Pro Ala SerSer Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val ArgLys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys AlaThr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly HisSer Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser GlnAla Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly LeuPhe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser ProGlu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala AspPhe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met AlaPro Ala Leu Gln Pro (SEQ ID NO:183)13198.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser PheLeu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro ThrPro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu LysSer Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala LeuGln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu GluLeu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro LeuSer Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu SerGln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln AlaLeu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr LeuGln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln MetGlu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly AlaMet Pro Ala Phe Ala (SEQ ID NO:184)13199.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser PheLeu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro ThrPro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu LysSer Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala LeuGln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu GluLeu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro LeuSer Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu SerGln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln AlaLeu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr LeuGln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln MetGlu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly AlaMet Pro Ala Phe Ala (SEQ ID NO:185)31104.PepLeu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu MetAsp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu ArgAsn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser ArgHis Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg GluLys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu GlnGln Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile IleHis His Leu Lys Arg Pro Pro Ala Pro Leu Tyr Val Glu Gly GlyGly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile AsnPro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met AlaThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly GlySer Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu CysAla Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu GlyHis Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro SerGln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser GlyLeu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile SerPro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val AlaAsp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly MetAla Pro Ala Leu Gln Pro (SEQ ID NO:186)31105.PepAsn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro CysLeu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile IleLys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe TyrLeu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly SerAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val Glu Gly GlyGly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile AsnPro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met AlaThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly GlySer Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu CysAla Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu GlyHis Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro SerGln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser GlyLeu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile SerPro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val AlaAsp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly MetAla Pro Ala Leu Gln Pro (SEQ ID NO:187)31106.PepAla Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp GlnGlu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu GlnAla Gln Glu Gln Gln Gly Gly Gly Ser Asn Cys Ser Ile Met IleAsp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu LeuAsp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met AspArg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala ValLys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser Ala Thr Ala Tyr Val Glu Gly GlyGly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile AsnPro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met AlaThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly GlySer Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu CysAla Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu GlyHis Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro SerGln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser GlyLeu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile SerPro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val AlaAsp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly MetAla Pro Ala Leu Gln Pro (SEQ ID NO:188)31107.PepAla Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr LeuVal Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser AsnCys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg ProPro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp ValSer Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu SerPhe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile GluAla Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr AlaAla Pro Ser Arg His Pro Ile Ile Ile Lys Thr Val Glu Gly GlyGly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile AsnPro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met AlaThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly GlySer Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu CysAla Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu GlyHis Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro SerGln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser GlyLeu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile SerPro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val AlaAsp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly MetAla Pro Ala Leu Gln Pro (SEQ ID NO:189)31108.PepLeu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu MetAsp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu ArgAsn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser ArgHis Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg GluLys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu GlnGln Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro ProAla Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu ProSer Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys GluSer His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro AlaPhe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val AlaSer His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu ArgHis Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser PheLeu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp GlyAla Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys HisPro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro TrpAla Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala GlyCys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly LeuLeu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr LeuAsp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile TrpGln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro(SEQ ID NO:190)31109.PepAsn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro CysLeu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile IleLys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe TyrLeu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly SerGly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile AspGlu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu AspPro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp ArgAsn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val LysAsn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu ProSer Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys GluSer His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro AlaPhe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val AlaSer His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu ArgHis Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser PheLeu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp GlyAla Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys HisPro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro TrpAla Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala GlyCys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly LeuLeu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr LeuAsp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile TrpGln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro(SEQ ID NO:191)31110.PepAla Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp GlnGlu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu GlnAla Gln Glu Gln Gln Gly Gly Gly Ser Gly Gly Gly Ser Gly GlyGly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His LeuLys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn AspGlu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro AsnLeu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala SerGly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro SerAla Thr Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu ProSer Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys GluSer His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro AlaPhe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val AlaSer His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu ArgHis Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser PheLeu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp GlyAla Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys HisPro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro TrpAla Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala GlyCys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly LeuLeu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr LeuAsp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile TrpGln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro(SEQ ID NO:192)31111.PepAla Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr LeuVal Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser GlyGly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp GluIle Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp ProAsn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg AsnLeu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys AsnLeu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu GlnPro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro IleIle Ile Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu ProSer Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys GluSer His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro AlaPhe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val AlaSer His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu ArgHis Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser PheLeu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp GlyAla Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys HisPro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro TrpAla Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala GlyCys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly LeuLeu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr LeuAsp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile TrpGln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro(SEQ ID NO:193)pMON15981MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThr (SEQ ID NO:194)pMON15982MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSer (SEQ ID NO:195)pMON15965MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAla (SEQ ID NO:196)pMON15966MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGly (SEQ ID NO:197)pMON15967MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro (SEQ ID NO:198)pMON31112.pepMetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeuProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleHisIleLysAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro(SEQ ID NO:199)pMON31113.pepMetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeuProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleIleIleArgAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro (SEQ ID NO:200)pMON31114.pepMetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeuProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleIleIleArgAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro(SEQ ID NO:201)pMON31115.pepMetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeuProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleHisIleLysAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGluAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro (SEQ ID NO:202)pMON28505AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGluAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysPro (SEQ ID NO:203)pMON28506AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGluAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisPro (SEQ ID NO:204)pMON28507AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro (SEQ ID NO:205)pMON28508AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuPro (SEQ ID NO:206)pMON28509AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGluAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaVal (SEQ ID NO:207)pMON28510AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeu (SEQ ID NO:208)pMON28511AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeu (SEQ ID NO:209)pMON28512AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu (SEQ ID NO:210)pMON28513AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln (SEQ ID NO:211)pMON28514AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThr (SEQ ID NO:212)pMON28515AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGluAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys (SEQ ID NO:213)pMON28516AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsn (SEQ ID NO:214)pMON28519AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysPro (SEQ ID NO:215)pMON28520AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisPro (SEQ ID NO:216)pMON28521AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro (SEQ ID NO:217)pMON28522AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuPro (SEQ ID NO:218)pMON28523AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaVal (SEQ ID NO:219)pMON28524AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeu (SEQ ID NO:220)pMON28525AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeu (SEQ ID NO:221)pMON28526AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu (SEQ ID NO:222)pMON28527AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln (SEQ ID NO:223)pMON28528AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThr (SEQ ID NO:224)pMON28529AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys (SEQ ID NO:225)pMON28530AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsn (SEQ ID NO:226)pMON28533AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysPro (SEQ ID NO:227)pMON28534AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisPro (SEQ ID NO:228)pMON28535AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGluAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro (SEQ ID NO:229)pMON28536AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGluAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuPro (SEQ ID NO:230)pMON28537AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaVal (SEQ ID NO:231)pMON28538AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPh&ArgGluLysLeuThrPheTyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyGluTrpLysThrGlnMetGluGluThrLysAlaGluAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeu (SEQ ID NO:232)pMON28539AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGluAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeu (SEQ ID NO:233)pMON28540AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu (SEQ ID NO:234)pMON28541AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln (SEQ ID NO:235)pMON28542AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThr (SEQ ID NO:236)pMON28543AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys (SEQ ID NO: 237)pMON28544AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsn (SEQ ID NO: 238)pMON28545AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAlaHisLys (SEQ ID NO:239)pMON32132SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg (SEQ ID NO: 252)PMON32133SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg (SEQ ID NO:253)PMON32134SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg (SEQ ID NO:254)pmon16017.pep 1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp 31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly 91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Leu Gly151 Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu166 Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys181 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu196 Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys211 Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His226 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly241 Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp256 Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu271 Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala286 Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala301 Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg316 His Leu Ala Gln Pro Asp Met Ala Thr Pro (SEQ ID NO:271)pmon16018.pep 1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp 31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly 31 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Leu Gly151 Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu176 Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys191 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu206 Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys221 Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His236 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly251 Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp266 Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu281 Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala296 Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala311 Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg326 His Leu Ala Gln Pro Asp Met Ala Thr Pro (SEQ ID NO:272)pmon16019.pep 1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp 31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly 91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Phe Leu151 Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala166 Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro181 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala196 Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys211 Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu226 Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp241 Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln256 Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln271 Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly286 Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser301 Tyr Arg Val Leu Arg His Leu Ala Gln Pro Asp Met Ala Thr Pro316 Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser (SEQ ID NO:273)pmon16020.pep 1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp 31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly 91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Glu Gln151 Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu166 Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu181 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro196 Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser211 Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile226 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val241 Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly256 Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe271 Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser286 His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His301 Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Ser316 Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu (SEQ ID NO:274)pmon16021.pep 1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp 31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly 91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Leu Leu151 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro166 Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser181 Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile196 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val211 Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly226 Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe241 Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser256 His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His271 Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Ser286 Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys301 Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr316 Tyr Lys Leu Cys His Pro Glu Glu Leu Val (SEQ ID NO:275)pmon16022.pep 1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp 31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly 91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Leu151 Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser166 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala181 Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu196 Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met211 Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala226 Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val241 Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg256 Val Leu Arg His Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gly271 Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu286 Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys301 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu316 Leu Gly His Ser Leu Gly Ile Pro Trp Ala (SEQ ID NO:276)pmon16023.pep 1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp 31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly 91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Gln Ala151 Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe166 Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu181 Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe196 Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro211 Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala226 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln241 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln256 Pro Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln271 Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly286 Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu301 Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile316 Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser (SEQ ID NO:277)pmon16024.pep 1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp 31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly 91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Leu Gln151 Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr166 Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly181 Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr196 Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu211 Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln226 Arg Arg Ala Gly Gly Valleu Val Ala Ser His Leu Gln Ser Phe241 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Asp256 Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe271 Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly286 Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His301 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp316 Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala (SEQ ID NO:278)pmon16025.pep 1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp 31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly 91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Leu Ala151 Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly166 Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr181 Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile196 Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro211 Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg226 Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu241 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Asp Met Ala256 Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu271 Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala286 Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu301 Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro316 Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln (SEQ ID NO:279)pmon16026.pep 1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp 31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly 91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Glu Leu151 Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala166 Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala181 Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg196 His Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gly Pro Ala Ser211 Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg226 Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala241 Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His256 Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln271 Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu286 Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro301 Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp316 Phe Ala Thr Thr Ile Trp Gln Gln Met Glu (SEQ ID NO:280)pmon16027.pep 1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp 31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly 91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Gly Met151 Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala166 Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His181 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu196 Ala Gln Pro Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu211 Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile226 Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr241 Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu256 Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu271 Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu286 Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu301 Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala316 Thr Thr Ile Trp Gln Gln Met Glu Glu Leu (SEQ ID NO:281)pmon16028.pep 1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp 31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly 91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Phe151 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Asp166 Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe181 Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly196 Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His211 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp226 Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly241 Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu256 Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu271 Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp286 Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr301 Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala316 Gly Gly Val Leu Val Ala Ser His Leu Gln (SEQ ID NO:282)MetAlaGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuAlaValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaAlaAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln (SEQ ID NO:284);MetAlaGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuAlaValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaAlaAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeu (SEQ ID NO:285)__________________________________________________________________________ The following examples will illustrate the invention in greater detail although it will be understood that the invention is not limited to these specific examples.

EXAMPLE 1

Construction of Parental BHK Expression Vector

A. Removal of AflIII site from mammalian expression plasmid.

A new mammalian expression vector was constructed to accept NcoI-HindIII or AflIII-HindIII gene fragments in-frame and 3' to the hIL-3 receptor agonist pMON13146 (WO 94/12638) gene and a mouse IgG2b linker fragment. First, the single AflIII site was removed from pMON3934, which is a derivative of pMON3359. pMON3359 is a pUC18-based vector containing a mammalian expression cassette. The cassette includes a herpes simplex viral promoter IE110 (-800 to +120) followed by a modified human IL-3 signal peptide sequence and an SV40 late poly-adenylation (poly-A) signal which has been subcloned into the pUC18 polylinker (See Hippenmeyer et al., Bio/Technology, 1993, pp.1037-1041). The modified human IL-3 signal sequence, which facilitates secretion of gene products outside of the cell, is flanked by a BamHI site on the 5' end and a unique NcoI site on the 3' end. A unique HindIII site is 3' to the NcoI site and 5' to the poly-A sequence. The DNA sequence encoding the signal peptide is shown below (restriction enzyme sites are indicated above). The ATG (methionine) codon within the NcoI site is in-frame with the initiator ATG of the signal peptide (underlined); BamHI NcoI 5'GGATCCACCATGAGCCTGCCCGTCCTGCTCCTGCTCCAACTCCTGGTCCGCCCCGCCATGG (SEQ ID NO:255)

The single AflIII site was removed from pMON3934 by digestion with AflIII followed by filling in the overhangs by addition of a DNA polymerase and nucleotides. The digested DNA fragment was purified via Magic PCR Clean up kit (Promega) and ligated with T4 DNA ligase. The ligation reaction was transformed into DH5.alpha. .TM. and the cells were plated onto LB-agar plus ampicillin. Individual colonies were screened for the loss of the AflIII site by restriction analysis with AflIII and HindIII which results in a single fragment if the AflIII site was removed. The resulting plasmid was designated pMON30275.

B. Transfer of hIL-3 receptor agonist pMON13416/IgG2b cassette into pMON30275.

The NcoI-HindIII fragment (ca. 425 bp) from pMON30245 was ligated to the NcoI-HindIII fragment (ca. 3800 bp) of the pMON30275. pMON30245 (WO 94/12638) contains the gene coding for hIL-3 receptor agonist pMON13416 joined to a mouse IgG2b hinge fragment. Immediately 3' to the IgG2b hinge and 5' to the HindIII site is an AflIII site. Genes can be cloned into the AflIII-HindIII sites as NcoI-HindIII or AflIII-HindIII fragments in frame with the hIL-3 variant pMON13416/IgG2b hinge to create novel chimeras. The NcoI site and the AflIII site have compatible overhangs and will ligate but both recognition sites are lost. The plasmid, pMON30304 containing the DNA sequence of (SEQ ID NO:78), coding for hIL-3 variant pMON13416 joined with a mouse IgG2b hinge region, was a result of this cloning.

EXAMPLE 2

Construction of an intermediate plasmid containing one copy of the c-mpl ligand (1-153) gene of the dimer template

In order to generate a plasmid DNA with the coding sequence of c-mpl (1-153) ligand followed by a unique EcoRI restriction site, the gene is isolated via reverse transcriptase/polymerase chain reaction (RT/PCR). Human fetal (lot #38130) and adult liver (lot #46018) A+RNA are obtained from Clontech (Palo Alto, Calif.) for source of c-mpl ligand messenger RNA (mRNA). The first strand cDNA reactions are carried out using a cDNA Cycle.TM. Kit obtained from Invitrogen (San Diego, Calif.). In the RT reaction, random primers and oligo dT primer are used to generate cDNA from a combination of human and fetal liver mRNA. For amplification of c-mpl ligand gene fragment encoding amino acids 1-153, the RT product serves as the template for PCR with a combination of the primers, Forward primer: c-mplNcoI (SEQ ID NO:13) and Reverse primer: Ecompl. The c-mplNcoI primer anneals to the c-mpl ligand gene (bases #279-311 based on c-mpl ligand sequence from Gene bank accession #L33410 or de Sauvage et al., Nature 369: 533-538 (1994)) and encodes a NcoI restriction enzyme site immediately 5' to the first codon (Ser+1) of c-mpl ligand. The NcoI restriction enzyme site codes for methionine and alanine codons prior to Ser+1 and includes codon degeneracy for the Ala codon and the first four codons (Ser, Pro, Ala, & Pro) of c-mpl ligand. The Ecompl primer anneals to bases #720-737 of c-mpl ligand and encodes an EcoRI site (GAATTC) in-frame with the c-mpl ligand gene immediately following Arg-153. The EcoRI site creates Glu and Phe codons following Arg-153. The ca. 480 bp PCR product was purified, digested with NcoI and EcoRI and ligated to the NcoI-EcoRI vector fragment of pMON3993 (ca. 4550 bp.). pMON3993 was a derivative of pMON3359 (described in Example 1). The human IL-3 signal peptide sequence, which had been subcloned as a BamHI fragment into the unique BamHI site between the IE110 promoter and poly-A signal, contains an NcoI site at its 3' end and is followed by a unique EcoRI site. The plasmid, pMON26458 containing the DNA sequence of (SEQ ID NO:79), coding for c-mpl ligand amino acids 1-153 (SEQ ID NO:161), was the result of this cloning.

EXAMPLE 3

Construction of the parental plasmids containing the second genes of the dimer templates

For amplification of c-mpl ligand gene fragments starting at amino acid 1 (Ser) with a termination codon following amino acid 153 (Arg), the RT reaction from Example 2 serves as the template for PCR with a combination of the following primers; c-mplNcoI (SEQ ID NO:13) (forward primer) and c-mplHindIII (SEQ ID NO:15) (reverse primer). The c-mplNcoI (SEQ ID NO:13) primer is described in Example 2. The c-mplHindIII (SEQ ID NO:15) primer, which anneals to bases #716-737 of c-mpl ligand, adds both a termination codon and a HindIII restriction enzyme site immediately following the final codon, Arg.sup.153.

Two types of PCR products are generated from the RT cDNA samples, one with a deletion of the codons for amino acids 112-115 and one without the deletion of these codons. The c-mpl ligand PCR products (ca. 480 bp) are digested with NcoI and HindIII restriction enzymes for transfer to a mammalian expression vector, pMON3934. pMON3934 is digested with NcoI and HindIII (ca. 3800 bp) and will accept the PCR products.

Plasmid, pMON32132 (SEQ ID NO:249), coding for c-mpl ligand amino acids 1-153 (SEQ ID NO:252) was a result of this cloning. Plasmid, pMON32134 (SEQ ID NO:250), coding for c-mpl ligand amino acids 1-153 (SEQ ID NO:253) was a result of this cloning. Plasmid, pMON32133 (SEQ ID NO:251), coding for c-mpl ligand amino acids 1-153 with a deletion of codons 112-115 (.DELTA.112-115) (SEQ ID NO:254) was also a result of this cloning.

EXAMPLE 4

Generation of PCR dimer template 5L with a .DELTA.112-115 deletion in the second c-mpl ligand gene

A PCR template for generating novel forms of c-mpl ligand is constructed by ligating the 3.7 Kbp BstXI/EcoRI fragment of pMON26458 to the 1 Kbp NcoI/BstXI fragment from pMON32133 (containing a deletion of amino acids 112-115) along with the EcoRI/AflIII 5L synthetic oligonucleotide linker 5L-5' (SEQ ID NO:18) and 5L-3' (SEQ ID NO:19).

The EcoRI end of the linker will ligate to the EcoRI end of pMON26458. The AflIII end of the linker will ligate to the NcoI site of pMON32133, and neither restriction site will be retained upon ligation. The BstXI sites of pMON26458 and pMON32133 will ligate as well. Plasmid, pMON28548, is a result of the cloning and contains the DNA sequence of (SEQ ID NO:80) which encodes amino acids 1-153 c-mpl ligand fused via a GluPheGlyGlyAsnMetAla (SEQ ID NO:222) linker to amino acids 1-153 c-mpl ligand that contains a deletion of amino acids 112-115 (SEQ ID NO:162).

EXAMPLE 5

Generation of PCR Dimer Template 4L

A PCR template for generating novel forms of c-mpl ligand is constructed by ligating the 3.7 Kbp BstXI/EcoRI fragment of pMON26458 to the 1 Kbp NcoI/BstXI fragment from pMON32132 along with the EcoRI/AflIII 4L synthetic oligonucleotide linker 4L-5' (SEQ ID NO:16) and 4L-3' (SEQ ID NO:17).

The EcoRI end of the linker will ligate to the EcoRI end of pMON26458. The AflIII end of the linker will ligate to the NcoI site of pMON32132, and neither restriction site will be retained upon ligation. The BstXI sites of pMON26458 and pMON32132 will ligate as well. The plasmid, pMON28500, is a result of the cloning and contains the DNA sequence of (SEQ ID NO:82) which encodes amino acids 1-153 c-mpl ligand fused via a GluPheGlyAsnMetAla (SEQ ID NO:223) linker (4L) to amino acids 1-153 c-mpl ligand (SEQ ID NO:163).

EXAMPLE 6

Generation of PCR Dimer Template 5L

A PCR template for generating novel forms of c-mpl ligand is constructed by ligating the 3.7 Kbp BstXI/EcoRI fragment of pMON26458 to the 1 Kbp NcoI/BstXI fragment from pMON32132 along with the EcoRI/AflIII 5L synthetic oligonucleotide linker 5L-5' (SEQ ID NO:18) and 5L-3' (SEQ ID NO:19).

The EcoRI end of the linker will ligate to the EcoRI end of pMON26458. The AflIII end of the linker will ligate to the NcoI site of pMON32132, and neither restriction site will be retained upon ligation. The BstXI sites of pMON26458 and pMON32132 will ligate as well. Plasmid, pMON28501 is a result of the cloning and contains the DNA sequence of (SEQ ID NO: 82) which encodes amino acids 1-153 c-mpl ligand fused via a GluPheGlyGlyAsnMetAla (SEQ ID NO:222) linker (5L) to amino acids 1-153 c-mpl ligand (SEQ ID NO:164).

EXAMPLE 7

Generation of PCR Dimer Templates 8L

A PCR template for generating novel forms of c-mpl ligand is constructed by ligating the 3.7 Kbp BstXI/EcoRI fragment of pMON26458 to the 1 Kbp NcoI/BstXI fragment from pMON32134 along with the EcoRI/AflIII 8L synthetic oligonucleotide linker 8L-5' (SEQ ID NO:20) and 8L-3' (SEQ ID NO:21).

The EcoRI end of the linker will ligate to the EcoRI end of pMON26458. The AflIII end of the linker will ligate to the NcoI site of pMON32134, and neither restriction site will be retained upon ligation. The BstXI sites of pMON26458 and pMON32134 will ligate as well. Plasmid, pMON28502 is a result of the cloning which contains the DNA sequence of (SEQ ID NO:83) and encodes amino acids 1-153 c-mpl ligand fused via a GluPheGlyGlyAsnGlyGlyAsnMetAla (SEQ ID NO:224) linker (8L) to amino acids 1-153 c-mpl ligand (SEQ ID NO:165).

EXAMPLES 8-44

Generation of novel c-mpl ligand genes with new N-terminus and C-terminus A. PCR generation of genes encoding novel c-mpl ligand receptor agonists.

Genes encoding novel c-mpl ligand receptor agonists were generated using Method III (Horlick et al., Prot. Eng. 5:427-433, 1992). The PCR reactions were carried out using dimer templates, pMONs 28500, 28501, 28502 or 28548 and one of the sets of synthetic primer sets below (The first number refers to the position of the first amino acid in the original sequence. For example, the 31-5' and 31-3' refers to the 5' and 3' oligo primers, receptively, for the sequence beginning at the codon corresponding to residue 31 of the original sequence.).

31-5' (SEQ ID NO:22) and 31-3' (SEQ ID NO:23), 35-5' (SEQ ID NO:24) and 35-3' (SEQ ID NO:25), 39-5' (SEQ ID NO:26) and 39-3' (SEQ ID NO:27), 43-5' (SEQ ID NO:28) and 43-3' (SEQ ID NO:29), 45-5' (SEQ ID NO:30) and 45-3' (SEQ ID NO:31), 49-5' (SEQ ID NO:32) and 49-3' (SEQ ID NO:33), 82-5' (SEQ ID NO:34) and 82-3' (SEQ ID NO:35), 109-5' (SEQ ID NO:36) and 109-3' (SEQ ID NO:37), 115-5' (SEQ ID NO:38) and 115-3' (SEQ ID NO:39), 120-5' (SEQ ID NO:40) and 120-3' (SEQ ID NO:41), 123-5' (SEQ ID NO:42) and 123-3' (SEQ ID NO:43), 126-5' (SEQ ID NO:44) and 126-3' (SEQ ID NO:45).

The templates and oligonucleotide sets used in the PCR reactions are shown in Table 4. The products that were generated were about 480 bp and were purified via Magic PCR Clean up kits (Promega).

B. Subcloning of novel c-mpl receptor agonist gene products into mammalian expression vector for generation of chimeras.

The c-mpl receptor agonist gene PCR products were digested with NcoI and HindIII or AflIII and HindIII restriction enzymes (ca. 470 bp) for transfer to a mammalian expression vector. The expression vector, pMON30304, was digested with NcoI and HindIII (ca. 4200 bp) and accepts the PCR products as NcoI-HindIII or AflIII-HindIII fragments. The restriction digest of the PCR product and the resulting plasmids are shown in Table 4.

TABLE 4__________________________________________________________________________ PCR Product Resulting Breakpoint PCR Product Restriction Plasmid in c-mplExample # PCR template Primer set Digest Linker pMON ligand__________________________________________________________________________Example 8 pMON28501 31 NcoI/HindIII 5L 28505 30-31Example 9 pMON28501 AflIII/HindIII 28506 34-35Example 10 pMON28501 NcoI/HindIII 28507 38-39Example 11 pMON28501 NcoI/HindIII 28508 42-43Example 12 pMON28501 NcoI/HindIII 28509 44-45Example 13 pMON28501 NcoI/HindIII 28510 48-49Example 14 pMON28501 NcoI/HindIII 28511 81-82Example 15 PMON28501 109 NcoI/HindIII 28512 108-109Example 16 PMON28501 116 NcoI/HindIII 28513 115-116Example 17 pMON28501 120 NcoI/HindIII 28514 119-120Example 18 pMON28501 123 NcoI/HindIII 28515 122-123Example 19 PMON28501 126 NcoI/HindIII 28516 125-126Example 20 pMON28500 NcoI/HindIII 28519 30-31Example 21 pMON28500 AflIII/HindIII 28520 34-35Example 22 pMON28500 NcoI/HindIII 28521 38-39Example 23 pMON28500 NcoI/HindIII 28522 42-43Example 24 pMON28500 NcoI/HindIII 28523 44-45Example 25 pMON28500 NcoI/HindIII 28524 48-49Example 26 PMON28500 NcoI/HindIII 28525 81-82Example 27 pMON28500 109 NcoI/HindIII 28526 108-109Example 28 pMON28500 116 NcoI/HindIII 28527 115-116Example 29 pMON28500 120 NcoI/HindIII 28528 119-120Example 30 pMON28500 123 NcoI/HindIII 28529 122-123Example 31 pMON28500 126 NcoI/HindIII 28530 125-126Example 32 pMON28502 NcoIIHindIII 28533 30-31Example 33 pMON28502 AflIII/HindIII 28534 34-35Example 34 pMON28502 NcoI/HindIII 28535 38-39Example 35 pMON28502 NcoI/HindIII 28536 42-43Example 36 pMON28502 45 NcoI/HindIII 8L 28537 44-45Example 37 pMON28502 49 NcoI/HindIII 8L 28538 48-49Example 38 pMON28502 82 NcoI/HindIII 8L 28539 81-82Example 39 pMON28502 109 NcoI/HindIII 8L 28540 108-109Example 40 pMON28502 116 NcoI/HindIII 8L 28541 115-116EXAMPLE 41 pMON28502 120 NcoI/HindIII 8L 28542 119-120Example 42 pMON28502 123 NcoI/HindIII 8L 28543 122-123Example 43 pMON28502 126 NcoI/HindIII 8L 28544 125-126Example 44 pMON28548 123 NcoI/HindIII 5L 28545 122-123__________________________________________________________________________

EXAMPLE 45

Construction of pMON15960

Construction of pMON15960, an intermediate plasmid used for constructing plasmids containing DNA sequences encoding G-CSF Ser.sup.17 with a new N-terminus and C-terminus. Plasmid pACYC177 (Chang, A. C. Y. and Cohen, S. N. J. Bacteriol. 134:1141-1156, 1978) DNA was digested with restriction enzymes HindIII and BamHI, resulting in a 3092 base pair HindIII, BamHI fragment. Plasmid, pMON13037 (WO 95/21254), DNA was digested with BglII and FspI, resulting in a 616 base pair BglII, FspI fragment. A second sample of plasmid, pMON13037, DNA was digested with NcoI and HindIII, resulting in a 556 base pair NcoI, HindIII fragment. The synthetic DNA oligonucleotides 1GGGSfor (SEQ ID NO:76) and 1GGGSrev (SEQ ID NO:77) were annealed to each other, and then digested with AflIII and FspI, resulting in a 21 base pair AflIII, FspI fragment. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and analyzed by restriction analysis to confirm the correct insert.

EXAMPLE 46

Construction of pMON15981

Construction of pMON15981, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Plasmid, pMON15960, DNA was digested with restriction enzyme SmaI and used as template in a PCR reaction using synthetic DNA oligonucleotides 38 stop (SEQ ID NO:65) and 39 start (SEQ ID NO:64) as primers, resulting in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes HindIII and NcoI, resulting in a HindIII, NcoI fragment of 558 base pairs. Plasmid, pMON13181, DNA was digested with HindIII and AflIII, resulting in a HindIII, AflIII fragment of 4068 base pairs. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid, pMON15981, contains the DNA sequence of (SEQ ID NO:155) which encodes the following amino acid sequence:

MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThr (SEQ ID NO:195)

EXAMPLE 47

Construction of pMON15982

Construction of pMON15982, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Plasmid, pMON15960, DNA was digested with restriction enzyme SmaI and used as template in a PCR reaction using synthetic DNA oligonucleotides 96 stop (SEQ ID NO:67) and 97 start (SEQ ID NO:66) as primers, resulting in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes HindIII and NcoI, resulting in a HindIII, NcoI fragment of 558 base pairs. Plasmid, pMON13181, DNA was digested with HindIII and AflIII, resulting in a HindIII, AflIII fragment of 4068 base pairs. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid, pMON15982, contains the DNA sequence of (SEQ ID NO:157) which encodes the following amino acid sequence:

MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSer (SEQ ID NO:196)

EXAMPLE 48

Construction of pMON15965

Construction of pMON15965, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Plasmid, pMON15960, DNA was digested with restriction enzyme SmaI and used as template in a PCR reaction using synthetic DNA oligonucleotides 142 stop (SEQ ID NO:73) and 141 start (SEQ ID NO:72) as primers, resulting in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes HindIII and NcoI, resulting in a HindIII, NcoI fragment of 558 base pairs. Plasmid, pMON13181, DNA was digested with HindIII and AflIII, resulting in a HindIII, AflIII fragment of 4068 base pairs. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid, pMON15965, contains the DNA sequence of (SEQ ID NO:157) which encodes the following amino acid sequence:

MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGluAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAla (SEQ ID NO:196)

EXAMPLE 49

Construction of pMON15966

Construction of pMON15966, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Plasmid, pMON15960, DNA was digested with restriction enzyme SmaI and used as template in a PCR reaction using synthetic DNA oligonucleotides 126 stop (SEQ ID NO:68) and 125 start (SEQ ID NO:69) as primers, resulting in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes HindIII and NcoI, resulting in a HindIII, NcoI fragment of 558 base pairs. Plasmid, pMON13181, DNA was digested with HindIII and AflIII, resulting in a HindIII, AflIII fragment of 4068 base pairs. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid, pMON15966, contains the DNA sequence of (SEQ ID NO:158) which encodes the following amino acid sequence:

MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGly (SEQ ID NO:197)

EXAMPLE 50

Construction of pMON15967

Construction of pMON15967, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Plasmid, pMON15960, DNA was digested with restriction enzyme SmaI and used as template in a PCR reaction using synthetic DNA oligonucleotides 132 stop (SEQ ID NO:71) and 133 start (SEQ ID NO:70) as primers, resulting in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes HindIII and NcoI, resulting in a HindIII, NcoI fragment of 558 base pairs. Plasmid, pMON13181, DNA was digested with HindIII and AflIII, resulting in a HindIII, AflIII fragment of 4068 base pairs. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid, pMON15967, contains the DNA sequence of (SEQ ID NO: 159) which encodes the following amino acid sequence:

MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro SEQ ID NO:198

EXAMPLE 51

Construction of pMON13180, an intermediate plasmid used for constructing Dlasmids that contain DNA sequence encoding multi-functional hematopoietic receptor agonists.

Plasmid, pMON13046 (WO 95/21254), DNA was digested with restriction endonucleases XmaI and SnaBI, resulting in a 4018 base pair vector fragment. The 4018 base pair XmaI-SnaBI fragment was purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.) in which the 25 base pair XmaI-SnaBI insert fragment is not retained. The complimentary pair of synthetic oligonucleotides, glyxal (SEQ ID NO:74) and glyxa2 (SEQ ID NO:75), were designed to remove sequence encoding a factor Xa cleavage site. When properly assembled these oligonucleotides also result in XmaI and SnaBI ends. The primers, Glyxa1 and glyxa2, were annealed in annealing buffer (20 mM Tris-HCl pH7.5, 10 mM MgCl.sub.2, 50 mM NaCl) by heating at 70.degree. C. for ten minutes and allowed to slow cool. The 4018 base pair XmaI-SnaBI fragment from pMON13046 was ligated with the assembled oligonucleotides using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from the transformants and analyzed using a PCR based assay. Plasmid DNA from selected transformants was sequenced to confirm the correct insertion of the oligonucleotides. The resulting plasmid was designated pMON13180 and contains the DNA sequence of (SEQ ID NO:258).

EXAMPLE 52

Construction of pMON13181. an intermediate plasmid used for constructing plasmids that contain DNA sequences encoding multi-functional hematopoietic receptor agonists.

Plasmid, pMON13047 (WO 95/21254), DNA was digested with restriction endonucleases XmaI and SnaBI, resulting in a 4063 base pair vector fragment. The 4063 base pair XmaI-SnaBI fragment was purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.) in which the 25 base pair XmaI-SnaBI insert fragment is not retained. The complimentary pair of synthetic oligonucleotides, glyxal (SEQ ID NO:74) and glyxa2 (SEQ ID NO:75), were designed to remove sequence encoding the factor Xa cleavage site. When properly assembled these oligonucleotides also result in XmaI and SnaBI ends. Glyxal and glyxa2 were annealed in annealing buffer by heating at 70.degree. C. for ten minutes and allowed to slow cool. The 4063 base pair XmaI-SnaBI fragment from pMON13047 was ligated with the assembled oligonucleotides using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from the transformants and analyzed using a PCR based assay. Plasmid DNA from selected transformants was sequenced to confirm the correct insertion of the oligonucleotides. The resulting plasmid was designated pMON13181 and contains the DNA sequence of (SEQ ID NO:257).

EXAMPLE 53

Construction of pMON13182

The new N-terminus/C-terminus gene in pMON13182 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 39 start (SEQ ID NO:64) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 38 stop (SEQ ID NO:65) and L-11 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser.sup.17 gene was created and amplified from the annealed Fragments Start and Stop using primers 39 start and 38 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13182.

E. coli strain JM101 was transformed with pMON13182 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13182, contains the DNA sequence of (SEQ ID NO:94) which encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu CysHis Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile ProTrp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu AlaGly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln GlyLeu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro ThrLeu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr IleTrp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln ProThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly GlySer Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu CysAla Thr (SEQ ID NO:166)

EXAMPLE 54

Construction of pMON13183

The new N-terminus/C-terminus gene in pMON13183 was created using Method I as described in Materials and Methods. "Fragment Start" was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 39 start (SEQ ID NO:64) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser17 sequence in pMON13037 using the primer set, 38 stop (SEQ ID NO:65) and L-l1 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser.sup.17 gene was created and amplified from the annealed Fragments Start and Stop using 39 start and 38 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13183.

E. coli strain JM101 was transformed with pMON13183 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13183, contains the DNA sequence of (SEQ ID NO:95) which encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Tyr Lys Leu CysHis Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile ProTrp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu AlaGly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln GlyLeu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro ThrLeu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr IleTrp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln ProThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly GlySer Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu CysAla Thr (SEQ ID NO:167)

EXAMPLE 55

Construction of pMON13184

The new N-terminus/C-terminus gene in pMON13184 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 97 start (SEQ ID NO:66) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 96 stop (SEQ ID NO:67) and L-11 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser.sup.17 gene was created and amplified from the annealed Fragments Start and Stop using 97 start and 96 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13184.

E. coli strain JM101 was transformed with pMON13184 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13184, contains the DNA sequence of (SEQ ID NO:96) which encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu GlyPro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala ThrThr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala LeuGln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser PheLeu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro SerGly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu GluGln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu LysLeu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val LeuLeu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser CysPro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu HisSer Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu GlyIle Ser (SEQ ID NO:168)

EXAMPLE 56

Construction of pMON13185

The new N-terminus/C-terminus gene in pMON13185 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 97 start (SEQ ID NO:66) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 96 stop (SEQ ID NO:67 and L-11 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser.sup.17 gene was created and amplified from the annealed Fragments Start and Stop using 97 start and 96 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13185.

E. coli strain JM101 was transformed with pMON13185 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13185, contains the DNA sequence of (SEQ ID NO:67) which encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Pne Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu GlyPro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala ThrThr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala LeuGln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser PheLeu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro SerGly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu GluGln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu LysLeu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val LeuLeu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser CysPro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu HisSer Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu GlyIle Ser (SEQ ID NO:169)

EXAMPLE 57

Construction of pMON13186

The new N-terminus/C-terminus gene in pMON13186 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 126 start (SEQ ID NO:68) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 125 stop (SEQ ID NO:69) and L-11 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser.sup.17 gene was created and amplified from the annealed Fragments Start and Stop using 126 start and 125 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13186.

E. coli strain JM101 was transformed with pMON13186 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13186, contains the DNA sequence of (SEQ ID NO:98) which encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala Pro AlaLeu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala PheGln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln SerPhe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln ProSer Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser LeuGlu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln GluLys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu ValLeu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser SerCys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln LeuHis Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu GluGly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln LeuAsp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu GluLeu Gly (SEQ ID NO:170)

EXAMPLE 58

Construction of pMON13187

The new N-terminus/C-terminus gene in pMON13187 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 126 start (SEQ ID NO:68) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 125 stop (SEQ ID NO:69) and L-11 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser.sup.17 gene was created and amplified from the annealed Fragments Start and Stop using 126 start and 125 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13187.

E. coli strain JM101 was transformed with pMON13187 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13187, contains the DNA sequence of (SEQ ID NO:99) which encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro AlaLeu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala PheGln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln SerPhe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln ProSer Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser LeuGlu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln GluLys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu ValLeu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser SerCys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln LeuHis Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu GluGly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln LeuAsp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu GluLeu Gly (SEQ ID NO:171)

EXAMPLE 59

Construction of pMON13188

The new N-terminus/C-terminus gene in pMON13188 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 133 start (SEQ ID NO:70) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 132 stop (SEQ ID NO:71) and L-11 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser.sup.17 gene was created and amplified from the annealed Fragments Start and Stop using 133 start and 132 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13188.

E. coli strain JM101 was transformed with pMON13188 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13188, contains the DNA sequence of (SEQ ID NO:100) which encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gln Gly AlaMet Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly ValLeu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr ArgVal Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly SerGln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile GlnGly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr LysLeu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu GlyIle Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu GlnLeu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu TyrGln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu GlyPro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala ThrThr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala LeuGln Pro (SEQ ID NO:172)

EXAMPLE 60

Construction of pMON13189

The new N-terminus/C-terminus gene in pMON13189 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 133 start (SEQ ID NO:70) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 132 stop (SEQ ID NO:71) and L-11 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser.sup.17 gene was created and amplified from the annealed Fragments Start and Stop using 133 start and 132 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13189.

E. coli strain JM101 was transformed with pMON13189 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13189, contains the DNA sequence of (SEQ ID NO:101) which encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly AlaMet Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly ValLeu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr ArgVal Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly SerGln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile GlnGly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr LysLeu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu GlyIle Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu GlnLeu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu TyrGln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu GlyPro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala ThrThr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala LeuGln Pro (SEQ ID NO:173)

EXAMPLE 61

Construction of pMON13190

The new N-terminus/C-terminus gene in pMON13190 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 142 start (SEQ ID NO:72) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 141 stop (SEQ ID NO:73) and L-11 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser.sup.17 gene was created and amplified from the annealed Fragments Start and Stop using 142 start and 141 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13190.

E. coli strain JM101 was transformed with pMON13190 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13190, contains the DNA sequence of (SEQ ID NO:102) which encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser PheLeu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro SerGly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu GluGln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu LysLeu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val LeuLeu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser CysPro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu HisSer Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu GlyIle Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu AspVal Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu LeuGly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro AlaPhe Ala (SEQ ID NO:174)

EXAMPLE 62

Construction of pMON13191

The new N-terminus/C-terminus gene in pMON13191 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 142 start (SEQ ID NO:72) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 141 stop (SEQ ID NO:73) and L-11 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser.sup.17 gene was created and amplified from the annealed Fragments Start and Stop using 142 start and 141 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13191.

E. coli strain JM101 was transformed with pMON13191 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13191, contains the DNA sequence of (SEQ ID NO:103) which encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser PheLeu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro SerGly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu GluGln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu LysLeu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val LeuLeu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser CysPro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu HisSer Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu GlyIle Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu AspVal Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu LeuGly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro AlaPhe Ala (SEQ ID NO:175)

EXAMPLE 63

Construction of pMON13192

The new N-terminus/C-terminus gene in pMON13192 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF sequence in pMON13037 using the primer set, 39 start (SEQ ID NO:64) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 38 stop (SEQ ID NO:65) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser.sup.17 gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser.sup.17 gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13192.

E. coli strain JM101 was transformed with pMON13192 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13192, contains the DNA sequence of (SEQ ID NO:104) which encodes the following amino acid sequence:

13192.Pept

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu CysHis Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile ProTrp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu AlaGly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln GlyLeu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro ThrLeu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr IleTrp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln ProThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr Pro LeuGly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser LeuGlu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln GluLys Leu Cys Ala Thr (SEQ ID NO:176)

EXAMPLE 64

Construction of pMON13193

The new N-terminus/C-terminus gene in pMON13193 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 39 start (SEQ ID NO:64) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 38 stop (SEQ ID NO:65) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser.sup.17 gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser.sup.17 gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13193.

E. coli strain JM101 was transformed with pMON13193 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13193, contains the DNA sequence of (SEQ ID NO:105) encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Tyr Lys Leu CysHis Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile ProTrp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu AlaGly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln GlyLeu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro ThrLeu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr IleTrp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln ProThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr Pro LeuGly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser LeuGlu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln GluLys Leu Cys Ala Thr (SEQ ID NO:177)

EXAMPLE 65

Construction of pMON25190

The new N-terminus/C-terminus gene in pMON25190 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF sequence in pMON13037 using the primer set, 97 start (SEQ ID NO:66) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 96 stop (SEQ ID NO:67) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser.sup.17 gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser.sup.17 gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON25190.

E. coli strain JM101 was transformed with pMON25190 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON25190, contains the DNA sequence of (SEQ ID NO:106) which encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu GlyPro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala ThrThr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala LeuGln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser PheLeu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro ThrPro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu LysSer Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala LeuGln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu GluLeu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro LeuSer Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu SerGln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln AlaLeu Glu Gly Ile Ser (SEQ ID NO:178)

EXAMPLE 66

Construction of pMON25191

The new N-terminus/C-terminus gene in pMON25191 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 97 start (SEQ ID NO:66) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 96 stop (SEQ ID NO:98) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser.sup.17 gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser.sup.17 gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON25191.

E. coli strain JM101 was transformed with pMON25191 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON25191, contains the DNA sequence of (SEQ ID NO:107) which encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu GlyPro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala ThrThr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala LeuGln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser PheLeu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro ThrPro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu LysSer Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala LeuGln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu GluLeu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro LeuSer Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu SerGln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln AlaLeu Glu Gly Ile Ser (SEQ ID NO:179)

EXAMPLE 67

Construction of pMON13194

The new N-terminus/C-terminus gene in pMON13194 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 126 start (SEQ ID NO:68) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 125 stop (SEQ ID NO:67) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser.sup.17 gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser.sup.17 gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13194.

E. coli strain JM101 was transformed with pMON13194 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13194, contains the DNA sequence of (SEQ ID NO:108) which encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala Pro AlaLeu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala PheGln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln SerPhe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln ProThr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu LeuLys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala AlaLeu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro GluGlu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala ProLeu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys LeuSer Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu GlnAla Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp ThrLeu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln GlnMet Glu Glu Leu Gly (SEQ ID NO:180)

EXAMPLE 68

Construction of pMON13195

The new N-terminus/C-terminus gene in pMON13195 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 126 start (SEQ ID NO:68) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 125 stop (SEQ ID NO:69) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser.sup.17 gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser.sup.17 gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13195.

E. coli strain JM101 was transformed with pMON13195 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13195, contains the DNA sequence of (SEQ ID NO:109) which encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro AlaLeu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala PheGln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln SerPhe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln ProThr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu LeuLys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala AlaLeu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro GluGlu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala ProLeu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys LeuSer Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu GlnAla Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp ThrLeu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln GlnMet Glu Glu Leu Gly (SEQ ID NO:181)

EXAMPLE 69

Construction of pMON13196

The new N-terminus/C-terminus gene in pMON13196 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF sequence in pMON13037 using the primer set, 133 start (SEQ ID NO:70) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 132 stop (SEQ ID NO:71) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser.sup.17 gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser.sup.17 gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13196.

E. coli strain JM101 was transformed with pMON13196 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13196, contains the DNA sequence of (SEQ ID NO:110) which encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gln Gly AlaMet Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly ValLeu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr ArgVal Leu Arg His Leu Ala Gln Pro Thr Pro Leu Gly Pro Ala SerSer Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val ArgLys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys AlaThr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly HisSer Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser GlnAla Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly LeuPhe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser ProGlu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala AspPhe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met AlaPro Ala Leu Gln Pro (SEQ ID NO:182)

EXAMPLE 70

Construction of pMON13197

The new N-terminus/C-terminus gene in pMON13197 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 133 start (SEQ ID NO:70) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 132 stop (SEQ ID NO:71) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser.sup.17 gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser.sup.17 gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13197.

E. coli strain JM101 was transformed with pMON13197 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13197, contains the DNA sequence of (SEQ ID NO:lll) which encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu CysHis Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile ProTrp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu AlaGly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln GlyLeu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro ThrLeu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr IleTrp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln ProThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr Pro LeuGly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser LeuGlu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln GluLys Leu Cys Ala Thr (SEQ ID NO:183)

EXAMPLE 71

Construction of pMON13198

The new N-terminus/C-terminus gene in pMON13198 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF sequence in pMON13037 using the primer set, 142 start (SEQ ID NO:72) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 141 stop (SEQ ID NO:73) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser.sup.17 gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser.sup.17 gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13198.

E. coli strain JM101 was transformed with pMON13198 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13198, contains the DNA sequence of (SEQ ID NO:112) which encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser PheLeu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro ThrPro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu LysSer Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala LeuGln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu GluLeu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro LeuSer Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu SerGln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln AlaLeu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr LeuGln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln MetGlu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly AlaMet Pro Ala Phe Ala (SEQ ID NO:184)

EXAMPLE 72

Construction of pMON13199

The new N-terminus/C-terminus gene in pMON13199 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 142 start (SEQ ID NO:72) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser.sup.17 sequence in pMON13037 using the primer set, 141 stop (SEQ ID NO:73) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser.sup.17 gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser.sup.17 gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13199.

E. coli strain JM101 was transformed with pMON13199 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13199, contains the DNA sequence of (SEQ ID NO:113) which encodes the following amino acid sequence:

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser PheLeu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro ThrPro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu LysSer Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala LeuGln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu GluLeu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro LeuSer Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu SerGln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln AlaLeu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr LeuGln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln MetGlu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly AlaMet Pro Ala Phe Ala (SEQ ID NO:185)

EXAMPLE 73

Construction of Tandemly-Duplicated Plasmid Template, Syntan1

To create the tandemly-duplicated hIL-3 receptor agonist pMON13416 template, Syntan1, three DNAs were joined by means of ligation using T4 DNA ligase (Boehringer Mannheim). The three DNAs are: 1) pMON13046, containing hIL-3 receptor agonist pMON13416, digested with BstEII and SnaBI; 2) the annealed complimentary pair of synthetic oligonucleotides, L1syn.for (SEQ ID NO:48) and L1syn.rev (SEQ ID NO:49), which contain sequence encoding the linker that connects the C-terminal and N-terminal ends of the original protein and a small amount of surrounding pMON13416 sequence and which when properly assembled result in BstEII and ClaI ends; and 3) a portion of hIL-3 receptor agonist pMON13416 digested from pMON13046 with ClaT (DNA had been grown in the dam- cells, DM1 (Life Technologies)) and SnaBI. The digested DNAs were resolved on a 0.9% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101).

A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Miniprep DNA was isolated from the transformants, and the transformants were screened using a PCR based assay. Plasmid DNA from selected transformants was sequenced to obtain the correct template. The resulting plasmid was designated syntan1 and contains the DNA sequence of (SEQ ID NO:84).

EXAMPLE 74

Construction of Tandemly-Duplicated Template, Syntan3

To create the tandemly-duplicated hIL-3 receptor agonist pMON13416 template, syntan3, three DNAs were joined by means of ligation using T4 DNA ligase (Boehringer Mannheim). The three DNAs are: 1) pMON13046, containing hIL-3 receptor agonist pMON13416, digested with BstEII and SnaBI; 2) the annealed complimentary pair of synthetic oligonucleotides, L3syn.for (SEQ ID NO:50) and L3syn.rev (SEQ ID NO:51), which contain sequence encoding the linker that connects the C-terminal and N-terminal ends of the original protein and a small amount of surrounding pMON13416 sequence and which when properly assembled result in BstEII and SnaBI ends; and 3) a portion of hIL-3 receptor agonist pMON13416 digested from pMON13046 with ClaI (DNA had been grown in the dam- cells, DM1 (Life Technologies)) and SnaBI. The digested DNAs were resolved on a 0.9% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101).

A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Miniprep DNA was isolated from the transformants, and the transformants were screened using a PCR based assay. Plasmid DNA from selected transformants was sequenced to obtain the correct template. The resulting plasmid was designated syntan3 and contains the DNA sequence of (SEQ ID NO:85).

EXAMPLE 75

Construction of pMON31104

The new N-terminus/C-terminus gene in pMON31104 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan1, using the primer set 35 start (SEQ ID NO:52) and 34 rev (SEQ ID NO:53).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, Calif.). The purified digested DNA fragment was ligated into the expression vector,pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, Calif.) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31104.

E. coli strain JM101 was transformed with pMON31104 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31104, contains the DNA sequence of (SEQ ID NO:86) which encodes the following amino acid sequence: Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu MetAsp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu ArgAsn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser ArgHis Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg GluLys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu GlnGln Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile IleHis His Leu Lys Arg Pro Pro Ala Pro Leu Tyr Val Glu Gly GlyGly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile AsnPro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met AlaThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly GlySer Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu CysAla Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu GlyHis Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro SerGln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser GlyLeu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile SerPro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val AlaAsp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly MetAla Pro Ala Leu Gln Pro (SEQ ID NO:186)

EXAMPLE 76

Construction of pMON31105

The new N-terminus/C-terminus gene in pMON31105 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan1, using the primer set 70 start (SEQ ID NO:54) and 69 rev (SEQ ID NO:55).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, Calif.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, Calif.) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31105.

E. coli strain JM101 was transformed with pMON31105 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31105, contains the DNA sequence of (SEQ ID NO:87) which encodes the protein with the following amino acid sequence: Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro CysLeu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile IleLys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe TyrLeu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly SerAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val Glu Gly GlyGly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile AsnPro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met AlaThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly GlySer Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu CysAla Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu GlyHis Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro SerGln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser GlyLeu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile SerPro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val AlaAsp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly MetAla Pro Ala Leu Gln Pro (SEQ ID NO:187)

EXAMPLE 77

Construction of pMON31106

The new N-terminus/C-terminus gene in pMON31106 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan1, using the primer set 91 start (SEQ ID NO:56) and 90 rev (SEQ ID NO:57).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, Calif.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, Calif.) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31106.

E. coli strain JM101 was transformed with pMON31106 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31106, contains the DNA sequence of (SEQ ID NO:80) which encodes the protein with the following amino acid sequence: Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp GlnGlu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu GlnAla Gln Glu Gln Gln Gly Gly Gly Ser Asn Cys Ser Ile Met IleAsp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu LeuAsp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met AspArg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala ValLys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser Ala Thr Ala Tyr Val Glu Gly GlyGly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile AsnPro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met AlaThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly GlySer Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu CysAla Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu GlyHis Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro SerGln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser GlyLeu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile SerPro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val AlaAsp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly MetAla Pro Ala Leu Gln Pro (SEQ ID NO:188)

EXAMPLE 78

Construction of pMON31107

The new N-terminus/C-terminus gene in pMON31107 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan1, using the primer set 101 start (SEQ ID NO:58) and 100 rev (SEQ ID NO:59).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested The DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, Calif.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, Calif.) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31107.

E. coli strain JM101 was transformed with pMON31107 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31107, contains the DNA sequence of (SEQ ID NO:89) which encodes the following amino acid sequence: Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr LeuVal Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser AsnCys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg ProPro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp ValSer Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu SerPhe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile GluAla Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr AlaAla Pro Ser Arg His Pro Ile Ile Ile Lys Tyr Val Glu Gly GlyGly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile AsnPro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met AlaThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly GlySer Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu CysAla Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu GlyHis Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro SerGln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser GlyLeu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile SerPro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val AlaAsp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly MetAla Pro Ala Leu Gln Pro (SEQ ID NO:189)

EXAMPLE 79

Construction of pMON31108

The new N-terminus/C-terminus gene in pMON31108 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan3, using the primer set 35 start (SEQ ID NO:52) and 34 rev (SEQ ID NO:53).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, Calif.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, Calif.) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31108.

E. coli strain JM101 was transformed with pMON31108 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31108, contains the DNA sequence of (SEQ ID NO:90) which encodes the following amino acid sequence: Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu MetAsp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu ArgAsn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser ArgHis Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg GluLys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu GlnGln Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro ProAla Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu ProSer Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys GluSer His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro AlaPhe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val AlaSer His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu ArgHis Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser PheLeu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp GlyAla Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys HisPro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro TrpAla Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala GlyCys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly LeuLeu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr LeuAsp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile TrpGln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro(SEQ ID NO:190)

EXAMPLE 80

Construction of pMON31109

The new N-terminus/C-terminus gene in pMON31109 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan3, using the primer set 70 start (SEQ ID NO:54) and 69 rev (SEQ ID NO:55).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, Calif.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, Calif.) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31109.

E. coli strain JM101 was transformed with pMON31109 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31109, contains the DNA sequence of (SEQ ID NO:91) which encodes the following amino acid sequence: Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro CysLeu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile IleLys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe TyrLeu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly SerGly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile AspGlu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu AspPro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp ArgAsn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val LysAsn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu ProSer Gly Pro Ile Ser Phr Ile Asn Pro Ser Pro Pro Ser Lys GluSer His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro AlaPhe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val AlaSer His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu ArgHis Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser PheLeu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp GlyAla Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys HisPro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro TrpAla Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala GlyCys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly LeuLeu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr LeuAsp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile TrpGln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro(SEQ ID NO:191)

EXAMPLE 81

Construction of pMON31110

The new N-terminus/C-terminus gene in pMON31110 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan3, using the primer set 91 start (SEQ ID NO:56) and 90 rev (SEQ ID NO:57).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, Calif.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, Calif.) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31110.

E. coli strain JM101 was transformed with pMON31110 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31110, contains the DNA sequence of (SEQ ID NO:92) which encodes the following amino acid sequence: Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp GlnGlu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu GlnAla Gln Glu Gln Gln Gly Gly Gly Ser Gly Gly Gly Ser Gly GlyGly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His LeuLys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn AspGlu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro AsnLeu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala SerGly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro SerAla Thr Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu ProSer Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys GluSer His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro AlaPhe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val AlaSer His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu ArgHis Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser PheLeu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp GlyAla Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys HisPro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro TrpAla Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala GlyCys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly LeuLeu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr LeuAsp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile TrpGln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro(SEQ ID NO:192)

EXAMPLE 82

Construction of pMON31111

The new N-terminus/C-terminus gene in pMON31111 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan3, using the primer set 101 start (SEQ ID NO:58) and 100 rev (SEQ ID NO:59).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, Calif.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, Calif.) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5.alpha. cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31111.

E. coli strain JM101 was transformed with pMON31111 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31111, contains the DNA sequence of (SEQ ID NO:93) which encodes the following amino acid sequence: Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr LeuVal Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser GlyGly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp GluIle Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp ProAsn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg AsnLeu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys AsnLeu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu GlnPro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro IleIle Ile Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu ProSer Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys GluSer His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro AlaPhe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val AlaSer His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu ArgHis Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser PheLeu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp GlyAla Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys HisPro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro TrpAla Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala GlyCys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly LeuLeu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr LeuAsp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile TrpGln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro(SEQ ID NO:193)

EXAMPLE 83

Construction of pMON31112

Construction of pMON31112, a plasmid containing DNA sequence encoding a multi-functional hematopoietic receptor agonist which activates the hIL-3 receptor and G-CSF receptor. Plasmid, pMON13189 DNA was digested with restriction enzymes NcoI and XmaI resulting in an NcoI, XmaI vector fragment that was isolated and purified from a 0.8% agarose gel. The DNA from a second plasmid, pMON13222 (WO 94/12639, U.S. Ser. No. 08/411,796) was digested with NcoI and EcoRI resulting in a 281 base pair NcoI, EcoRI fragment. This fragment was isolated and purified from a 1.0% agarose gel. Two oligonucleotides SYNNOXA1.REQ (SEQ ID NO:240) and SYNNOXA2.REQ (SEQ ID NO:241) were annealed and ligated with the 281 base pair DNA fragment from pMON13222 to the DNA vector fragment from pMON13189. A portion of the ligation mixture was then transformed into E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment, and sequenced to confirm the correct inserts.

The plasmid, pMON31112, contains the DNA sequence of (SEQ ID NO:114) which encodes the following amino acid sequence:

MetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeuProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleHisIleLysAspGlyAspTrpAsnGluPheArgArGlysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro(SEQ ID NO:199)

Construction of pMON31113

Construction of pMON31113, a plasmid containing DNA sequence encoding a multi-functional hematopoietic receptor agonist which activates the hIL-3 receptor and G-CSF receptor. Plasmid, pMON13197 DNA was digested with restriction enzymes NcoI and XmaI resulting in an NcoI, XmaI vector fragment that was isolated and purified from a 0.8% agarose gel. The DNA from a second plasmid, pMON13239 (WO 94/12639, U.S. Ser. No. 08/411,796) was digested with NcoI and EcoRI resulting in a 281 base pair NcoI, EcoRI fragment. This fragment was isolated and purified from a 1.0% agarose gel. Two oligonucleotides SYNNOXA1.REQ (SEQ ID NO:240) and SYNNOXA2.REQ (SEQ ID NO:241) were annealed and ligated with the 281 base pair DNA fragment from pMON13239 to the DNA vector fragment from pMON13197. A portion of the ligation mixture was then transformed into E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment, and sequenced to confirm the correct inserts.

The plasmid, pMON31113, contains the DNA sequence of (SEQ ID NO:115) which encodes the following amino acid sequence: MetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeuProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleIleIleArgAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro(SEQ ID NO:200)

EXAMPLE 85

Construction of pMON31114

Construction of pMON31114, a plasmid containing DNA sequence encoding a multi-functional hematopoietic receptor agonist which activates the hIL-3 receptor and G-CSF receptor. Plasmid, pMON13189 DNA was digested with restriction enzymes NcoI and XmaI resulting in an NcoI, XmaI vector fragment that was isolated and purified from a 0.8% agarose gel. The DNA from a second plasmid, pMON13239 (WO 94/12639, U.S. Ser. No. 08/411,796), was digested with NcoI and EcoRI resulting in a 281 base pair NcoI, EcoRI fragment. This fragment was isolated and purified from a 1.0% agarose gel. Two oligonucleotides SYNNOXA1.REQ (SEQ ID NO:240) and SYNNOXA2.REQ (SEQ ID NO:241) were annealed and ligated with the 281 base pair DNA fragment from pMON13239 to the DNA vector fragment from pMON13189. A portion of the ligation mixture was then transformed into E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment, and sequenced to confirm the correct inserts.

The plasmid, pMON31114, contains the DNA sequence of (SEQ ID NO:116) which encodes the following amino acid sequence:

MetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeuProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspI1eLeuMetGluAsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProcysLeuProLeuAlaThrAlaAlaProThrArgHisProIleIleIleArgAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro(SEQ ID NO:201)

EXAMPLE 86

Construction of pMON31115

Construction of pMON31115, a plasmid containing DNA sequence encoding a multi-functional hematopoietic receptor agonist which activates the hIL-3 receptor and G-CSF receptor. Plasmid, pMON13197 DNA was digested with restriction enzymes NcoI and XmaI resulting in an NcoI, XmaI vector fragment that was isolated and purified from a 0.8% agarose gel. The DNA from a second plasmid, pMON13222, was digested with NcoI and EcoRI resulting in a 281 base pair NcoI, EcoRI fragment. This fragment was isolated and purified from a 1.0% agarose gel. Two oligonucleotides SYNNOXA1.REQ (SEQ ID NO:240) and SYNNOXA2.REQ (SEQ ID NO:241) were annealed and ligated with the 281 base pair DNA fragment from pMON13222 to the DNA vector fragment from pMON13197. A portion of the ligation mixture was then transformed into E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment, and sequenced to confirm the correct inserts.

The plasmid, pMON31115, contains the DNA sequence of (SEQ ID NO:117) which encodes the following amino acid sequence:

MetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeuProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleHisIleLysAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValargLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro(SEQ ID NO:202)

EXAMPLE 87

Determination of the in vitro activity of multi-functional hematopoietic receptor agonist proteins

The protein concentration of the multi-functional hematopoietic receptor agonist protein can be determined using a sandwich ELISA based on an affinity purified polyclonal antibody. Alternatively the protein concentration can be determined by amino acid composition analysis. The bioactivity of the multi-functional hematopoietic receptor agonist can be determined in a number of in vitro assays. For example a multi-functional hematopoietic receptor agonist which binds the hIL-3 receptor and G-CSF receptor can be assayed in cell proliferation assays using cell lines expressing the hIL-3 and/or G-CSF receptors. One such assay is the AML-193 cell proliferation assay. AML-193 cells respond to IL-3 and G-CSF which allows for the combined bioactivity of the IL-3/G-CSF multi-functional hematopoietic receptor agonist to be determined. Another such assay is the TF1 cell proliferation assay.

In addition other factor dependent cell lines, such as M-NFS-60 (ATCC. CRL 1838) or 32D which are murine IL-3 dependent cell line, may be used. The activity of IL-3 is species specific whereas G-CSF is not, therefore the bioactivity of the G-CSF component of the IL-3/G-CSF multi-functional hematopoietic receptor agonist can be determined independently. Cell lines, such as BHK or murine Baf/3, which do not express the receptor for a given ligand can be transfected with a plasmid containing a gene encoding the desired receptor. An example of such a cell line is BaF3 transfected with the hG-CSF receptor (BaF3/hG-CSF). The activity of the multi-functional hematopoietic receptor agonist in these cell lines can be compared with hIL-3 or G-CSF alone or together. The bioactivity of examples of multi-functional hematopoietic receptor agonists of the present invention assayed in the BaF3/hG-CSF cell proliferation and TF1 cell proliferation assays is shown in Table 5 and Table 6. The bioactivity of the multi-functional hematopoietic receptor agonist is expressed as relative activity compared with a standard protein pMON13056 (WO 95/21254). The bioactivity of examples of multi-functional hematopoietic receptor agonists of the present invention assayed in the BaF3/c-mpl cell proliferation and TF1 cell proliferation assays is shown in Table 7 and Table 8.

TABLE 5______________________________________CELL PROLIFERATIVE ACTIVITYOF DUAL IL-3/G-CSF RECEPTOR AGONISTS BaF3/hG-CSF receptor TF1 cell proliferation cell proliferation assaypMON relative activity* relative activity*______________________________________13182 0.015 1.113183 0.02 nd13184 0.01 0.313185 0.023 0.3613186 0.36 0.4513187 0.07 0.2613188 0.64 1.313189 0.58 1.3713190 0.045 1.213191 0.14 2.713192 0.09 2.213193 0.06 3.025190 nd25191 0.43 1.213194 nd13195 1.3 4.313196 0.66 0.513197 0.6 0.7713198 0.6 0.513199 nd15982 0.7 1.915981 0.068 1.215965 0.7 0.8215966 0.36 1.4815967 0.62 1.37______________________________________ nd = not determined *The bioactivity of the multifunctional hematopoietic receptor agonist is expressed as relative activity compared with a standard protein pMON13056 n = 3 or greater TABLE 6______________________________________CELL PROLIFERATIVE ACTIVITYOF DUAL IL-3/G-CSF RECEPTOR AGONISTS BaF3/hG-CSF receptor TF1 cell proliferation cell proliferation assay assaypMON relative activity relative activity______________________________________31104 + +31105 + +31106 + +31107 nd nd31108 + +31109 + +31110 nd nd31111 nd nd31112 + +31113 + +31114 + +31115 + +31116 nd nd31117 nd nd______________________________________ nd = not determined .dagger. The bioactivity (n = 1 or 2) of the multifunctional hematopoieti receptor agonist is expressed as relative activity compared with a standard protein pMON13056. "+" indicates that the molecule was comparable to pMON13056. TABLE 7______________________________________CELL PROLIFERATION ACTIVITY Baf3/c-mpl receptor TF1 cell proliferation cell proliferation assay assaypMON activity* activity______________________________________28505 - +28506 + -28507 + -28508 + -28509 + -28510 + -28511 +28512 +28513 +28514 +28519 + -28520 + -28521 + -28522 + -28523 + -28524 + -28525 +28526 +28533 +28534 + -28535 + -28536 + -28537 +28538 + -28539 +28540 +28541 +28542 +28543 +28544 +28545 +______________________________________ *Activity measured in the Baf3 cell line transfected with the cmpl receptor, relative to cmpl ligand (1-153). .dagger. Activity measured relative to pMON13056.

In a similar manner other factor dependent cell lines known to those skilled in the art can be used to measure the bioactivity of the desired multi-functional hematopoietic receptor agonist. The methylcellulose assay can be used to determine the effect of the multi-functional hematopoietic receptor agonists on the expansion of the hematopoietic progenitor cells and the pattern of the different types of hematopoietic colonies in vitro. The methylcellulose assay can provide an estimate of precursor frequency since one measures the frequency of progenitors per 100,000 input cells. Long term, stromal dependent cultures have been used to delineate primitive hematopoietic progenitors and stem cells. This assay can be used to determine whether the multi-functional hematopoietic receptor agonist stimulates the expansion of very primitive progenitors and/or stem cells. In addition, limiting dilution cultures can be performed which will indicate the frequency of primitive progenitors stimulated by the multi-functional hematopoietic receptor agonist.

TABLE 8______________________________________ c-mpl receptor agonist IL-3 agonist activity activity (AML cell (Baf/3-c-mpl cellpMON # proliferation assay) proliferation assay______________________________________28505 + -28506 - +28507 - +28508 - +28509 - +28510 - +28511 +28512 +28513 +28514 +28515 +28519 - +28520 - +28521 - +28522 - +28523 - +28524 - +28525 +28526 +28527 +28528 +28529 +28535 - +28539 +28540 +28541 +28542 +28545 +______________________________________

EXAMPLE 88

G-CSF variants which contain single or multiple amino acid substitutions were made using PCR mutagenesis techniques as described in WO 94/12639 and WO 94/12638. These and other variants (i.e. amino acid substitutions, insertions or deletions and N-terminal or C-terminal extensions) could also be made, by one skilled in the art, using a variety of other methods including synthetic gene assembly or site-directed mutagenesis (see Taylor et al., Nucl. Acids Res., 13: 7864-8785 [1985]; Kunkel et al., Proc. Natl. Acad. Sci. USA, 82: 488-492 [1985]; Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., [1989], (WO 94/12639) and (WO 94/12638)). These substitutions can be made one at a time or in combination with other amino acid substitutions, and/or deletions, and/or insertions and/or extensions. After sequence verification of the changes, the plasmid DNA can be transfected into an appropriate mammalian cell, insect cell or bacterial strain such as E. coli for production. Known variants of G-CSF, which are active, include substitutions at positions 1 (Thr to Ser, Arg or Gly, 2 (Pro to Leu), 3 (Leu to Arg or Ser) and 17 (Cys to Ser) and deletions of amino acids 1-11 (Kuga et al. Biochemicla and Biophysical Research Comm. 159:103-111 (1989)). These G-CSF amino acid substitution variants can be used as the template to create the G-CSF receptor agonists in which a new N-terminus and new C-terminus are created. Examples of G-CSF amino acid substitution variants are shown in Table 9.

EXAMPLE 89

Bioactivity determination of G-CSF amino acid substitution variants

The G-CSF amino acid substitution variants can be assayed for cell proliferation activity using the Baf/3 cell line transfected with the human G-CSF receptor. The bioactivity of examples of G-CSF amino acid substitution variants is shown in Table 9 relative to native human G-CSF. A "+" indicates a comparable activity to native and a "-" indicates significantly reduced or no measurable activity.

TABLE 9______________________________________CELL PROLIFERATION ACTIVITY OF G-CSF VARIANTS IN BAF3CELL LINE TRANSFECTED WITH THE HUMAN G-CSF RECEPTORaa position native aa mutant aa activity*______________________________________13 Phe Ser +13 Phe +13 Phe +13 Phe +16 Lys +16 Lys +16 Lys +16 Lys +18 Leu +18 Leu +18 Leu +18 Leu +18 Leu +19 Glu - Ala19 Glu - Thr19 Glu - Arg19 Glu - Pro19 Glu - Leu19 Glu - Ser22 Arg +22 Arg +22 Arg +22 Arg +24 Ile +24 Ile +24 Ile +27 Asp +30 Ala +30 Ala +34 Lys +43 His +43 His +43 His +43 His +43 His +43 His +43 His +43 His +43 His +44 Pro +44 Pro +44 Pro +44 Pro +44 Pro +44 Pro +44 Pro +44 Pro +44 Pro +46 Glu +46 Glu +47 Leu +49 Leu +49 Leu +49 Leu +50 Leu +54 Leu +67 Gln +67 Gln +67 Gln +70 Gln +70 Gln +70 Gln +70 Gln +104 Asp +104 Asp +108 Leu +108 Leu +108 Leu +108 Leu +108 Leu +108 Leu +115 Thr +115 Thr +115 Thr +144 Phe +144 Phe +144 Phe +144 Phe +144 Phe +146 Arg +147 Arg +156 His - Asp156 His +156 His +159 Ser +159 Ser +159 Ser +159 Ser +159 Ser +162 Glu - Gly162 Glu +162 Glu +163 Val +163 Val +163 Val +165 Tyr nd169 Ser +169 Ser +169 Ser +170 His +170 His +______________________________________ *activity relative to native hGCSF nd = not determined

EXAMPLE 90

Cysteine Substitution Variants

The multi-functional receptor agonists may comprise sequence rearranged c-mpl receptor agonist, which also have the substitution of the cysteine residues at position 7 and/or 151 with an another amino acid, which can be prepared by the methods described in Examples 1-89 and by other methods known to those skilled in the art. One such c-mpl receptor agonist has the breakpoint at 115/116 and alanine at positions 7 and 151. This c-mpl receptor agonist has the following amino acid:

MetAlaGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuAlaValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaAlaAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuPro ProGln (SEQ ID NO:284), and is encoded by the following DNA sequence; 1 ATGGCTGGCA GGACCACAGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG 51 CTTCCAACAC CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG101 GGTCCACCCT CGCCGTCAGG GAATTCGGCG GCAACATGGC GTCTCCGGCG151 CCGCCTGCTG CTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA201 TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA251 CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGA ATGGAAAACC301 CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT351 GCTGGAGGGA GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT401 CATCCCTCCT GGGGCAGCTT TCTGGACAGG TCCGTCTCCT CCTTGGGGCC451 CTGCAGAGCC TCCTTGGAAC CCAGCTTCCT CCACAG (SEQ ID NO:287). Another c-mpl receptor agonist has the breakpoint at 81/82 and alanine at positions 7 and 151. This c-mpl receptor agonist has the following amino acid; MetAlaGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuAlaValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaAlaAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGly GlnLeu, (SEQ ID NO:285), and is encoded by the following DNA sequence; 1 ATGGCTGGAC CCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACA 51 GGTCCGTCTC CTCCTTGGGG CCCTGCAGAG CCTCCTTGGA ACCCAGCTTC101 CTCCACAGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CATCTTCCTG151 AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG201 AGGGTCCACC CTCGCCGTCA GGGAATTCGG CGGCAACATG GCGTCTCCGG251 CGCCGCCTGC TGCTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC301 CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC351 TACACCTGTC CTGCTGCCTG CTGTGGACTT TAGCTTGGGA GAATGGAAAA401 CCCAGATGGA GGAGACCAAG GCACAGGACA TTCTGGGAGC AGTGACCCTT451 CTGCTGGAGG GAGTGATGGC AGCACGGGGA CAACTG (SEQ ID NO:286)

EXAMPLES 91-103

The plasmids in Table 10 contain genes encoding multi-functional hematopoietic receptor agonists comprising a sequence rearranged G-CSF receptor agonists that were made by the method of Horlich et al (Protein Eng. 5:427-431, 1992). As described in Materials and Methods, the tandem repeat of the G-CSF Ser.sup.17 gene was maintained on a pACYC177 based plasmid (Chang and Cohen, J. Bacteriol. 1341141-1156, 1978), containing the sequence; GAG ATG GCT, encoding; Asp Met Ala, following immediately downstream of amino acid 174 of the first copy of the G-CSF Ser.sup.17 gene and immediately preceeding amino acid 1 of the second copy of the G-CSF Ser.sup.17 gene. The resulting sequence rearranged G-CSF receptor agonists have the linker; Asp Met Ala, between the original C-terminus and original N-terminus of G-CSF Ser.sup.17. The sequence rearranged G-CSF receptor agonists encoded by the plasmids of Table 10 were identified using a G-CSF receptor binding screen (Wantanabe et al. Analyt. Biochem 195:38-44, 1991). The multi-functional receptor agonists shown in Table 10 had G-CSF receptor binding comparable to or better than native recombinant hG-CSF.

TABLE 10______________________________________plasmid proteindesignation breakpoint gene sequence sequence______________________________________pMON16017 2-3 SEQ ID NO:294 SEQ ID NO:306pMON16018 10-11 SEQ ID NO:288 SEQ ID NO:300pMON16019 12-13 SEQ ID NO:291 SEQ ID NO:303pMON16021 48-49 SEQ ID NO:295 SEQ ID NO:307pMON16022 59-60 SEQ ID NO:296 SEQ ID NO:308pMON16023 66-67 SEQ ID NO:297 SEQ ID NO:309pMON16024 68-69 SEQ ID NO:298 SEQ ID NO:310pMON16025 122-123 SEQ ID NO:289 SEQ ID NO:301pMON16028 158-159 SEQ ID NO:292 SEQ ID NO:304pMON16025 70-71 SEQ ID NO:299 SEQ ID NO:311pMON16027 124-125 SEQ ID NO:290 SEQ ID NO:302pMON16020 18-19 SEQ ID NO:293 SEQ ID NO:305pMON16029 169-170 SEQ ID NO:313 SEQ ID NO:312______________________________________

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

More details concerning the molecular biology techniques, protein purification and bioassays can be found in WO 94/12639, WO 94/12638, WO 95/20976, WO 95/21197, WO 95/20977, WO 95/21254, are hereby incorporated by reference in their entirety.

All references, patents or applications cited herein are incorporated by reference in their entirety as if written herein.

Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. It is intended that all such other examples be included within the scope of the appended claims.

__________________________________________________________________________# SEQUENCE LISTING- (1) GENERAL INFORMATION:- (iii) NUMBER OF SEQUENCES: 313- (2) INFORMATION FOR SEQ ID NO:1:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 174 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: protein- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 1#/note= "Xaa at position 1 is Thr, Ser, Arg, - # Tyr or Gly;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 2#/note= "Xaa at position 2 is Pro or Leu;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 3#/note= "Xaa at position 3 is Leu,#or Ser;" Arg, Tyr- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 13#/note= "Xaa at position 13 is Phe, Ser, His, - # Thr or Pro;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 16#/note= "Xaa at position 16 is Lys, Pro, Ser, - # thr or His;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 17#/note= "Xaa at position 17 is Cys, Ser, Gly, - # Ala, Ile, Tyr or Arg;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 18#/note= "Xaa at position 18 is Leu, Thr, Pro, - # His, Ile or Cys;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 22#/note= "Xaa at position 22 is Arg, Tyr, Ser, - # Thr or Ala;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 24#/note= "Xaa at position 24 is Ile,#or Leu;" Pro, Tyr- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 27#/note= "Xaa at position 27 is Asp, or Gly;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 30#/note= "Xaa at position 30 is Ala,#or Gly;" Ile, Leu- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 34#/note= "Xaa at position 34 is Lys or Ser;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 36#/note= "Xaa at position 36 is Cys or Ser;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 42#/note= "Xaa at position 42 is Cys or Ser;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 43#/note= "Xaa at position 43 is His, Thr, Gly, - # Val, Lys, Trp, Ala, Arg, Cys, or Leu;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 44#/note= "Xaa at position 44 is Pro, Gly, Arg, - # Asp, Val, Ala, His, Trp, Gln, or Thr;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 46#/note= "Xaa at position 46 is Glu, Arg, Phe, - # Arg, Ile or Ala;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 47#/note= "Xaa at position 47 is Leu or Thr;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 49#/note= "Xaa at position 49 is Leu,#or Ser;" Phe, Arg- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 50#/note= "Xaa at position 50 is Leu, Ile, His, - # Pro or Tyr;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 54#/note= "Xaa at position 54 is Leu or His;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 64#/note= "Xaa at position 64 is Cys or Ser;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 67#/note= "Xaa at position 67 is Gln,#or Cys;" Lys, Leu- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 70#/note= "Xaa at position 70 is Gln, Pro, Leu, - # Arg or Ser;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 74#/note= "Xaa at position 74 is Cys or Ser;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 104#/note= "Xaa at position 104 is Asp,#Val;" Gly or- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 108#/note= "Xaa at position 108 is Leu, Ala, Val, - # Arg, Trp, Gln or Gly;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 115#/note= "Xaa at position 115 is Thr,#or Ala;" His, Leu- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 120#/note= "Xaa at position 120 is Gln, Gly, Arg, - # Lys or His"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 123#/note= "Xaa at position 123 is Glu,#or Thr" Arg, Phe- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 144#/note= "Xaa at position 144 is Phe, His, Arg, - # Pro, Leu, Gln or Glu;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 146#/note= "Xaa at position146 is Arg or Gln;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 147#/note= "Xaa ap position 147 is Arg or Gln;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 156#/note= "Xaa at position 156 is His,#Ser;" Gly or- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 159#/note= "Xaa at position 159 is Ser, Arg, Thr, - # Tyr, Val or Gly;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 162#/note= "Xaa at position 162 is Glu,#or Trp;" Leu, Gly- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 163#/note= "Xaa at position 163 is Val,#or Ala;" Gly, Arg- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 169#/note= "Xaa at position 169 is Arg, Ser, Leu, - # Arg or Cys;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 170#/note= "Xaa at position 170 is His,#Ser;" Arg or- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:- Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu Pro Gl - #n Ser Xaa Leu Leu Xaa# 15- Xaa Xaa Glu Gln Val Xaa Lys Xaa Gln Gly Xa - #a Gly Ala Xaa Leu Gln# 30- Glu Xaa Leu Xaa Ala Thr Tyr Lys Leu Xaa Xa - #a Xaa Glu Xaa Xaa Val# 45- Xaa Xaa Gly His Ser Xaa Gly Ile Pro Trp Al - #a Pro Leu Ser Ser Xaa# 60- Pro Ser Xaa Ala Leu Xaa Leu Ala Gly Xaa Le - #u Ser Gln Leu His Ser#80- Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Al - #a Leu Glu Gly Ile Ser# 95- Pro Glu Leu Gly Pro Thr Leu Xaa Thr Leu Gl - #n Xaa Asp Val Ala Asp# 110- Phe Ala Xaa Thr Ile Trp Gln Gln Met Glu Xa - #a Xaa Gly Met Ala Pro# 125- Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Al - #a Phe Ala Ser Ala Xaa# 140- Gln Xaa Xaa Ala Gly Gly Val Leu Val Ala Se - #r Xaa Leu Gln Xaa Phe145 1 - #50 1 - #55 1 -#60- Leu Xaa Xaa Ser Tyr Arg Val Leu Xaa Xaa Le - #u Ala Gln Pro# 170- (2) INFORMATION FOR SEQ ID NO:2:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 133 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 17#/note= "Xaa at position 17 is Ser, Lys, Gly, - # Asp, Met, Gln, or Arg;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 18#/note= "Xaa at position 18 is Asn, His, Leu, - # Ile, Phe, Arg, or Gln;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 19#/note= "Xaa at position 19 is Met, Phe, Ile, - # Arg, Gly, Ala, or Cys;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 20#/note= "Xaa at position 20 is Ile, Cys, Gln, - # Glu, Arg, Pro, or Ala;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 21#/note= "Xaa at position 21 is Asp,#Val;" Phe, Lys, - # Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 22#/note= "Xaa at position 22 is Glu,#Gly;" Trp, Pro, - # Ser, Ala, His, Asp, Asn, Gln, Leu, Val or- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 23#/note= "Xaa at position 23 is Ile, Val, Ala, - # Gly, Trp, Lys, Phe, Leu, Ser, or Arg;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 24#/note= "Xaa at position 24 is Ile, Gly, Val, - # Arg, Ser, Phe, Leu;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 25#/note= "Xaa at position 25 is Thr, His, Gly, - # Gln, Arg, Pro, or Ala;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 26#/note= "Xaa at position 26 is His, Thr, Phe, - # Gly, Arg, Ala, Trp;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 27#/note= "Xaa at position 27 is Leu, Gly, Arg, - # Thr, Ser, or Ala;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 28#/note= "Xaa at position 28 is Lys, Arg, Leu, - # Gln, Gly, Pro, Val or Trp;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 29#/note= "Xaa at position 29 is Gln, Asn, Leu, - # Pro, Arg, or Val;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 30#/note= "Xaa at position 30 is Pro, His, Thr, - # Gly, Asp, Gln, Ser, Leu, or L..."- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 31#/note= "Xaa at position 31 is Pro, Asp, Gly, - # Ala, Arg, Leu, or Gln;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 32#/note= "Xaa at position 32 is Leu, Val, Arg, - # Gln, Asn, Gly, Ala, or Glu;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 33#/note= "Xaa at position 33 is Pro, Leu, Gln, - # Ala, Thr, or Glu;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 34#/note= "Xaa at position 34 is Leu, Val, Gly, - # Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile- # or Met;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 35#/note= "Xaa at position 35 is Leu, Ala, Gly, - # Asn, Pro, Gln, or Val;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 36#/note= "Xaa at position 36 is Asp,#Val;" Leu, or- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 37#/note= "Xaa at position 37 is Phe, Ser, Pro, - # Trp, or Ile;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 38#/note= "Xaa at position 38 is Asn, or Ala;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 40#/note= "Xaa at position 40 is Leu,#Arg;" Trp, or- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 41#/note= "Xaa at position 41 is Asn, Cys, Arg, - # Leu, His, Met, or pro;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 42#/note= "Xaa at position 42 is Gly, Asp, Ser, - # Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr- #, Ile, Met or Ala;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 43#/note= "Xaa at position 43 is Glu, Asn, Tyr, - # Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly- #, or Ser;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 44#/note= "Xaa at position 44 is Asp, Ser, Leu, - # Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala- # or Pro;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 45#/note= "Xaa at position 45 is Gln, Pro, Phe, - # Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg- #, Ser, Ala,#or His;" Ile, Glu- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 46#/note= "Xaa at position 46 is Asp, Phe, Ser, - # Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr- #, Ile, Val or Gly;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 47#/note= "Xaa at position 47 is Ile, Gly, Val, - # Ser, Arg, Pro, or His;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 48#/note= "Xaa at position 48 is Leu, Ser, Cys, - # Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met- #, Val or Asn;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 49#/note= "Xaa at position 49 is Met, Arg, Ala, - # Gly, Pro, Asn, His, or Asp;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 50#/note= "Xaa at position 50 is Glu, Leu, Thr, - # Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His- #, Phe, Met or Gln;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 51#/note= "Xaa at position 51 is Asn, Arg, Met, - # Pro, Ser, Thr, or his;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 52#/note= "Xaa at position 52 is Asn, His, Arg, - # Leu, Gly, Ser, or Thr;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 53#/note= "Xaa at position 53 is Leu, Thr, Ala, - # Gly, Glu, Pro, Lys, Ser, or M..."- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 54#/note= "Xaa at position 54 is Arg,#Leu;" Asp, Ile, - # Ser, Val, Thr, Gln, Asn, Lys, His, Ala or- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 55#/note= "Xaa at position 55 is Arg, Thr, Val, - # Ser, Leu, or Gly;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 56#/note= "Xaa at position 56 is Pro, Gly, Cys, - # Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe- #, Leu, Val or Lys;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 57#/note= "Xaa at position 57 is Asn or Gly;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 58#/note= "Xaa at position 58 is Leu, Ser, Asp, - # Arg, Gln, Val, or Cys;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 59#/note= "Xaa at position 59 is Glu, Tyr, His, - # Leu, Pro, or Arg;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 60#/note= "Xaa at position 60 is Ala, Ser, Pro, - # Tyr, Asn, or Thr;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 61#/note= "Xaa at position 61 is Phe, Asn, Glu, - # Pro, Lys, Arg, or Ser;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 62#/note= "Xaa at position 62 is Asn, His, Val, - # Arg, Pro, Thr, Asp, or Ile;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 63#/note= "Xaa at position 63 is Arg, Tyr, Trp, - # Lys, Ser, His, Pro, or Val;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 64#/note= "Xaa at position 64 is Ala, Asn, Pro, - # Ser, or Lys;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 65#/note= "Xaa at position 65 is Val, Thr, Pro, - # His, Leu, Phe, or Ser;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 66#/note= "Xaa at position 66 is Lys, Ile, Arg, - # Val, Asn, Glu, or Ser;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 67#/note= "Xaa at postion 67 is Ser, Ala, Phe, - # Val, Gly, Asn, Ile, Pro, or His;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 68#/note= "Xaa at position 68 is Leu, Val, Trp, - # Ser, Ile, Phe, Thr, or His;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 69#/note= "Xaa at position 69 is Gln, Ala, Pro, - # Thr, Glu, Arg, Trp, Gly, or L..."- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 70#/note= "Xaa at position 70 is Asn, Leu, Val, - # Trp, pro, or Ala;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 71#/note= "Xaa at position 71 is Ala, Met, Leu, - # Pro, Arg, Glu, Thr, Gln, Trp, or Asn;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 72#/note= "Xaa at position 72 is Ser, Glu, Met, - # Ala, His, Asn, Arg, or Asp;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 73#/note= "Xaa at position 73 is Ala, Glu, Asp, - # Leu, Ser, Gly, Thr, or Arg;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 74#/note= "Xaa at position 74 is Ile, Met, Thr, - # Pro, Arg, Gly, Ala;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 75#/note= "Xaa at position 75 is Glu, Lys, Gly, - # Asp, Pro, Trp, Arg, Ser, Gln, or Leu;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 76#/note= "Xaa at position 76 is Ser, Val, Ala, - # Asn, Trp, Glu, Pro, Gly, or A..."- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 77#/note= "Xaa at position 77 is Ile, Ser, Arg, - # Thr, or Leu;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 78#/note= "Xaa at position 78 is Leu, Ala, Ser, - # Glu, Phe, Gly, or Arg;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 79#/note= "Xaa at position 79 is Lys, Thr, Asn, - # Met, Arg, Ile, Gly, or Asp;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 80#/note= "Xaa position at 80 is Asn, Trp, Val, - # Gly, Thr, Leu, Glu, or Arg;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 81#/note= "Xaa at position 81 is Leu, Gln, Gly, - # Ala, Trp, Arg, Val, or Lys;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 82#/note= "Xaa at position 82 is Leu, Gln, Lys, - # Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala- #, Tyr, Phe,#or Val;" Ile, Met- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 83#/note= "Xaa at position 83 is Pro, Ala, Thr, - # Trp, Arg, or Met;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 84#/note= "Xaa at position 84 is Cys, Glu, Gly, - # Arg, Met, or Val;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 85#/note= "Xaa at position 85 is Leu, Asn, Val, - # or Gln;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 86#/note= "Xaa at position 86 is Pro, Cys, Arg, - # Ala, or Lys;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 87#/note= "Xaa at position 87 is Leu, Ser, Trp, - # or Gly;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 88#/note= "Xaa at position 88 is Ala, Lys, Arg, - # Val, or Trp;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 89#/note= "Xaa at position 89 is Thr, Asp, Cys, - # Leu, Val, Glu, His, Asn, or S..."- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 90#/note= "Xaa at position 90 is Ala, Pro, Ser, - # Thr, Gly, Asp, Ile, or ,Met;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 91#/note= "Xaa at position 91 is Ala, Pro, Ser, - # Thr, Phe, Leu, Asp, or His;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 92#/note= "Xaa at position 92 is Pro, Phe, Arg, - # Ser, Lys, His, Ala, Gly, Ile or Leu;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 93#/note= "Xaa at position 93 is Thr, Asp, Ser, - # Asn, Pro, Ala, Leu, or Arg;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 94#/note= "Xaa at position 94 is Arg, Ile, Ser, - # Glu, Leu, Val, Gln, Lys, His, Ala, or Pro;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 95#/note= "Xaa at position 95 is His, Gln, Pro, - # Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala- #, Trp, Phe,#Tyr;" Ile, or- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 96#/note= "Xaa at position 96 is Pro, Lys, Tyr, - # Gly, Ile, or Thr;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 97#/note= "Xaa at position 97 is Ile, Val, Lys, - # Ala, or Asn;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 98#/note= "Xaa at position 98 is His, Ile, Asn, - # Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met- #, Val, Lys, Arg, Tyr, - # or Pro;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 99#/note= "Xaa at position 99 is Ile, Leu, Arg, - # Asp, Val, Pro, Gln, Gly, Ser, Phe, or His;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 100#/note= "Xaa at position 100 is Lys, Tyr, Leu, - # His, Arg, Ile, Ser, Gln, or ..."- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 101#/note= "Xaa at position is Asp, Pro, Met, - # Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala- #, Gly, Ile,#Gln;" Leu, or- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 102#/note= "Xaa at position 102 is Gly, Leu, Glu, - # Lys, Ser, Tyr, or Pro;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 103#/note= "Xaa at position 103 is Asp, or Ser;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 104#/note= "Xaa at position 104 is Trp, Val, Cys, - # Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe- #, or Gly;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 105#/note= "Xaa at position 105 is Asn, Pro, Ala, - # Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp- #, or His;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 106#/note= "Xaa at position 106 is Glu, Ser, Ala, - # Lys, Thr, Ile, Gly, or Pro;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 108#/note= "Xaa at position 108 is Arg, Lys, Asp, - # Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 109#/note= "Xaa at position 109 is Arg, Thr, Pro, - # Glu, Tyr, Leu, Ser, or Gly;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 110#/note= "Xaa at position 110 is Lys, Ala, Asn, - # Thr, Leu, Arg, Gln, His, Glu, Ser, or Trp;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 111#/note= "Xaa at position 111 is Leu, Ile, Arg, - # Asp, or Met;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 112#/note= "Xaa at position 112 is Thr, Val, Gln, - # Tyr, Glu, His, Ser, or Phe;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 113#/note= "Xaa at position 113 is Phe, Ser, Cys, - # His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val- # or Asn;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 114#/note= "Xaa at position 114 is Tyr, Cys, His, - # Ser, Trp, Arg, or Leu;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 115#/note= "Xaa at position 115 is Leu, Asn, Val, - # Pro, Arg, Ala, His, Thr, Trp, or Met;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 116#/note= "Xaa at position 116 is Lys, Leu, Pro, - # Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn- #, His, Ala, Tyr, Phe, - # Gln, or Ile;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 117#/note= "Xaa at position 117 is Thr, Ser, Asn, - # Ile, Trp, Lys, or Pro;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 118#/note= "Xaa at position 118 is Leu, Ser, Pro, - # Ala, Glu, Cys, Asp, or Tyr;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 119#/note= "Xaa at position 119 is Glu, Ser, Lys, - # Pro, leu, Thr, Tyr, or Arg;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 120#/note= "Xaa at position 120 is Asn, Ala, Pro, - # Leu, His, Val, or Gln;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 121#/note= "Xaa at position 121 is Ala, Ser, Ile, - # Asn, Pro, Lys, Asp, or Gly;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 122#/note= "Xaa at position 122 is Gln, Ser, Met, - # Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 123#/note= "Xaa at position 123 is Ala, Met, Glu, - # His, Ser, Pro, Tyr, or Leu;"- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:- Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Th - #r Ser Trp Val Asn Cys# 15- Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa - #a Xaa Xaa Xaa Xaa Xaa# 30- Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xa - #a Xaa Xaa Xaa Xaa Xaa# 45- Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa - #a Xaa Xaa Xaa Xaa Xaa# 60- Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa - #a Xaa Xaa Xaa Xaa Xaa#80- Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa - #a Xaa Xaa Xaa Xaa Xaa# 95- Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ph - #e Xaa Xaa Xaa Xaa Xaa# 110- Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa - #a Gln Gln Thr Thr Leu# 125- Ser Leu Ala Ile Phe 130- (2) INFORMATION FOR SEQ ID NO:3:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 332 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: protein- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 112#/note= "position 112 is deleted or Leu, Ala, - # Val, Ile, Pro, Phe, Trp, or M..."- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 113#/note= "position 113 is deleted or Pro, Phe, - # Ala, Leu, Ile, Trp, or Met"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 114#/note= "position 114 is deleted or Pro, Phe, - # Ala, Val, Leu, Ile, Trp or Met"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 115#/note= "position 115 is deleted or Gln, Gly, - # Ser, Thr, Tyr or Asn"- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:- Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu# 15- Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val# 30- His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu# 45- Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu# 60- Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln#80- Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln# 95- Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Xaa# 110- Xaa Xaa Xaa Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe# 125- Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu# 140- Val Gly Gly Ser Thr Leu Cys Val Arg Arg Al - #a Pro Pro Thr Thr Ala145 1 - #50 1 - #55 1 -#60- Val Pro Ser Arg Thr Ser Leu Val Leu Thr Le - #u Asn Glu Leu Pro Asn# 175- Arg Thr Ser Gly Leu Leu Glu Thr Asn Phe Th - #r Ala Ser Ala Arg Thr# 190- Thr Gly Ser Gly Leu Leu Lys Trp Gln Gln Gl - #y Phe Arg Ala Lys Ile# 205- Pro Gly Leu Leu Asn Gln Thr Ser Arg Ser Le - #u Asp Gln Ile Pro Gly# 220- Tyr Leu Asn Arg Ile His Glu Leu Leu Asn Gl - #y Thr Arg Gly Leu Phe225 2 - #30 2 - #35 2 -#40- Pro Gly Pro Ser Arg Arg Thr Leu Gly Ala Pr - #o Asp Ile Ser Ser Gly# 255- Thr Ser Asp Thr Gly Ser Leu Pro Pro Asn Le - #u Gln Pro Gly Tyr Ser# 270- Pro Ser Pro Thr His Pro Pro Thr Gly Gln Ty - #r Thr Leu Phe Pro Leu# 285- Pro Pro Thr Leu Pro Thr Pro Val Val Gln Le - #u His Pro Leu Leu Pro# 300- Asp Pro Ser Ala Pro Thr Pro Thr Pro Thr Se - #r Pro Leu Leu Asn Thr305 3 - #10 3 - #15 3 -#20- Ser Tyr Thr His Ser Gln Asn Leu Ser Gln Gl - #u Gly# 330- (2) INFORMATION FOR SEQ ID NO:4:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 base p - #airs (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:# 5- (2) INFORMATION FOR SEQ ID NO:5:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 3 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (ix) FEATURE: (A) NAME/KEY: Peptide (B) LOCATION: 1#/note= "where x=(glyglyglyglyser)n and where - # n is an interger"- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:- Xaa Ala Ala- (2) INFORMATION FOR SEQ ID NO:6:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 3 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (ix) FEATURE: (A) NAME/KEY: Peptide (B) LOCATION: 1- (ix) FEATURE: (A) NAME/KEY: Peptide (B) LOCATION: 1#/note= "where XaaR INFORMATION: =(glyglyg - #lyglyglyser)n and where n is an integer"- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:- Xaa Ala Ala1- (2) INFORMATION FOR SEQ ID NO:7:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 3 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (ix) FEATURE: (A) NAME/KEY: Peptide (B) LOCATION: 1#/note= "where xaa = (gly(n)ser)m and where - # n is an integer and m is an int..."- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:- Xaa Ala Ala1- (2) INFORMATION FOR SEQ ID NO:8:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 3 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (ix) FEATURE: (A) NAME/KEY: Peptide (B) LOCATION: 1#/note= "where Xaa=(alaglyser)n and#is an integer"where n- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:- Xaa Ala Ala1- (2) INFORMATION FOR SEQ ID NO:9:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 36 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:- Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gl - #y Ser Glu Gly Gly Gly# 15- Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Se - #r Glu Gly Gly Gly Ser# 30- Gly Gly Gly Ser 35- (2) INFORMATION FOR SEQ ID NO:10:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 24 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:- Ile Ser Glu Pro Ser Gly Pro Ile Ser Thr Il - #e Asn Pro Ser Pro Pro# 15- Ser Lys Glu Ser His Lys Ser Pro 20- (2) INFORMATION FOR SEQ ID NO:11:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 28 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:- Ile Glu Gly Arg Ile Ser Glu Pro Ser Gly Pr - #o Ile Ser Thr Ile Asn# 15- Pro Ser Pro Pro Ser Lys Glu Ser His Lys Se - #r Pro# 25- (2) INFORMATION FOR SEQ ID NO:12:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 4 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:- Gly Gly Gly Ser1- (2) INFORMATION FOR SEQ ID NO:13:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 45 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:#45 CNGC NCCNCCTGCT TGTGCACTCC GAGTC- (2) INFORMATION FOR SEQ ID NO:14:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:# 30 ACGC AGAGGGTGGA- (2) INFORMATION FOR SEQ ID NO:15:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 33 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:# 33 CGCA GAGGGTGGAC CCT- (2) INFORMATION FOR SEQ ID NO:16:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 10 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:# 10- (2) INFORMATION FOR SEQ ID NO:17:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 10 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:# 10- (2) INFORMATION FOR SEQ ID NO:18:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 13 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:# 13- (2) INFORMATION FOR SEQ ID NO:19:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 13 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:# 13- (2) INFORMATION FOR SEQ ID NO:20:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 22 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:# 22GGC AA- (2) INFORMATION FOR SEQ ID NO:21:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 22 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:# 22CGC CG- (2) INFORMATION FOR SEQ ID NO:22:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 27 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:# 27 ACCC TTTGCCT- (2) INFORMATION FOR SEQ ID NO:23:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:# 29 ACTG GCTCAGTCT- (2) INFORMATION FOR SEQ ID NO:24:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 27 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:# 27 CACC TGTCCTG- (2) INFORMATION FOR SEQ ID NO:25:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:# 29 GAAC CTCTGGGCA- (2) INFORMATION FOR SEQ ID NO:26:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 27 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:# 27 TGCC TGCTGTG- (2) INFORMATION FOR SEQ ID NO:27:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:# 29 TAGG CAAAGGGTG- (2) INFORMATION FOR SEQ ID NO:28:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:# 30 ACTT TAGCTTGGGA- (2) INFORMATION FOR SEQ ID NO:29:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:# 29 GCAG GACAGGTGT- (2) INFORMATION FOR SEQ ID NO:30:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 27 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:# 27 GCTT GGGAGAA- (2) INFORMATION FOR SEQ ID NO:31:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:# 29 CAGG CAGCAGGAC- (2) INFORMATION FOR SEQ ID NO:32:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 27 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:# 27 GGAA AACCCAG- (2) INFORMATION FOR SEQ ID NO:33:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:# 29 TAAA GTCCACAGC- (2) INFORMATION FOR SEQ ID NO:34:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 27 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:# 27 CTTG CCTCTCA- (2) INFORMATION FOR SEQ ID NO:35:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:# 29 GTCC CCGTGCTGC- (2) INFORMATION FOR SEQ ID NO:36:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 27 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:# 27 AGCT TCCTCCA- (2) INFORMATION FOR SEQ ID NO:37:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:# 29 GGCT CTGCAGGGC- (2) INFORMATION FOR SEQ ID NO:38:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 27 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:# 27 CCAC AGCTCAC- (2) INFORMATION FOR SEQ ID NO:39:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:# 30 GAGG AAGCTGGGTT- (2) INFORMATION FOR SEQ ID NO:40:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:# 30 AGGA TCCCAATGCC- (2) INFORMATION FOR SEQ ID NO:41:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:# 29 TCCT GCGCTGTGG- (2) INFORMATION FOR SEQ ID NO:42:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:# 30 ATGC CATCTTCCTG- (2) INFORMATION FOR SEQ ID NO:43:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:# 29 GAGC TGTGGTCCT- (2) INFORMATION FOR SEQ ID NO:44:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:# 30 TCCT GAGCTTCCAA- (2) INFORMATION FOR SEQ ID NO:45:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 32 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:# 32 GATC CTTGTGAGCT GT- (2) INFORMATION FOR SEQ ID NO:46:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 83 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "SYNTHETIC"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:- AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GC - #TCAACAGT 60# 83AGGC TCC- (2) INFORMATION FOR SEQ ID NO:47:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 83 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:- CCGGGGAGCC TCCACCGCCC TCTACGTACT GTTGAGCCTG CGCGTTCTCC AA - #GGTTTTCA 60# 83ACGA CGG- (2) INFORMATION FOR SEQ ID NO:48:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 59 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:- GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTAACTGCTC TA - #TAATGAT 59- (2) INFORMATION FOR SEQ ID NO:49:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 56 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:- CGATCATTAT AGAGCAGTTA GAGCCACCAC CCTGTTGTTC CTGCGCTTGC TC - #AAGG 56- (2) INFORMATION FOR SEQ ID NO:50:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 80 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:- GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTGGCGGTGG CA - #GCGGCGGC 60# 80 TAAT- (2) INFORMATION FOR SEQ ID NO:51:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 80 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:- CGATCATTAT AGAGCAGTTA GAACCGCCGC CGCTGCCACC GCCAGAGCCA CC - #ACCCTGTT 60# 80 AAGG- (2) INFORMATION FOR SEQ ID NO:52:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:# 30 GGAC CCGAACAACC- (2) INFORMATION FOR SEQ ID NO:53:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 28 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:# 28 GGTG CAGGTGGT- (2) INFORMATION FOR SEQ ID NO:54:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 32 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:# 32 TGCA TCAGGTATTG AG- (2) INFORMATION FOR SEQ ID NO:55:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 28 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:# 28 AAGT TCTTGACA- (2) INFORMATION FOR SEQ ID NO:56:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 32 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:# 32 ACCC TCTCGACATC CA- (2) INFORMATION FOR SEQ ID NO:57:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 28 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:# 28 GTGG CAGAGGGC- (2) INFORMATION FOR SEQ ID NO:58:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 32 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:# 32 AGGT GACTGGCAAG AA- (2) INFORMATION FOR SEQ ID NO:59:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 28 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:# 28 ATGA TGATTGGA- (2) INFORMATION FOR SEQ ID NO:60:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 54 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:- GCTCTGAGAG CCGCCAGAGC CGCCAGAGGG CTGCGCAAGG TGGCGTAGAA CG - #CG 54- (2) INFORMATION FOR SEQ ID NO:61:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 54 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:- CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AG - #AG 54- (2) INFORMATION FOR SEQ ID NO:62:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 18 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:# 18 CG- (2) INFORMATION FOR SEQ ID NO:63:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 21 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:#21 CCAG C- (2) INFORMATION FOR SEQ ID NO:64:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 32 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:# 32 CAAG CTGTGCCACC CC- (2) INFORMATION FOR SEQ ID NO:65:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 36 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:# 36 GGTG GCACACAGCT TCTCCT- (2) INFORMATION FOR SEQ ID NO:66:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 32 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:# 32 CGAG TTGGGTCCCA CC- (2) INFORMATION FOR SEQ ID NO:67:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 36 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:# 36 GGAT ATCCCTTCCA GGGCCT- (2) INFORMATION FOR SEQ ID NO:68:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 32 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:# 32 GGCC CCTGCCCTGC AG- (2) INFORMATION FOR SEQ ID NO:69:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 36 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:# 36 TCCC AGTTCTTCCA TCTGCT- (2) INFORMATION FOR SEQ ID NO:70:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 32 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:# 32 CCAG GGTGCCATGC CG- (2) INFORMATION FOR SEQ ID NO:71:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 36 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:# 36 GGGC TGCAGGGCAG GGGCCA- (2) INFORMATION FOR SEQ ID NO:72:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 36 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:# 36 GGGC TGCAGGGCAG GGGCCA- (2) INFORMATION FOR SEQ ID NO:73:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 36 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:# 36 GGCG AAGGCCGGCA TGGCAC- (2) INFORMATION FOR SEQ ID NO:74:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 21 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:#21 GCTC C- (2) INFORMATION FOR SEQ ID NO:75:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 25 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:# 25 GCCC TCTAC- (2) INFORMATION FOR SEQ ID NO:76:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 53 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:- TTCTACGCCA CCTTGCGCAG CCCGGCGGCG GCTCTGACAT GTCTACACCA TT - #G 53- (2) INFORMATION FOR SEQ ID NO:77:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 53 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:- CAATGGTGTA GACATGTCAG AGCCGCCGCC GGGCTGCGCA AGGTGGCGTA GA - #A 53- (2) INFORMATION FOR SEQ ID NO:78:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 439 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420#439 TGT- (2) INFORMATION FOR SEQ ID NO:79:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 465 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:- TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT 60- GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG 120- CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA 180- CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA 240- CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC 300- CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GA - #CCACAGCT 360- CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AA - #AGGTGCGT 420# 465GG GTCCACCCTC TGCGTCAGGG AATTC- (2) INFORMATION FOR SEQ ID NO:80:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 927 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:- TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT 60- GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG 120- CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA 180- CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA 240- CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC 300- CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GA - #CCACAGCT 360- CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AA - #AGGTGCGT 420- TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCGG CA - #ACATGGCG 480- TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT 540- GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG 600- CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA 660- CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA 720- CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC 780- CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGGGCAGGA CCACAGCTCA CA - #AGGATCCC 840- AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CC - #TGATGCTT 900# 927 TCTG CGTCAGG- (2) INFORMATION FOR SEQ ID NO:81:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 936 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:- TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT 60- GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG 120- CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA 180- CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA 240- CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC 300- CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GA - #CCACAGCT 360- CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AA - #AGGTGCGT 420- TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCAA CA - #TGGCGTCT 480- CCCGCTCCGC CTGCTTGTGA CCTCCGAGTC CTCAGTAAAC TGCTTCGTGA CT - #CCCATGTC 540- CTTCACAGCA GACTGAGCCA GTGCCCAGAG GTTCACCCTT TGCCTACACC TG - #TCCTGCTG 600- CCTGCTGTGG ACTTTAGCTT GGGAGAATGG AAAACCCAGA TGGAGGAGAC CA - #AGGCACAG 660- GACATTCTGG GAGCAGTGAC CCTTCTGCTG GAGGGAGTGA TGGCAGCACG GG - #GACAACTG 720- GGACCCACTT GCCTCTCATC CCTCCTGGGG CAGCTTTCTG GACAGGTCCG TC - #TCCTCCTT 780- GGGGCCCTGC AGAGCCTCCT TGGAACCCAG CTTCCTCCAC AGGGCAGGAC CA - #CAGCTCAC 840- AAGGATCCCA ATGCCATCTT CCTGAGCTTC CAACACCTGC TCCGAGGAAA GG - #TGCGTTTC 900# 936 GGTC CACCCTCTGC GTCAGG- (2) INFORMATION FOR SEQ ID NO:82:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 939 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:- TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT 60- GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG 120- CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA 180- CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA 240- CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC 300- CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GA - #CCACAGCT 360- CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AA - #AGGTGCGT 420- TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCGG CA - #ACATGGCG 480- TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT 540- GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG 600- CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA 660- CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA 720- CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC 780- CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GA - #CCACAGCT 840- CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AA - #AGGTGCGT 900# 939 GAGG GTCCACCCTC TGCGTCAGG- (2) INFORMATION FOR SEQ ID NO:83:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 948 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:- TCCCCAGCGC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT 60- GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG 120- CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA 180- CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA 240- CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC 300- CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GA - #CCACAGCT 360- CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AA - #AGGTGCGT 420- TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCGG CA - #ACGGCGGC 480- AACATGGCGT CCCCAGCGCC GCCTGCTTGT GACCTCCGAG TCCTCAGTAA AC - #TGCTTCGT 540- GACTCCCATG TCCTTCACAG CAGACTGAGC CAGTGCCCAG AGGTTCACCC TT - #TGCCTACA 600- CCTGTCCTGC TGCCTGCTGT GGACTTTAGC TTGGGAGAAT GGAAAACCCA GA - #TGGAGGAG 660- ACCAAGGCAC AGGACATTCT GGGAGCAGTG ACCCTTCTGC TGGAGGGAGT GA - #TGGCAGCA 720- CGGGGACAAC TGGGACCCAC TTGCCTCTCA TCCCTCCTGG GGCAGCTTTC TG - #GACAGGTC 780- CGTCTCCTCC TTGGGGCCCT GCAGAGCCTC CTTGGAACCC AGCTTCCTCC AC - #AGGGCAGG 840- ACCACAGCTC ACAAGGATCC CAATGCCATC TTCCTGAGCT TCCAACACCT GC - #TCCGAGGA 900# 948TGCT TGTAGGAGGG TCCACCCTCT GCGTCAGG- (2) INFORMATION FOR SEQ ID NO:84:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 688 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:- CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GA - #CCACCTGC 60- ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA TG - #GACCGAAA 120- CCTTCGACTT CCAAACCTGG AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AA - #AATGCATC 180- AGGTATTGAG GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CG - #GCCGCACC 240- CTCTCGACAT CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AA - #AAACTGAC 300- GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CT - #AACTGCTC 360- TATAATGATC GATGAAATTA TACATCACTT AAAGAGACCA CCTGCACCTT TG - #CTGGACCC 420- GAACAACCTC AATGACGAAG ACGTCTCTAT CCTGATGGAC CGAAACCTTC GA - #CTTCCAAA 480- CCTGGAGAGC TTCGTAAGGG CTGTCAAGAA CTTAGAAAAT GCATCAGGTA TT - #GAGGCAAT 540- TCTTCGTAAT CTCCAACCAT GTCTGCCCTC TGCCACGGCC GCACCCTCTC GA - #CATCCAAT 600- CATCATCAAG GCAGGTGACT GGCAAGAATT CCGGGAAAAA CTGACGTTCT AT - #CTGGTTAC 660# 688 GAAC AACAGTAC- (2) INFORMATION FOR SEQ ID NO:85:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 712 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "SYNTHETIC"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:- CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GA - #CCACCTGC 60- ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA TG - #GACCGAAA 120- CCTTCGACTT CCAAACCTGG AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AA - #AATGCATC 180- AGGTATTGAG GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CG - #GCCGCACC 240- CTCTCGACAT CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AA - #AAACTGAC 300- GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CT - #GGCGGTGG 360- CAGCGGCGGC GGTTCTAACT GCTCTATAAT GATCGATGAA ATTATACATC AC - #TTAAAGAG 420- ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CT - #ATCCTGAT 480- GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AG - #AACTTAGA 540- AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CC - #TCTGCCAC 600- GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AA - #TTCCGGGA 660- AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT AC - # 712- (2) INFORMATION FOR SEQ ID NO:86:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 975 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:- ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 60- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 120- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 180- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 240- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TA - #ACTGCTCT 300- ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTT GT - #ACGTAGAG 360- GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CC - #CGTCTCCT 420- CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GC - #CGGCCTTC 480- GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GC - #AGAGCTTC 540- CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CT - #CTGGCGGC 600- TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CG - #ATGGCGCA 660- GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GC - #TGGTGCTG 720- CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CC - #AGGCCCTG 780- CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GG - #GGCTCCTG 840- CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GC - #AGCTGGAC 900- GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GG - #CCCCTGCC 960# 975- (2) INFORMATION FOR SEQ ID NO:87:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 975 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:- ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 60- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 120- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 180- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 240- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TA - #ACTGCTCT 300- ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTT GT - #ACGTAGAG 360- GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CC - #CGTCTCCT 420- CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GC - #CGGCCTTC 480- GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GC - #AGAGCTTC 540- CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CT - #CTGGCGGC 600- TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CG - #ATGGCGCA 660- GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GC - #TGGTGCTG 720- CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CC - #AGGCCCTG 780- CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GG - #GGCTCCTG 840- CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GC - #AGCTGGAC 900- GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GG - #CCCCTGCC 960# 975- (2) INFORMATION FOR SEQ ID NO:88:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 975 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:- ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AG - #AATTCCGG 60- GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GG - #GTGGTGGC 120- TCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 180- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 240- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 300- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CT - #ACGTAGAG 360- GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CC - #CGTCTCCT 420- CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GC - #CGGCCTTC 480- GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GC - #AGAGCTTC 540- CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CT - #CTGGCGGC 600- TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CG - #ATGGCGCA 660- GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GC - #TGGTGCTG 720- CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CC - #AGGCCCTG 780- CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GG - #GGCTCCTG 840- CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GC - #AGCTGGAC 900- GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GG - #CCCCTGCC 960# 975- (2) INFORMATION FOR SEQ ID NO:89:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 975 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:- ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GG - #TTACCCTT 60- GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTAACTGCT CTATAATGAT CG - #ATGAAATT 120- ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CA - #ATGACGAA 180- GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CT - #TCGTAAGG 240- GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TC - #TCCAACCA 300- TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GT - #ACGTAGAG 360- GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CC - #CGTCTCCT 420- CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GC - #CGGCCTTC 480- GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GC - #AGAGCTTC 540- CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CT - #CTGGCGGC 600- TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CG - #ATGGCGCA 660- GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GC - #TGGTGCTG 720- CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CC - #AGGCCCTG 780- CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GG - #GGCTCCTG 840- CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GC - #AGCTGGAC 900- GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GG - #CCCCTGCC 960# 975- (2) INFORMATION FOR SEQ ID NO:90:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 999 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:- ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 60- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 120- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 180- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 240- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TG - #GCGGTGGC 300- AGCGGCGGCG GTTCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA CT - #TAAAGAGA 360- CCACCTGCAC CTTTGTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GT - #CTGGTCCA 420- ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AA - #ACATGGCT 480- ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AG - #GGGTCCTG 540- GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CC - #ACCTTGCG 600- CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AG - #AGCAAGTG 660- AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CT - #ACAAGCTG 720- TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GG - #CTCCCCTG 780- AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CC - #ATAGCGGC 840- CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GT - #TGGGTCCC 900- ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GC - #AGCAGATG 960# 999 CCCC TGCCCTGCAG CCCTAATAA- (2) INFORMATION FOR SEQ ID NO:91:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 999 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:- ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG TC - #TGCCCTCT 60- GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG CAGGTGACTG GC - #AAGAATTC 120- CGGGAAAAAC TGACGTTCTA TCTGGTTACC CTTGAGCAAG CGCAGGAACA AC - #AGGGTGGT 180- GGCTCTGGCG GTGGCAGCGG CGGCGGTTCT AACTGCTCTA TAATGATCGA TG - #AAATTATA 240- CATCACTTAA AGAGACCACC TGCACCTTTG CTGGACCCGA ACAACCTCAA TG - #ACGAAGAC 300- GTCTCTATCC TGATGGACCG AAACCTTCGA CTTCCAAACC TGGAGAGCTT CG - #TAAGGGCT 360- GTCAAGAACT TAGAATACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GT - #CTGGTCCA 420- ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AA - #ACATGGCT 480- ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AG - #GGGTCCTG 540- GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CC - #ACCTTGCG 600- CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AG - #AGCAAGTG 660- AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CT - #ACAAGCTG 720- TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GG - #CTCCCCTG 780- AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CC - #ATAGCGGC 840- CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GT - #TGGGTCCC 900- ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GC - #AGCAGATG 960# 999 CCCC TGCCCTGCAG CCCTAATAA- (2) INFORMATION FOR SEQ ID NO:92:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 999 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:- ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AG - #AATTCCGG 60- GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GG - #GTGGTGGC 120- TCTGGCGGTG GCAGCGGCGG CGGTTCTAAC TGCTCTATAA TGATCGATGA AA - #TTATACAT 180- CACTTAAAGA GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA CG - #AAGACGTC 240- TCTATCCTGA TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT AA - #GGGCTGTC 300- AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC GTAATCTCCA AC - #CATGTCTG 360- CCCTCTGCCA CGGCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GT - #CTGGTCCA 420- ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AA - #ACATGGCT 480- ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AG - #GGGTCCTG 540- GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CC - #ACCTTGCG 600- CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AG - #AGCAAGTG 660- AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CT - #ACAAGCTG 720- TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GG - #CTCCCCTG 780- AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CC - #ATAGCGGC 840- CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GT - #TGGGTCCC 900- ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GC - #AGCAGATG 960# 999 CCCC TGCCCTGCAG CCCTAATAA- (2) INFORMATION FOR SEQ ID NO:93:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 999 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:- ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GG - #TTACCCTT 60- GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTGGCGGTG GCAGCGGCGG CG - #GTTCTAAC 120- TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGC AC - #CTTTGCTG 180- GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA TGGACCGAAA CC - #TTCGACTT 240- CCAAACCTGG AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCATC AG - #GTATTGAG 300- GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC CT - #CTCGACAT 360- CCAATCATCA TCAAGTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GT - #CTGGTCCA 420- ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AA - #ACATGGCT 480- ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AG - #GGGTCCTG 540- GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CC - #ACCTTGCG 600- CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AG - #AGCAAGTG 660- AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CT - #ACAAGCTG 720- TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GG - #CTCCCCTG 780- AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CC - #ATAGCGGC 840- CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GT - #TGGGTCCC 900- ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GC - #AGCAGATG 960# 999 CCCC TGCCCTGCAG CCCTAATAA- (2) INFORMATION FOR SEQ ID NO:94:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 918 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT ACAAGCTGTG CC - #ACCCCGAG 420- GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CT - #CCTGCCCC 480- AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TT - #TCCTCTAC 540- CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CT - #TGGACACA 600- CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AG - #AACTGGGA 660- ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TG - #CTTTCCAG 720- CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GG - #TGTCGTAC 780- CGCGTTCTAC GCCACCTTGC GCAGCCCTCT GGCGGCTCTG GCGGCTCTCA GA - #GCTTCCTG 840- CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CC - #AGGAGAAG 900# 918 AA- (2) INFORMATION FOR SEQ ID NO:95:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 963 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTTACAAG CTGTGCCACC CCGAGGAGCT GG - #TGCTGCTC 480- GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GG - #CCCTGCAG 540- CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GC - #TCCTGCAG 600- GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GC - #TGGACGTC 660- GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CC - #CTGCCCTG 720- CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GG - #CAGGAGGG 780- GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TC - #TACGCCAC 840- CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC TCTCAGAGCT TCCTGCTCAA GT - #CTTTAGAG 900- CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TG - #CCACCTAA 960# 963- (2) INFORMATION FOR SEQ ID NO:96:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 918 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC CCGAGTTGGG TC - #CCACCTTG 420- GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GA - #TGGAAGAA 480- CTGGGAATGG CCCCTGCCCT GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CG - #CCTCTGCT 540- TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CC - #TGGAGGTG 600- TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG GCTCTGGCGG CT - #CTCAGAGC 660- TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA AAGATCCAGG GCGATGGCGC AG - #CGCTCCAG 720- GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GC - #TCGGACAC 780- TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GC - #AGCTGGCA 840- GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GC - #AGGCCCTG 900# 918 AA- (2) INFORMATION FOR SEQ ID NO:97:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 963 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTCCCGAG TTGGGTCCCA CCTTGGACAC AC - #TGCAGCTG 480- GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AA - #TGGCCCCT 540- GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GC - #GCCGGGCA 600- GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CC - #GCGTTCTA 660- CGCCACCTTG CGCAGCCCTC TGGCGGCTCT GGCGGCTCTC AGAGCTTCCT GC - #TCAAGTCT 720- TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GC - #TGTGTGCC 780- ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GG - #GCATCCCC 840- TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CT - #TGAGCCAA 900- CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GA - #TATCCTAA 960# 963- (2) INFORMATION FOR SEQ ID NO:98:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 918 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA TGGCCCCTGC CC - #TGCAGCCC 420- ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AG - #GGGTCCTG 480- GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CC - #ACCTTGCG 540- CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AG - #AGCAAGTG 600- AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CT - #ACAAGCTG 660- TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GG - #CTCCCCTG 720- AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CC - #ATAGCGGC 780- CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GT - #TGGGTCCC 840- ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GC - #AGCAGATG 900# 918 AA- (2) INFORMATION FOR SEQ ID NO:99:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 963 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTATGGCC CCTGCCCTGC AGCCCACCCA GG - #GTGCCATG 480- CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TA - #GCCATCTG 540- CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CT - #CTGGCGGC 600- TCTGGCGGCT CTCAGAGCTT CCTGCTCAAG TCTTTAGAGC AAGTGAGAAA GA - #TCCAGGGC 660- GATGGCGCAG CGCTCCAGGA GAAGCTGTGT GCCACCTACA AGCTGTGCCA CC - #CCGAGGAG 720- CTGGTGCTGC TCGGACACTC TCTGGGCATC CCCTGGGCTC CCCTGAGCTC CT - #GCCCCAGC 780- CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA GCGGCCTTTT CC - #TCTACCAG 840- GGGCTCCTGC AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTT GG - #ACACACTG 900- CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA AC - #TGGGATAA 960# 963- (2) INFORMATION FOR SEQ ID NO:100:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 918 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA CCCAGGGTGC CA - #TGCCGGCC 420- TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TC - #TGCAGAGC 480- TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTCTGG CG - #GCTCTGGC 540- GGCTCTCAGA GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GAAAGATCCA GG - #GCGATGGC 600- GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GG - #AGCTGGTG 660- CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CA - #GCCAGGCC 720- CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA CC - #AGGGGCTC 780- CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC AC - #TGCAGCTG 840- GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AA - #TGGCCCCT 900# 918 AA- (2) INFORMATION FOR SEQ ID NO:101:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 963 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CT - #CTGCTTTC 480- CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GG - #AGGTGTCG 540- TACCGCGTTC TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TC - #AGAGCTTC 600- CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GC - #TCCAGGAG 660- AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CG - #GACACTCT 720- CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GC - #TGGCAGGC 780- TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GG - #CCCTGGAA 840- GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CG - #CCGACTTT 900- GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GC - #AGCCCTAA 960# 963- (2) INFORMATION FOR SEQ ID NO:102:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 918 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT CTGCTTTCCA GC - #GCCGGGCA 420- GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CC - #GCGTTCTA 480- CGCCACCTTG CGCAGCCCTC TGGCGGCTCT GGCGGCTCTC AGAGCTTCCT GC - #TCAAGTCT 540- TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GC - #TGTGTGCC 600- ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GG - #GCATCCCC 660- TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CT - #TGAGCCAA 720- CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GA - #TATCCCCC 780- GAGTTGGGTC CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC CA - #CCACCATC 840- TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA GG - #GTGCCATG 900# 918 AA- (2) INFORMATION FOR SEQ ID NO:103:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 963 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "SYNTHETIC"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTTCTGCT TTCCAGCGCC GGGCAGGAGG GG - #TCCTGGTT 480- GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CC - #TTGCGCAG 540- CCCTCTGGCG GCTCTGGCGG CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GC - #AAGTGAGA 600- AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CA - #AGCTGTGC 660- CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TC - #CCCTGAGC 720- TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TA - #GCGGCCTT 780- TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GG - #GTCCCACC 840- TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GC - #AGATGGAA 900- GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CT - #TCGCCTAA 960# 963- (2) INFORMATION FOR SEQ ID NO:104:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 927 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT ACAAGCTGTG CC - #ACCCCGAG 420- GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CT - #CCTGCCCC 480- AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TT - #TCCTCTAC 540- CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CT - #TGGACACA 600- CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AG - #AACTGGGA 660- ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TG - #CTTTCCAG 720- CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GG - #TGTCGTAC 780- CGCGTTCTAC GCCACCTTGC GCAGCCCACA CCATTGGGCC CTGCCAGCTC CC - #TGCCCCAG 840- AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGG CG - #CAGCGCTC 900# 927 CCAC CTAATAA- (2) INFORMATION FOR SEQ ID NO:105:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 972 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTTACAAG CTGTGCCACC CCGAGGAGCT GG - #TGCTGCTC 480- GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GG - #CCCTGCAG 540- CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GC - #TCCTGCAG 600- GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GC - #TGGACGTC 660- GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CC - #CTGCCCTG 720- CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GG - #CAGGAGGG 780- GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TC - #TACGCCAC 840- CTTGCGCAGC CCACACCATT GGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CC - #TGCTCAAG 900- TCTTTAGAGC AAGTGAGAAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GA - #AGCTGTGT 960# 972- (2) INFORMATION FOR SEQ ID NO:106:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 927 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC CCGAGTTGGG TC - #CCACCTTG 420- GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GA - #TGGAAGAA 480- CTGGGAATGG CCCCTGCCCT GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CG - #CCTCTGCT 540- TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CC - #TGGAGGTG 600- TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCACACCAT TGGGCCCTGC CA - #GCTCCCTG 660- CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CG - #ATGGCGCA 720- GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GC - #TGGTGCTG 780- CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CC - #AGGCCCTG 840- CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GG - #GGCTCCTG 900# 927 TATC CTAATAA- (2) INFORMATION FOR SEQ ID NO:107:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 972 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTCCCGAG TTGGGTCCCA CCTTGGACAC AC - #TGCAGCTG 480- GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AA - #TGGCCCCT 540- GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GC - #GCCGGGCA 600- GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CC - #GCGTTCTA 660- CGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT CCCTGCCCCA GA - #GCTTCCTG 720- CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CC - #AGGAGAAG 780- CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG AC - #ACTCTCTG 840- GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GG - #CAGGCTGC 900- TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CC - #TGGAAGGG 960# 972- (2) INFORMATION FOR SEQ ID NO:108:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 927 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA TGGCCCCTGC CC - #TGCAGCCC 420- ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AG - #GGGTCCTG 480- GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CC - #ACCTTGCG 540- CAGCCCACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CA - #AGTCTTTA 600- GAGCAAGTGA GAAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GT - #GTGCCACC 660- TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CA - #TCCCCTGG 720- GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GA - #GCCAACTC 780- CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT AT - #CCCCCGAG 840- TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CA - #CCATCTGG 900# 927 TGGG ATAATAA- (2) INFORMATION FOR SEQ ID NO:109:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 972 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "DNA (synthetic)"PTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTATGGCC CCTGCCCTGC AGCCCACCCA GG - #GTGCCATG 480- CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TA - #GCCATCTG 540- CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CA - #CACCATTG 600- GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AG - #TGAGAAAG 660- ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GC - #TGTGCCAC 720- CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CC - #TGAGCTCC 780- TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG CG - #GCCTTTTC 840- CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TC - #CCACCTTG 900- GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GA - #TGGAAGAA 960# 972- (2) INFORMATION FOR SEQ ID NO:110:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 927 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA CCCAGGGTGC CA - #TGCCGGCC 420- TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TC - #TGCAGAGC 480- TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCACACC AT - #TGGGCCCT 540- GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG AA - #AGATCCAG 600- GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CC - #ACCCCGAG 660- GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CT - #CCTGCCCC 720- AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TT - #TCCTCTAC 780- CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CT - #TGGACACA 840- CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AG - #AACTGGGA 900# 927 AGCC CTAATAA- (2) INFORMATION FOR SEQ ID NO:111:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 972 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CT - #CTGCTTTC 480- CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GG - #AGGTGTCG 540- TACCGCGTTC TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CT - #CCCTGCCC 600- CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TG - #GCGCAGCG 660- CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GG - #TGCTGCTC 720- GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GG - #CCCTGCAG 780- CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GC - #TCCTGCAG 840- GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GC - #TGGACGTC 900- GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CC - #CTGCCCTG 960# 972- (2) INFORMATION FOR SEQ ID NO:112:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 927 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT CTGCTTTCCA GC - #GCCGGGCA 420- GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CC - #GCGTTCTA 480- CGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT CCCTGCCCCA GA - #GCTTCCTG 540- CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CC - #AGGAGAAG 600- CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG AC - #ACTCTCTG 660- GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GG - #CAGGCTGC 720- TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CC - #TGGAAGGG 780- ATATCCCCCG AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGC CG - #ACTTTGCC 840- ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA GC - #CCACCCAG 900# 927 TCGC CTAATAA- (2) INFORMATION FOR SEQ ID NO:113:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 972 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTTCTGCT TTCCAGCGCC GGGCAGGAGG GG - #TCCTGGTT 480- GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CC - #TTGCGCAG 540- CCCACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GT - #CTTTAGAG 600- CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TG - #CCACCTAC 660- AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CC - #CCTGGGCT 720- CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CC - #AACTCCAT 780- AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CC - #CCGAGTTG 840- GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CA - #TCTGGCAG 900- CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CA - #TGCCGGCC 960# 972- (2) INFORMATION FOR SEQ ID NO:114:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 963 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:- ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GC - #CACCGCTG 60- CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTAAT GG - #ACAATAAC 120- CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GA - #ATGCATCA 180- GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CGCTAGCCAC GG - #CCGCACCC 240- ACGCGACATC CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TA - #AACTGACC 300- TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CT - #CTGCTTTC 480- CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GG - #AGGTGTCG 540- TACCGCGTTC TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TC - #AGAGCTTC 600- CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GC - #TCCAGGAG 660- AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CG - #GACACTCT 720- CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GC - #TGGCAGGC 780- TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GG - #CCCTGGAA 840- GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CG - #CCGACTTT 900- GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GC - #AGCCCTAA 960# 963- (2) INFORMATION FOR SEQ ID NO:115:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 972 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:- ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GC - #CACCGCTG 60- CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTGAT GG - #AAAATAAC 120- CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GA - #ATGCATCA 180- GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CCCTGGCCAC GG - #CCGCACCC 240- ACGCGACATC CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TA - #AACTGACC 300- TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CT - #CTGCTTTC 480- CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GG - #AGGTGTCG 540- TACCGCGTTC TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CT - #CCCTGCCC 600- CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TG - #GCGCAGCG 660- CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GG - #TGCTGCTC 720- GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GG - #CCCTGCAG 780- CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GC - #TCCTGCAG 840- GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GC - #TGGACGTC 900- GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CC - #CTGCCCTG 960# 972- (2) INFORMATION FOR SEQ ID NO:116:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 963 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:- ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GC - #CACCGCTG 60- CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTGAT GG - #AAAATAAC 120- CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GA - #ATGCATCA 180- GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CCCTGGCCAC GG - #CCGCACCC 240- ACGCGACATC CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TA - #AACTGACC 300- TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CT - #CTGCTTTC 480- CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GG - #AGGTGTCG 540- TACCGCGTTC TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TC - #AGAGCTTC 600- CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GC - #TCCAGGAG 660- AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CG - #GACACTCT 720- CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GC - #TGGCAGGC 780- TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GG - #CCCTGGAA 840- GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CG - #CCGACTTT 900- GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GC - #AGCCCTAA 960# 963- (2) INFORMATION FOR SEQ ID NO:117:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 972 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:- ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GC - #CACCGCTG 60- CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTAAT GG - #ACAATAAC 120- CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GA - #ATGCATCA 180- GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CGCTAGCCAC GG - #CCGCACCC 240- ACGCGACATC CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TA - #AACTGACC 300- TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CT - #CTGCTTTC 480- CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GG - #AGGTGTCG 540- TACCGCGTTC TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CT - #CCCTGCCC 600- CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TG - #GCGCAGCG 660- CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GG - #TGCTGCTC 720- GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GG - #CCCTGCAG 780- CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GC - #TCCTGCAG 840- GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GC - #TGGACGTC 900- GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CC - #CTGCCCTG 960# 972- (2) INFORMATION FOR SEQ ID NO:118:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 918 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGA GGTTCACCCT TTGCCTACAC CTGTCCTGCT GC - #CTGCTGTG 480- GACTTTAGCT TGGGAGAATG GAAAACCCAG ATGGAGGAGA CCAAGGCACA GG - #ACATTCTG 540- GGAGCAGTGA CCCTTCTGCT GGAGGGAGTG ATGGCAGCAC GGGGACAACT GG - #GACCCACT 600- TGCCTCTCAT CCCTCCTGGG GCAGCTTTCT GGACAGGTCC GTCTCCTCCT TG - #GGGCCCTG 660- CAGAGCCTCC TTGGAACCCA GCTTCCTCCA CAGGGCAGGA CCACAGCTCA CA - #AGGATCCC 720- AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CC - #TGATGCTT 780- GTAGGAGGGT CCACCCTCTG CGTCAGGGAA TTCGGCGGCA ACATGGCGTC TC - #CCGCTCCG 840- CCTGCTTGTG ACCTCCGAGT CCTCAGTAAA CTGCTTCGTG ACTCCCATGT CC - #TTCACAGC 900# 918 CA- (2) INFORMATION FOR SEQ ID NO:119:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 918 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGTT GCCTACACCT GTCCTGCTGC CTGCTGTGGA CT - #TTAGCTTG 480- GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGG AG - #CAGTGACC 540- CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CC - #TCTCATCC 600- CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GA - #GCCTCCTT 660- GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TG - #CCATCTTC 720- CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AG - #GAGGGTCC 780- ACCCTCTGCG TCAGGGAATT CGGCGGCAAC ATGGCGTCTC CCGCTCCGCC TG - #CTTGTGAC 840- CTCCGAGTCC TCAGTAAACT GCTTCGTGAC TCCCATGTCC TTCACAGCAG AC - #TGAGCCAG 900# 918 CT- (2) INFORMATION FOR SEQ ID NO:120:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 918 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AG - #AATGGAAA 480- ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TC - #TGCTGGAG 540- GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CC - #TGGGGCAG 600- CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG GCCCTGCAGA GCCTCCTTGG AA - #CCCAGCTT 660- CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GA - #GCTTCCAA 720- CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CC - #TCTGCGTC 780- AGGGAATTCG GCGGCAACAT GGCGTCTCCC GCTCCGCCTG CTTGTGACCT CC - #GAGTCCTC 840- AGTAAACTGC TTCGTGACTC CCATGTCCTT CACAGCAGAC TGAGCCAGTG CC - #CAGAGGTT 900# 918 CT- (2) INFORMATION FOR SEQ ID NO:121:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 918 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CC - #AGATGGAG 480- GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AG - #TGATGGCA 540- GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TT - #CTGGACAG 600- GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TC - #CACAGGGC 660- AGGACCACAG CTCACAAGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CC - #TGCTCCGA 720- GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GG - #AATTCGGC 780- GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TA - #AACTGCTT 840- CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CC - #CTTTGCCT 900# 918 CT- (2) INFORMATION FOR SEQ ID NO:122:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 918 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GG - #AGGAGACC 480- AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GG - #CAGCACGG 540- GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG AC - #AGGTCCGT 600- CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC TTCCTCCACA GG - #GCAGGACC 660- ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC AACACCTGCT CC - #GAGGAAAG 720- GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGGGAATT CG - #GCGGCAAC 780- ATGGCGTCTC CCGCTCCGCC TGCTTGTGAC CTCCGAGTCC TCAGTAAACT GC - #TTCGTGAC 840- TCCCATGTCC TTCACAGCAG ACTGAGCCAG TGCCCAGAGG TTCACCCTTT GC - #CTACACCT 900# 918 TG- (2) INFORMATION FOR SEQ ID NO:123:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 907 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCGGTTAC CCTTGAGCAA GCGCAGGAAC AACAGTACGT AGAGGGCGGT GG - #AGGCTCCC 360- CGGGGAACCG TCTGGTCCAA TCTCTACTAT CAACCCGTCT CCTCCGTCTA AA - #GAATCTCA 420- TAAACTCCAA ACATGGGAGA ATGGAAAACC CAGATGGAGG AGACCAAGGC AC - #AGGACATT 480- CTGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CT - #GGGACCCA 540- CTTGCTCTCA TCCCTCCTGG GGCAGCTTTC TGGACAGGTC CGTCTCCTCC TT - #GGGGCCCT 600- GCAGGCCTCC TTGGAACCCA GCTTCCTCCA CAGGGCAGGA CCACAGCTCA CA - #AGGATCCC 660- AATGCATCTT CCTGAGCTTC CAACACCTGC TCCGAGGAAA GGTGCGTTTC CT - #GATGCTTG 720- TAGGGGGTCC ACCCTCTGCG TCAGGGAATT CGGCGGCAAC ATGGCGTCTC CC - #GCTCCGCC 780- TGCTGTGACC TCCGAGTCCT CAGTAAACTG CTTCGTGACT CCCATGTCCT TC - #ACAGCAGA 840- CTGACCAGTG CCCAGAGGTT CACCCTTTGC CTACACCTGT CCTGCTGCCT GC - #TGTGGACT 900# 907- (2) INFORMATION FOR SEQ ID NO:124:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 918 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGG ACCCACTTGC CTCTCATCCC TCCTGGGGCA GC - #TTTCTGGA 480- CAGGTCCGTC TCCTCCTTGG GGCCCTGCAG AGCCTCCTTG GAACCCAGCT TC - #CTCCACAG 540- GGCAGGACCA CAGCTCACAA GGATCCCAAT GCCATCTTCC TGAGCTTCCA AC - #ACCTGCTC 600- CGAGGAAAGG TGCGTTTCCT GATGCTTGTA GGAGGGTCCA CCCTCTGCGT CA - #GGGAATTC 660- GGCGGCAACA TGGCGTCTCC CGCTCCGCCT GCTTGTGACC TCCGAGTCCT CA - #GTAAACTG 720- CTTCGTGACT CCCATGTCCT TCACAGCAGA CTGAGCCAGT GCCCAGAGGT TC - #ACCCTTTG 780- CCTACACCTG TCCTGCTGCC TGCTGTGGAC TTTAGCTTGG GAGAATGGAA AA - #CCCAGATG 840- GAGGAGACCA AGGCACAGGA CATTCTGGGA GCAGTGACCC TTCTGCTGGA GG - #GAGTGATG 900# 918 TG- (2) INFORMATION FOR SEQ ID NO:125:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 848 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AG - #CTCACAAG 480- GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GC - #GTTTCCTG 540- ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACAT GG - #CGTCTCCC 600- GCTCCGCCTG CTTGTGACCT CCGAGTCCTC AGTAAACTGC TTCGTGACTC CC - #ATGTCCTT 660- CACAGCAGAC TGAGCCAGTG CCCAGAGGTT CACCCTTTGC CTACACCTGT CC - #TGCTGCCT 720- GCTGTGGACT TTAGCTTGGG AGAATGGAAA ACCCAGATGG AGGAGACCAA GG - #CACAGGAC 780- ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGG AC - #AACTGGGA 840# 848- (2) INFORMATION FOR SEQ ID NO:126:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 918 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CA - #TCTTCCTG 480- AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AG - #GGTCCACC 540- CTCTGCGTCA GGGAATTCGG CGGCAACATG GCGTCTCCCG CTCCGCCTGC TT - #GTGACCTC 600- CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GA - #GCCAGTGC 660- CCAGAGGTTC ACCCTTTGCC TACACCTGTC CTGCTGCCTG CTGTGGACTT TA - #GCTTGGGA 720- GAATGGAAAA CCCAGATGGA GGAGACCAAG GCACAGGACA TTCTGGGAGC AG - #TGACCCTT 780- CTGCTGGAGG GAGTGATGGC AGCACGGGGA CAACTGGGAC CCACTTGCCT CT - #CATCCCTC 840- CTGGGGCAGC TTTCTGGACA GGTCCGTCTC CTCCTTGGGG CCCTGCAGAG CC - #TCCTTGGA 900# 918 AG- (2) INFORMATION FOR SEQ ID NO:127:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 918 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG CT - #TCCAACAC 480- CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCT CT - #GCGTCAGG 540- GAATTCGGCG GCAACATGGC GTCTCCCGCT CCGCCTGCTT GTGACCTCCG AG - #TCCTCAGT 600- AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AG - #AGGTTCAC 660- CCTTTGCCTA CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGA AT - #GGAAAACC 720- CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT GC - #TGGAGGGA 780- GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT CATCCCTCCT GG - #GGCAGCTT 840- TCTGGACAGG TCCGTCTCCT CCTTGGGGCC CTGCAGAGCC TCCTTGGAAC CC - #AGCTTCCT 900# 918 CA- (2) INFORMATION FOR SEQ ID NO:128:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 918 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CC - #TGCTCCGA 480- GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GG - #AATTCGGC 540- GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TA - #AACTGCTT 600- CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CC - #CTTTGCCT 660- ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CC - #AGATGGAG 720- GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AG - #TGATGGCA 780- GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TT - #CTGGACAG 840- GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TC - #CACAGGGC 900# 918 AG- (2) INFORMATION FOR SEQ ID NO:129:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 918 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AG - #GAAAGGTG 480- CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CG - #GCAACATG 540- GCGTCTCCCG CTCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TC - #GTGACTCC 600- CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TA - #CACCTGTC 660- CTGCTGCCTG CTGTGGACTT TAGCTTGGGA GAATGGAAAA CCCAGATGGA GG - #AGACCAAG 720- GCACAGGACA TTCTGGGAGC AGTGACCCTT CTGCTGGAGG GAGTGATGGC AG - #CACGGGGA 780- CAACTGGGAC CCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACA GG - #TCCGTCTC 840- CTCCTTGGGG CCCTGCAGAG CCTCCTTGGA ACCCAGCTTC CTCCACAGGG CA - #GGACCACA 900# 918 AT- (2) INFORMATION FOR SEQ ID NO:130:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 915 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGA GGTTCACCCT TTGCCTACAC CTGTCCTGCT GC - #CTGCTGTG 480- GACTTTAGCT TGGGAGAATG GAAAACCCAG ATGGAGGAGA CCAAGGCACA GG - #ACATTCTG 540- GGAGCAGTGA CCCTTCTGCT GGAGGGAGTG ATGGCAGCAC GGGGACAACT GG - #GACCCACT 600- TGCCTCTCAT CCCTCCTGGG GCAGCTTTCT GGACAGGTCC GTCTCCTCCT TG - #GGGCCCTG 660- CAGAGCCTCC TTGGAACCCA GCTTCCTCCA CAGGGCAGGA CCACAGCTCA CA - #AGGATCCC 720- AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CC - #TGATGCTT 780- GTAGGAGGGT CCACCCTCTG CGTCAGGGAA TTCGGCAACA TGGCGTCTCC CG - #CTCCGCCT 840- GCTTGTGACC TCCGAGTCCT CAGTAAACTG CTTCGTGACT CCCATGTCCT TC - #ACAGCAGA 900# 915- (2) INFORMATION FOR SEQ ID NO:131:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 915 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGTT GCCTACACCT GTCCTGCTGC CTGCTGTGGA CT - #TTAGCTTG 480- GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGG AG - #CAGTGACC 540- CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CC - #TCTCATCC 600- CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GA - #GCCTCCTT 660- GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TG - #CCATCTTC 720- CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AG - #GAGGGTCC 780- ACCCTCTGCG TCAGGGAATT CGGCAACATG GCGTCTCCCG CTCCGCCTGC TT - #GTGACCTC 840- CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GA - #GCCAGTGC 900# 915- (2) INFORMATION FOR SEQ ID NO:132:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 915 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AG - #AATGGAAA 480- ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TC - #TGCTGGAG 540- GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CC - #TGGGGCAG 600- CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG GCCCTGCAGA GCCTCCTTGG AA - #CCCAGCTT 660- CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GA - #GCTTCCAA 720- CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CC - #TCTGCGTC 780- AGGGAATTCG GCAACATGGC GTCTCCCGCT CCGCCTGCTT GTGACCTCCG AG - #TCCTCAGT 840- AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AG - #AGGTTCAC 900# 915- (2) INFORMATION FOR SEQ ID NO:133:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 915 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CC - #AGATGGAG 480- GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AG - #TGATGGCA 540- GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TT - #CTGGACAG 600- GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TC - #CACAGGGC 660- AGGACCACAG CTCACAAGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CC - #TGCTCCGA 720- GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GG - #AATTCGGC 780- AACATGGCGT CTCCCGCTCC GCCTGCTTGT GACCTCCGAG TCCTCAGTAA AC - #TGCTTCGT 840- GACTCCCATG TCCTTCACAG CAGACTGAGC CAGTGCCCAG AGGTTCACCC TT - #TGCCTACA 900# 915- (2) INFORMATION FOR SEQ ID NO:134:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 915 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GG - #AGGAGACC 480- AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GG - #CAGCACGG 540- GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG AC - #AGGTCCGT 600- CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC TTCCTCCACA GG - #GCAGGACC 660- ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC AACACCTGCT CC - #GAGGAAAG 720- GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGGGAATT CG - #GCAACATG 780- GCGTCTCCCG CTCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TC - #GTGACTCC 840- CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TA - #CACCTGTC 900# 915- (2) INFORMATION FOR SEQ ID NO:135:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 915 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGG AGAATGGAAA ACCCAGATGG AGGAGACCAA GG - #CACAGGAC 480- ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGG AC - #AACTGGGA 540- CCCACTTGCC TCTCATCCCT CCTGGGGCAG CTTTCTGGAC AGGTCCGTCT CC - #TCCTTGGG 600- GCCCTGCAGA GCCTCCTTGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AG - #CTCACAAG 660- GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GC - #GTTTCCTG 720- ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCAACATGGC GT - #CTCCCGCT 780- CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA TG - #TCCTTCAC 840- AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA CACCTGTCCT GC - #TGCCTGCT 900# 915- (2) INFORMATION FOR SEQ ID NO:136:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 915 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGG ACCCACTTGC CTCTCATCCC TCCTGGGGCA GC - #TTTCTGGA 480- CAGGTCCGTC TCCTCCTTGG GGCCCTGCAG AGCCTCCTTG GAACCCAGCT TC - #CTCCACAG 540- GGCAGGACCA CAGCTCACAA GGATCCCAAT GCCATCTTCC TGAGCTTCCA AC - #ACCTGCTC 600- CGAGGAAAGG TGCGTTTCCT GATGCTTGTA GGAGGGTCCA CCCTCTGCGT CA - #GGGAATTC 660- GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TA - #AACTGCTT 720- CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CC - #CTTTGCCT 780- ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CC - #AGATGGAG 840- GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AG - #TGATGGCA 900# 915- (2) INFORMATION FOR SEQ ID NO:137:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 915 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AG - #CTCACAAG 480- GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GC - #GTTTCCTG 540- ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCAACATGGC GT - #CTCCCGCT 600- CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA TG - #TCCTTCAC 660- AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA CACCTGTCCT GC - #TGCCTGCT 720- GTGGACTTTA GCTTGGGAGA ATGGAAAACC CAGATGGAGG AGACCAAGGC AC - #AGGACATT 780- CTGGGAGCAG TGACCCTTCT GCTGGAGGGA GTGATGGCAG CACGGGGACA AC - #TGGGACCC 840- ACTTGCCTCT CATCCCTCCT GGGGCAGCTT TCTGGACAGG TCCGTCTCCT CC - #TTGGGGCC 900# 915- (2) INFORMATION FOR SEQ ID NO:138:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 915 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CA - #TCTTCCTG 480- AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AG - #GGTCCACC 540- CTCTGCGTCA GGGAATTCGG CAACATGGCG TCTCCCGCTC CGCCTGCTTG TG - #ACCTCCGA 600- GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CC - #AGTGCCCA 660- GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CT - #TGGGAGAA 720- TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GA - #CCCTTCTG 780- CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC AT - #CCCTCCTG 840- GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CC - #TTGGAACC 900# 915- (2) INFORMATION FOR SEQ ID NO:139:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 915 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG CT - #TCCAACAC 480- CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCT CT - #GCGTCAGG 540- GAATTCGGCA ACATGGCGTC TCCCGCTCCG CCTGCTTGTG ACCTCCGAGT CC - #TCAGTAAA 600- CTGCTTCGTG ACTCCCATGT CCTTCACAGC AGACTGAGCC AGTGCCCAGA GG - #TTCACCCT 660- TTGCCTACAC CTGTCCTGCT GCCTGCTGTG GACTTTAGCT TGGGAGAATG GA - #AAACCCAG 720- ATGGAGGAGA CCAAGGCACA GGACATTCTG GGAGCAGTGA CCCTTCTGCT GG - #AGGGAGTG 780- ATGGCAGCAC GGGGACAACT GGGACCCACT TGCCTCTCAT CCCTCCTGGG GC - #AGCTTTCT 840- GGACAGGTCC GTCTCCTCCT TGGGGCCCTG CAGAGCCTCC TTGGAACCCA GC - #TTCCTCCA 900# 915- (2) INFORMATION FOR SEQ ID NO:140:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 915 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CC - #TGCTCCGA 480- GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GG - #AATTCGGC 540- AACATGGCGT CTCCCGCTCC GCCTGCTTGT GACCTCCGAG TCCTCAGTAA AC - #TGCTTCGT 600- GACTCCCATG TCCTTCACAG CAGACTGAGC CAGTGCCCAG AGGTTCACCC TT - #TGCCTACA 660- CCTGTCCTGC TGCCTGCTGT GGACTTTAGC TTGGGAGAAT GGAAAACCCA GA - #TGGAGGAG 720- ACCAAGGCAC AGGACATTCT GGGAGCAGTG ACCCTTCTGC TGGAGGGAGT GA - #TGGCAGCA 780- CGGGGACAAC TGGGACCCAC TTGCCTCTCA TCCCTCCTGG GGCAGCTTTC TG - #GACAGGTC 840- CGTCTCCTCC TTGGGGCCCT GCAGAGCCTC CTTGGAACCC AGCTTCCTCC AC - #AGGGCAGG 900# 915- (2) INFORMATION FOR SEQ ID NO:141:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 915 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AG - #GAAAGGTG 480- CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CA - #ACATGGCG 540- TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT 600- GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG 660- CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA 720- CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA 780- CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC 840- CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GA - #CCACAGCT 900# 915- (2) INFORMATION FOR SEQ ID NO:142:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 921 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- GACTTCCAAA CCTGGAGAGC TTCGTAAGGG CTGTCAAGAA CTTAGAAAAT GC - #ATCAGGTA 180- TGAGGCAATT CTTCGTAATC TCCAACCATG TCTGCCCTCT GCCACGGCCG CA - #CCCTCTCG 240- CATCCAATCA TCATCAAGGC AGGTGACTGG CAAGAATTCC GGGAAAAACT GA - #CGTTCTAT 300- TGGTTACCCT TGAGCAAGCG CAGGAACAAC AGTACGTAGA GGGCGGTGGA GG - #CTCCCCGG 360- TAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA AT - #CTCATAAA 420- TCTCCAAACA TGGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TG - #TGGACTTT 480- AGCTTGGGAG AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TC - #TGGGAGCA 540- GTGACCCTTC TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CA - #CTTGCCTC 600- TCATCCCTCC TGGGGCAGCT TTCTGGACAG GTCCGTCTCC TCCTTGGGGC CC - #TGCAGAGC 660- CTCCTTGGAA CCCAGCTTCC TCCACAGGGC AGGACCACAG CTCACAAGGA TC - #CCAATGCC 720- ATCTTCCTGA GCTTCCAACA CCTGCTCCGA GGAAAGGTGC GTTTCCTGAT GC - #TTGTAGGA 780- GGGTCCACCC TCTGCGTCAG GGAATTCGGC GGCAACGGCG GCAACATGGC GT - #CCCCAGCG 840- CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA TG - #TCCTTCAC 900# 921CC A- (2) INFORMATION FOR SEQ ID NO:143:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 927 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGTT GCCTACACCT GTCCTGCTGC CTGCTGTGGA CT - #TTAGCTTG 480- GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGG AG - #CAGTGACC 540- CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CC - #TCTCATCC 600- CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GA - #GCCTCCTT 660- GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TG - #CCATCTTC 720- CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AG - #GAGGGTCC 780- ACCCTCTGCG TCAGGGAATT CGGCGGCAAC GGCGGCAACA TGGCGTCCCC AG - #CGCCGCCT 840- GCTTGTGACC TCCGAGTCCT CAGTAAACTG CTTCGTGACT CCCATGTCCT TC - #ACAGCAGA 900# 927 AGGT TCACCCT- (2) INFORMATION FOR SEQ ID NO:144:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 927 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AG - #AATGGAAA 480- ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TC - #TGCTGGAG 540- GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CC - #TGGGGCAG 600- CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG GCCCTGCAGA GCCTCCTTGG AA - #CCCAGCTT 660- CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GA - #GCTTCCAA 720- CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CC - #TCTGCGTC 780- AGGGAATTCG GCGGCAACGG CGGCAACATG GCGTCCCCAG CGCCGCCTGC TT - #GTGACCTC 840- CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GA - #GCCAGTGC 900# 927 TGCC TACACCT- (2) INFORMATION FOR SEQ ID NO:145:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 927 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CC - #AGATGGAG 480- GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AG - #TGATGGCA 540- GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TT - #CTGGACAG 600- GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TC - #CACAGGGC 660- AGGACCACAG CTCACAAGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CC - #TGCTCCGA 720- GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GG - #AATTCGGC 780- GGCAACGGCG GCAACATGGC GTCCCCAGCG CCGCCTGCTT GTGACCTCCG AG - #TCCTCAGT 840- AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AG - #AGGTTCAC 900# 927 TCCT GCTGCCT- (2) INFORMATION FOR SEQ ID NO:146:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 927 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GG - #AGGAGACC 480- AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GG - #CAGCACGG 540- GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG AC - #AGGTCCGT 600- CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC TTCCTCCACA GG - #GCAGGACC 660- ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC AACACCTGCT CC - #GAGGAAAG 720- GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGGGAATT CG - #GCGGCAAC 780- GGCGGCAACA TGGCGTCCCC AGCGCCGCCT GCTTGTGACC TCCGAGTCCT CA - #GTAAACTG 840- CTTCGTGACT CCCATGTCCT TCACAGCAGA CTGAGCCAGT GCCCAGAGGT TC - #ACCCTTTG 900# 927 TGCC TGCTGTG- (2) INFORMATION FOR SEQ ID NO:147:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 927 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGG AGAATGGAAA ACCCAGATGG AGGAGACCAA GG - #CACAGGAC 480- ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGG AC - #AACTGGGA 540- CCCACTTGCC TCTCATCCCT CCTGGGGCAG CTTTCTGGAC AGGTCCGTCT CC - #TCCTTGGG 600- GCCCTGCAGA GCCTCCTTGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AG - #CTCACAAG 660- GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GC - #GTTTCCTG 720- ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACGG CG - #GCAACATG 780- GCGTCCCCAG CGCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TC - #GTGACTCC 840- CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TA - #CACCTGTC 900# 927 ACTT TAGCTTG- (2) INFORMATION FOR SEQ ID NO:148:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 927 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGG ACCCACTTGC CTCTCATCCC TCCTGGGGCA GC - #TTTCTGGA 480- CAGGTCCGTC TCCTCCTTGG GGCCCTGCAG AGCCTCCTTG GAACCCAGCT TC - #CTCCACAG 540- GGCAGGACCA CAGCTCACAA GGATCCCAAT GCCATCTTCC TGAGCTTCCA AC - #ACCTGCTC 600- CGAGGAAAGG TGCGTTTCCT GATGCTTGTA GGAGGGTCCA CCCTCTGCGT CA - #GGGAATTC 660- GGCGGCAACG GCGGCAACAT GGCGTCCCCA GCGCCGCCTG CTTGTGACCT CC - #GAGTCCTC 720- AGTAAACTGC TTCGTGACTC CCATGTCCTT CACAGCAGAC TGAGCCAGTG CC - #CAGAGGTT 780- CACCCTTTGC CTACACCTGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AG - #AATGGAAA 840- ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TC - #TGCTGGAG 900# 927 GGGG ACAACTG- (2) INFORMATION FOR SEQ ID NO:149:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 927 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AG - #CTCACAAG 480- GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GC - #GTTTCCTG 540- ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACGG CG - #GCAACATG 600- GCGTCCCCAG CGCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TC - #GTGACTCC 660- CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TA - #CACCTGTC 720- CTGCTGCCTG CTGTGGACTT TAGCTTGGGA GAATGGAAAA CCCAGATGGA GG - #AGACCAAG 780- GCACAGGACA TTCTGGGAGC AGTGACCCTT CTGCTGGAGG GAGTGATGGC AG - #CACGGGGA 840- CAACTGGGAC CCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACA GG - #TCCGTCTC 900# 927 AGAG CCTCCTT- (2) INFORMATION FOR SEQ ID NO:150:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 927 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CA - #TCTTCCTG 480- AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AG - #GGTCCACC 540- CTCTGCGTCA GGGAATTCGG CGGCAACGGC GGCAACATGG CGTCCCCAGC GC - #CGCCTGCT 600- TGTGACCTCC GAGTCCTCAG TAAACTGCTT CGTGACTCCC ATGTCCTTCA CA - #GCAGACTG 660- AGCCAGTGCC CAGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TG - #TGGACTTT 720- AGCTTGGGAG AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TC - #TGGGAGCA 780- GTGACCCTTC TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CA - #CTTGCCTC 840- TCATCCCTCC TGGGGCAGCT TTCTGGACAG GTCCGTCTCC TCCTTGGGGC CC - #TGCAGAGC 900# 927 TTCC TCCACAG- (2) INFORMATION FOR SEQ ID NO:151:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 927 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG CT - #TCCAACAC 480- CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCT CT - #GCGTCAGG 540- GAATTCGGCG GCAACGGCGG CAACATGGCG TCCCCAGCGC CGCCTGCTTG TG - #ACCTCCGA 600- GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CC - #AGTGCCCA 660- GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CT - #TGGGAGAA 720- TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GA - #CCCTTCTG 780- CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC AT - #CCCTCCTG 840- GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CC - #TTGGAACC 900# 927 GCAG GACCACA- (2) INFORMATION FOR SEQ ID NO:152:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 927 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CC - #TGCTCCGA 480- GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GG - #AATTCGGC 540- GGCAACGGCG GCAACATGGC GTCCCCAGCG CCGCCTGCTT GTGACCTCCG AG - #TCCTCAGT 600- AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AG - #AGGTTCAC 660- CCTTTGCCTA CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGA AT - #GGAAAACC 720- CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT GC - #TGGAGGGA 780- GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT CATCCCTCCT GG - #GGCAGCTT 840- TCTGGACAGG TCCGTCTCCT CCTTGGGGCC CTGCAGAGCC TCCTTGGAAC CC - #AGCTTCCT 900# 927 CAGC TCACAAG- (2) INFORMATION FOR SEQ ID NO:153:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 927 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AG - #GAAAGGTG 480- CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CG - #GCAACGGC 540- GGCAACATGG CGTCCCCAGC GCCGCCTGCT TGTGACCTCC GAGTCCTCAG TA - #AACTGCTT 600- CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CC - #CTTTGCCT 660- ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CC - #AGATGGAG 720- GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AG - #TGATGGCA 780- GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TT - #CTGGACAG 840- GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TC - #CACAGGGC 900# 927 AGGA TCCCAAT- (2) INFORMATION FOR SEQ ID NO:154:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 906 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT 60- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT 120- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT 180- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT 240- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC 300- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC 360- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT 420- CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CC - #TGCTCCGA 480- GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GG - #AATTCGGC 540- GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TA - #AACTGCTT 600- CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CC - #CTTTGCCT 660- ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CC - #AGATGGAG 720- GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AG - #TGATGGCA 780- GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TT - #CTGGACAG 840- GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGGGCAG GA - #CCACAGCT 900# 906- (2) INFORMATION FOR SEQ ID NO:155:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 993 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GTCTTACAAG CTGTGCCACC CCGAGGAGCT GG - #TGCTGCTC 480- GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GG - #CCCTGCAG 540- CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GC - #TCCTGCAG 600- GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GC - #TGGACGTC 660- GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CC - #CTGCCCTG 720- CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GG - #CAGGAGGG 780- GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TC - #TACGCCAC 840- CTTGCGCAGC CCGGCGGCGG CTCTGACATG GCTACACCAT TAGGCCCTGC CA - #GCTCCCTG 900- CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGGA AGATCCAGGG CG - #ATGGCGCA 960# 993 TGTG TGCCACCTAA TAA- (2) INFORMATION FOR SEQ ID NO:156:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 993 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GTCTCCCGAG TTGGGTCCCA CCTTGGACAC AC - #TGCAGCTG 480- GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AA - #TGGCCCCT 540- GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GC - #GCCGGGCA 600- GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CC - #GCGTTCTA 660- CGCCACCTTG CGCAGCCCGG CGGCGGCTCT GACATGGCTA CACCATTAGG CC - #CTGCCAGC 720- TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGGAAGAT CC - #AGGGCGAT 780- GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC CG - #AGGAGCTG 840- GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CC - #CCAGCCAG 900- GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CT - #ACCAGGGG 960# 993 AAGG GATATCCTAA TAA- (2) INFORMATION FOR SEQ ID NO:157:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 993 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GTCTTCTGCT TTCCAGCGCC GGGCAGGAGG GG - #TCCTGGTT 480- GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CC - #TTGCGCAG 540- CCCGGCGGCG GCTCTGACAT GGCTACACCA TTAGGCCCTG CCAGCTCCCT GC - #CCCAGAGC 600- TTCCTGCTCA AGTCTTTAGA GCAAGTGAGG AAGATCCAGG GCGATGGCGC AG - #CGCTCCAG 660- GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GC - #TCGGACAC 720- TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GC - #AGCTGGCA 780- GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GC - #AGGCCCTG 840- GAAGGGATAT CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CG - #TCGCCGAC 900- TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC CC - #TGCAGCCC 960# 993 CGGC CTTCGCCTAA TAA- (2) INFORMATION FOR SEQ ID NO:158:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 993 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GTCTATGGCC CCTGCCCTGC AGCCCACCCA GG - #GTGCCATG 480- CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TA - #GCCATCTG 540- CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CG - #GCGGCGGC 600- TCTGACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CC - #TGCTCAAG 660- TCTTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GA - #AGCTGTGT 720- GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TC - #TGGGCATC 780- CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CT - #GCTTGAGC 840- CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AG - #GGATATCC 900- CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT TG - #CCACCACC 960# 993 AAGA ACTGGGATAA TAA- (2) INFORMATION FOR SEQ ID NO:159:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 993 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GTCTACCCAG GGTGCCATGC CGGCCTTCGC CT - #CTGCTTTC 480- CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GG - #AGGTGTCG 540- TACCGCGTTC TACGCCACCT TGCGCAGCCC GGCGGCGGCT CTGACATGGC TA - #CACCATTA 600- GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AG - #TGAGGAAG 660- ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GC - #TGTGCCAC 720- CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CC - #TGAGCTCC 780- TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG CG - #GCCTTTTC 840- CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TC - #CCACCTTG 900- GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GA - #TGGAAGAA 960# 993 CCCT GCAGCCCTAA TAA- (2) INFORMATION FOR SEQ ID NO:160:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1027 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:- ATGGCTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CA - #AGTCTTTA 60- GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GT - #GTGCCACC 120- TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CA - #TCCCCTGG 180- GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GA - #GCCAACTC 240- CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT AT - #CCCCCGAG 300- TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CA - #CCATCTGG 360- CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG TG - #CCATGCCG 420- GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CC - #ATCTGCAG 480- AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCGG CG - #GCGGCTCT 540- GACATGGCTA CACCATTGGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GC - #TCAAGTCT 600- TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GC - #TGTGTGCC 660- ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GG - #GCATCCCC 720- TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CT - #TGAGCCAA 780- CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GA - #TATCCCCC 840- GAGTTGGGTC CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC CA - #CCACCATC 900- TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA TC - #CTGGTTGC 960- TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TT - #GCGCAGCC1020# 1027- (2) INFORMATION FOR SEQ ID NO:161:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 155 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:- Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu# 15- Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val# 30- His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu# 45- Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu# 60- Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln#80- Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln# 95- Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu# 110- Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe# 125- Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu# 140- Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph - #e145 1 - #50 1 - #55- (2) INFORMATION FOR SEQ ID NO:162:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 309 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:162:- Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu# 15- Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val# 30- His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu# 45- Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu# 60- Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln#80- Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln# 95- Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu# 110- Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe# 125- Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu# 140- Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph - #e Gly Gly Asn Met Ala145 1 - #50 1 - #55 1 -#60- Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu# 175- Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val# 190- His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu# 205- Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu# 220- Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln225 2 - #30 2 - #35 2 -#40- Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln# 255- Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Gly# 270- Arg Thr Thr Ala His Lys Asp Pro Asn Ala Il - #e Phe Leu Ser Phe Gln# 285- His Leu Leu Arg Gly Lys Val Arg Phe Leu Me - #t Leu Val Gly Gly Ser# 300- Thr Leu Cys Val Arg305- (2) INFORMATION FOR SEQ ID NO:163:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 312 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:- Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu# 15- Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val# 30- His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu# 45- Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu# 60- Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln#80- Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln# 95- Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu# 110- Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe# 125- Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu# 140- Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph - #e Gly Asn Met Ala Ser145 1 - #50 1 - #55 1 -#60- Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Le - #u Ser Lys Leu Leu Arg# 175- Asp Ser His Val Leu His Ser Arg Leu Ser Gl - #n Cys Pro Glu Val His# 190- Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Va - #l Asp Phe Ser Leu Gly# 205- Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Al - #a Gln Asp Ile Leu Gly# 220- Ala Val Thr Leu Leu Leu Glu Gly Val Met Al - #a Ala Arg Gly Gln Leu225 2 - #30 2 - #35 2 -#40- Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gl - #n Leu Ser Gly Gln Val# 255- Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Le - #u Gly Thr Gln Leu Pro# 270- Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pr - #o Asn Ala Ile Phe Leu# 285- Ser Phe Gln His Leu Leu Arg Gly Lys Val Ar - #g Phe Leu Met Leu Val# 300- Gly Gly Ser Thr Leu Cys Val Arg305 3 - #10- (2) INFORMATION FOR SEQ ID NO:164:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 313 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:- Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu# 15- Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val# 30- His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu# 45- Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu# 60- Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln#80- Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln# 95- Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu# 110- Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe# 125- Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu# 140- Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph - #e Gly Gly Asn Met Ala145 1 - #50 1 - #55 1 -#60- Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu# 175- Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val# 190- His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu# 205- Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu# 220- Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln225 2 - #30 2 - #35 2 -#40- Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln# 255- Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu# 270- Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe# 285- Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu# 300- Val Gly Gly Ser Thr Leu Cys Val Arg305 3 - #10- (2) INFORMATION FOR SEQ ID NO:165:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 316 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:- Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu# 15- Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val# 30- His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu# 45- Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu# 60- Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln#80- Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln# 95- Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu# 110- Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe# 125- Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu# 140- Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph - #e Gly Gly Asn Gly Gly145 1 - #50 1 - #55 1 -#60- Asn Met Ala Ser Pro Ala Pro Pro Ala Cys As - #p Leu Arg Val Leu Ser# 175- Lys Leu Leu Arg Asp Ser His Val Leu His Se - #r Arg Leu Ser Gln Cys# 190- Pro Glu Val His Pro Leu Pro Thr Pro Val Le - #u Leu Pro Ala Val Asp# 205- Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Gl - #u Glu Thr Lys Ala Gln# 220- Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Gl - #u Gly Val Met Ala Ala225 2 - #30 2 - #35 2 -#40- Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Se - #r Leu Leu Gly Gln Leu# 255- Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Le - #u Gln Ser Leu Leu Gly# 270- Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Al - #a His Lys Asp Pro Asn# 285- Ala Ile Phe Leu Ser Phe Gln His Leu Leu Ar - #g Gly Lys Val Arg Phe# 300- Leu Met Leu Val Gly Gly Ser Thr Leu Cys Va - #l Arg305 3 - #10 3 - #15- (2) INFORMATION FOR SEQ ID NO:166:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 302 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser# 125- Asn Met Ala Tyr Lys Leu Cys His Pro Glu Gl - #u Leu Val Leu Leu Gly# 140- His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se - #r Ser Cys Pro Ser Gln145 1 - #50 1 - #55 1 -#60- Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le - #u His Ser Gly Leu Phe# 175- Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl - #y Ile Ser Pro Glu Leu# 190- Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Va - #l Ala Asp Phe Ala Thr# 205- Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Me - #t Ala Pro Ala Leu Gln# 220- Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Se - #r Ala Phe Gln Arg Arg225 2 - #30 2 - #35 2 -#40- Ala Gly Gly Val Leu Val Ala Ser His Leu Gl - #n Ser Phe Leu Glu Val# 255- Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pr - #o Ser Gly Gly Ser Gly# 270- Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Gl - #u Gln Val Arg Lys Ile# 285- Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Le - #u Cys Ala Thr# 300- (2) INFORMATION FOR SEQ ID NO:167:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 317 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser# 125- Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn# 140- Met Ala Tyr Lys Leu Cys His Pro Glu Glu Le - #u Val Leu Leu Gly His145 1 - #50 1 - #55 1 -#60- Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Se - #r Cys Pro Ser Gln Ala# 175- Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu Hi - #s Ser Gly Leu Phe Leu# 190- Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Il - #e Ser Pro Glu Leu Gly# 205- Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Al - #a Asp Phe Ala Thr Thr# 220- Ile Trp Gln Gln Met Glu Glu Leu Gly Met Al - #a Pro Ala Leu Gln Pro225 2 - #30 2 - #35 2 -#40- Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Al - #a Phe Gln Arg Arg Ala# 255- Gly Gly Val Leu Val Ala Ser His Leu Gln Se - #r Phe Leu Glu Val Ser# 270- Tyr Arg Val Leu Arg His Leu Ala Gln Pro Se - #r Gly Gly Ser Gly Gly# 285- Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gl - #n Val Arg Lys Ile Gln# 300- Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cy - #s Ala Thr305 3 - #10 3 - #15- (2) INFORMATION FOR SEQ ID NO:168:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 302 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:168:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser# 125- Asn Met Ala Pro Glu Leu Gly Pro Thr Leu As - #p Thr Leu Gln Leu Asp# 140- Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gl - #n Met Glu Glu Leu Gly145 1 - #50 1 - #55 1 -#60- Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Al - #a Met Pro Ala Phe Ala# 175- Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Le - #u Val Ala Ser His Leu# 190- Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Le - #u Arg His Leu Ala Gln# 205- Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Ph - #e Leu Leu Lys Ser Leu# 220- Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Al - #a Ala Leu Gln Glu Lys225 2 - #30 2 - #35 2 -#40- Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Gl - #u Glu Leu Val Leu Leu# 255- Gly His Ser Leu Gly Ile Pro Trp Ala Pro Le - #u Ser Ser Cys Pro Ser# 270- Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gl - #n Leu His Ser Gly Leu# 285- Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Gl - #u Gly Ile Ser# 300- (2) INFORMATION FOR SEQ ID NO:169:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 317 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser# 125- Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn# 140- Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Th - #r Leu Gln Leu Asp Val145 1 - #50 1 - #55 1 -#60- Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Me - #t Glu Glu Leu Gly Met# 175- Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser# 190- Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln# 205- Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro# 220- Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Le - #u Leu Lys Ser Leu Glu225 2 - #30 2 - #35 2 -#40- Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Al - #a Leu Gln Glu Lys Leu# 255- Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Gl - #u Leu Val Leu Leu Gly# 270- His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se - #r Ser Cys Pro Ser Gln# 285- Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le - #u His Ser Gly Leu Phe# 300- Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl - #y Ile Ser305 3 - #10 3 - #15- (2) INFORMATION FOR SEQ ID NO:170:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 302 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser# 125- Asn Met Ala Met Ala Pro Ala Leu Gln Pro Th - #r Gln Gly Ala Met Pro# 140- Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gl - #y Gly Val Leu Val Ala145 1 - #50 1 - #55 1 -#60- Ser His Leu Gln Ser Phe Leu Glu Val Ser Ty - #r Arg Val Leu Arg His# 175- Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Se - #r Gln Ser Phe Leu Leu# 190- Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gl - #y Asp Gly Ala Ala Leu# 205- Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cy - #s His Pro Glu Glu Leu# 220- Val Leu Leu Gly His Ser Leu Gly Ile Pro Tr - #p Ala Pro Leu Ser Ser225 2 - #30 2 - #35 2 -#40- Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cy - #s Leu Ser Gln Leu His# 255- Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gl - #n Ala Leu Glu Gly Ile# 270- Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Le - #u Gln Leu Asp Val Ala# 285- Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Gl - #u Glu Leu Gly# 300- (2) INFORMATION FOR SEQ ID NO:171:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 317 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser# 125- Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn# 140- Met Ala Met Ala Pro Ala Leu Gln Pro Thr Gl - #n Gly Ala Met Pro Ala145 1 - #50 1 - #55 1 -#60- Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gl - #y Val Leu Val Ala Ser# 175- His Leu Gln Ser Phe Leu Glu Val Ser Tyr Ar - #g Val Leu Arg His Leu# 190- Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gl - #n Ser Phe Leu Leu Lys# 205- Ser Leu Glu Gln Val Arg Lys Ile Gln Gly As - #p Gly Ala Ala Leu Gln# 220- Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys Hi - #s Pro Glu Glu Leu Val225 2 - #30 2 - #35 2 -#40- Leu Leu Gly His Ser Leu Gly Ile Pro Trp Al - #a Pro Leu Ser Ser Cys# 255- Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Le - #u Ser Gln Leu His Ser# 270- Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Al - #a Leu Glu Gly Ile Ser# 285- Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gl - #n Leu Asp Val Ala Asp# 300- Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Gl - #u Leu Gly305 3 - #10 3 - #15- (2) INFORMATION FOR SEQ ID NO:172:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 302 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser# 125- Asn Met Ala Thr Gln Gly Ala Met Pro Ala Ph - #e Ala Ser Ala Phe Gln# 140- Arg Arg Ala Gly Gly Val Leu Val Ala Ser Hi - #s Leu Gln Ser Phe Leu145 1 - #50 1 - #55 1 -#60- Glu Val Ser Tyr Arg Val Leu Arg His Leu Al - #a Gln Pro Ser Gly Gly# 175- Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Se - #r Leu Glu Gln Val Arg# 190- Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Gl - #u Lys Leu Cys Ala Thr# 205- Tyr Lys Leu Cys His Pro Glu Glu Leu Val Le - #u Leu Gly His Ser Leu# 220- Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pr - #o Ser Gln Ala Leu Gln225 2 - #30 2 - #35 2 -#40- Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gl - #y Leu Phe Leu Tyr Gln# 255- Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pr - #o Glu Leu Gly Pro Thr# 270- Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Ph - #e Ala Thr Thr Ile Trp# 285- Gln Gln Met Glu Glu Leu Gly Met Ala Pro Al - #a Leu Gln Pro# 300- (2) INFORMATION FOR SEQ ID NO:173:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 317 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser# 125- Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn# 140- Met Ala Thr Gln Gly Ala Met Pro Ala Phe Al - #a Ser Ala Phe Gln Arg145 1 - #50 1 - #55 1 -#60- Arg Ala Gly Gly Val Leu Val Ala Ser His Le - #u Gln Ser Phe Leu Glu# 175- Val Ser Tyr Arg Val Leu Arg His Leu Ala Gl - #n Pro Ser Gly Gly Ser# 190- Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Le - #u Glu Gln Val Arg Lys# 205- Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Ly - #s Leu Cys Ala Thr Tyr# 220- Lys Leu Cys His Pro Glu Glu Leu Val Leu Le - #u Gly His Ser Leu Gly225 2 - #30 2 - #35 2 -#40- Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Se - #r Gln Ala Leu Gln Leu# 255- Ala Gly Cys Leu Ser Gln Leu His Ser Gly Le - #u Phe Leu Tyr Gln Gly# 270- Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Gl - #u Leu Gly Pro Thr Leu# 285- Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Al - #a Thr Thr Ile Trp Gln# 300- Gln Met Glu Glu Leu Gly Met Ala Pro Ala Le - #u Gln Pro305 3 - #10 3 - #15- (2) INFORMATION FOR SEQ ID NO:174:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 302 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser# 125- Asn Met Ala Ser Ala Phe Gln Arg Arg Ala Gl - #y Gly Val Leu Val Ala# 140- Ser His Leu Gln Ser Phe Leu Glu Val Ser Ty - #r Arg Val Leu Arg His145 1 - #50 1 - #55 1 -#60- Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Se - #r Gln Ser Phe Leu Leu# 175- Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gl - #y Asp Gly Ala Ala Leu# 190- Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cy - #s His Pro Glu Glu Leu# 205- Val Leu Leu Gly His Ser Leu Gly Ile Pro Tr - #p Ala Pro Leu Ser Ser# 220- Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cy - #s Leu Ser Gln Leu His225 2 - #30 2 - #35 2 -#40- Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gl - #n Ala Leu Glu Gly Ile# 255- Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Le - #u Gln Leu Asp Val Ala# 270- Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Gl - #u Glu Leu Gly Met Ala# 285- Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pr - #o Ala Phe Ala# 300- (2) INFORMATION FOR SEQ ID NO:175:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 317 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser# 125- Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn# 140- Met Ala Ser Ala Phe Gln Arg Arg Ala Gly Gl - #y Val Leu Val Ala Ser145 1 - #50 1 - #55 1 -#60- His Leu Gln Ser Phe Leu Glu Val Ser Tyr Ar - #g Val Leu Arg His Leu# 175- Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gl - #n Ser Phe Leu Leu Lys# 190- Ser Leu Glu Gln Val Arg Lys Ile Gln Gly As - #p Gly Ala Ala Leu Gln# 205- Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys Hi - #s Pro Glu Glu Leu Val# 220- Leu Leu Gly His Ser Leu Gly Ile Pro Trp Al - #a Pro Leu Ser Ser Cys225 2 - #30 2 - #35 2 -#40- Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Le - #u Ser Gln Leu His Ser# 255- Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Al - #a Leu Glu Gly Ile Ser# 270- Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gl - #n Leu Asp Val Ala Asp# 285- Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Gl - #u Leu Gly Met Ala Pro# 300- Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Al - #a Phe Ala305 3 - #10 3 - #15- (2) INFORMATION FOR SEQ ID NO:176:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 305 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser# 125- Asn Met Ala Tyr Lys Leu Cys His Pro Glu Gl - #u Leu Val Leu Leu Gly# 140- His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se - #r Ser Cys Pro Ser Gln145 1 - #50 1 - #55 1 -#60- Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le - #u His Ser Gly Leu Phe# 175- Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl - #y Ile Ser Pro Glu Leu# 190- Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Va - #l Ala Asp Phe Ala Thr# 205- Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Me - #t Ala Pro Ala Leu Gln# 220- Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Se - #r Ala Phe Gln Arg Arg225 2 - #30 2 - #35 2 -#40- Ala Gly Gly Val Leu Val Ala Ser His Leu Gl - #n Ser Phe Leu Glu Val# 255- Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pr - #o Thr Pro Leu Gly Pro# 270- Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Ly - #s Ser Leu Glu Gln Val# 285- Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gl - #n Glu Lys Leu Cys Ala# 300- Thr305- (2) INFORMATION FOR SEQ ID NO:177:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 320 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser# 125- Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn# 140- Met Ala Tyr Lys Leu Cys His Pro Glu Glu Le - #u Val Leu Leu Gly His145 1 - #50 1 - #55 1 -#60- Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Se - #r Cys Pro Ser Gln Ala# 175- Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu Hi - #s Ser Gly Leu Phe Leu# 190- Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Il - #e Ser Pro Glu Leu Gly# 205- Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Al - #a Asp Phe Ala Thr Thr# 220- Ile Trp Gln Gln Met Glu Glu Leu Gly Met Al - #a Pro Ala Leu Gln Pro225 2 - #30 2 - #35 2 -#40- Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Al - #a Phe Gln Arg Arg Ala# 255- Gly Gly Val Leu Val Ala Ser His Leu Gln Se - #r Phe Leu Glu Val Ser# 270- Tyr Arg Val Leu Arg His Leu Ala Gln Pro Th - #r Pro Leu Gly Pro Ala# 285- Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Se - #r Leu Glu Gln Val Arg# 300- Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Gl - #u Lys Leu Cys Ala Thr305 3 - #10 3 - #15 3 -#20- (2) INFORMATION FOR SEQ ID NO:178:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 305 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser# 125- Asn Met Ala Pro Glu Leu Gly Pro Thr Leu As - #p Thr Leu Gln Leu Asp# 140- Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gl - #n Met Glu Glu Leu Gly145 1 - #50 1 - #55 1 -#60- Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Al - #a Met Pro Ala Phe Ala# 175- Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Le - #u Val Ala Ser His Leu# 190- Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Le - #u Arg His Leu Ala Gln# 205- Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pr - #o Gln Ser Phe Leu Leu# 220- Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gl - #y Asp Gly Ala Ala Leu225 2 - #30 2 - #35 2 -#40- Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cy - #s His Pro Glu Glu Leu# 255- Val Leu Leu Gly His Ser Leu Gly Ile Pro Tr - #p Ala Pro Leu Ser Ser# 270- Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cy - #s Leu Ser Gln Leu His# 285- Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gl - #n Ala Leu Glu Gly Ile# 300- Ser305- (2) INFORMATION FOR SEQ ID NO:179:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 320 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser# 125- Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn# 140- Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Th - #r Leu Gln Leu Asp Val145 1 - #50 1 - #55 1 -#60- Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Me - #t Glu Glu Leu Gly Met# 175- Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser# 190- Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln# 205- Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro# 220- Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gl - #n Ser Phe Leu Leu Lys225 2 - #30 2 - #35 2 -#40- Ser Leu Glu Gln Val Arg Lys Ile Gln Gly As - #p Gly Ala Ala Leu Gln# 255- Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys Hi - #s Pro Glu Glu Leu Val# 270- Leu Leu Gly His Ser Leu Gly Ile Pro Trp Al - #a Pro Leu Ser Ser Cys# 285- Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Le - #u Ser Gln Leu His Ser# 300- Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Al - #a Leu Glu Gly Ile Ser305 3 - #10 3 - #15 3 -#20- (2) INFORMATION FOR SEQ ID NO:180:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 305 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser# 125- Asn Met Ala Met Ala Pro Ala Leu Gln Pro Th - #r Gln Gly Ala Met Pro# 140- Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gl - #y Gly Val Leu Val Ala145 1 - #50 1 - #55 1 -#60- Ser His Leu Gln Ser Phe Leu Glu Val Ser Ty - #r Arg Val Leu Arg His# 175- Leu Ala Gln Pro Thr Pro Leu Gly Pro Ala Se - #r Ser Leu Pro Gln Ser# 190- Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Ly - #s Ile Gln Gly Asp Gly# 205- Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Ty - #r Lys Leu Cys His Pro# 220- Glu Glu Leu Val Leu Leu Gly His Ser Leu Gl - #y Ile Pro Trp Ala Pro225 2 - #30 2 - #35 2 -#40- Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Le - #u Ala Gly Cys Leu Ser# 255- Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gl - #y Leu Leu Gln Ala Leu# 270- Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Le - #u Asp Thr Leu Gln Leu# 285- Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gl - #n Gln Met Glu Glu Leu# 300- Gly305- (2) INFORMATION FOR SEQ ID NO:181:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 320 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser# 125- Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn# 140- Met Ala Met Ala Pro Ala Leu Gln Pro Thr Gl - #n Gly Ala Met Pro Ala145 1 - #50 1 - #55 1 -#60- Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gl - #y Val Leu Val Ala Ser# 175- His Leu Gln Ser Phe Leu Glu Val Ser Tyr Ar - #g Val Leu Arg His Leu# 190- Ala Gln Pro Thr Pro Leu Gly Pro Ala Ser Se - #r Leu Pro Gln Ser Phe# 205- Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Il - #e Gln Gly Asp Gly Ala# 220- Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Ly - #s Leu Cys His Pro Glu225 2 - #30 2 - #35 2 -#40- Glu Leu Val Leu Leu Gly His Ser Leu Gly Il - #e Pro Trp Ala Pro Leu# 255- Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Al - #a Gly Cys Leu Ser Gln# 270- Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Le - #u Leu Gln Ala Leu Glu# 285- Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu As - #p Thr Leu Gln Leu Asp# 300- Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gl - #n Met Glu Glu Leu Gly305 3 - #10 3 - #15 3 -#20- (2) INFORMATION FOR SEQ ID NO:182:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 305 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser# 125- Asn Met Ala Thr Gln Gly Ala Met Pro Ala Ph - #e Ala Ser Ala Phe Gln# 140- Arg Arg Ala Gly Gly Val Leu Val Ala Ser Hi - #s Leu Gln Ser Phe Leu145 1 - #50 1 - #55 1 -#60- Glu Val Ser Tyr Arg Val Leu Arg His Leu Al - #a Gln Pro Thr Pro Leu# 175- Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Le - #u Leu Lys Ser Leu Glu# 190- Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Al - #a Leu Gln Glu Lys Leu# 205- Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Gl - #u Leu Val Leu Leu Gly# 220- His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se - #r Ser Cys Pro Ser Gln225 2 - #30 2 - #35 2 -#40- Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le - #u His Ser Gly Leu Phe# 255- Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl - #y Ile Ser Pro Glu Leu# 270- Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Va - #l Ala Asp Phe Ala Thr# 285- Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Me - #t Ala Pro Ala Leu Gln# 300- Pro305- (2) INFORMATION FOR SEQ ID NO:183:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 320 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser# 125- Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn# 140- Met Ala Thr Gln Gly Ala Met Pro Ala Phe Al - #a Ser Ala Phe Gln Arg145 1 - #50 1 - #55 1 -#60- Arg Ala Gly Gly Val Leu Val Ala Ser His Le - #u Gln Ser Phe Leu Glu# 175- Val Ser Tyr Arg Val Leu Arg His Leu Ala Gl - #n Pro Thr Pro Leu Gly# 190- Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Le - #u Lys Ser Leu Glu Gln# 205- Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Le - #u Gln Glu Lys Leu Cys# 220- Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Le - #u Val Leu Leu Gly His225 2 - #30 2 - #35 2 -#40- Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Se - #r Cys Pro Ser Gln Ala# 255- Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu Hi - #s Ser Gly Leu Phe Leu# 270- Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Il - #e Ser Pro Glu Leu Gly# 285- Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Al - #a Asp Phe Ala Thr Thr# 300- Ile Trp Gln Gln Met Glu Glu Leu Gly Met Al - #a Pro Ala Leu Gln Pro305 3 - #10 3 - #15 3 -#20- (2) INFORMATION FOR SEQ ID NO:184:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 305 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser# 125- Asn Met Ala Ser Ala Phe Gln Arg Arg Ala Gl - #y Gly Val Leu Val Ala# 140- Ser His Leu Gln Ser Phe Leu Glu Val Ser Ty - #r Arg Val Leu Arg His145 1 - #50 1 - #55 1 -#60- Leu Ala Gln Pro Thr Pro Leu Gly Pro Ala Se - #r Ser Leu Pro Gln Ser# 175- Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Ly - #s Ile Gln Gly Asp Gly# 190- Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Ty - #r Lys Leu Cys His Pro# 205- Glu Glu Leu Val Leu Leu Gly His Ser Leu Gl - #y Ile Pro Trp Ala Pro# 220- Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Le - #u Ala Gly Cys Leu Ser225 2 - #30 2 - #35 2 -#40- Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gl - #y Leu Leu Gln Ala Leu# 255- Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Le - #u Asp Thr Leu Gln Leu# 270- Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gl - #n Gln Met Glu Glu Leu# 285- Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gl - #y Ala Met Pro Ala Phe# 300- Ala305- (2) INFORMATION FOR SEQ ID NO:185:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 320 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:- Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro# 15- Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser# 30- Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val# 45- Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu# 60- Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg#80- His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys# 95- Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr# 110- Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser# 125- Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn# 140- Met Ala Ser Ala Phe Gln Arg Arg Ala Gly Gl - #y Val Leu Val Ala Ser145 1 - #50 1 - #55 1 -#60- His Leu Gln Ser Phe Leu Glu Val Ser Tyr Ar - #g Val Leu Arg His Leu# 175- Ala Gln Pro Thr Pro Leu Gly Pro Ala Ser Se - #r Leu Pro Gln Ser Phe# 190- Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Il - #e Gln Gly Asp Gly Ala# 205- Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Ly - #s Leu Cys His Pro Glu# 220- Glu Leu Val Leu Leu Gly His Ser Leu Gly Il - #e Pro Trp Ala Pro Leu225 2 - #30 2 - #35 2 -#40- Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Al - #a Gly Cys Leu Ser Gln# 255- Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Le - #u Leu Gln Ala Leu Glu# 270- Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu As - #p Thr Leu Gln Leu Asp# 285- Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gl - #n Met Glu Glu Leu Gly# 300- Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Al - #a Met Pro Ala Phe Ala305 3 - #10 3 - #15 3 -#20- (2) INFORMATION FOR SEQ ID NO:186:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 321 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:- Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va - #l Ser Ile Leu Met Asp# 15- Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph - #e Val Arg Ala Val Lys# 30- Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il - #e Leu Arg Asn Leu Gln# 45- Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se - #r Arg His Pro Ile Ile# 60- Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl - #u Lys Leu Thr Phe Tyr#80- Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl - #n Gly Gly Gly Ser Asn# 95- Cys Ser Ile Met Ile Asp Glu Ile Ile His Hi - #s Leu Lys Arg Pro Pro# 110- Ala Pro Leu Tyr Val Glu Gly Gly Gly Gly Se - #r Pro Gly Glu Pro Ser# 125- Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pr - #o Ser Lys Glu Ser His# 140- Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser145 1 - #50 1 - #55 1 -#60- Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln# 175- Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro# 190- Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Le - #u Leu Lys Ser Leu Glu# 205- Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Al - #a Leu Gln Glu Lys Leu# 220- Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Gl - #u Leu Val Leu Leu Gly225 2 - #30 2 - #35 2 -#40- His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se - #r Ser Cys Pro Ser Gln# 255- Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le - #u His Ser Gly Leu Phe# 270- Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl - #y Ile Ser Pro Glu Leu# 285- Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Va - #l Ala Asp Phe Ala Thr# 300- Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Me - #t Ala Pro Ala Leu Gln305 3 - #10 3 - #15 3 -#20- Pro- (2) INFORMATION FOR SEQ ID NO:187:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 321 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:- Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg As - #n Leu Gln Pro Cys Leu# 15- Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pr - #o Ile Ile Ile Lys Ala# 30- Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Th - #r Phe Tyr Leu Val Thr# 45- Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gl - #y Ser Asn Cys Ser Ile# 60- Met Ile Asp Glu Ile Ile His His Leu Lys Ar - #g Pro Pro Ala Pro Leu#80- Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va - #l Ser Ile Leu Met Asp# 95- Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph - #e Val Arg Ala Val Lys# 110- Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Se - #r Pro Gly Glu Pro Ser# 125- Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pr - #o Ser Lys Glu Ser His# 140- Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser145 1 - #50 1 - #55 1 -#60- Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln# 175- Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro# 190- Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Le - #u Leu Lys Ser Leu Glu# 205- Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Al - #a Leu Gln Glu Lys Leu# 220- Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Gl - #u Leu Val Leu Leu Gly225 2 - #30 2 - #35 2 -#40- His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se - #r Ser Cys Pro Ser Gln# 255- Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le - #u His Ser Gly Leu Phe# 270- Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl - #y Ile Ser Pro Glu Leu# 285- Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Va - #l Ala Asp Phe Ala Thr# 300- Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Me - #t Ala Pro Ala Leu Gln305 3 - #10 3 - #15 3 -#20- Pro- (2) INFORMATION FOR SEQ ID NO:188:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 321 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:- Ala Pro Ser Arg His Pro Ile Ile Ile Lys Al - #a Gly Asp Trp Gln Glu# 15- Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Th - #r Leu Glu Gln Ala Gln# 30- Glu Gln Gln Gly Gly Gly Ser Asn Cys Ser Il - #e Met Ile Asp Glu Ile# 45- Ile His His Leu Lys Arg Pro Pro Ala Pro Le - #u Leu Asp Pro Asn Asn# 60- Leu Asn Asp Glu Asp Val Ser Ile Leu Met As - #p Arg Asn Leu Arg Leu#80- Pro Asn Leu Glu Ser Phe Val Arg Ala Val Ly - #s Asn Leu Glu Asn Ala# 95- Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gl - #n Pro Cys Leu Pro Ser# 110- Ala Thr Ala Tyr Val Glu Gly Gly Gly Gly Se - #r Pro Gly Glu Pro Ser# 125- Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pr - #o Ser Lys Glu Ser His# 140- Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser145 1 - #50 1 - #55 1 -#60- Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln# 175- Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro# 190- Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Le - #u Leu Lys Ser Leu Glu# 205- Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Al - #a Leu Gln Glu Lys Leu# 220- Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Gl - #u Leu Val Leu Leu Gly225 2 - #30 2 - #35 2 -#40- His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se - #r Ser Cys Pro Ser Gln# 255- Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le - #u His Ser Gly Leu Phe# 270- Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl - #y Ile Ser Pro Glu Leu# 285- Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Va - #l Ala Asp Phe Ala Thr# 300- Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Me - #t Ala Pro Ala Leu Gln305 3 - #10 3 - #15 3 -#20- Pro- (2) INFORMATION FOR SEQ ID NO:189:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 321 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:- Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Le - #u Thr Phe Tyr Leu Val# 15- Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gl - #y Gly Ser Asn Cys Ser# 30- Ile Met Ile Asp Glu Ile Ile His His Leu Ly - #s Arg Pro Pro Ala Pro# 45- Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu As - #p Val Ser Ile Leu Met# 60- Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Se - #r Phe Val Arg Ala Val#80- Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Al - #a Ile Leu Arg Asn Leu# 95- Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pr - #o Ser Arg His Pro Ile# 110- Ile Ile Lys Tyr Val Glu Gly Gly Gly Gly Se - #r Pro Gly Glu Pro Ser# 125- Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pr - #o Ser Lys Glu Ser His# 140- Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser145 1 - #50 1 - #55 1 -#60- Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln# 175- Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro# 190- Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Le - #u Leu Lys Ser Leu Glu# 205- Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Al - #a Leu Gln Glu Lys Leu# 220- Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Gl - #u Leu Val Leu Leu Gly225 2 - #30 2 - #35 2 -#40- His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se - #r Ser Cys Pro Ser Gln# 255- Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le - #u His Ser Gly Leu Phe# 270- Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl - #y Ile Ser Pro Glu Leu# 285- Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Va - #l Ala Asp Phe Ala Thr# 300- Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Me - #t Ala Pro Ala Leu Gln305 3 - #10 3 - #15 3 -#20- Pro- (2) INFORMATION FOR SEQ ID NO:190:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 329 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:- Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va - #l Ser Ile Leu Met Asp# 15- Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph - #e Val Arg Ala Val Lys# 30- Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il - #e Leu Arg Asn Leu Gln# 45- Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se - #r Arg His Pro Ile Ile# 60- Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl - #u Lys Leu Thr Phe Tyr#80- Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl - #n Gly Gly Gly Ser Gly# 95- Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Il - #e Met Ile Asp Glu Ile# 110- Ile His His Leu Lys Arg Pro Pro Ala Pro Le - #u Tyr Val Glu Gly Gly# 125- Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il - #e Ser Thr Ile Asn Pro# 140- Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr - #o Asn Met Ala Thr Gln145 1 - #50 1 - #55 1 -#60- Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gl - #n Arg Arg Ala Gly Gly# 175- Val Leu Val Ala Ser His Leu Gln Ser Phe Le - #u Glu Val Ser Tyr Arg# 190- Val Leu Arg His Leu Ala Gln Pro Ser Gly Gl - #y Ser Gly Gly Ser Gln# 205- Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Ar - #g Lys Ile Gln Gly Asp# 220- Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Th - #r Tyr Lys Leu Cys His225 2 - #30 2 - #35 2 -#40- Pro Glu Glu Leu Val Leu Leu Gly His Ser Le - #u Gly Ile Pro Trp Ala# 255- Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gl - #n Leu Ala Gly Cys Leu# 270- Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gl - #n Gly Leu Leu Gln Ala# 285- Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Th - #r Leu Asp Thr Leu Gln# 300- Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Tr - #p Gln Gln Met Glu Glu305 3 - #10 3 - #15 3 -#20- Leu Gly Met Ala Pro Ala Leu Gln Pro 325- (2) INFORMATION FOR SEQ ID NO:191:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 329 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:- Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg As - #n Leu Gln Pro Cys Leu# 15- Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pr - #o Ile Ile Ile Lys Ala# 30- Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Th - #r Phe Tyr Leu Val Thr# 45- Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gl - #y Ser Gly Gly Gly Ser# 60- Gly Gly Gly Ser Asn Cys Ser Ile Met Ile As - #p Glu Ile Ile His His#80- Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pr - #o Asn Asn Leu Asn Asp# 95- Glu Asp Val Ser Ile Leu Met Asp Arg Asn Le - #u Arg Leu Pro Asn Leu# 110- Glu Ser Phe Val Arg Ala Val Lys Asn Leu Gl - #u Tyr Val Glu Gly Gly# 125- Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il - #e Ser Thr Ile Asn Pro# 140- Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr - #o Asn Met Ala Thr Gln145 1 - #50 1 - #55 1 -#60- Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gl - #n Arg Arg Ala Gly Gly# 175- Val Leu Val Ala Ser His Leu Gln Ser Phe Le - #u Glu Val Ser Tyr Arg# 190- Val Leu Arg His Leu Ala Gln Pro Ser Gly Gl - #y Ser Gly Gly Ser Gln# 205- Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Ar - #g Lys Ile Gln Gly Asp# 220- Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Th - #r Tyr Lys Leu Cys His225 2 - #30 2 - #35 2 -#40- Pro Glu Glu Leu Val Leu Leu Gly His Ser Le - #u Gly Ile Pro Trp Ala# 255- Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gl - #n Leu Ala Gly Cys Leu# 270- Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gl - #n Gly Leu Leu Gln Ala# 285- Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Th - #r Leu Asp Thr Leu Gln# 300- Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Tr - #p Gln Gln Met Glu Glu305 3 - #10 3 - #15 3 -#20- Leu Gly Met Ala Pro Ala Leu Gln Pro 325- (2) INFORMATION FOR SEQ ID NO:192:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 329 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:- Ala Pro Ser Arg His Pro Ile Ile Ile Lys Al - #a Gly Asp Trp Gln Glu# 15- Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Th - #r Leu Glu Gln Ala Gln# 30- Glu Gln Gln Gly Gly Gly Ser Gly Gly Gly Se - #r Gly Gly Gly Ser Asn# 45- Cys Ser Ile Met Ile Asp Glu Ile Ile His Hi - #s Leu Lys Arg Pro Pro# 60- Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn As - #p Glu Asp Val Ser Ile#80- Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Le - #u Glu Ser Phe Val Arg# 95- Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Il - #e Glu Ala Ile Leu Arg# 110- Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Al - #a Tyr Val Glu Gly Gly# 125- Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il - #e Ser Thr Ile Asn Pro# 140- Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr - #o Asn Met Ala Thr Gln145 1 - #50 1 - #55 1 -#60- Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gl - #n Arg Arg Ala Gly Gly# 175- Val Leu Val Ala Ser His Leu Gln Ser Phe Le - #u Glu Val Ser Tyr Arg# 190- Val Leu Arg His Leu Ala Gln Pro Ser Gly Gl - #y Ser Gly Gly Ser Gln# 205- Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Ar - #g Lys Ile Gln Gly Asp# 220- Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Th - #r Tyr Lys Leu Cys His225 2 - #30 2 - #35 2 -#40- Pro Glu Glu Leu Val Leu Leu Gly His Ser Le - #u Gly Ile Pro Trp Ala# 255- Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gl - #n Leu Ala Gly Cys Leu# 270- Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gl - #n Gly Leu Leu Gln Ala# 285- Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Th - #r Leu Asp Thr Leu Gln# 300- Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Tr - #p Gln Gln Met Glu Glu305 3 - #10 3 - #15 3 -#20- Leu Gly Met Ala Pro Ala Leu Gln Pro 325- (2) INFORMATION FOR SEQ ID NO:193:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 299 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:- Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Il - #e Met Ile Asp Glu Ile# 15- Ile His His Leu Lys Arg Pro Pro Ala Pro Le - #u Leu Asp Pro Asn Asn# 30- Leu Asn Asp Glu Asp Val Ser Ile Leu Met As - #p Arg Asn Leu Arg Leu# 45- Pro Asn Leu Glu Ser Phe Val Arg Ala Val Ly - #s Asn Leu Glu Asn Ala# 60- Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gl - #n Pro Cys Leu Pro Ser#80- Ala Thr Ala Ala Pro Ser Arg His Pro Ile Il - #e Ile Lys Tyr Val Glu# 95- Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gl - #y Pro Ile Ser Thr Ile# 110- Asn Pro Ser Pro Pro Ser Lys Glu Ser His Ly - #s Ser Pro Asn Met Ala# 125- Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Al - #a Phe Gln Arg Arg Ala# 140- Gly Gly Val Leu Val Ala Ser His Leu Gln Se - #r Phe Leu Glu Val Ser145 1 - #50 1 - #55 1 -#60- Tyr Arg Val Leu Arg His Leu Ala Gln Pro Se - #r Gly Gly Ser Gly Gly# 175- Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gl - #n Val Arg Lys Ile Gln# 190- Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cy - #s Ala Thr Tyr Lys Leu# 205- Cys His Pro Glu Glu Leu Val Leu Leu Gly Hi - #s Ser Leu Gly Ile Pro# 220- Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Al - #a Leu Gln Leu Ala Gly225 2 - #30 2 - #35 2 -#40- Cys Leu Ser Gln Leu His Ser Gly Leu Phe Le - #u Tyr Gln Gly Leu Leu# 255- Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gl - #y Pro Thr Leu Asp Thr# 270- Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Th - #r Ile Trp Gln Gln Met# 285- Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pr - #o# 295- (2) INFORMATION FOR SEQ ID NO:194:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 329 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:194:- Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys# 15- Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp# 30- Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser# 45- Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala# 60- Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro#80- Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg# 95- Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Tyr Lys Leu Cys His Pro Gl - #u Glu Leu Val Leu Leu145 1 - #50 1 - #55 1 -#60- Gly His Ser Leu Gly Ile Pro Trp Ala Pro Le - #u Ser Ser Cys Pro Ser# 175- Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gl - #n Leu His Ser Gly Leu# 190- Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Gl - #u Gly Ile Ser Pro Glu# 205- Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu As - #p Val Ala Asp Phe Ala# 220- Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl - #y Met Ala Pro Ala Leu225 2 - #30 2 - #35 2 -#40- Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Al - #a Ser Ala Phe Gln Arg# 255- Arg Ala Gly Gly Val Leu Val Ala Ser His Le - #u Gln Ser Phe Leu Glu# 270- Val Ser Tyr Arg Val Leu Arg His Leu Ala Gl - #n Pro Gly Gly Gly Ser# 285- Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Se - #r Leu Pro Gln Ser Phe# 300- Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Il - #e Gln Gly Asp Gly Ala305 3 - #10 3 - #15 3 -#20- Ala Leu Gln Glu Lys Leu Cys Ala Thr 325- (2) INFORMATION FOR SEQ ID NO:195:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 329 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:195:- Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys# 15- Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp# 30- Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser# 45- Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala# 60- Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro#80- Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg# 95- Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Pro Glu Leu Gly Pro Thr Le - #u Asp Thr Leu Gln Leu145 1 - #50 1 - #55 1 -#60- Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gl - #n Gln Met Glu Glu Leu# 175- Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gl - #y Ala Met Pro Ala Phe# 190- Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Va - #l Leu Val Ala Ser His# 205- Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Va - #l Leu Arg His Leu Ala# 220- Gln Pro Gly Gly Gly Ser Asp Met Ala Thr Pr - #o Leu Gly Pro Ala Ser225 2 - #30 2 - #35 2 -#40- Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Le - #u Glu Gln Val Arg Lys# 255- Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Ly - #s Leu Cys Ala Thr Tyr# 270- Lys Leu Cys His Pro Glu Glu Leu Val Leu Le - #u Gly His Ser Leu Gly# 285- Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Se - #r Gln Ala Leu Gln Leu# 300- Ala Gly Cys Leu Ser Gln Leu His Ser Gly Le - #u Phe Leu Tyr Gln Gly305 3 - #10 3 - #15 3 -#20- Leu Leu Gln Ala Leu Glu Gly Ile Ser 325- (2) INFORMATION FOR SEQ ID NO:196:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 329 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:196:- Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys# 15- Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp# 30- Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser# 45- Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala# 60- Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro#80- Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg# 95- Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Ser Ala Phe Gln Arg Arg Al - #a Gly Gly Val Leu Val145 1 - #50 1 - #55 1 -#60- Ala Ser His Leu Gln Ser Phe Leu Glu Val Se - #r Tyr Arg Val Leu Arg# 175- His Leu Ala Gln Pro Gly Gly Gly Ser Asp Me - #t Ala Thr Pro Leu Gly# 190- Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Le - #u Lys Ser Leu Glu Gln# 205- Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Le - #u Gln Glu Lys Leu Cys# 220- Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Le - #u Val Leu Leu Gly His225 2 - #30 2 - #35 2 -#40- Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Se - #r Cys Pro Ser Gln Ala# 255- Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu Hi - #s Ser Gly Leu Phe Leu# 270- Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Il - #e Ser Pro Glu Leu Gly# 285- Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Al - #a Asp Phe Ala Thr Thr# 300- Ile Trp Gln Gln Met Glu Glu Leu Gly Met Al - #a Pro Ala Leu Gln Pro305 3 - #10 3 - #15 3 -#20- Thr Gln Gly Ala Met Pro Ala Phe Ala 325- (2) INFORMATION FOR SEQ ID NO:197:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 329 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:197:- Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys# 15- Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp# 30- Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser# 45- Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala# 60- Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro#80- Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg# 95- Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Met Ala Pro Ala Leu Gln Pr - #o Thr Gln Gly Ala Met145 1 - #50 1 - #55 1 -#60- Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Al - #a Gly Gly Val Leu Val# 175- Ala Ser His Leu Gln Ser Phe Leu Glu Val Se - #r Tyr Arg Val Leu Arg# 190- His Leu Ala Gln Pro Gly Gly Gly Ser Asp Me - #t Ala Thr Pro Leu Gly# 205- Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Le - #u Lys Ser Leu Glu Gln# 220- Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Le - #u Gln Glu Lys Leu Cys225 2 - #30 2 - #35 2 -#40- Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Le - #u Val Leu Leu Gly His# 255- Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Se - #r Cys Pro Ser Gln Ala# 270- Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu Hi - #s Ser Gly Leu Phe Leu# 285- Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Il - #e Ser Pro Glu Leu Gly# 300- Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Al - #a Asp Phe Ala Thr Thr305 3 - #10 3 - #15 3 -#20- Ile Trp Gln Gln Met Glu Glu Leu Gly 325- (2) INFORMATION FOR SEQ ID NO:198:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 329 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:198:- Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys# 15- Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp# 30- Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser# 45- Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala# 60- Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro#80- Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg# 95- Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Thr Gln Gly Ala Met Pro Al - #a Phe Ala Ser Ala Phe145 1 - #50 1 - #55 1 -#60- Gln Arg Arg Ala Gly Gly Val Leu Val Ala Se - #r His Leu Gln Ser Phe# 175- Leu Glu Val Ser Tyr Arg Val Leu Arg His Le - #u Ala Gln Pro Gly Gly# 190- Gly Ser Asp Met Ala Thr Pro Leu Gly Pro Al - #a Ser Ser Leu Pro Gln# 205- Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Ar - #g Lys Ile Gln Gly Asp# 220- Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Th - #r Tyr Lys Leu Cys His225 2 - #30 2 - #35 2 -#40- Pro Glu Glu Leu Val Leu Leu Gly His Ser Le - #u Gly Ile Pro Trp Ala# 255- Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gl - #n Leu Ala Gly Cys Leu# 270- Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gl - #n Gly Leu Leu Gln Ala# 285- Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Th - #r Leu Asp Thr Leu Gln# 300- Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Tr - #p Gln Gln Met Glu Glu305 3 - #10 3 - #15 3 -#20- Leu Gly Met Ala Pro Ala Leu Gln Pro 325- (2) INFORMATION FOR SEQ ID NO:199:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 319 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:199:- Met Ala Asn Cys Ser Asn Met Ile Asp Glu Il - #e Ile Thr His Leu Lys# 15- Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn As - #n Leu Asn Gly Glu Asp# 30- Gln Asp Ile Leu Met Asp Asn Asn Leu Arg Ar - #g Pro Asn Leu Glu Ala# 45- Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Al - #a Ser Ala Ile Glu Ser# 60- Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Le - #u Ala Thr Ala Ala Pro#80- Thr Arg His Pro Ile His Ile Lys Asp Gly As - #p Trp Asn Glu Phe Arg# 95- Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Gl - #u Asn Ala Gln Ala Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Thr Gln Gly Ala Met Pro Al - #a Phe Ala Ser Ala Phe145 1 - #50 1 - #55 1 -#60- Gln Arg Arg Ala Gly Gly Val Leu Val Ala Se - #r His Leu Gln Ser Phe# 175- Leu Glu Val Ser Tyr Arg Val Leu Arg His Le - #u Ala Gln Pro Ser Gly# 190- Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Ly - #s Ser Leu Glu Gln Val# 205- Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gl - #n Glu Lys Leu Cys Ala# 220- Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Va - #l Leu Leu Gly His Ser225 2 - #30 2 - #35 2 -#40- Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cy - #s Pro Ser Gln Ala Leu# 255- Gln Leu Ala Gly Cys Leu Ser Gln Leu His Se - #r Gly Leu Phe Leu Tyr# 270- Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Se - #r Pro Glu Leu Gly Pro# 285- Thr Leu Asp Thr Leu Gln Leu Asp Val Ala As - #p Phe Ala Thr Thr Ile# 300- Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pr - #o Ala Leu Gln Pro305 3 - #10 3 - #15- (2) INFORMATION FOR SEQ ID NO:200:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 322 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:200:- Met Ala Asn Cys Ser Asn Met Ile Asp Glu Il - #e Ile Thr His Leu Lys# 15- Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn As - #n Leu Asn Gly Glu Asp# 30- Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Ar - #g Pro Asn Leu Glu Ala# 45- Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Al - #a Ser Ala Ile Glu Ser# 60- Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Le - #u Ala Thr Ala Ala Pro#80- Thr Arg His Pro Ile Ile Ile Arg Asp Gly As - #p Trp Asn Glu Phe Arg# 95- Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Gl - #u Asn Ala Gln Ala Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Thr Gln Gly Ala Met Pro Al - #a Phe Ala Ser Ala Phe145 1 - #50 1 - #55 1 -#60- Gln Arg Arg Ala Gly Gly Val Leu Val Ala Se - #r His Leu Gln Ser Phe# 175- Leu Glu Val Ser Tyr Arg Val Leu Arg His Le - #u Ala Gln Pro Thr Pro# 190- Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Ph - #e Leu Leu Lys Ser Leu# 205- Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Al - #a Ala Leu Gln Glu Lys# 220- Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Gl - #u Glu Leu Val Leu Leu225 2 - #30 2 - #35 2 -#40- Gly His Ser Leu Gly Ile Pro Trp Ala Pro Le - #u Ser Ser Cys Pro Ser# 255- Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gl - #n Leu His Ser Gly Leu# 270- Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Gl - #u Gly Ile Ser Pro Glu# 285- Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu As - #p Val Ala Asp Phe Ala# 300- Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl - #y Met Ala Pro Ala Leu305 3 - #10 3 - #15 3 -#20- Gln Pro- (2) INFORMATION FOR SEQ ID NO:201:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 319 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:- Met Ala Asn Cys Ser Asn Met Ile Asp Glu Il - #e Ile Thr His Leu Lys# 15- Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn As - #n Leu Asn Gly Glu Asp# 30- Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Ar - #g Pro Asn Leu Glu Ala# 45- Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Al - #a Ser Ala Ile Glu Ser# 60- Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Le - #u Ala Thr Ala Ala Pro#80- Thr Arg His Pro Ile Ile Ile Arg Asp Gly As - #p Trp Asn Glu Phe Arg# 95- Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Gl - #u Asn Ala Gln Ala Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Thr Gln Gly Ala Met Pro Al - #a Phe Ala Ser Ala Phe145 1 - #50 1 - #55 1 -#60- Gln Arg Arg Ala Gly Gly Val Leu Val Ala Se - #r His Leu Gln Ser Phe# 175- Leu Glu Val Ser Tyr Arg Val Leu Arg His Le - #u Ala Gln Pro Ser Gly# 190- Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Ly - #s Ser Leu Glu Gln Val# 205- Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gl - #n Glu Lys Leu Cys Ala# 220- Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Va - #l Leu Leu Gly His Ser225 2 - #30 2 - #35 2 -#40- Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cy - #s Pro Ser Gln Ala Leu# 255- Gln Leu Ala Gly Cys Leu Ser Gln Leu His Se - #r Gly Leu Phe Leu Tyr# 270- Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Se - #r Pro Glu Leu Gly Pro# 285- Thr Leu Asp Thr Leu Gln Leu Asp Val Ala As - #p Phe Ala Thr Thr Ile# 300- Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pr - #o Ala Leu Gln Pro305 3 - #10 3 - #15- (2) INFORMATION FOR SEQ ID NO:202:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 322 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:202:- Met Ala Asn Cys Ser Asn Met Ile Asp Glu Il - #e Ile Thr His Leu Lys# 15- Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn As - #n Leu Asn Gly Glu Asp# 30- Gln Asp Ile Leu Met Asp Asn Asn Leu Arg Ar - #g Pro Asn Leu Glu Ala# 45- Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Al - #a Ser Ala Ile Glu Ser# 60- Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Le - #u Ala Thr Ala Ala Pro#80- Thr Arg His Pro Ile His Ile Lys Asp Gly As - #p Trp Asn Glu Phe Arg# 95- Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Gl - #u Asn Ala Gln Ala Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Thr Gln Gly Ala Met Pro Al - #a Phe Ala Ser Ala Phe145 1 - #50 1 - #55 1 -#60- Gln Arg Arg Ala Gly Gly Val Leu Val Ala Se - #r His Leu Gln Ser Phe# 175- Leu Glu Val Ser Tyr Arg Val Leu Arg His Le - #u Ala Gln Pro Thr Pro# 190- Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Ph - #e Leu Leu Lys Ser Leu# 205- Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Al - #a Ala Leu Gln Glu Lys# 220- Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Gl - #u Glu Leu Val Leu Leu225 2 - #30 2 - #35 2 -#40- Gly His Ser Leu Gly Ile Pro Trp Ala Pro Le - #u Ser Ser Cys Pro Ser# 255- Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gl - #n Leu His Ser Gly Leu# 270- Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Gl - #u Gly Ile Ser Pro Glu# 285- Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu As - #p Val Ala Asp Phe Ala# 300- Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl - #y Met Ala Pro Ala Leu305 3 - #10 3 - #15 3 -#20- Gln Pro- (2) INFORMATION FOR SEQ ID NO:203:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 306 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:203:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Glu Val His Pro Leu Pro Thr Pro Va - #l Leu Leu Pro Ala Val145 1 - #50 1 - #55 1 -#60- Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Me - #t Glu Glu Thr Lys Ala# 175- Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Le - #u Glu Gly Val Met Ala# 190- Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Se - #r Ser Leu Leu Gly Gln# 205- Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Al - #a Leu Gln Ser Leu Leu# 220- Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Th - #r Ala His Lys Asp Pro225 2 - #30 2 - #35 2 -#40- Asn Ala Ile Phe Leu Ser Phe Gln His Leu Le - #u Arg Gly Lys Val Arg# 255- Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cy - #s Val Arg Glu Phe Gly# 270- Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cy - #s Asp Leu Arg Val Leu# 285- Ser Lys Leu Leu Arg Asp Ser His Val Leu Hi - #s Ser Arg Leu Ser Gln# 300- Cys Pro305- (2) INFORMATION FOR SEQ ID NO:204:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 306 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:204:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu145 1 - #50 1 - #55 1 -#60- Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu# 175- Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln# 190- Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln# 205- Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu# 220- Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe225 2 - #30 2 - #35 2 -#40- Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu# 255- Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph - #e Gly Gly Asn Met Ala# 270- Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu# 285- Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val# 300- His Pro305- (2) INFORMATION FOR SEQ ID NO:205:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 306 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:205:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Val Leu Leu Pro Ala Val Asp Phe Se - #r Leu Gly Glu Trp Lys145 1 - #50 1 - #55 1 -#60- Thr Gln Met Glu Glu Thr Lys Ala Gln Asp Il - #e Leu Gly Ala Val Thr# 175- Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gl - #y Gln Leu Gly Pro Thr# 190- Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gl - #y Gln Val Arg Leu Leu# 205- Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gl - #n Leu Pro Pro Gln Gly# 220- Arg Thr Thr Ala His Lys Asp Pro Asn Ala Il - #e Phe Leu Ser Phe Gln225 2 - #30 2 - #35 2 -#40- His Leu Leu Arg Gly Lys Val Arg Phe Leu Me - #t Leu Val Gly Gly Ser# 255- Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Me - #t Ala Ser Pro Ala Pro# 270- Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Le - #u Leu Arg Asp Ser His# 285- Val Leu His Ser Arg Leu Ser Gln Cys Pro Gl - #u Val His Pro Leu Pro# 300- Thr Pro305- (2) INFORMATION FOR SEQ ID NO:206:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 306 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:206:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Ala Val Asp Phe Ser Leu Gly Glu Tr - #p Lys Thr Gln Met Glu145 1 - #50 1 - #55 1 -#60- Glu Thr Lys Ala Gln Asp Ile Leu Gly Ala Va - #l Thr Leu Leu Leu Glu# 175- Gly Val Met Ala Ala Arg Gly Gln Leu Gly Pr - #o Thr Cys Leu Ser Ser# 190- Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Le - #u Leu Leu Gly Ala Leu# 205- Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gl - #n Gly Arg Thr Thr Ala# 220- His Lys Asp Pro Asn Ala Ile Phe Leu Ser Ph - #e Gln His Leu Leu Arg225 2 - #30 2 - #35 2 -#40- Gly Lys Val Arg Phe Leu Met Leu Val Gly Gl - #y Ser Thr Leu Cys Val# 255- Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Al - #a Pro Pro Ala Cys Asp# 270- Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Se - #r His Val Leu His Ser# 285- Arg Leu Ser Gln Cys Pro Glu Val His Pro Le - #u Pro Thr Pro Val Leu# 300- Leu Pro305- (2) INFORMATION FOR SEQ ID NO:207:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 306 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:207:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Asp Phe Ser Leu Gly Glu Trp Lys Th - #r Gln Met Glu Glu Thr145 1 - #50 1 - #55 1 -#60- Lys Ala Gln Asp Ile Leu Gly Ala Val Thr Le - #u Leu Leu Glu Gly Val# 175- Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cy - #s Leu Ser Ser Leu Leu# 190- Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Le - #u Gly Ala Leu Gln Ser# 205- Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Ar - #g Thr Thr Ala His Lys# 220- Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln Hi - #s Leu Leu Arg Gly Lys225 2 - #30 2 - #35 2 -#40- Val Arg Phe Leu Met Leu Val Gly Gly Ser Th - #r Leu Cys Val Arg Glu# 255- Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pr - #o Ala Cys Asp Leu Arg# 270- Val Leu Ser Lys Leu Leu Arg Asp Ser His Va - #l Leu His Ser Arg Leu# 285- Ser Gln Cys Pro Glu Val His Pro Leu Pro Th - #r Pro Val Leu Leu Pro# 300- Ala Val305- (2) INFORMATION FOR SEQ ID NO:208:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 306 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:208:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Gly Glu Trp Lys Thr Gln Met Glu Gl - #u Thr Lys Ala Gln Asp145 1 - #50 1 - #55 1 -#60- Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gl - #y Val Met Ala Ala Arg# 175- Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Le - #u Leu Gly Gln Leu Ser# 190- Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gl - #n Ser Leu Leu Gly Thr# 205- Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala Hi - #s Lys Asp Pro Asn Ala# 220- Ile Phe Leu Ser Phe Gln His Leu Leu Arg Gl - #y Lys Val Arg Phe Leu225 2 - #30 2 - #35 2 -#40- Met Leu Val Gly Gly Ser Thr Leu Cys Val Ar - #g Glu Phe Gly Gly Asn# 255- Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Le - #u Arg Val Leu Ser Lys# 270- Leu Leu Arg Asp Ser His Val Leu His Ser Ar - #g Leu Ser Gln Cys Pro# 285- Glu Val His Pro Leu Pro Thr Pro Val Leu Le - #u Pro Ala Val Asp Phe# 300- Ser Leu305- (2) INFORMATION FOR SEQ ID NO:209:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 306 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:209:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Gly Pro Thr Cys Leu Ser Ser Leu Le - #u Gly Gln Leu Ser Gly145 1 - #50 1 - #55 1 -#60- Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Se - #r Leu Leu Gly Thr Gln# 175- Leu Pro Pro Gln Gly Arg Thr Thr Ala His Ly - #s Asp Pro Asn Ala Ile# 190- Phe Leu Ser Phe Gln His Leu Leu Arg Gly Ly - #s Val Arg Phe Leu Met# 205- Leu Val Gly Gly Ser Thr Leu Cys Val Arg Gl - #u Phe Gly Gly Asn Met# 220- Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Ar - #g Val Leu Ser Lys Leu225 2 - #30 2 - #35 2 -#40- Leu Arg Asp Ser His Val Leu His Ser Arg Le - #u Ser Gln Cys Pro Glu# 255- Val His Pro Leu Pro Thr Pro Val Leu Leu Pr - #o Ala Val Asp Phe Ser# 270- Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Th - #r Lys Ala Gln Asp Ile# 285- Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Va - #l Met Ala Ala Arg Gly# 300- Gln Leu305- (2) INFORMATION FOR SEQ ID NO:210:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 306 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:210:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Gly Thr Gln Leu Pro Pro Gln Gly Ar - #g Thr Thr Ala His Lys145 1 - #50 1 - #55 1 -#60- Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln Hi - #s Leu Leu Arg Gly Lys# 175- Val Arg Phe Leu Met Leu Val Gly Gly Ser Th - #r Leu Cys Val Arg Glu# 190- Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pr - #o Ala Cys Asp Leu Arg# 205- Val Leu Ser Lys Leu Leu Arg Asp Ser His Va - #l Leu His Ser Arg Leu# 220- Ser Gln Cys Pro Glu Val His Pro Leu Pro Th - #r Pro Val Leu Leu Pro225 2 - #30 2 - #35 2 -#40- Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Th - #r Gln Met Glu Glu Thr# 255- Lys Ala Gln Asp Ile Leu Gly Ala Val Thr Le - #u Leu Leu Glu Gly Val# 270- Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cy - #s Leu Ser Ser Leu Leu# 285- Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Le - #u Gly Ala Leu Gln Ser# 300- Leu Leu305- (2) INFORMATION FOR SEQ ID NO:211:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 306 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:211:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Gly Arg Thr Thr Ala His Lys Asp Pr - #o Asn Ala Ile Phe Leu145 1 - #50 1 - #55 1 -#60- Ser Phe Gln His Leu Leu Arg Gly Lys Val Ar - #g Phe Leu Met Leu Val# 175- Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gl - #y Gly Asn Met Ala Ser# 190- Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Le - #u Ser Lys Leu Leu Arg# 205- Asp Ser His Val Leu His Ser Arg Leu Ser Gl - #n Cys Pro Glu Val His# 220- Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Va - #l Asp Phe Ser Leu Gly225 2 - #30 2 - #35 2 -#40- Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Al - #a Gln Asp Ile Leu Gly# 255- Ala Val Thr Leu Leu Leu Glu Gly Val Met Al - #a Ala Arg Gly Gln Leu# 270- Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gl - #n Leu Ser Gly Gln Val# 285- Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Le - #u Gly Thr Gln Leu Pro# 300- Pro Gln305- (2) INFORMATION FOR SEQ ID NO:212:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 306 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:212:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Ala His Lys Asp Pro Asn Ala Ile Ph - #e Leu Ser Phe Gln His145 1 - #50 1 - #55 1 -#60- Leu Leu Arg Gly Lys Val Arg Phe Leu Met Le - #u Val Gly Gly Ser Thr# 175- Leu Cys Val Arg Glu Phe Gly Gly Asn Met Al - #a Ser Pro Ala Pro Pro# 190- Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Le - #u Arg Asp Ser His Val# 205- Leu His Ser Arg Leu Ser Gln Cys Pro Glu Va - #l His Pro Leu Pro Thr# 220- Pro Val Leu Leu Pro Ala Val Asp Phe Ser Le - #u Gly Glu Trp Lys Thr225 2 - #30 2 - #35 2 -#40- Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Le - #u Gly Ala Val Thr Leu# 255- Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gl - #n Leu Gly Pro Thr Cys# 270- Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gl - #n Val Arg Leu Leu Leu# 285- Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Le - #u Pro Pro Gln Gly Arg# 300- Thr Thr305- (2) INFORMATION FOR SEQ ID NO:213:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 306 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:213:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Asp Pro Asn Ala Ile Phe Leu Ser Ph - #e Gln His Leu Leu Arg145 1 - #50 1 - #55 1 -#60- Gly Lys Val Arg Phe Leu Met Leu Val Gly Gl - #y Ser Thr Leu Cys Val# 175- Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Al - #a Pro Pro Ala Cys Asp# 190- Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Se - #r His Val Leu His Ser# 205- Arg Leu Ser Gln Cys Pro Glu Val His Pro Le - #u Pro Thr Pro Val Leu# 220- Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Tr - #p Lys Thr Gln Met Glu225 2 - #30 2 - #35 2 -#40- Glu Thr Lys Ala Gln Asp Ile Leu Gly Ala Va - #l Thr Leu Leu Leu Glu# 255- Gly Val Met Ala Ala Arg Gly Gln Leu Gly Pr - #o Thr Cys Leu Ser Ser# 270- Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Le - #u Leu Leu Gly Ala Leu# 285- Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gl - #n Gly Arg Thr Thr Ala# 300- His Lys305- (2) INFORMATION FOR SEQ ID NO:214:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 306 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:214:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Ala Ile Phe Leu Ser Phe Gln His Le - #u Leu Arg Gly Lys Val145 1 - #50 1 - #55 1 -#60- Arg Phe Leu Met Leu Val Gly Gly Ser Thr Le - #u Cys Val Arg Glu Phe# 175- Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Al - #a Cys Asp Leu Arg Val# 190- Leu Ser Lys Leu Leu Arg Asp Ser His Val Le - #u His Ser Arg Leu Ser# 205- Gln Cys Pro Glu Val His Pro Leu Pro Thr Pr - #o Val Leu Leu Pro Ala# 220- Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gl - #n Met Glu Glu Thr Lys225 2 - #30 2 - #35 2 -#40- Ala Gln Asp Ile Leu Gly Ala Val Thr Leu Le - #u Leu Glu Gly Val Met# 255- Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Le - #u Ser Ser Leu Leu Gly# 270- Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gl - #y Ala Leu Gln Ser Leu# 285- Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Th - #r Thr Ala His Lys Asp# 300- Pro Asn305- (2) INFORMATION FOR SEQ ID NO:215:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 305 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:215:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Glu Val His Pro Leu Pro Thr Pro Va - #l Leu Leu Pro Ala Val145 1 - #50 1 - #55 1 -#60- Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Me - #t Glu Glu Thr Lys Ala# 175- Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Le - #u Glu Gly Val Met Ala# 190- Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Se - #r Ser Leu Leu Gly Gln# 205- Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Al - #a Leu Gln Ser Leu Leu# 220- Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Th - #r Ala His Lys Asp Pro225 2 - #30 2 - #35 2 -#40- Asn Ala Ile Phe Leu Ser Phe Gln His Leu Le - #u Arg Gly Lys Val Arg# 255- Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cy - #s Val Arg Glu Phe Gly# 270- Asn Met Ala Ser Pro Ala Pro Pro Ala Cys As - #p Leu Arg Val Leu Ser# 285- Lys Leu Leu Arg Asp Ser His Val Leu His Se - #r Arg Leu Ser Gln Cys# 300- Pro305- (2) INFORMATION FOR SEQ ID NO:216:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 305 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:216:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu145 1 - #50 1 - #55 1 -#60- Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu# 175- Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln# 190- Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln# 205- Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu# 220- Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe225 2 - #30 2 - #35 2 -#40- Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu# 255- Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph - #e Gly Asn Met Ala Ser# 270- Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Le - #u Ser Lys Leu Leu Arg# 285- Asp Ser His Val Leu His Ser Arg Leu Ser Gl - #n Cys Pro Glu Val His# 300- Pro305- (2) INFORMATION FOR SEQ ID NO:217:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 305 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:217:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Val Leu Leu Pro Ala Val Asp Phe Se - #r Leu Gly Glu Trp Lys145 1 - #50 1 - #55 1 -#60- Thr Gln Met Glu Glu Thr Lys Ala Gln Asp Il - #e Leu Gly Ala Val Thr# 175- Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gl - #y Gln Leu Gly Pro Thr# 190- Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gl - #y Gln Val Arg Leu Leu# 205- Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gl - #n Leu Pro Pro Gln Gly# 220- Arg Thr Thr Ala His Lys Asp Pro Asn Ala Il - #e Phe Leu Ser Phe Gln225 2 - #30 2 - #35 2 -#40- His Leu Leu Arg Gly Lys Val Arg Phe Leu Me - #t Leu Val Gly Gly Ser# 255- Thr Leu Cys Val Arg Glu Phe Gly Asn Met Al - #a Ser Pro Ala Pro Pro# 270- Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Le - #u Arg Asp Ser His Val# 285- Leu His Ser Arg Leu Ser Gln Cys Pro Glu Va - #l His Pro Leu Pro Thr# 300- Pro305- (2) INFORMATION FOR SEQ ID NO:218:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 305 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:218:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Ala Val Asp Phe Ser Leu Gly Glu Tr - #p Lys Thr Gln Met Glu145 1 - #50 1 - #55 1 -#60- Glu Thr Lys Ala Gln Asp Ile Leu Gly Ala Va - #l Thr Leu Leu Leu Glu# 175- Gly Val Met Ala Ala Arg Gly Gln Leu Gly Pr - #o Thr Cys Leu Ser Ser# 190- Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Le - #u Leu Leu Gly Ala Leu# 205- Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gl - #n Gly Arg Thr Thr Ala# 220- His Lys Asp Pro Asn Ala Ile Phe Leu Ser Ph - #e Gln His Leu Leu Arg225 2 - #30 2 - #35 2 -#40- Gly Lys Val Arg Phe Leu Met Leu Val Gly Gl - #y Ser Thr Leu Cys Val# 255- Arg Glu Phe Gly Asn Met Ala Ser Pro Ala Pr - #o Pro Ala Cys Asp Leu# 270- Arg Val Leu Ser Lys Leu Leu Arg Asp Ser Hi - #s Val Leu His Ser Arg# 285- Leu Ser Gln Cys Pro Glu Val His Pro Leu Pr - #o Thr Pro Val Leu Leu# 300- Pro305- (2) INFORMATION FOR SEQ ID NO:219:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 305 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:219:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Asp Phe Ser Leu Gly Glu Trp Lys Th - #r Gln Met Glu Glu Thr145 1 - #50 1 - #55 1 -#60- Lys Ala Gln Asp Ile Leu Gly Ala Val Thr Le - #u Leu Leu Glu Gly Val# 175- Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cy - #s Leu Ser Ser Leu Leu# 190- Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Le - #u Gly Ala Leu Gln Ser# 205- Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Ar - #g Thr Thr Ala His Lys# 220- Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln Hi - #s Leu Leu Arg Gly Lys225 2 - #30 2 - #35 2 -#40- Val Arg Phe Leu Met Leu Val Gly Gly Ser Th - #r Leu Cys Val Arg Glu# 255- Phe Gly Asn Met Ala Ser Pro Ala Pro Pro Al - #a Cys Asp Leu Arg Val# 270- Leu Ser Lys Leu Leu Arg Asp Ser His Val Le - #u His Ser Arg Leu Ser# 285- Gln Cys Pro Glu Val His Pro Leu Pro Thr Pr - #o Val Leu Leu Pro Ala# 300- Val305- (2) INFORMATION FOR SEQ ID NO:220:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 305 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:220:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Gly Glu Trp Lys Thr Gln Met Glu Gl - #u Thr Lys Ala Gln Asp145 1 - #50 1 - #55 1 -#60- Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gl - #y Val Met Ala Ala Arg# 175- Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Le - #u Leu Gly Gln Leu Ser# 190- Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gl - #n Ser Leu Leu Gly Thr# 205- Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala Hi - #s Lys Asp Pro Asn Ala# 220- Ile Phe Leu Ser Phe Gln His Leu Leu Arg Gl - #y Lys Val Arg Phe Leu225 2 - #30 2 - #35 2 -#40- Met Leu Val Gly Gly Ser Thr Leu Cys Val Ar - #g Glu Phe Gly Asn Met# 255- Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Ar - #g Val Leu Ser Lys Leu# 270- Leu Arg Asp Ser His Val Leu His Ser Arg Le - #u Ser Gln Cys Pro Glu# 285- Val His Pro Leu Pro Thr Pro Val Leu Leu Pr - #o Ala Val Asp Phe Ser# 300- Leu305- (2) INFORMATION FOR SEQ ID NO:221:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 305 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:221:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Gly Pro Thr Cys Leu Ser Ser Leu Le - #u Gly Gln Leu Ser Gly145 1 - #50 1 - #55 1 -#60- Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Se - #r Leu Leu Gly Thr Gln# 175- Leu Pro Pro Gln Gly Arg Thr Thr Ala His Ly - #s Asp Pro Asn Ala Ile# 190- Phe Leu Ser Phe Gln His Leu Leu Arg Gly Ly - #s Val Arg Phe Leu Met# 205- Leu Val Gly Gly Ser Thr Leu Cys Val Arg Gl - #u Phe Gly Asn Met Ala# 220- Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu225 2 - #30 2 - #35 2 -#40- Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val# 255- His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu# 270- Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu# 285- Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln# 300- Leu305- (2) INFORMATION FOR SEQ ID NO:222:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 305 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:222:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Gly Thr Gln Leu Pro Pro Gln Gly Ar - #g Thr Thr Ala His Lys145 1 - #50 1 - #55 1 -#60- Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln Hi - #s Leu Leu Arg Gly Lys# 175- Val Arg Phe Leu Met Leu Val Gly Gly Ser Th - #r Leu Cys Val Arg Glu# 190- Phe Gly Asn Met Ala Ser Pro Ala Pro Pro Al - #a Cys Asp Leu Arg Val# 205- Leu Ser Lys Leu Leu Arg Asp Ser His Val Le - #u His Ser Arg Leu Ser# 220- Gln Cys Pro Glu Val His Pro Leu Pro Thr Pr - #o Val Leu Leu Pro Ala225 2 - #30 2 - #35 2 -#40- Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gl - #n Met Glu Glu Thr Lys# 255- Ala Gln Asp Ile Leu Gly Ala Val Thr Leu Le - #u Leu Glu Gly Val Met# 270- Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Le - #u Ser Ser Leu Leu Gly# 285- Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gl - #y Ala Leu Gln Ser Leu# 300- Leu305- (2) INFORMATION FOR SEQ ID NO:223:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 305 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:223:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Gly Arg Thr Thr Ala His Lys Asp Pr - #o Asn Ala Ile Phe Leu145 1 - #50 1 - #55 1 -#60- Ser Phe Gln His Leu Leu Arg Gly Lys Val Ar - #g Phe Leu Met Leu Val# 175- Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gl - #y Asn Met Ala Ser Pro# 190- Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Se - #r Lys Leu Leu Arg Asp# 205- Ser His Val Leu His Ser Arg Leu Ser Gln Cy - #s Pro Glu Val His Pro# 220- Leu Pro Thr Pro Val Leu Leu Pro Ala Val As - #p Phe Ser Leu Gly Glu225 2 - #30 2 - #35 2 -#40- Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gl - #n Asp Ile Leu Gly Ala# 255- Val Thr Leu Leu Leu Glu Gly Val Met Ala Al - #a Arg Gly Gln Leu Gly# 270- Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Le - #u Ser Gly Gln Val Arg# 285- Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gl - #y Thr Gln Leu Pro Pro# 300- Gln305- (2) INFORMATION FOR SEQ ID NO:224:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 305 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:224:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Gly Arg Thr Thr Ala His Lys Asp Pr - #o Asn Ala Ile Phe Leu145 1 - #50 1 - #55 1 -#60- Ser Phe Gln His Leu Leu Arg Gly Lys Val Ar - #g Phe Leu Met Leu Val# 175- Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gl - #y Asn Met Ala Ser Pro# 190- Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Se - #r Lys Leu Leu Arg Asp# 205- Ser His Val Leu His Ser Arg Leu Ser Gln Cy - #s Pro Glu Val His Pro# 220- Leu Pro Thr Pro Val Leu Leu Pro Ala Val As - #p Phe Ser Leu Gly Glu225 2 - #30 2 - #35 2 -#40- Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gl - #n Asp Ile Leu Gly Ala# 255- Val Thr Leu Leu Leu Glu Gly Val Met Ala Al - #a Arg Gly Gln Leu Gly# 270- Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Le - #u Ser Gly Gln Val Arg# 285- Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gl - #y Thr Gln Leu Pro Pro# 300- Gln305- (2) INFORMATION FOR SEQ ID NO:225:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 305 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:225:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Asp Pro Asn Ala Ile Phe Leu Ser Ph - #e Gln His Leu Leu Arg145 1 - #50 1 - #55 1 -#60- Gly Lys Val Arg Phe Leu Met Leu Val Gly Gl - #y Ser Thr Leu Cys Val# 175- Arg Glu Phe Gly Asn Met Ala Ser Pro Ala Pr - #o Pro Ala Cys Asp Leu# 190- Arg Val Leu Ser Lys Leu Leu Arg Asp Ser Hi - #s Val Leu His Ser Arg# 205- Leu Ser Gln Cys Pro Glu Val His Pro Leu Pr - #o Thr Pro Val Leu Leu# 220- Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Ly - #s Thr Gln Met Glu Glu225 2 - #30 2 - #35 2 -#40- Thr Lys Ala Gln Asp Ile Leu Gly Ala Val Th - #r Leu Leu Leu Glu Gly# 255- Val Met Ala Ala Arg Gly Gln Leu Gly Pro Th - #r Cys Leu Ser Ser Leu# 270- Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Le - #u Leu Gly Ala Leu Gln# 285- Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln Gl - #y Arg Thr Thr Ala His# 300- Lys305- (2) INFORMATION FOR SEQ ID NO:226:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 305 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:226:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Ala Ile Phe Leu Ser Phe Gln His Le - #u Leu Arg Gly Lys Val145 1 - #50 1 - #55 1 -#60- Arg Phe Leu Met Leu Val Gly Gly Ser Thr Le - #u Cys Val Arg Glu Phe# 175- Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cy - #s Asp Leu Arg Val Leu# 190- Ser Lys Leu Leu Arg Asp Ser His Val Leu Hi - #s Ser Arg Leu Ser Gln# 205- Cys Pro Glu Val His Pro Leu Pro Thr Pro Va - #l Leu Leu Pro Ala Val# 220- Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Me - #t Glu Glu Thr Lys Ala225 2 - #30 2 - #35 2 -#40- Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Le - #u Glu Gly Val Met Ala# 255- Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Se - #r Ser Leu Leu Gly Gln# 270- Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Al - #a Leu Gln Ser Leu Leu# 285- Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Th - #r Ala His Lys Asp Pro# 300- Asn305- (2) INFORMATION FOR SEQ ID NO:227:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 309 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:227:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu145 1 - #50 1 - #55 1 -#60- Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu# 175- Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln# 190- Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln# 205- Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu# 220- Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe225 2 - #30 2 - #35 2 -#40- Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu# 255- Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph - #e Gly Gly Asn Gly Gly# 270- Asn Met Ala Ser Pro Ala Pro Pro Ala Cys As - #p Leu Arg Val Leu Ser# 285- Lys Leu Leu Arg Asp Ser His Val Leu His Se - #r Arg Leu Ser Gln Cys# 300- Pro Glu Val His Pro305- (2) INFORMATION FOR SEQ ID NO:228:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 309 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:228:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu145 1 - #50 1 - #55 1 -#60- Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu# 175- Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln# 190- Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln# 205- Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu# 220- Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe225 2 - #30 2 - #35 2 -#40- Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu# 255- Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph - #e Gly Gly Asn Gly Gly# 270- Asn Met Ala Ser Pro Ala Pro Pro Ala Cys As - #p Leu Arg Val Leu Ser# 285- Lys Leu Leu Arg Asp Ser His Val Leu His Se - #r Arg Leu Ser Gln Cys# 300- Pro Glu Val His Pro305- (2) INFORMATION FOR SEQ ID NO:229:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 309 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:229:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Val Leu Leu Pro Ala Val Asp Phe Se - #r Leu Gly Glu Trp Lys145 1 - #50 1 - #55 1 -#60- Thr Gln Met Glu Glu Thr Lys Ala Gln Asp Il - #e Leu Gly Ala Val Thr# 175- Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gl - #y Gln Leu Gly Pro Thr# 190- Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gl - #y Gln Val Arg Leu Leu# 205- Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gl - #n Leu Pro Pro Gln Gly# 220- Arg Thr Thr Ala His Lys Asp Pro Asn Ala Il - #e Phe Leu Ser Phe Gln225 2 - #30 2 - #35 2 -#40- His Leu Leu Arg Gly Lys Val Arg Phe Leu Me - #t Leu Val Gly Gly Ser# 255- Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Gl - #y Gly Asn Met Ala Ser# 270- Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Le - #u Ser Lys Leu Leu Arg# 285- Asp Ser His Val Leu His Ser Arg Leu Ser Gl - #n Cys Pro Glu Val His# 300- Pro Leu Pro Thr Pro305- (2) INFORMATION FOR SEQ ID NO:230:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 309 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:230:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Ala Val Asp Phe Ser Leu Gly Glu Tr - #p Lys Thr Gln Met Glu145 1 - #50 1 - #55 1 -#60- Glu Thr Lys Ala Gln Asp Ile Leu Gly Ala Va - #l Thr Leu Leu Leu Glu# 175- Gly Val Met Ala Ala Arg Gly Gln Leu Gly Pr - #o Thr Cys Leu Ser Ser# 190- Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Le - #u Leu Leu Gly Ala Leu# 205- Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gl - #n Gly Arg Thr Thr Ala# 220- His Lys Asp Pro Asn Ala Ile Phe Leu Ser Ph - #e Gln His Leu Leu Arg225 2 - #30 2 - #35 2 -#40- Gly Lys Val Arg Phe Leu Met Leu Val Gly Gl - #y Ser Thr Leu Cys Val# 255- Arg Glu Phe Gly Gly Asn Gly Gly Asn Met Al - #a Ser Pro Ala Pro Pro# 270- Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Le - #u Arg Asp Ser His Val# 285- Leu His Ser Arg Leu Ser Gln Cys Pro Glu Va - #l His Pro Leu Pro Thr# 300- Pro Val Leu Leu Pro305- (2) INFORMATION FOR SEQ ID NO:231:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 309 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:231:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Asp Phe Ser Leu Gly Glu Trp Lys Th - #r Gln Met Glu Glu Thr145 1 - #50 1 - #55 1 -#60- Lys Ala Gln Asp Ile Leu Gly Ala Val Thr Le - #u Leu Leu Glu Gly Val# 175- Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cy - #s Leu Ser Ser Leu Leu# 190- Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Le - #u Gly Ala Leu Gln Ser# 205- Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Ar - #g Thr Thr Ala His Lys# 220- Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln Hi - #s Leu Leu Arg Gly Lys225 2 - #30 2 - #35 2 -#40- Val Arg Phe Leu Met Leu Val Gly Gly Ser Th - #r Leu Cys Val Arg Glu# 255- Phe Gly Gly Asn Gly Gly Asn Met Ala Ser Pr - #o Ala Pro Pro Ala Cys# 270- Asp Leu Arg Val Leu Ser Lys Leu Leu Arg As - #p Ser His Val Leu His# 285- Ser Arg Leu Ser Gln Cys Pro Glu Val His Pr - #o Leu Pro Thr Pro Val# 300- Leu Leu Pro Ala Val305- (2) INFORMATION FOR SEQ ID NO:232:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 309 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:232:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Gly Glu Trp Lys Thr Gln Met Glu Gl - #u Thr Lys Ala Gln Asp145 1 - #50 1 - #55 1 -#60- Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gl - #y Val Met Ala Ala Arg# 175- Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Le - #u Leu Gly Gln Leu Ser# 190- Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gl - #n Ser Leu Leu Gly Thr# 205- Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala Hi - #s Lys Asp Pro Asn Ala# 220- Ile Phe Leu Ser Phe Gln His Leu Leu Arg Gl - #y Lys Val Arg Phe Leu225 2 - #30 2 - #35 2 -#40- Met Leu Val Gly Gly Ser Thr Leu Cys Val Ar - #g Glu Phe Gly Gly Asn# 255- Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Al - #a Cys Asp Leu Arg Val# 270- Leu Ser Lys Leu Leu Arg Asp Ser His Val Le - #u His Ser Arg Leu Ser# 285- Gln Cys Pro Glu Val His Pro Leu Pro Thr Pr - #o Val Leu Leu Pro Ala# 300- Val Asp Phe Ser Leu305- (2) INFORMATION FOR SEQ ID NO:233:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 309 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:233:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Gly Pro Thr Cys Leu Ser Ser Leu Le - #u Gly Gln Leu Ser Gly145 1 - #50 1 - #55 1 -#60- Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Se - #r Leu Leu Gly Thr Gln# 175- Leu Pro Pro Gln Gly Arg Thr Thr Ala His Ly - #s Asp Pro Asn Ala Ile# 190- Phe Leu Ser Phe Gln His Leu Leu Arg Gly Ly - #s Val Arg Phe Leu Met# 205- Leu Val Gly Gly Ser Thr Leu Cys Val Arg Gl - #u Phe Gly Gly Asn Gly# 220- Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cy - #s Asp Leu Arg Val Leu225 2 - #30 2 - #35 2 -#40- Ser Lys Leu Leu Arg Asp Ser His Val Leu Hi - #s Ser Arg Leu Ser Gln# 255- Cys Pro Glu Val His Pro Leu Pro Thr Pro Va - #l Leu Leu Pro Ala Val# 270- Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Me - #t Glu Glu Thr Lys Ala# 285- Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Le - #u Glu Gly Val Met Ala# 300- Ala Arg Gly Gln Leu305- (2) INFORMATION FOR SEQ ID NO:234:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 309 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:234:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Gly Thr Gln Leu Pro Pro Gln Gly Ar - #g Thr Thr Ala His Lys145 1 - #50 1 - #55 1 -#60- Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln Hi - #s Leu Leu Arg Gly Lys# 175- Val Arg Phe Leu Met Leu Val Gly Gly Ser Th - #r Leu Cys Val Arg Glu# 190- Phe Gly Gly Asn Gly Gly Asn Met Ala Ser Pr - #o Ala Pro Pro Ala Cys# 205- Asp Leu Arg Val Leu Ser Lys Leu Leu Arg As - #p Ser His Val Leu His# 220- Ser Arg Leu Ser Gln Cys Pro Glu Val His Pr - #o Leu Pro Thr Pro Val225 2 - #30 2 - #35 2 -#40- Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Gl - #u Trp Lys Thr Gln Met# 255- Glu Glu Thr Lys Ala Gln Asp Ile Leu Gly Al - #a Val Thr Leu Leu Leu# 270- Glu Gly Val Met Ala Ala Arg Gly Gln Leu Gl - #y Pro Thr Cys Leu Ser# 285- Ser Leu Leu Gly Gln Leu Ser Gly Gln Val Ar - #g Leu Leu Leu Gly Ala# 300- Leu Gln Ser Leu Leu305- (2) INFORMATION FOR SEQ ID NO:235:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 309 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:235:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Gly Arg Thr Thr Ala His Lys Asp Pr - #o Asn Ala Ile Phe Leu145 1 - #50 1 - #55 1 -#60- Ser Phe Gln His Leu Leu Arg Gly Lys Val Ar - #g Phe Leu Met Leu Val# 175- Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gl - #y Gly Asn Gly Gly Asn# 190- Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Le - #u Arg Val Leu Ser Lys# 205- Leu Leu Arg Asp Ser His Val Leu His Ser Ar - #g Leu Ser Gln Cys Pro# 220- Glu Val His Pro Leu Pro Thr Pro Val Leu Le - #u Pro Ala Val Asp Phe225 2 - #30 2 - #35 2 -#40- Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Gl - #u Thr Lys Ala Gln Asp# 255- Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gl - #y Val Met Ala Ala Arg# 270- Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Le - #u Leu Gly Gln Leu Ser# 285- Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gl - #n Ser Leu Leu Gly Thr# 300- Gln Leu Pro Pro Gln305- (2) INFORMATION FOR SEQ ID NO:236:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 309 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:236:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Ala His Lys Asp Pro Asn Ala Ile Ph - #e Leu Ser Phe Gln His145 1 - #50 1 - #55 1 -#60- Leu Leu Arg Gly Lys Val Arg Phe Leu Met Le - #u Val Gly Gly Ser Thr# 175- Leu Cys Val Arg Glu Phe Gly Gly Asn Gly Gl - #y Asn Met Ala Ser Pro# 190- Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Se - #r Lys Leu Leu Arg Asp# 205- Ser His Val Leu His Ser Arg Leu Ser Gln Cy - #s Pro Glu Val His Pro# 220- Leu Pro Thr Pro Val Leu Leu Pro Ala Val As - #p Phe Ser Leu Gly Glu225 2 - #30 2 - #35 2 -#40- Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gl - #n Asp Ile Leu Gly Ala# 255- Val Thr Leu Leu Leu Glu Gly Val Met Ala Al - #a Arg Gly Gln Leu Gly# 270- Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Le - #u Ser Gly Gln Val Arg# 285- Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gl - #y Thr Gln Leu Pro Pro# 300- Gln Gly Arg Thr Thr305- (2) INFORMATION FOR SEQ ID NO:237:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 309 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:237:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Asp Pro Asn Ala Ile Phe Leu Ser Ph - #e Gln His Leu Leu Arg145 1 - #50 1 - #55 1 -#60- Gly Lys Val Arg Phe Leu Met Leu Val Gly Gl - #y Ser Thr Leu Cys Val# 175- Arg Glu Phe Gly Gly Asn Gly Gly Asn Met Al - #a Ser Pro Ala Pro Pro# 190- Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Le - #u Arg Asp Ser His Val# 205- Leu His Ser Arg Leu Ser Gln Cys Pro Glu Va - #l His Pro Leu Pro Thr# 220- Pro Val Leu Leu Pro Ala Val Asp Phe Ser Le - #u Gly Glu Trp Lys Thr225 2 - #30 2 - #35 2 -#40- Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Le - #u Gly Ala Val Thr Leu# 255- Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gl - #n Leu Gly Pro Thr Cys# 270- Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gl - #n Val Arg Leu Leu Leu# 285- Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Le - #u Pro Pro Gln Gly Arg# 300- Thr Thr Ala His Lys305- (2) INFORMATION FOR SEQ ID NO:238:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 309 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:238:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Ala Ile Phe Leu Ser Phe Gln His Le - #u Leu Arg Gly Lys Val145 1 - #50 1 - #55 1 -#60- Arg Phe Leu Met Leu Val Gly Gly Ser Thr Le - #u Cys Val Arg Glu Phe# 175- Gly Gly Asn Gly Gly Asn Met Ala Ser Pro Al - #a Pro Pro Ala Cys Asp# 190- Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Se - #r His Val Leu His Ser# 205- Arg Leu Ser Gln Cys Pro Glu Val His Pro Le - #u Pro Thr Pro Val Leu# 220- Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Tr - #p Lys Thr Gln Met Glu225 2 - #30 2 - #35 2 -#40- Glu Thr Lys Ala Gln Asp Ile Leu Gly Ala Va - #l Thr Leu Leu Leu Glu# 255- Gly Val Met Ala Ala Arg Gly Gln Leu Gly Pr - #o Thr Cys Leu Ser Ser# 270- Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Le - #u Leu Leu Gly Ala Leu# 285- Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gl - #n Gly Arg Thr Thr Ala# 300- His Lys Asp Pro Asn305- (2) INFORMATION FOR SEQ ID NO:239:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 302 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:239:- Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg# 15- Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val# 30- Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe# 45- Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile# 60- Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser#80- Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu# 95- Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln# 110- Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile# 125- Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro# 140- Asn Met Asp Pro Asn Ala Ile Phe Leu Ser Ph - #e Gln His Leu Leu Arg145 1 - #50 1 - #55 1 -#60- Gly Lys Val Arg Phe Leu Met Leu Val Gly Gl - #y Ser Thr Leu Cys Val# 175- Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Al - #a Pro Pro Ala Cys Asp# 190- Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Se - #r His Val Leu His Ser# 205- Arg Leu Ser Gln Cys Pro Glu Val His Pro Le - #u Pro Thr Pro Val Leu# 220- Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Tr - #p Lys Thr Gln Met Glu225 2 - #30 2 - #35 2 -#40- Glu Thr Lys Ala Gln Asp Ile Leu Gly Ala Va - #l Thr Leu Leu Leu Glu# 255- Gly Val Met Ala Ala Arg Gly Gln Leu Gly Pr - #o Thr Cys Leu Ser Ser# 270- Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Le - #u Leu Leu Gly Ala Leu# 285- Gln Ser Leu Leu Gly Thr Gln Gly Arg Thr Th - #r Ala His Lys# 300- (2) INFORMATION FOR SEQ ID NO:240:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 83 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:240:- AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GC - #TCAACAGT 60# 83AGGC TCC- (2) INFORMATION FOR SEQ ID NO:241:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 83 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:241:- CCGGGGAGCC TCCACCGCCC TCTACGTACT GTTGAGCCTG CGCGTTCTCC AA - #GGTTTTCA 60# 83ACGA CGG- (2) INFORMATION FOR SEQ ID NO:242:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 8 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:242:- Gly Gly Gly Ser Gly Gly Gly Ser1 5- (2) INFORMATION FOR SEQ ID NO:243:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 12 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:243:- Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gl - #y Ser# 10- (2) INFORMATION FOR SEQ ID NO:244:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 7 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:244:- Ser Gly Gly Ser Gly Gly Ser1 5- (2) INFORMATION FOR SEQ ID NO:245:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 6 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:245:- Glu Phe Gly Asn Met Ala1 5- (2) INFORMATION FOR SEQ ID NO:246:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 7 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:246:- Glu Phe Gly Gly Asn Met Ala1 5- (2) INFORMATION FOR SEQ ID NO:247:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 10 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:247:- Glu Phe Gly Gly Asn Gly Gly Asn Met Ala# 10- (2) INFORMATION FOR SEQ ID NO:248:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 7 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:248:- Gly Gly Ser Asp Met Ala Gly1 5- (2) INFORMATION FOR SEQ ID NO:249:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 459 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "SYNTHETIC"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:249:- TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT 60- GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG 120- CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA 180- CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA 240- CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC 300- CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GA - #CCACAGCT 360- CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AA - #AGGTGCGT 420# 459 GAGG GTCCACCCTC TGCGTCAGG- (2) INFORMATION FOR SEQ ID NO:250:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 447 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "SYNTHETIC"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:250:- TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT 60- GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG 120- CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA 180- CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA 240- CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC 300- CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGGGCAGGA CCACAGCTCA CA - #AGGATCCC 360- AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CC - #TGATGCTT 420# 447 TCTG CGTCAGG- (2) INFORMATION FOR SEQ ID NO:251:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 459 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "SYNTHETIC"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:251:- TCCCCAGCGC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT 60- GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG 120- CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA 180- CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA 240- CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC 300- CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GA - #CCACAGCT 360- CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AA - #AGGTGCGT 420# 459 GAGG GTCCACCCTC TGCGTCAGG- (2) INFORMATION FOR SEQ ID NO:252:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 153 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:252:- Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu# 15- Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val# 30- His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu# 45- Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu# 60- Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln#80- Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln# 95- Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu# 110- Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe# 125- Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu# 140- Val Gly Gly Ser Thr Leu Cys Val Arg145 1 - #50- (2) INFORMATION FOR SEQ ID NO:253:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 149 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:253:- Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu# 15- Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val# 30- His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu# 45- Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu# 60- Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln#80- Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln# 95- Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Gly# 110- Arg Thr Thr Ala His Lys Asp Pro Asn Ala Il - #e Phe Leu Ser Phe Gln# 125- His Leu Leu Arg Gly Lys Val Arg Phe Leu Me - #t Leu Val Gly Gly Ser# 140- Thr Leu Cys Val Arg145- (2) INFORMATION FOR SEQ ID NO:254:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 153 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:254:- Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu# 15- Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val# 30- His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu# 45- Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu# 60- Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln#80- Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln# 95- Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu# 110- Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe# 125- Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu# 140- Val Gly Gly Ser Thr Leu Cys Val Arg145 1 - #50- (2) INFORMATION FOR SEQ ID NO:255:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 64 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "SYNTHETIC"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:255:- GGATCCACCA TGAGCCGCCT GCCCGTCCTG CTCCTGCTCC AACTCCTGGT CC - #GCCCCGCC 60# 64- (2) INFORMATION FOR SEQ ID NO:256:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 153 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: protein- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 112#/note= "position 112 is deleted or Leu, Ala, - #VAl, Ile, Pro, Phe, Trp or Met"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 113#/note= "positoin 113 is deleted or Pro, Phe, - # Ala, Val, Leu, Ile, Trp or Met"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 114#/note= "position 114 is deleted or Pro, Phe, - # Ala, Val, Leu, Ile, Trp or Met"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 115#/note= "positon 115 is deleted or Gln, Gly, - # Ser, Thr, Tyr, or Asn"- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:256:- Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu# 15- Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val# 30- His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu# 45- Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu# 60- Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln#80- Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln# 95- Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Xaa# 110- Xaa Xaa Xaa Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe# 125- Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu# 140- Val Gly Gly Ser Thr Leu Cys Val Arg145 1 - #50- (2) INFORMATION FOR SEQ ID NO:257:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 464 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "SYNTHETIC"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:257:- CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AG - #ACCACCTG 60- CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT CTCTATCCTG AT - #GGATCGAA 120- ACCTTCGACT TCCAAACCTG GAGAGCTTCG TAAGGGCTGT CAAGAACTTA GA - #AAATGCAT 180- CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC AC - #GGCCGCAC 240- CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GA - #AAAACTGA 300- CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GTACGTAGAG GG - #CGGTGGAG 360- GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCT CC - #GTCTAAAG 420#464 AAAC ATGTAAGGTA CCGCATGCAA GCTT- (2) INFORMATION FOR SEQ ID NO:258:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 100 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "SYNTHETIC"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:258:- AAAACAAGAA GAAAGGCGAT AAAAAGGTTG TGGTAAGAGA AATGGATAAA AA - #GGGGTCGG 60# 100 TTAA AAAAGAGGAA GTAGGTCAAG- (2) INFORMATION FOR SEQ ID NO:259:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 11808 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:259:- ACGTACTCCA TGGCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA CT - #TAAAGAGA 60- CCACCTGCAC CTTTGCTGGA CCCGAACAAC CTCAATGACG AAGACGTCTC TA - #TCCTGATG 120- GATCGAAACC TTCGACTTCC AAACCTGGAG AGCTTCGTAA GGGCTGTCAA GA - #ACTTAGAA 180- AATGCATCAG GTATTGAGGC AATTCTTCGT AATCTCCAAC CATGTCTGCC CT - #CTGCCACG 240- GCCGCACCCT CTCGACATCC AATCATCATC AAGGCAGGTG ACTGGCAAGA AT - #TCCGGGAA 300- AAACTGACGT TCTATCTGGT TACCCTTGAG CAAGCGCAGG AACAACAGTA CG - #TAGAGGGC 360- GGTGGAGGCT CCCCGGGTGA ACCGTCTGGT CCAATCTCTA CTATCAACCC GT - #CTCCTCCG 420- TCTAAAGAAT CTCATAAATC TCCAAACATG GCTTTAGGCC CTGCCAGCTC CC - #TGCCCCAG 480- AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC AGGGCGATGG CG - #CAGCGCTC 540- CAGGAGAAGC TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GC - #TGCTCGGA 600- CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CC - #TGCAGCTG 660- GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCT CC - #TGCAGGCC 720- CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCT GG - #ACGTCGCC 780- GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCC TG - #CCCTGCAG 840- CCCACCCAGG GTGCCATGCC GGCCTTCGCC TCTGCTTTCC AGCGCCGGGC AG - #GAGGGGTC 900- CTGGTTGCTA GCCATCTGCA GAGCTTCCTG GAGGTGTCGT ACCGCGTTCT AC - #GCCACCTT 960- GCGCAGCCCG ACATGGCTAC ACCAACGTAC TCCATGGCTA ACTGCTCTAT AA - #TGATCGAT1020- GAAATTATAC ATCACTTAAA GAGACCACCT GCACCTTTGC TGGACCCGAA CA - #ACCTCAAT1080- GACGAAGACG TCTCTATCCT GATGGATCGA AACCTTCGAC TTCCAAACCT GG - #AGAGCTTC1140- GTAAGGGCTG TCAAGAACTT AGAAAATGCA TCAGGTATTG AGGCAATTCT TC - #GTAATCTC1200- CAACCATGTC TGCCCTCTGC CACGGCCGCA CCCTCTCGAC ATCCAATCAT CA - #TCAAGGCA1260- GGTGACTGGC AAGAATTCCG GGAAAAACTG ACGTTCTATC TGGTTACCCT TG - #AGCAAGCG1320- CAGGAACAAC AGTACGTAGA GGGCGGTGGA GGCTCCCCGG GTGAACCGTC TG - #GTCCAATC1380- TCTACTATCA ACCCGTCTCC TCCGTCTAAA GAATCTCATA AATCTCCAAA CA - #TGGCTCAG1440- AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC AGGGCGATGG CG - #CAGCGCTC1500- CAGGAGAAGC TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GC - #TGCTCGGA1560- CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CC - #TGCAGCTG1620- GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCT CC - #TGCAGGCC1680- CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCT GG - #ACGTCGCC1740- GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCC TG - #CCCTGCAG1800- CCCACCCAGG GTGCCATGCC GGCCTTCGCC TCTGCTTTCC AGCGCCGGGC AG - #GAGGGGTC1860- CTGGTTGCTA GCCATCTGCA GAGCTTCCTG GAGGTGTCGT ACCGCGTTCT AC - #GCCACCTT1920- GCGCAGCCCG ACATGGCTAC ACCATTAGGC CCTGCCAGCT CCCTGCCCAC GT - #ACTCCATG1980- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT2040- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA TC - #GAAACCTT2100- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT2160- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT2220- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC2280- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC2340- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT2400- CATAAATCTC CAAACATGGC TTTCCTGCTC AAGTCTTTAG AGCAAGTGAG GA - #AGATCCAG2460- GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CC - #ACCCCGAG2520- GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CT - #CCTGCCCC2580- AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TT - #TCCTCTAC2640- CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CT - #TGGACACA2700- CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AG - #AACTGGGA2760- ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TG - #CTTTCCAG2820- CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GG - #TGTCGTAC2880- CGCGTTCTAC GCCACCTTGC GCAGCCCGAC ATGGCTACAC CATTAGGCCC TG - #CCAGCTCC2940- CTGCCCCAGA GCACGTACTC CATGGCTAAC TGCTCTATAA TGATCGATGA AA - #TTATACAT3000- CACTTAAAGA GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA CG - #AAGACGTC3060- TCTATCCTGA TGGATCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT AA - #GGGCTGTC3120- AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC GTAATCTCCA AC - #CATGTCTG3180- CCCTCTGCCA CGGCCGCACC CTCTCGACAT CCAATCATCA TCAAGGCAGG TG - #ACTGGCAA3240- GAATTCCGGG AAAAACTGAC GTTCTATCTG GTTACCCTTG AGCAAGCGCA GG - #AACAACAG3300- TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TA - #CTATCAAC3360- CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTGAGCA AG - #TGAGGAAG3420- ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GC - #TGTGCCAC3480- CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CC - #TGAGCTCC3540- TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG CG - #GCCTTTTC3600- CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TC - #CCACCTTG3660- GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GA - #TGGAAGAA3720- CTGGGAATGG CCCCTGCCCT GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CG - #CCTCTGCT3780- TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CC - #TGGAGGTG3840- TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCGACATGG CTACACCATT AG - #GCCCTGCC3900- AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG TCTTTAACGT ACTCCATGGC TA - #ACTGCTCT3960- ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTT GC - #TGGACCCG4020- AACAACCTCA ATGACGAAGA CGTCTCTATC CTGATGGATC GAAACCTTCG AC - #TTCCAAAC4080- CTGGAGAGCT TCGTAAGGGC TGTCAAGAAC TTAGAAAATG CATCAGGTAT TG - #AGGCAATT4140- CTTCGTAATC TCCAACCATG TCTGCCCTCT GCCACGGCCG CACCCTCTCG AC - #ATCCAATC4200- ATCATCAAGG CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTA TC - #TGGTTACC4260- CTTGAGCAAG CGCAGGAACA ACAGTACGTA GAGGGCGGTG GAGGCTCCCC GG - #GTGAACCG4320- TCTGGTCCAA TCTCTACTAT CAACCCGTCT CCTCCGTCTA AAGAATCTCA TA - #AATCTCCA4380- AACATGGCTC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CT - #CCTGCCCC4440- AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TT - #TCCTCTAC4500- CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CT - #TGGACACA4560- CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AG - #AACTGGGA4620- ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TG - #CTTTCCAG4680- CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GG - #TGTCGTAC4740- CGCGTTCTAC GCCACCTTGC GCAGCCCGAC ATGGCTACAC CATTAGGCCC TG - #CCAGCTCC4800- CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GGAAGATCCA GG - #GCGATGGC4860- GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GG - #AGCTGGTG4920- ACGTACTCCA TGGCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA CT - #TAAAGAGA4980- CCACCTGCAC CTTTGCTGGA CCCGAACAAC CTCAATGACG AAGACGTCTC TA - #TCCTGATG5040- GATCGAAACC TTCGACTTCC AAACCTGGAG AGCTTCGTAA GGGCTGTCAA GA - #ACTTAGAA5100- AATGCATCAG GTATTGAGGC AATTCTTCGT AATCTCCAAC CATGTCTGCC CT - #CTGCCACG5160- GCCGCACCCT CTCGACATCC AATCATCATC AAGGCAGGTG ACTGGCAAGA AT - #TCCGGGAA5220- AAACTGACGT TCTATCTGGT TACCCTTGAG CAAGCGCAGG AACAACAGTA CG - #TAGAGGGC5280- GGTGGAGGCT CCCCGGGTGA ACCGTCTGGT CCAATCTCTA CTATCAACCC GT - #CTCCTCCG5340- TCTAAAGAAT CTCATAAATC TCCAAACATG GCTCCCCTGA GCTCCTGCCC CA - #GCCAGGCC5400- CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA CC - #AGGGGCTC5460- CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC AC - #TGCAGCTG5520- GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AA - #TGGCCCCT5580- GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GC - #GCCGGGCA5640- GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CC - #GCGTTCTA5700- CGCCACCTTG CGCAGCCCGA CATGGCTACA CCATTAGGCC CTGCCAGCTC CC - #TGCCCCAG5760- AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC AGGGCGATGG CG - #CAGCGCTC5820- CAGGAGAAGC TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GC - #TGCTCGGA5880- CACTCTCTGG GCATCCCCTG GGCTACGTAC TCCATGGCTA ACTGCTCTAT AA - #TGATCGAT5940- GAAATTATAC ATCACTTAAA GAGACCACCT GCACCTTTGC TGGACCCGAA CA - #ACCTCAAT6000- GACGAAGACG TCTCTATCCT GATGGATCGA AACCTTCGAC TTCCAAACCT GG - #AGAGCTTC6060- GTAAGGGCTG TCAAGAACTT AGAAAATGCA TCAGGTATTG AGGCAATTCT TC - #GTAATCTC6120- CAACCATGTC TGCCCTCTGC CACGGCCGCA CCCTCTCGAC ATCCAATCAT CA - #TCAAGGCA6180- GGTGACTGGC AAGAATTCCG GGAAAAACTG ACGTTCTATC TGGTTACCCT TG - #AGCAAGCG6240- CAGGAACAAC AGTACGTAGA GGGCGGTGGA GGCTCCCCGG GTGAACCGTC TG - #GTCCAATC6300- TCTACTATCA ACCCGTCTCC TCCGTCTAAA GAATCTCATA AATCTCCAAA CA - #TGGCTCAG6360- GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CT - #ACCAGGGG6420- CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CCACCTTGGA CA - #CACTGCAG6480- CTGGACGTCG CCGACTTTGC CACCACCATC TGGCAGCAGA TGGAAGAACT GG - #GAATGGCC6540- CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT CC - #AGCGCCGG6600- GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GT - #ACCGCGTT6660- CTACGCCACC TTGCGCAGCC CGACATGGCT ACACCATTAG GCCCTGCCAG CT - #CCCTGCCC6720- CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TG - #GCGCAGCG6780- CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GG - #TGCTGCTC6840- GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCAC GT - #ACTCCATG6900- GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT6960- TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA TC - #GAAACCTT7020- CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT7080- ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT7140- CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC7200- TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC7260- CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT7320- CATAAATCTC CAAACATGGC TCTGCAGCTG GCAGGCTGCT TGAGCCAACT CC - #ATAGCGGC7380- CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GT - #TGGGTCCC7440- ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GC - #AGCAGATG7500- GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCACCCAGG GTGCCATGCC GG - #CCTTCGCC7560- TCTGCTTTCC AGCGCCGGGC AGGAGGGGTC CTGGTTGCTA GCCATCTGCA GA - #GCTTCCTG7620- GAGGTGTCGT ACCGCGTTCT ACGCCACCTT GCGCAGCCCG ACATGGCTAC AC - #CATTAGGC7680- CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GA - #GGAAGATC7740- CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GT - #GCCACCCC7800- GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GA - #GCTCCTGC7860- CCCAGCCAGG CCACGTACTC CATGGCTAAC TGCTCTATAA TGATCGATGA AA - #TTATACAT7920- CACTTAAAGA GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA CG - #AAGACGTC7980- TCTATCCTGA TGGATCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT AA - #GGGCTGTC8040- AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC GTAATCTCCA AC - #CATGTCTG8100- CCCTCTGCCA CGGCCGCACC CTCTCGACAT CCAATCATCA TCAAGGCAGG TG - #ACTGGCAA8160- GAATTCCGGG AAAAACTGAC GTTCTATCTG GTTACCCTTG AGCAAGCGCA GG - #AACAACAG8220- TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TA - #CTATCAAC8280- CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTCTGGC AG - #GCTGCTTG8340- AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT GG - #AAGGGATA8400- TCCCCCGAGT TGGGTCCCAC CTTGGACACA CTGCAGCTGG ACGTCGCCGA CT - #TTGCCACC8460- ACCATCTGGC AGCAGATGGA AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CA - #CCCAGGGT8520- GCCATGCCGG CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GG - #TTGCTAGC8580- CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC GC - #AGCCCGAC8640- ATGGCTACAC CATTAGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CA - #AGTCTTTA8700- GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GT - #GTGCCACC8760- TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CA - #TCCCCTGG8820- GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGACGT ACTCCATGGC TA - #ACTGCTCT8880- ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTT GC - #TGGACCCG8940- AACAACCTCA ATGACGAAGA CGTCTCTATC CTGATGGATC GAAACCTTCG AC - #TTCCAAAC9000- CTGGAGAGCT TCGTAAGGGC TGTCAAGAAC TTAGAAAATG CATCAGGTAT TG - #AGGCAATT9060- CTTCGTAATC TCCAACCATG TCTGCCCTCT GCCACGGCCG CACCCTCTCG AC - #ATCCAATC9120- ATCATCAAGG CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTA TC - #TGGTTACC9180- CTTGAGCAAG CGCAGGAACA ACAGTACGTA GAGGGCGGTG GAGGCTCCCC GG - #GTGAACCG9240- TCTGGTCCAA TCTCTACTAT CAACCCGTCT CCTCCGTCTA AAGAATCTCA TA - #AATCTCCA9300- AACATGGCTG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CA - #TGCCGGCC9360- TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TC - #TGCAGAGC9420- TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCGACAT GG - #CTACACCA9480- TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC TTCCTGCTCA AGTCTTTAGA GC - #AAGTGAGG9540- AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CA - #AGCTGTGC9600- CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TC - #CCCTGAGC9660- TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TA - #GCGGCCTT9720- TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GG - #GTCCCACC9780- TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GC - #AGATGGAA9840- ACGTACTCCA TGGCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA CT - #TAAAGAGA9900- CCACCTGCAC CTTTGCTGGA CCCGAACAAC CTCAATGACG AAGACGTCTC TA - #TCCTGATG9960- GATCGAAACC TTCGACTTCC AAACCTGGAG AGCTTCGTAA GGGCTGTCAA GA - #ACTTAGAA10020- AATGCATCAG GTATTGAGGC AATTCTTCGT AATCTCCAAC CATGTCTGCC CT - #CTGCCACG10080- GCCGCACCCT CTCGACATCC AATCATCATC AAGGCAGGTG ACTGGCAAGA AT - #TCCGGGAA10140- AAACTGACGT TCTATCTGGT TACCCTTGAG CAAGCGCAGG AACAACAGTA CG - #TAGAGGGC10200- GGTGGAGGCT CCCCGGGTGA ACCGTCTGGT CCAATCTCTA CTATCAACCC GT - #CTCCTCCG10260- TCTAAAGAAT CTCATAAATC TCCAAACATG GCTGGAATGG CCCCTGCCCT GC - #AGCCCACC10320- CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC GGGCAGGAGG GG - #TCCTGGTT10380- GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CC - #TTGCGCAG10440- CCCGACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CC - #TGCTCAAG10500- TCTTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GA - #AGCTGTGT10560- GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TC - #TGGGCATC10620- CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CT - #GCTTGAGC10680- CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AG - #GGATATCC10740- CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT TG - #CCACCACC10800- ATCTGGCAGC AGATGGAAGA ACTGACGTAC TCCATGGCTA ACTGCTCTAT AA - #TGATCGAT10860- GAAATTATAC ATCACTTAAA GAGACCACCT GCACCTTTGC TGGACCCGAA CA - #ACCTCAAT10920- GACGAAGACG TCTCTATCCT GATGGATCGA AACCTTCGAC TTCCAAACCT GG - #AGAGCTTC10980- GTAAGGGCTG TCAAGAACTT AGAAAATGCA TCAGGTATTG AGGCAATTCT TC - #GTAATCTC11040- CAACCATGTC TGCCCTCTGC CACGGCCGCA CCCTCTCGAC ATCCAATCAT CA - #TCAAGGCA11100- GGTGACTGGC AAGAATTCCG GGAAAAACTG ACGTTCTATC TGGTTACCCT TG - #AGCAAGCG11160- CAGGAACAAC AGTACGTAGA GGGCGGTGGA GGCTCCCCGG GTGAACCGTC TG - #GTCCAATC11220- TCTACTATCA ACCCGTCTCC TCCGTCTAAA GAATCTCATA AATCTCCAAA CA - #TGGCTAGC11280- TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCGACAT GG - #CTACACCA11340- TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC TTCCTGCTCA AGTCTTTAGA GC - #AAGTGAGG11400- AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CA - #AGCTGTGC11460- CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TC - #CCCTGAGC11520- TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TA - #GCGGCCTT11580- TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GG - #GTCCCACC11640- TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GC - #AGATGGAA11700- GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CT - #TCGCCTCT11760# 11808CAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAG- (2) INFORMATION FOR SEQ ID NO:260:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 975 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:260:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTCAGAGC TTCCTGCTCA AGTCTTTAGA GC - #AAGTGAGG 480- AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CA - #AGCTGTGC 540- CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TC - #CCCTGAGC 600- TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TA - #GCGGCCTT 660- TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GG - #GTCCCACC 720- TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GC - #AGATGGAA 780- GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CT - #TCGCCTCT 840- GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CT - #TCCTGGAG 900- GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCGACA TGGCTACACC AT - #TAGGCCCT 960# 975- (2) INFORMATION FOR SEQ ID NO:261:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 975 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:261:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTCAGAGC TTCCTGCTCA AGTCTTTAGA GC - #AAGTGAGG 480- AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CA - #AGCTGTGC 540- CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TC - #CCCTGAGC 600- TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TA - #GCGGCCTT 660- TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GG - #GTCCCACC 720- TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GC - #AGATGGAA 780- GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CT - #TCGCCTCT 840- GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CT - #TCCTGGAG 900- GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCGACA TGGCTACACC AT - #TAGGCCCT 960# 975- (2) INFORMATION FOR SEQ ID NO:262:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 975 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:262:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTGAGCAA GTGAGGAAGA TCCAGGGCGA TG - #GCGCAGCG 480- CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GG - #TGCTGCTC 540- GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GG - #CCCTGCAG 600- CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GC - #TCCTGCAG 660- GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GC - #TGGACGTC 720- GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CC - #CTGCCCTG 780- CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GG - #CAGGAGGG 840- GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TC - #TACGCCAC 900- CTTGCGCAGC CCGACATGGC TACACCATTA GGCCCTGCCA GCTCCCTGCC CC - #AGAGCTTC 960# 975- (2) INFORMATION FOR SEQ ID NO:263:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 975 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:263:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTCTGCTC GGACACTCTC TGGGCATCCC CT - #GGGCTCCC 480- CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA AC - #TCCATAGC 540- GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CG - #AGTTGGGT 600- CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CT - #GGCAGCAG 660- ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GC - #CGGCCTTC 720- GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GC - #AGAGCTTC 780- CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCGACATGGC TA - #CACCATTA 840- GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AG - #TGAGGAAG 900- ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GC - #TGTGCCAC 960# 975- (2) INFORMATION FOR SEQ ID NO:264:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 975 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:264:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CC - #TGCAGCTG 480- GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCT CC - #TGCAGGCC 540- CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCT GG - #ACGTCGCC 600- GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCC TG - #CCCTGCAG 660- CCCACCCAGG GTGCCATGCC GGCCTTCGCC TCTGCTTTCC AGCGCCGGGC AG - #GAGGGGTC 720- CTGGTTGCTA GCCATCTGCA GAGCTTCCTG GAGGTGTCGT ACCGCGTTCT AC - #GCCACCTT 780- GCGCAGCCCG ACATGGCTAC ACCATTAGGC CCTGCCAGCT CCCTGCCCCA GA - #GCTTCCTG 840- CTCAAGTCTT TAGAGCAAGT GAGGAAGATC CAGGGCGATG GCGCAGCGCT CC - #AGGAGAAG 900- CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG AC - #ACTCTCTG 960# 975- (2) INFORMATION FOR SEQ ID NO:265:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 975 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:265:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTCAGGCC CTGCAGCTGG CAGGCTGCTT GA - #GCCAACTC 480- CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT AT - #CCCCCGAG 540- TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CA - #CCATCTGG 600- CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG TG - #CCATGCCG 660- GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CC - #ATCTGCAG 720- AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCGA CA - #TGGCTACA 780- CCATTAGGCC CTGCCAGCTC CCTGCCCCAG AGCTTCCTGC TCAAGTCTTT AG - #AGCAAGTG 840- AGGAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CT - #ACAAGCTG 900- TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GG - #CTCCCCTG 960# 975- (2) INFORMATION FOR SEQ ID NO:266:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 975 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:266:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTCTGCAG CTGGCAGGCT GCTTGAGCCA AC - #TCCATAGC 480- GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CG - #AGTTGGGT 540- CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CT - #GGCAGCAG 600- ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GC - #CGGCCTTC 660- GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GC - #AGAGCTTC 720- CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCGACATGGC TA - #CACCATTA 780- GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AG - #TGAGGAAG 840- ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GC - #TGTGCCAC 900- CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CC - #TGAGCTCC 960# 975- (2) INFORMATION FOR SEQ ID NO:267:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 975 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:267:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTCTGGCA GGCTGCTTGA GCCAACTCCA TA - #GCGGCCTT 480- TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GG - #GTCCCACC 540- TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GC - #AGATGGAA 600- GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CT - #TCGCCTCT 660- GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CT - #TCCTGGAG 720- GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCGACA TGGCTACACC AT - #TAGGCCCT 780- GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG GA - #AGATCCAG 840- GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CC - #ACCCCGAG 900- GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CT - #CCTGCCCC 960# 975- (2) INFORMATION FOR SEQ ID NO:268:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 975 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:268:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTGAACTG GGAATGGCCC CTGCCCTGCA GC - #CCACCCAG 480- GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CC - #TGGTTGCT 540- AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT TG - #CGCAGCCC 600- GACATGGCTA CACCATTAGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GC - #TCAAGTCT 660- TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GC - #TGTGTGCC 720- ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GG - #GCATCCCC 780- TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CT - #TGAGCCAA 840- CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GA - #TATCCCCC 900- GAGTTGGGTC CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC CA - #CCACCATC 960# 975- (2) INFORMATION FOR SEQ ID NO:269:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 975 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:269:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTGGAATG GCCCCTGCCC TGCAGCCCAC CC - #AGGGTGCC 480- ATGCCGGCCT TCGCCTCTGC TTTCCAGCGC CGGGCAGGAG GGGTCCTGGT TG - #CTAGCCAT 540- CTGCAGAGCT TCCTGGAGGT GTCGTACCGC GTTCTACGCC ACCTTGCGCA GC - #CCGACATG 600- GCTACACCAT TAGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GT - #CTTTAGAG 660- CAAGTGAGGA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TG - #CCACCTAC 720- AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CC - #CCTGGGCT 780- CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CC - #AACTCCAT 840- AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CC - #CCGAGTTG 900- GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CA - #TCTGGCAG 960# 975- (2) INFORMATION FOR SEQ ID NO:270:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 975 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:270:- ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA 60- CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC 120- CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA 180- GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC 240- TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG 300- TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC 360- TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA 420- TCTCATAAAT CTCCAAACAT GGCTAGCTTC CTGGAGGTGT CGTACCGCGT TC - #TACGCCAC 480- CTTGCGCAGC CCGACATGGC TACACCATTA GGCCCTGCCA GCTCCCTGCC CC - #AGAGCTTC 540- CTGCTCAAGT CTTTAGAGCA AGTGAGGAAG ATCCAGGGCG ATGGCGCAGC GC - #TCCAGGAG 600- AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CG - #GACACTCT 660- CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GC - #TGGCAGGC 720- TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GG - #CCCTGGAA 780- GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CG - #CCGACTTT 840- GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GC - #AGCCCACC 900- CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC GGGCAGGAGG GG - #TCCTGGTT 960# 975- (2) INFORMATION FOR SEQ ID NO:271:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 325 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:271:- Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys# 15- Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp# 30- Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser# 45- Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala# 60- Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro#80- Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg# 95- Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Leu Gly Pro Ala Ser Ser Le - #u Pro Gln Ser Phe Leu145 1 - #50 1 - #55 1 -#60- Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gl - #n Gly Asp Gly Ala Ala# 175- Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Le - #u Cys His Pro Glu Glu# 190- Leu Val Leu Leu Gly His Ser Leu Gly Ile Pr - #o Trp Ala Pro Leu Ser# 205- Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gl - #y Cys Leu Ser Gln Leu# 220- His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Le - #u Gln Ala Leu Glu Gly225 2 - #30 2 - #35 2 -#40- Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Th - #r Leu Gln Leu Asp Val# 255- Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Me - #t Glu Glu Leu Gly Met# 270- Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser# 285- Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln# 300- Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro305 3 - #10 3 - #15 3 -#20- Asp Met Ala Thr Pro 325- (2) INFORMATION FOR SEQ ID NO:272:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 325 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:272:- Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys# 15- Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp# 30- Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser# 45- Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala# 60- Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro#80- Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg# 95- Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Leu Gly Pro Ala Ser Ser Le - #u Pro Gln Ser Phe Leu145 1 - #50 1 - #55 1 -#60- Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gl - #n Gly Asp Gly Ala Ala# 175- Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Le - #u Cys His Pro Glu Glu# 190- Leu Val Leu Leu Gly His Ser Leu Gly Ile Pr - #o Trp Ala Pro Leu Ser# 205- Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gl - #y Cys Leu Ser Gln Leu# 220- His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Le - #u Gln Ala Leu Glu Gly225 2 - #30 2 - #35 2 -#40- Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Th - #r Leu Gln Leu Asp Val# 255- Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Me - #t Glu Glu Leu Gly Met# 270- Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser# 285- Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln# 300- Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro305 3 - #10 3 - #15 3 -#20- Asp Met Ala Thr Pro 325- (2) INFORMATION FOR SEQ ID NO:273:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 325 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:273:- Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys# 15- Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp# 30- Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser# 45- Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala# 60- Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro#80- Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg# 95- Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Phe Leu Leu Lys Ser Leu Gl - #u Gln Val Arg Lys Ile145 1 - #50 1 - #55 1 -#60- Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Le - #u Cys Ala Thr Tyr Lys# 175- Leu Cys His Pro Glu Glu Leu Val Leu Leu Gl - #y His Ser Leu Gly Ile# 190- Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gl - #n Ala Leu Gln Leu Ala# 205- Gly Cys Leu Ser Gln Leu His Ser Gly Leu Ph - #e Leu Tyr Gln Gly Leu# 220- Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Le - #u Gly Pro Thr Leu Asp225 2 - #30 2 - #35 2 -#40- Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Th - #r Thr Ile Trp Gln Gln# 255- Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gl - #n Pro Thr Gln Gly Ala# 270- Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Ar - #g Ala Gly Gly Val Leu# 285- Val Ala Ser His Leu Gln Ser Phe Leu Glu Va - #l Ser Tyr Arg Val Leu# 300- Arg His Leu Ala Gln Pro Asp Met Ala Thr Pr - #o Leu Gly Pro Ala Ser305 3 - #10 3 - #15 3 -#20- Ser Leu Pro Gln Ser 325- (2) INFORMATION FOR SEQ ID NO:274:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 325 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:274:- Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys# 15- Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp# 30- Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser# 45- Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala# 60- Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro#80- Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg# 95- Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Glu Gln Val Arg Lys Ile Gl - #n Gly Asp Gly Ala Ala145 1 - #50 1 - #55 1 -#60- Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Le - #u Cys His Pro Glu Glu# 175- Leu Val Leu Leu Gly His Ser Leu Gly Ile Pr - #o Trp Ala Pro Leu Ser# 190- Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gl - #y Cys Leu Ser Gln Leu# 205- His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Le - #u Gln Ala Leu Glu Gly# 220- Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Th - #r Leu Gln Leu Asp Val225 2 - #30 2 - #35 2 -#40- Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Me - #t Glu Glu Leu Gly Met# 255- Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser# 270- Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln# 285- Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro# 300- Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Se - #r Leu Pro Gln Ser Phe305 3 - #10 3 - #15 3 -#20- Leu Leu Lys Ser Leu 325- (2) INFORMATION FOR SEQ ID NO:275:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 325 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:275:- Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys# 15- Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp# 30- Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser# 45- Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala# 60- Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro#80- Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg# 95- Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Leu Leu Gly His Ser Leu Gl - #y Ile Pro Trp Ala Pro145 1 - #50 1 - #55 1 -#60- Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Le - #u Ala Gly Cys Leu Ser# 175- Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gl - #y Leu Leu Gln Ala Leu# 190- Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Le - #u Asp Thr Leu Gln Leu# 205- Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gl - #n Gln Met Glu Glu Leu# 220- Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gl - #y Ala Met Pro Ala Phe225 2 - #30 2 - #35 2 -#40- Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Va - #l Leu Val Ala Ser His# 255- Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Va - #l Leu Arg His Leu Ala# 270- Gln Pro Asp Met Ala Thr Pro Leu Gly Pro Al - #a Ser Ser Leu Pro Gln# 285- Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Ar - #g Lys Ile Gln Gly Asp# 300- Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Th - #r Tyr Lys Leu Cys His305 3 - #10 3 - #15 3 -#20- Pro Glu Glu Leu Val 325- (2) INFORMATION FOR SEQ ID NO:276:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 325 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:276:- Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys# 15- Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp# 30- Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser# 45- Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala# 60- Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro#80- Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg# 95- Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Pro Leu Ser Ser Cys Pro Se - #r Gln Ala Leu Gln Leu145 1 - #50 1 - #55 1 -#60- Ala Gly Cys Leu Ser Gln Leu His Ser Gly Le - #u Phe Leu Tyr Gln Gly# 175- Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Gl - #u Leu Gly Pro Thr Leu# 190- Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Al - #a Thr Thr Ile Trp Gln# 205- Gln Met Glu Glu Leu Gly Met Ala Pro Ala Le - #u Gln Pro Thr Gln Gly# 220- Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Ar - #g Arg Ala Gly Gly Val225 2 - #30 2 - #35 2 -#40- Leu Val Ala Ser His Leu Gln Ser Phe Leu Gl - #u Val Ser Tyr Arg Val# 255- Leu Arg His Leu Ala Gln Pro Asp Met Ala Th - #r Pro Leu Gly Pro Ala# 270- Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Se - #r Leu Glu Gln Val Arg# 285- Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Gl - #u Lys Leu Cys Ala Thr# 300- Tyr Lys Leu Cys His Pro Glu Glu Leu Val Le - #u Leu Gly His Ser Leu305 3 - #10 3 - #15 3 -#20- Gly Ile Pro Trp Ala 325- (2) INFORMATION FOR SEQ ID NO:277:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 325 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:277:- Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys# 15- Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp# 30- Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser# 45- Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala# 60- Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro#80- Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg# 95- Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Gln Ala Leu Gln Leu Ala Gl - #y Cys Leu Ser Gln Leu145 1 - #50 1 - #55 1 -#60- His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Le - #u Gln Ala Leu Glu Gly# 175- Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Th - #r Leu Gln Leu Asp Val# 190- Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Me - #t Glu Glu Leu Gly Met# 205- Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser# 220- Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln225 2 - #30 2 - #35 2 -#40- Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro# 255- Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Se - #r Leu Pro Gln Ser Phe# 270- Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Il - #e Gln Gly Asp Gly Ala# 285- Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Ly - #s Leu Cys His Pro Glu# 300- Glu Leu Val Leu Leu Gly His Ser Leu Gly Il - #e Pro Trp Ala Pro Leu305 3 - #10 3 - #15 3 -#20- Ser Ser Cys Pro Ser 325- (2) INFORMATION FOR SEQ ID NO:278:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 325 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:278:- Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys# 15- Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp# 30- Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser# 45- Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala# 60- Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro#80- Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg# 95- Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Leu Gln Leu Ala Gly Cys Le - #u Ser Gln Leu His Ser145 1 - #50 1 - #55 1 -#60- Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Al - #a Leu Glu Gly Ile Ser# 175- Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gl - #n Leu Asp Val Ala Asp# 190- Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Gl - #u Leu Gly Met Ala Pro# 205- Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Al - #a Phe Ala Ser Ala Phe# 220- Gln Arg Arg Ala Gly Gly Val Leu Val Ala Se - #r His Leu Gln Ser Phe225 2 - #30 2 - #35 2 -#40- Leu Glu Val Ser Tyr Arg Val Leu Arg His Le - #u Ala Gln Pro Asp Met# 255- Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pr - #o Gln Ser Phe Leu Leu# 270- Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gl - #y Asp Gly Ala Ala Leu# 285- Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cy - #s His Pro Glu Glu Leu# 300- Val Leu Leu Gly His Ser Leu Gly Ile Pro Tr - #p Ala Pro Leu Ser Ser305 3 - #10 3 - #15 3 -#20- Cys Pro Ser Gln Ala 325- (2) INFORMATION FOR SEQ ID NO:279:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 325 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:279:- Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys# 15- Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp# 30- Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser# 45- Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala# 60- Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro#80- Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg# 95- Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Leu Ala Gly Cys Leu Ser Gl - #n Leu His Ser Gly Leu145 1 - #50 1 - #55 1 -#60- Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Gl - #u Gly Ile Ser Pro Glu# 175- Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu As - #p Val Ala Asp Phe Ala# 190- Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl - #y Met Ala Pro Ala Leu# 205- Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Al - #a Ser Ala Phe Gln Arg# 220- Arg Ala Gly Gly Val Leu Val Ala Ser His Le - #u Gln Ser Phe Leu Glu225 2 - #30 2 - #35 2 -#40- Val Ser Tyr Arg Val Leu Arg His Leu Ala Gl - #n Pro Asp Met Ala Thr# 255- Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Se - #r Phe Leu Leu Lys Ser# 270- Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gl - #y Ala Ala Leu Gln Glu# 285- Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pr - #o Glu Glu Leu Val Leu# 300- Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pr - #o Leu Ser Ser Cys Pro305 3 - #10 3 - #15 3 -#20- Ser Gln Ala Leu Gln 325- (2) INFORMATION FOR SEQ ID NO:280:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 325 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:280:- Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys# 15- Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp# 30- Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser# 45- Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala# 60- Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro#80- Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg# 95- Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Glu Leu Gly Met Ala Pro Al - #a Leu Gln Pro Thr Gln145 1 - #50 1 - #55 1 -#60- Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gl - #n Arg Arg Ala Gly Gly# 175- Val Leu Val Ala Ser His Leu Gln Ser Phe Le - #u Glu Val Ser Tyr Arg# 190- Val Leu Arg His Leu Ala Gln Pro Asp Met Al - #a Thr Pro Leu Gly Pro# 205- Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Ly - #s Ser Leu Glu Gln Val# 220- Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gl - #n Glu Lys Leu Cys Ala225 2 - #30 2 - #35 2 -#40- Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Va - #l Leu Leu Gly His Ser# 255- Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cy - #s Pro Ser Gln Ala Leu# 270- Gln Leu Ala Gly Cys Leu Ser Gln Leu His Se - #r Gly Leu Phe Leu Tyr# 285- Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Se - #r Pro Glu Leu Gly Pro# 300- Thr Leu Asp Thr Leu Gln Leu Asp Val Ala As - #p Phe Ala Thr Thr Ile305 3 - #10 3 - #15 3 -#20- Trp Gln Gln Met Glu 325- (2) INFORMATION FOR SEQ ID NO:281:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 325 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:281:- Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys# 15- Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp# 30- Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser# 45- Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala# 60- Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro#80- Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg# 95- Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Gly Met Ala Pro Ala Leu Gl - #n Pro Thr Gln Gly Ala145 1 - #50 1 - #55 1 -#60- Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Ar - #g Ala Gly Gly Val Leu# 175- Val Ala Ser His Leu Gln Ser Phe Leu Glu Va - #l Ser Tyr Arg Val Leu# 190- Arg His Leu Ala Gln Pro Asp Met Ala Thr Pr - #o Leu Gly Pro Ala Ser# 205- Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Le - #u Glu Gln Val Arg Lys# 220- Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Ly - #s Leu Cys Ala Thr Tyr225 2 - #30 2 - #35 2 -#40- Lys Leu Cys His Pro Glu Glu Leu Val Leu Le - #u Gly His Ser Leu Gly# 255- Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Se - #r Gln Ala Leu Gln Leu# 270- Ala Gly Cys Leu Ser Gln Leu His Ser Gly Le - #u Phe Leu Tyr Gln Gly# 285- Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Gl - #u Leu Gly Pro Thr Leu# 300- Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Al - #a Thr Thr Ile Trp Gln305 3 - #10 3 - #15 3 -#20- Gln Met Glu Glu Leu 325- (2) INFORMATION FOR SEQ ID NO:282:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 325 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:282:- Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys# 15- Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp# 30- Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser# 45- Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala# 60- Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro#80- Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg# 95- Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln# 110- Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro# 125- Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser# 140- Pro Asn Met Ala Ser Phe Leu Glu Val Ser Ty - #r Arg Val Leu Arg His145 1 - #50 1 - #55 1 -#60- Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gl - #y Pro Ala Ser Ser Leu# 175- Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gl - #n Val Arg Lys Ile Gln# 190- Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cy - #s Ala Thr Tyr Lys Leu# 205- Cys His Pro Glu Glu Leu Val Leu Leu Gly Hi - #s Ser Leu Gly Ile Pro# 220- Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Al - #a Leu Gln Leu Ala Gly225 2 - #30 2 - #35 2 -#40- Cys Leu Ser Gln Leu His Ser Gly Leu Phe Le - #u Tyr Gln Gly Leu Leu# 255- Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gl - #y Pro Thr Leu Asp Thr# 270- Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Th - #r Ile Trp Gln Gln Met# 285- Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pr - #o Thr Gln Gly Ala Met# 300- Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Al - #a Gly Gly Val Leu Val305 3 - #10 3 - #15 3 -#20- Ala Ser His Leu Gln 325- (2) INFORMATION FOR SEQ ID NO:283:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 153 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 7#/note= "Xaa at position 7 is Ser or Ala;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 112#/note= "Xaa at position 112 is: deleted o - #r Leu, Ala, Val, Ile, Pro, Phe, Trp, or Met;- #"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 113#/note= "Xaa at position 113 is: deleted o - #r Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met;- #"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 114#/note= "Xaa at position 114 is: deleted o - #r Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met;- #"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 115#/note= "Xaa at position 115 is: deleted o - #r Gln, Gly, Ser, Thr, Tyr, or Asn;"- (ix) FEATURE: (A) NAME/KEY: Modified-sit - #e (B) LOCATION: 151#/note= "Xaa at position 151 is Ser or Ala;"- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:283:- Ser Pro Ala Pro Pro Ala Xaa Asp Leu Arg Va - #l Leu Ser Lys Leu Leu# 15- Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val# 30- His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu# 45- Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu# 60- Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln#80- Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln# 95- Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Xaa# 110- Xaa Xaa Xaa Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe# 125- Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu# 140- Val Gly Gly Ser Thr Leu Xaa Val Arg145 1 - #50- (2) INFORMATION FOR SEQ ID NO:284:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 162 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:284:- Met Ala Gly Arg Thr Thr Ala His Lys Asp Pr - #o Asn Ala Ile Phe Leu# 15- Ser Phe Gln His Leu Leu Arg Gly Lys Val Ar - #g Phe Leu Met Leu Val# 30- Gly Gly Ser Thr Leu Ala Val Arg Glu Phe Gl - #y Gly Asn Met Ala Ser# 45- Pro Ala Pro Pro Ala Ala Asp Leu Arg Val Le - #u Ser Lys Leu Leu Arg# 60- Asp Ser His Val Leu His Ser Arg Leu Ser Gl - #n Cys Pro Glu Val His#80- Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Va - #l Asp Phe Ser Leu Gly# 95- Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Al - #a Gln Asp Ile Leu Gly# 110- Ala Val Thr Leu Leu Leu Glu Gly Val Met Al - #a Ala Arg Gly Gln Leu# 125- Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gl - #n Leu Ser Gly Gln Val# 140- Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Le - #u Gly Thr Gln Leu Pro145 1 - #50 1 - #55 1 -#60- Pro Gln- (2) INFORMATION FOR SEQ ID NO:285:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 162 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:285:- Met Ala Gly Pro Thr Cys Leu Ser Ser Leu Le - #u Gly Gln Leu Ser Gly# 15- Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Se - #r Leu Leu Gly Thr Gln# 30- Leu Pro Pro Gln Gly Arg Thr Thr Ala His Ly - #s Asp Pro Asn Ala Ile# 45- Phe Leu Ser Phe Gln His Leu Leu Arg Gly Ly - #s Val Arg Phe Leu Met# 60- Leu Val Gly Gly Ser Thr Leu Ala Val Arg Gl - #u Phe Gly Gly Asn Met#80- Ala Ser Pro Ala Pro Pro Ala Ala Asp Leu Ar - #g Val Leu Ser Lys Leu# 95- Leu Arg Asp Ser His Val Leu His Ser Arg Le - #u Ser Gln Cys Pro Glu# 110- Val His Pro Leu Pro Thr Pro Val Leu Leu Pr - #o Ala Val Asp Phe Ser# 125- Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Th - #r Lys Ala Gln Asp Ile# 140- Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Va - #l Met Ala Ala Arg Gly145 1 - #50 1 - #55 1 -#60- Gln Leu- (2) INFORMATION FOR SEQ ID NO:286:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 180 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide "- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:286:- Ala Thr Gly Gly Cys Thr Gly Gly Ala Cys Cy - #s Cys Ala Cys Thr Thr# 15- Gly Cys Cys Thr Cys Thr Cys Ala Thr Cys Cy - #s Cys Thr Cys Cys Thr# 30- Gly Gly Gly Gly Cys Ala Gly Cys Thr Thr Th - #r Cys Thr Gly Gly Ala# 45- Cys Ala Gly Gly Thr Cys Cys Gly Thr Cys Th - #r Cys Cys Thr Cys Cys# 60- Thr Thr Gly Gly Gly Gly Cys Cys Cys Thr Gl - #y Cys Ala Gly Ala Gly#80- Cys Cys Thr Cys Cys Thr Thr Gly Gly Ala Al - #a Cys Cys Cys Ala Gly# 95- Cys Thr Thr Cys Cys Thr Cys Cys Ala Cys Al - #a Gly Gly Gly Cys Ala# 110- Gly Gly Ala Cys Cys Ala Cys Ala Gly Cys Th - #r Cys Ala Cys Ala Ala# 125- Gly Gly Ala Thr Cys Cys Cys Ala Ala Thr Gl - #y Cys Cys Ala Thr Cys# 140- Thr Thr Cys Cys Thr Gly Ala Gly Cys Thr Th - #r Cys Cys Ala Ala Cys145 1 - #50 1 - #55 1 -#60- Ala Cys Cys Thr Gly Cys Thr Cys Cys Gly Al - #a Gly Gly Ala Ala Ala# 175- Gly Gly Thr Gly 180- (2) INFORMATION FOR SEQ ID NO:287:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 486 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:287:- ATGGCTGGCA GGACCACAGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG CT - #TCCAACAC 60- CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCT CG - #CCGTCAGG 120- GAATTCGGCG GCAACATGGC GTCTCCGGCG CCGCCTGCTG CTGACCTCCG AG - #TCCTCAGT 180- AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AG - #AGGTTCAC 240- CCTTTGCCTA CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGA AT - #GGAAAACC 300- CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT GC - #TGGAGGGA 360- GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT CATCCCTCCT GG - #GGCAGCTT 420- TCTGGACAGG TCCGTCTCCT CCTTGGGGCC CTGCAGAGCC TCCTTGGAAC CC - #AGCTTCCT 480# 486- (2) INFORMATION FOR SEQ ID NO:288:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 531 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:288:- CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TG - #GCGCAGCG 60- CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GG - #TGCTGCTC 120- GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GG - #CCCTGCAG 180- CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GC - #TCCTGCAG 240- GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GC - #TGGACGTC 300- GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CC - #CTGCCCTG 360- CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GG - #CAGGAGGG 420- GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TC - #TACGCCAC 480# 531ACATGGC TACACCATTA GGCCCTGCCA GCTCCCTGCC C- (2) INFORMATION FOR SEQ ID NO:289:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 531 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:289:- GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CT - #TCGCCTCT 60- GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CT - #TCCTGGAG 120- GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCGACA TGGCTACACC AT - #TAGGCCCT 180- GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG GA - #AGATCCAG 240- GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CC - #ACCCCGAG 300- GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CT - #CCTGCCCC 360- AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TT - #TCCTCTAC 420- CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CT - #TGGACACA 480# 531TCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA A- (2) INFORMATION FOR SEQ ID NO:290:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 531 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:290:- GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CT - #CTGCTTTC 60- CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GG - #AGGTGTCG 120- TACCGCGTTC TACGCCACCT TGCGCAGCCC GACATGGCTA CACCATTAGG CC - #CTGCCAGC 180- TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGGAAGAT CC - #AGGGCGAT 240- GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC CG - #AGGAGCTG 300- GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CC - #CCAGCCAG 360- GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CT - #ACCAGGGG 420- CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CCACCTTGGA CA - #CACTGCAG 480# 531ACTTTGC CACCACCATC TGGCAGCAGA TGGAAGAACT G- (2) INFORMATION FOR SEQ ID NO:291:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 531 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:291:- TTCCTGCTCA AGTCTTTAGA GCAAGTGAGG AAGATCCAGG GCGATGGCGC AG - #CGCTCCAG 60- GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GC - #TCGGACAC 120- TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GC - #AGCTGGCA 180- GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GC - #AGGCCCTG 240- GAAGGGATAT CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CG - #TCGCCGAC 300- TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC CC - #TGCAGCCC 360- ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AG - #GGGTCCTG 420- GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CC - #ACCTTGCG 480# 531CTACACC ATTAGGCCCT GCCAGCTCCC TGCCCCAGAG C- (2) INFORMATION FOR SEQ ID NO:292:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 531 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:292:- AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCGA CA - #TGGCTACA 60- CCATTAGGCC CTGCCAGCTC CCTGCCCCAG AGCTTCCTGC TCAAGTCTTT AG - #AGCAAGTG 120- AGGAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CT - #ACAAGCTG 180- TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GG - #CTCCCCTG 240- AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CC - #ATAGCGGC 300- CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GT - #TGGGTCCC 360- ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GC - #AGCAGATG 420- GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCACCCAGG GTGCCATGCC GG - #CCTTCGCC 480# 531GCCGGGC AGGAGGGGTC CTGGTTGCTA GCCATCTGCA G- (2) INFORMATION FOR SEQ ID NO:293:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 531 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:293:- AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCGA CA - #TGGCTACA 60- CCATTAGGCC CTGCCAGCTC CCTGCCCCAG AGCTTCCTGC TCAAGTCTTT AG - #AGCAAGTG 120- AGGAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CT - #ACAAGCTG 180- TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GG - #CTCCCCTG 240- AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CC - #ATAGCGGC 300- CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GT - #TGGGTCCC 360- ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GC - #AGCAGATG 420- GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCACCCAGG GTGCCATGCC GG - #CCTTCGCC 480# 531GCCGGGC AGGAGGGGTC CTGGTTGCTA GCCATCTGCA G- (2) INFORMATION FOR SEQ ID NO:294:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 531 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:294:- TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC TTCCTGCTCA AGTCTTTAGA GC - #AAGTGAGG 60- AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CA - #AGCTGTGC 120- CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TC - #CCCTGAGC 180- TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TA - #GCGGCCTT 240- TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GG - #GTCCCACC 300- TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GC - #AGATGGAA 360- GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CT - #TCGCCTCT 420- GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CT - #TCCTGGAG 480# 531TTCTACG CCACCTTGCG CAGCCCGACA TGGCTACACC A- (2) INFORMATION FOR SEQ ID NO:295:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 531 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:295:- CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CA - #GCCAGGCC 60- CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA CC - #AGGGGCTC 120- CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC AC - #TGCAGCTG 180- GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AA - #TGGCCCCT 240- GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GC - #GCCGGGCA 300- GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CC - #GCGTTCTA 360- CGCCACCTTG CGCAGCCCGA CATGGCTACA CCATTAGGCC CTGCCAGCTC CC - #TGCCCCAG 420- AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC AGGGCGATGG CG - #CAGCGCTC 480# 531GTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT G- (2) INFORMATION FOR SEQ ID NO:296:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 531 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:296:- CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CC - #AACTCCAT 60- AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CC - #CCGAGTTG 120- GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CA - #TCTGGCAG 180- CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CA - #TGCCGGCC 240- TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TC - #TGCAGAGC 300- TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCGACAT GG - #CTACACCA 360- TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC TTCCTGCTCA AGTCTTTAGA GC - #AAGTGAGG 420- AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CA - #AGCTGTGC 480# 531TGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC T- (2) INFORMATION FOR SEQ ID NO:297:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 531 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:297:- CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA GCGGCCTTTT CC - #TCTACCAG 60- GGGCTCCTGC AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTT GG - #ACACACTG 120- CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA AC - #TGGGAATG 180- GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC ATGCCGGCCT TCGCCTCTGC TT - #TCCAGCGC 240- CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT CTGCAGAGCT TCCTGGAGGT GT - #CGTACCGC 300- GTTCTACGCC ACCTTGCGCA GCCCGACATG GCTACACCAT TAGGCCCTGC CA - #GCTCCCTG 360- CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGGA AGATCCAGGG CG - #ATGGCGCA 420- GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GC - #TGGTGCTG 480# 531TGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG C- (2) INFORMATION FOR SEQ ID NO:298:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 531 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:298:- CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA CC - #AGGGGCTC 60- CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC AC - #TGCAGCTG 120- GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AA - #TGGCCCCT 180- GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GC - #GCCGGGCA 240- GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CC - #GCGTTCTA 300- CGCCACCTTG CGCAGCCCGA CATGGCTACA CCATTAGGCC CTGCCAGCTC CC - #TGCCCCAG 360- AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC AGGGCGATGG CG - #CAGCGCTC 420- CAGGAGAAGC TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GC - #TGCTCGGA 480# 531TCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC C- (2) INFORMATION FOR SEQ ID NO:299:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 531 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:299:- CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GC - #TCCTGCAG 60- GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GC - #TGGACGTC 120- GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CC - #CTGCCCTG 180- CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GG - #CAGGAGGG 240- GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TC - #TACGCCAC 300- CTTGCGCAGC CCGACATGGC TACACCATTA GGCCCTGCCA GCTCCCTGCC CC - #AGAGCTTC 360- CTGCTCAAGT CTTTAGAGCA AGTGAGGAAG ATCCAGGGCG ATGGCGCAGC GC - #TCCAGGAG 420- AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CG - #GACACTCT 480# 531GGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA G- (2) INFORMATION FOR SEQ ID NO:300:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 177 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:300:- Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Va - #l Arg Lys Ile Gln Gly# 15- Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Al - #a Thr Tyr Lys Leu Cys# 30- His Pro Glu Glu Leu Val Leu Leu Gly His Se - #r Leu Gly Ile Pro Trp# 45- Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Le - #u Gln Leu Ala Gly Cys# 60- Leu Ser Gln Leu His Ser Gly Leu Phe Leu Ty - #r Gln Gly Leu Leu Gln#80- Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pr - #o Thr Leu Asp Thr Leu# 95- Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Il - #e Trp Gln Gln Met Glu# 110- Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Th - #r Gln Gly Ala Met Pro# 125- Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gl - #y Gly Val Leu Val Ala# 140- Ser His Leu Gln Ser Phe Leu Glu Val Ser Ty - #r Arg Val Leu Arg His145 1 - #50 1 - #55 1 -#60- Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gl - #y Pro Ala Ser Ser Leu# 175- Pro- (2) INFORMATION FOR SEQ ID NO:301:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 177 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:301:- Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Th - #r Gln Gly Ala Met Pro# 15- Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gl - #y Gly Val Leu Val Ala# 30- Ser His Leu Gln Ser Phe Leu Glu Val Ser Ty - #r Arg Val Leu Arg His# 45- Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gl - #y Pro Ala Ser Ser Leu# 60- Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gl - #n Val Arg Lys Ile Gln#80- Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cy - #s Ala Thr Tyr Lys Leu# 95- Cys His Pro Glu Glu Leu Val Leu Leu Gly Hi - #s Ser Leu Gly Ile Pro# 110- Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Al - #a Leu Gln Leu Ala Gly# 125- Cys Leu Ser Gln Leu His Ser Gly Leu Phe Le - #u Tyr Gln Gly Leu Leu# 140- Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gl - #y Pro Thr Leu Asp Thr145 1 - #50 1 - #55 1 -#60- Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Th - #r Ile Trp Gln Gln Met# 175- Glu- (2) INFORMATION FOR SEQ ID NO:302:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 177 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:302:- Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gl - #y Ala Met Pro Ala Phe# 15- Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Va - #l Leu Val Ala Ser His# 30- Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Va - #l Leu Arg His Leu Ala# 45- Gln Pro Asp Met Ala Thr Pro Leu Gly Pro Al - #a Ser Ser Leu Pro Gln# 60- Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Ar - #g Lys Ile Gln Gly Asp#80- Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Th - #r Tyr Lys Leu Cys His# 95- Pro Glu Glu Leu Val Leu Leu Gly His Ser Le - #u Gly Ile Pro Trp Ala# 110- Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gl - #n Leu Ala Gly Cys Leu# 125- Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gl - #n Gly Leu Leu Gln Ala# 140- Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Th - #r Leu Asp Thr Leu Gln145 1 - #50 1 - #55 1 -#60- Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Tr - #p Gln Gln Met Glu Glu# 175- Leu- (2) INFORMATION FOR SEQ ID NO:303:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 177 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:303:- Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Ly - #s Ile Gln Gly Asp Gly# 15- Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Ty - #r Lys Leu Cys His Pro# 30- Glu Glu Leu Val Leu Leu Gly His Ser Leu Gl - #y Ile Pro Trp Ala Pro# 45- Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Le - #u Ala Gly Cys Leu Ser# 60- Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gl - #y Leu Leu Gln Ala Leu#80- Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Le - #u Asp Thr Leu Gln Leu# 95- Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gl - #n Gln Met Glu Glu Leu# 110- Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gl - #y Ala Met Pro Ala Phe# 125- Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Va - #l Leu Val Ala Ser His# 140- Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Va - #l Leu Arg His Leu Ala145 1 - #50 1 - #55 1 -#60- Gln Pro Asp Met Ala Thr Pro Leu Gly Pro Al - #a Ser Ser Leu Pro Gln# 175- Ser- (2) INFORMATION FOR SEQ ID NO:304:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 177 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:304:- Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro# 15- Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Se - #r Leu Pro Gln Ser Phe# 30- Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Il - #e Gln Gly Asp Gly Ala# 45- Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Ly - #s Leu Cys His Pro Glu# 60- Glu Leu Val Leu Leu Gly His Ser Leu Gly Il - #e Pro Trp Ala Pro Leu#80- Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Al - #a Gly Cys Leu Ser Gln# 95- Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Le - #u Leu Gln Ala Leu Glu# 110- Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu As - #p Thr Leu Gln Leu Asp# 125- Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gl - #n Met Glu Glu Leu Gly# 140- Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Al - #a Met Pro Ala Phe Ala145 1 - #50 1 - #55 1 -#60- Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Le - #u Val Ala Ser His Leu# 175- Gln- (2) INFORMATION FOR SEQ ID NO:305:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 177 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:305:- Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Al - #a Ala Leu Gln Glu Lys# 15- Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Gl - #u Glu Leu Val Leu Leu# 30- Gly His Ser Leu Gly Ile Pro Trp Ala Pro Le - #u Ser Ser Cys Pro Ser# 45- Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gl - #n Leu His Ser Gly Leu# 60- Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Gl - #u Gly Ile Ser Pro Glu#80- Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu As - #p Val Ala Asp Phe Ala# 95- Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl - #y Met Ala Pro Ala Leu# 110- Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Al - #a Ser Ala Phe Gln Arg# 125- Arg Ala Gly Gly Val Leu Val Ala Ser His Le - #u Gln Ser Phe Leu Glu# 140- Val Ser Tyr Arg Val Leu Arg His Leu Ala Gl - #n Pro Asp Met Ala Thr145 1 - #50 1 - #55 1 -#60- Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Se - #r Phe Leu Leu Lys Ser# 175- Leu- (2) INFORMATION FOR SEQ ID NO:306:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 177 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:306:- Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Ph - #e Leu Leu Lys Ser Leu# 15- Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Al - #a Ala Leu Gln Glu Lys# 30- Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Gl - #u Glu Leu Val Leu Leu# 45- Gly His Ser Leu Gly Ile Pro Trp Ala Pro Le - #u Ser Ser Cys Pro Ser# 60- Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gl - #n Leu His Ser Gly Leu#80- Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Gl - #u Gly Ile Ser Pro Glu# 95- Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu As - #p Val Ala Asp Phe Ala# 110- Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl - #y Met Ala Pro Ala Leu# 125- Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Al - #a Ser Ala Phe Gln Arg# 140- Arg Ala Gly Gly Val Leu Val Ala Ser His Le - #u Gln Ser Phe Leu Glu145 1 - #50 1 - #55 1 -#60- Val Ser Tyr Arg Val Leu Arg His Leu Ala Gl - #n Pro Asp Met Ala Thr# 175- Pro- (2) INFORMATION FOR SEQ ID NO:307:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 177 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:307:- Leu Leu Gly His Ser Leu Gly Ile Pro Trp Al - #a Pro Leu Ser Ser Cys# 15- Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Le - #u Ser Gln Leu His Ser# 30- Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Al - #a Leu Glu Gly Ile Ser# 45- Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gl - #n Leu Asp Val Ala Asp# 60- Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Gl - #u Leu Gly Met Ala Pro#80- Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Al - #a Phe Ala Ser Ala Phe# 95- Gln Arg Arg Ala Gly Gly Val Leu Val Ala Se - #r His Leu Gln Ser Phe# 110- Leu Glu Val Ser Tyr Arg Val Leu Arg His Le - #u Ala Gln Pro Asp Met# 125- Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pr - #o Gln Ser Phe Leu Leu# 140- Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gl - #y Asp Gly Ala Ala Leu145 1 - #50 1 - #55 1 -#60- Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cy - #s His Pro Glu Glu Leu# 175- Val- (2) INFORMATION FOR SEQ ID NO:308:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 177 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:308:- Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gl - #n Leu Ala Gly Cys Leu# 15- Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gl - #n Gly Leu Leu Gln Ala# 30- Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Th - #r Leu Asp Thr Leu Gln# 45- Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Tr - #p Gln Gln Met Glu Glu# 60- Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gl - #n Gly Ala Met Pro Ala#80- Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gl - #y Val Leu Val Ala Ser# 95- His Leu Gln Ser Phe Leu Glu Val Ser Tyr Ar - #g Val Leu Arg His Leu# 110- Ala Gln Pro Asp Met Ala Thr Pro Leu Gly Pr - #o Ala Ser Ser Leu Pro# 125- Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Va - #l Arg Lys Ile Gln Gly# 140- Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Al - #a Thr Tyr Lys Leu Cys145 1 - #50 1 - #55 1 -#60- His Pro Glu Glu Leu Val Leu Leu Gly His Se - #r Leu Gly Ile Pro Trp# 175- Ala- (2) INFORMATION FOR SEQ ID NO:309:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 177 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:309:- Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gl - #n Leu His Ser Gly Leu# 15- Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Gl - #u Gly Ile Ser Pro Glu# 30- Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu As - #p Val Ala Asp Phe Ala# 45- Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl - #y Met Ala Pro Ala Leu# 60- Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Al - #a Ser Ala Phe Gln Arg#80- Arg Ala Gly Gly Val Leu Val Ala Ser His Le - #u Gln Ser Phe Leu Glu# 95- Val Ser Tyr Arg Val Leu Arg His Leu Ala Gl - #n Pro Asp Met Ala Thr# 110- Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Se - #r Phe Leu Leu Lys Ser# 125- Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gl - #y Ala Ala Leu Gln Glu# 140- Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pr - #o Glu Glu Leu Val Leu145 1 - #50 1 - #55 1 -#60- Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pr - #o Leu Ser Ser Cys Pro# 175- Ser- (2) INFORMATION FOR SEQ ID NO:310:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 177 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:310:- Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu Hi - #s Ser Gly Leu Phe Leu# 15- Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Il - #e Ser Pro Glu Leu Gly# 30- Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Al - #a Asp Phe Ala Thr Thr# 45- Ile Trp Gln Gln Met Glu Glu Leu Gly Met Al - #a Pro Ala Leu Gln Pro# 60- Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Al - #a Phe Gln Arg Arg Ala#80- Gly Gly Val Leu Val Ala Ser His Leu Gln Se - #r Phe Leu Glu Val Ser# 95- Tyr Arg Val Leu Arg His Leu Ala Gln Pro As - #p Met Ala Thr Pro Leu# 110- Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Le - #u Leu Lys Ser Leu Glu# 125- Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Al - #a Leu Gln Glu Lys Leu# 140- Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Gl - #u Leu Val Leu Leu Gly145 1 - #50 1 - #55 1 -#60- His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se - #r Ser Cys Pro Ser Gln# 175- Ala- (2) INFORMATION FOR SEQ ID NO:311:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 177 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:311:- Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gl - #y Leu Phe Leu Tyr Gln# 15- Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pr - #o Glu Leu Gly Pro Thr# 30- Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Ph - #e Ala Thr Thr Ile Trp# 45- Gln Gln Met Glu Glu Leu Gly Met Ala Pro Al - #a Leu Gln Pro Thr Gln# 60- Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gl - #n Arg Arg Ala Gly Gly#80- Val Leu Val Ala Ser His Leu Gln Ser Phe Le - #u Glu Val Ser Tyr Arg# 95- Val Leu Arg His Leu Ala Gln Pro Asp Met Al - #a Thr Pro Leu Gly Pro# 110- Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Ly - #s Ser Leu Glu Gln Val# 125- Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gl - #n Glu Lys Leu Cys Ala# 140- Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Va - #l Leu Leu Gly His Ser145 1 - #50 1 - #55 1 -#60- Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cy - #s Pro Ser Gln Ala Leu# 175- Gln- (2) INFORMATION FOR SEQ ID NO:312:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 177 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:312:- His Leu Ala Gln Pro Asp Met Ala Thr Pro Le - #u Gly Pro Ala Ser Ser# 15- Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Gl - #u Gln Val Arg Lys Ile# 30- Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Le - #u Cys Ala Thr Tyr Lys# 45- Leu Cys His Pro Glu Glu Leu Val Leu Leu Gl - #y His Ser Leu Gly Ile# 60- Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gl - #n Ala Leu Gln Leu Ala#80- Gly Cys Leu Ser Gln Leu His Ser Gly Leu Ph - #e Leu Tyr Gln Gly Leu# 95- Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Le - #u Gly Pro Thr Leu Asp# 110- Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Th - #r Thr Ile Trp Gln Gln# 125- Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gl - #n Pro Thr Gln Gly Ala# 140- Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Ar - #g Ala Gly Gly Val Leu145 1 - #50 1 - #55 1 -#60- Val Ala Ser His Leu Gln Ser Phe Leu Glu Va - #l Ser Tyr Arg Val Leu# 175- Arg- (2) INFORMATION FOR SEQ ID NO:313:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 531 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: other nucleic acid#= "synthetic"DESCRIPTION: /desc- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:313:- CACCTTGCGC AGCCCGACAT GGCTACACCA TTAGGCCCTG CCAGCTCCCT GC - #CCCAGAGC 60- TTCCTGCTCA AGTCTTTAGA GCAAGTGAGG AAGATCCAGG GCGATGGCGC AG - #CGCTCCAG 120- GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GC - #TCGGACAC 180- TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GC - #AGCTGGCA 240- GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GC - #AGGCCCTG 300- GAAGGGATAT CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CG - #TCGCCGAC 360- TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC CC - #TGCAGCCC 420- ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AG - #GGGTCCTG 480# 531TGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG C__________________________________________________________________________

Claims

1. A hematopoietic protein comprising; an amino acid sequence of the formula:

R1-L1-R2, R2-L1-R1, R1-R2, or R2-R1

wherein R1 is a biologically active human c-mpl ligand comprising a modified amino acid sequence selected from the group consisting of:

(a) an amino acid sequence of SEQ ID NO:256

wherein;

Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe, Trp, or Met;

Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met;

Xaa at position 114 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met;

Xaa at position 115 is deleted or Gln, Gly, Ser, Thr, Tyr, or Asn; and

wherein the N-terminus is joined to the C-terminus directly or through a linker (L2) capable of joining the N-terminus to the C-terminus wherein new C-termini and N-termini are created between the amino acid reside pairs of SEQ ID NO:256 selected from the group consisting of:

26-27, 27-28, 28-29, 29-30, 30-31, 32-33, 33-34, 34-35, 36-37, 37-38, 38-39, 40-41, 41-42, 42-43, 43-44, 44-45, 46-47, 47-48, 48-49, 50-51, 51-52, 52-53, 53-54, 54-55, 55-56, 56-57, 57-58, 58-59, 59-60, 78-79, 79-80, 80-81, 81-82, 82-83, 83-84, 84-85, 85-86, 86-87, 87-88, 88-89, 108-109, 109-110, 110-111, 111-112, 112-113, 113-114, 114-115, 115-116, 116-117, 117-118, 118-119, 119-120, 120-121, 121-122, 122-123, 123-124, 124-125, 125-126, 126-127 or 127-128; and

(b) an amino acid sequence of SEQ ID NO:283

wherein;

Xaa at position 7 is Ser or Ala;

Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe, Trp, or Met;

Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met;

Xaa at position 114 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met;

Xaa at position 115 is deleted or Gln, Gly, Ser, Thr, Tyr, or Asn;

Xaa at position 151 is Ser or Ala;

wherein the N-terminus is joined to the C-terminus directly or through a linker (L2) capable of joining the N-terminus to the C-terminus wherein new C-termini and N-termini are created between the amino acid reside pairs of SEQ ID NO:283 selected from the group consisting of:

2- 27. 27-28, 28-29, 29-30, 30-31, 32-33, 33-34, 34-35, 36-37, 37-38, 38-39, 40-41, 41-42, 42-43, 43-44, 44-45, 46-47, 47-48, 48-49, 50-51, 51-52, 52-53, 53-54, 54-55, 55-56, 56-57, 57-58, 58-59, 59-60, 78-79, 79-80, 80-81, 81-82, 82-83, 83-84, 84-85, 85-86, 86-87, 87-88, 88-89, 108-109, 109-110, 110-111, 111-112, 112-113, 113-114, 114-115, 115-116, 116-117, 117-118, 118-119, 119-120, 120-121, 121-122, 122-123, 123-124, 124-125, 125-126, 126-127 or 127-128;

R2 is selected from the group consisting of: a biologically active human IL-3 variant comprising a modified amino acid sequence of (SEQ ID NO:2)

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg;

Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;

Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys;

Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;

Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val;

Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly;

Xaa at position 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg;

Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu;

Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;

Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp;

Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;

Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;

Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val;

Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys;

Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;

Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu;

Xaa at position 33 is Pro, Leu, Gln, Ala, Thr, or Glu;

Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met;

Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln, or Val;

Xaa at position 36 is Asp, Leu, or Val;

Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile;

Xaa at position 38 is Asn, or Ala;

Xaa at position 40 is Leu, Trp, or Arg;

Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro;

Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met or Ala;

Xaa at position 43 is Glu, Asn,. Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser;

Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro;

Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu or His;

Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly;

Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His;

Xaa at position 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn;

Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;

Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gln;

Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;

Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;

Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu;

Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;

Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys;

Xaa at position 57 is Asn or Gly;

Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;

Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg;

Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr;

Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;

Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile;

Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;

Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys;

Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;

Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;

Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His;

Xaa at position 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His;

Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu;

Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;

Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn;

Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;

Xaa at position 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala;

Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu;

Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;

Xaa at position 77 is Ile, Ser, Arg, Thr, or Leu;

Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;

Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp;

Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;

Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;

Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val;

Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met;

Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val;

Xaa at position 85 is Leu, Asn, Val, or Gln;

Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;

Xaa at position 87 is Leu, Ser, Trp, or Gly;

Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;

Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser;

Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met;

Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;

Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu;

Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;

Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro;

Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr Asn, Lys, Ser, Ala, Trp, Phe, Ile, or Tyr;

Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr;

Xaa at position 97 is Ile, Val, Lys, Ala, or Asn;

Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;

Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe, or His;

Xaa at position 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, or Pro;

Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln;

Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;

Xaa at position 103 is Asp, or Ser;

Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, or Gly;

Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;

Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;

Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;

Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;

Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, or Trp;

Xaa at position 111 is Leu, Ile, Arg, Asp, or Met;

Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe;

Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn;

Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;

Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met;

Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile;

Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro;

Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;

Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;

Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gln;

Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;

Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;

Xaa at position 123 is Ala, Met, Glu, His, Ser., Pro, Tyr, or Leu;

wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; and wherein from 1 to 14 amino acids are optionally deleted from the N-terminus and/or from 1 to 15 amino acids are optionally deleted from the C-terminus of said modified human IL-3 amino acid sequence;

a colony stimulating factor, a cytokine, a lymphokine, an interleukin, and a hematopoietic growth factor;

L1 is a linker capable of linking R1 to R2; and

said hematopoietic protein is optionally immediately preceded by (methionine-1), (alanine-1) or (methionine-2, alanine-1).

2. The hematopoietic protein as recited in claim 1 wherein said protein is selected from the group consisting of;

SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, and SEQ ID NO:239.

3. A nucleic acid molecule encoding said hematopoietic protein of claim 2.

4. The nucleic acid molecule according to claim 3 selected from group consisting of:

SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, and SEQ ID NO:154.

5. The hematopoietic protein as recited in claim 1 wherein said c-mpl receptor agonist is selected from the group consisting of:

MetAlaGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuAlaValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaAlaAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln (SEQ ID NO:284); andMetAlaGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuAlaValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaAlaAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeu (SEQ ID NO:285)

6. A nucleic acid molecule encoding said hematopoietic protein of claim 5.

7. A nucleic acid molecule encoding said hematopoietic protein of claim 1.

8. A method for selective ex vivo expansion of hematopoietic stem cells, comprising the steps of;

(a) separating hematopoietic stem cells from other cells;

(b) culturing the separated hematopoietic stem cells from step (a) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 1, effective to expand said hematopoietic stem cells; and

(c) harvesting the cultured hematopoietic cells of step (b).

9. A method for treatment of a patient having a hematopoietic disorder, comprising the steps of;

(a) removing hematopoietic cells from said patient;

(b) separating hematopoietic stem cells from other cells removed from said patient;

(c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 1 effective to expand and/or differentiate the hematopoietic stem cells;

(d) harvesting the cultured hematopoietic cells from step (c); and

(e) introducing the cultured hematopoietic cells from step (d) into said patient to increase the number of hematopoietic cells.

10. A method of expanding the transducing hematopoietic cells for use in gene therapy, comprising the steps of;

(a) removing hematopoietic cells from a patient;

(b) separating hematopoietic stem cells from other cells removed from the patient in step (a);

(c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 1 effective to expand the hematopoietic stem cells;

(d) transducing the cultured hematopoietic cells from step (c) by introducing DNA into said cultured hematopoietic cells; and

(e) harvesting said transduced hematopoietic cells.

11. A pharmaceutical composition comprising; the hematopoietic protein according to claim 1; at least one colony stimulating factor, cytokine, lymphokine, interleukin, or hematopoietic growth factor selected from the group consisting of: GM-CSF, G-CSF, c-mpl ligand (TPO), MGDF, M-CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-3, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, LIF, flt3 ligand, and stem cell factor (SCF); and a pharmaceutically acceptable carrier.

12. A method of stimulating the production of hematopoietic cells in a patient comprising the step of; administering to said patient an amount of the composition as recited in claim 11, effective to stimulate the production of hematopoietic cells.

13. A method for selective ex vivo expansion of hematopoietic cells, comprising the steps of;

(a) culturing hematopoietic cells with a culture medium comprising; an amount of the composition of claim 11, effective to expand said hematopoietic cells; and

(b) harvesting the cultured hematopoietic cells of step (a).

14. A method for selective ex vivo expansion of hematopoietic stem cells, comprising the steps of;

(a) separating hematopoietic stem cells from other cells;

(b) culturing the separated hematopoietic stem cells from step (a) with a selected culture medium comprising; an amount of the composition of claim 11, effective to expand said hematopoietic stem cells; and

(c) harvesting the cultured hematopoietic cells of step (b).

15. A method for treatment of a patient having a hematopoietic disorder, comprising the steps of;

(a) removing hematopoietic cells from said patient;

(b) separating hematopoietic stem cells from other cells removed from said patient;

(c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the composition of claim 11, effective to expand and/or differentiate the hematopoietic stem cells;

(d) harvesting the cultured hematopoietic cells from step (c); and

(e) introducing the cultured hematopoietic cells from step (d) into said patient to increase the number of hematopoietic cells.

16. A method of expanding and transducing hematopoietic cells for use in gene therapy, comprising the steps of;

(a) removing hematopoietic cells from a patient;

(b) separating hematopoietic stem cells from other cells removed from the patient in step (a);

(c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 11 effective to expand the hematopoietic stem cells;

(d) transducing the cultured hematopoietic cells from step (c) by introducing DNA into said cultured hematopoietic cells; and

(e) harvesting said transduced hematopoietic cells.

17. A hematopoietic protein comprising; an amino acid sequence of the formula:

R1-L1-R2, R2-L1-R1, R1-R2, or R2-R1

wherein R1 is a biologically active human c-mpl ligand comprising a modified amino acid sequence of SEQ ID NO:256

wherein;

Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe, Trp, or Met;

Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met;

Xaa at position 114 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met;

Xaa at position 115 is deleted or Gln, Gly, Ser, Thr, Tyr, or Asn; and

wherein the N-terminus is joined to the C-terminus directly or through a linker (L2) capable of joining the N-terminus to the C-terminus wherein new C-termini and N-termini are created between the amino acid reside pairs of SEQ ID NO:256 selected from the group consisting of:

26-27, 27-28, 28-29, 29-30, 30-31, 32-33, 33-34, 34-35, 36-37, 37-38, 38-39, 40-41, 41-42, 42-43, 43-44, 44-45, 46-47, 47-48, 48-49, 50-51, 51-52, 52-53, 53-54, 54-55, 55-56, 56-57, 57-58, 58-59, 59-60, 78-79, 79-80, 80-81, 81-82, 82-83, 83-84, 84-85, 85-86, 86-87, 87-88, 88-89, 108-109, 109-110, 110-111, 111-112, 112-113, 113-114, 114-115, 115-116, 116-117, 117-118, 118-119, 119-120, 120-121, 121-122, 122-123, 123-124, 124-125, 125-126, 126-127 or 127-128;

R2 is selected from the group consisting of: a biologically active human IL-3 variant comprising a modified amino acid sequence of SEQ ID NO:2

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg;

Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;

Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys;

Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;

Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val;

Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly;

Xaa at position 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg;

Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu;

Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;

Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp;

Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;

Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;

Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val;

Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys;

Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;

Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu;

Xaa at position 33 is Pro, Leu, Gln, Ala, Thr, or Glu;

Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met;

Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln, or Val;

Xaa at position 36 is Asp, Leu, or Val;

Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile;

Xaa at position 38 is Asn, or Ala;

Xaa at position 40 is Leu, Trp, or Arg;

Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro;

Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met or Ala;

Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser;

Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro;

Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu or His;

Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly;

Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His;

Xaa at position 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn;

Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;

Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gln;

Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;

Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;

Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu;

Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;

Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys;

Xaa at position 57 is Asn or. Gly;

Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;

Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg;

Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr;

Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;

Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile;

Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;

Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys;

Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;

Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;

Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His;

Xaa at position 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His;

Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu;

Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;

Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn;

Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;

Xaa at position 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala;

Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu;

Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;

Xaa at position 77 is Ile, Ser, Arg, Thr, or Leu;

Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;

Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp;

Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;

Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;

Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val;

Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met;

Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val;

Xaa at position 85 is Leu, Asn, Val, or Gln;

Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;

Xaa at position 87 is Leu, Ser, Trp, or Gly;

Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;

Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser;

Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met;

Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;

Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu;

Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;

Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro;

Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile, or Tyr;

Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr;

Xaa at position 97 is Ile, Val, Lys, Ala, or Asn;

Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;

Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe, or His;

Xaa at position 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, or Pro;

Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln;

Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;

Xaa at position 103 is Asp, or Ser;

Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, or Gly;

Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;

Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;

Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;

Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;

Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, or Trp;

Xaa at position Ill is Leu, Ile, Arg, Asp, or Met;

Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe;

Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn;

Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;

Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met;

Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser,.Asn, His, Ala, Tyr, Phe, Gln, or Ile;

Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro;

Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;

Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;

Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gln;

Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;

Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;

Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

wherein from 1 to 14 amino acids are optionally deleted from the N-terminus and/or from 1 to 15 amino acids are optionally deleted from the C-terminus of said modified human IL-3 amino acid sequence; and wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3;

a colony stimulating factor, a cytokine, a lymphokine, an interleukin, and a hematopoietic growth factor;

L1 is a linker capable of linking R1 to R2; and

said hematopoietic protein is optionally immediately preceded by (methionine-1), (alanine-1) or (methionine-2, alanine-1).

18. A nucleic acid molecule encoding said hematopoietic protein of claim 17.

19. The hematopoietic protein of claim 1 or 17 wherein said colony stimulating factor, cytokine, interleukin, or hematopoietic growth factor, is selected from the group consisting of GM-CSF, G-CSF, G-CSF Ser17, c-mpl ligand (TPO), MGDF, M-CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-3, IL-5, IL 6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, LIF, flt3 ligand, human growth hormone, and stem cell factor (SCF).

20. The hematopoietic protein as recited in claim 19 wherein said linker (L2) is selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247 and SEQ ID NO: 248.

21. A method for treatment of a patient having a hematopoietic disorder, comprising the steps of;

(a) removing hematopoietic cells from said patient;

(b) separating hematopoietic stem cells from other cells removed from said patient;

(c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 20 effective to expand and/or differentiate the hematopoietic stem cells;

(d) harvesting the cultured hematopoietic cells from step (c); and

(e) introducing the cultured hematopoietic cells from step (d) into said patient to increase the number of hematopoietic cells.

22. A nucleic acid molecule encoding said hematopoietic protein of claim 20.

23. A method of producing a hematopoietic protein comprising: growing under suitable nutrient conditions, a host cell transformed or transfected with a replicable vector comprising a nucleic acid molecule of claim 22 under conditions which result in the expression of said hematopoietic protein and recovering said hematopoietic protein.

24. A pharmaceutical composition comprising; the hematopoietic protein according to claim 20 and a pharmaceutically acceptable carrier.

25. A method of stimulating the production of hematopoietic cells in a patient comprising the step of; administering to said patient an amount of the hematopoietic protein as recited in claim 20, effective to stimulate the production of hematopoietic cells.

26. A method for selective ex vivo expansion of hematopoietic stem cells, comprising the steps of;

(a) separating hematopoietic stem cells from other cells;

(b) culturing the separated hematopoietic stem cells from step (a) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 20, effective to expand said hematopoietic stem cells; and

(c) harvesting the cultured hematopoietic cells of step (b).

27. A method of expanding and transducing hematopoietic cells for use in gene therapy, comprising the steps of;

(a) removing hematopoietic cells from a patient;

(b) separating hematopoietic stem cells from other cells removed from the patient in step (a);

(c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 20 effective to expand the hematopoietic stem cells;

(d) transducing the cultured hematopoietic cells from step (c) by introducing DNA into said cultured hematopoietic cells; and

(e) harvesting said transduced hematopoietic cells.

28. A nucleic acid molecule encoding said hematopoietic protein of claim 19.

29. A method of producing a hematopoietic protein comprising: growing under suitable nutrient conditions, a host cell transformed or transfected with a replicable vector comprising a nucleic acid molecule of claim 28 under conditions which result in the expression of said hematopoietic protein and recovering said hematopoietic protein.

30. A pharmaceutical composition comprising; the hematopoietic protein according to claim 19 and a pharmaceutically acceptable carrier.

31. A method of stimulating the production of hematopoietic cells in a patient comprising the step of; administering to said patient an amount of the hematopoietic protein as recited in claim 19, effective to stimulate the production of hematopoietic cells.

32. A method for selective ex vivo expansion of hematopoietic cells, comprising the steps of;

(a) culturing hematopoietic cells with a culture medium comprising; an amount of the hematopoietic protein of claim 19, effective to expand said hematopoietic cells; and

(b) harvesting the cultured hematopoietic cells of step (a).

33. A method for selective ex vivo expansion of hematopoietic stem cells, comprising the steps of;

(a) separating hematopoietic stem cells from other cells;

(b) culturing the separated hematopoietic stem cells from step (a) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 19, effective to expand said hematopoietic stem cells; and

(c) harvesting the cultured hematopoietic cells of step (b).

34. A method for treatment of a patient having a hematopoietic disorder, comprising the steps of;

(a) removing hematopoietic cells from said patient;

(b) separating hematopoietic stem cells from other cells removed from said patient;

(c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 19 effective to expand and/or differentiate the hematopoietic stem cells;

(d) harvesting the cultured hematopoietic cells from step (c); and

(e) introducing the cultured hematopoietic cells from step (d) into said patient to increase the number of hematopoietic cells.

35. A method of expanding and transducing hematopoietic cells for use in gene therapy, comprising the steps of;

(a) removing hematopoietic cells from a patient;

(b) separating hematopoietic stem cells from other cells removed from the patient in step (a);

(c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 19 effective to expand the hematopoietic stem cells;

(d) transducing the cultured hematopoietic cells from step (c) by introducing DNA into said cultured hematopoietic cells; and

(e) harvesting said transduced hematopoietic cells.

36. A hematopoietic protein comprising; an amino acid sequence of the formula:

R1-L1-R2, R2-L1-R1, R1-R2, or R2-R1

wherein R1 is a biologically active human c-mpl ligand comprising a modified amino acid sequence of SEQ ID NO:256

wherein;

Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe, Trp, or Met;

Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met;

Xaa at position 114 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met;

Xaa at position 115 is deleted or Gln, Gly, Ser, Thr, Tyr, or Asn; and

wherein the N-terminus is joined to the C-terminus directly or through a linker (L2) capable of joining the N-terminus to the C-terminus wherein new C-termini and N-termini are created between the amino acid reside pairs of SEQ ID NO:256 selected from the group consisting of:

2- 27. 27-28, 28-29, 29-30, 30-31, 32-33, 33-34, 34-35, 36-37, 37-38, 38-39, 40-41, 41-42, 42-43, 43-44, 44-45, 46-47, 47-48, 48-49, 50-51, 51-52, 52-53, 53-54, 54-55, 55-56, 56-57, 57-58, 58-59, 59-60, 78-79, 79-80, 80-81, 81-82, 82-83, 83-84, 84-85, 85-86, 86-87, 87-88, 88-89, 108-109, 109-110, 110-111, 111-112, 112-113, 113-114, 114-115, 115-116, 116-117, 117-118, 118-119, 119-120, 120-121, 121-122, 122-123, 123-124, 124-125, 125-126, 126-127 or 127-128;

R2 is a biologically active human IL-3 variant comprising a modified amino acid sequence of SEQ ID NO:2

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg;

Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;

Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys;

Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;

Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val;

Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly;

Xaa at position 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg;

Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu;

Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;

Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp;

Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;

Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;

Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val;

Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys;

Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;

Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu;

Xaa at position 33 is Pro, Leu, Gln, Ala, Thr, or Glu;

Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met;

Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln, or Val;

Xaa at position 36 is Asp, Leu, or Val;

Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile;

Xaa at position 38 is Asn, or Ala;

Xaa at position 40 is Leu, Trp, or Arg;

Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro;

Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met or Ala;

Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser;

Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro;

Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu or His;

Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly;

Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His;

Xaa at position 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn;

Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;

Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gln;

Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;

Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;

Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu;

Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;

Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys;

Xaa at position 57 is Asn or Gly;

Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;

Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg;

Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr;

Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;

Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile;

Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;

Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys;

Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;

Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;

Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His;

Xaa at position 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His;

Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu;

Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;

Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn;

Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;

Xaa at position 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala;

Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu;

Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;

Xaa at position 77 is Ile, Ser, Arg, Thr, or Leu;

Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;

Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp;

Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;

Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;

Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val;

Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met;

Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val;

Xaa at position 85 is Leu, Asn, Val, or Gln;

Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;

Xaa at position 87 is Leu, Ser, Trp, or Gly;

Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;

Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser;

Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met;

Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;

Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu;

Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;

Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro;

Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile, or Tyr;

Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr;

Xaa at position 97 is Ile, Val, Lys, Ala, or Asn;

Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;

Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe, or His;

Xaa at position 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, or Pro;

Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln;

Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;

Xaa at position 103 is Asp, or Ser;

Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, or Gly;

Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;

Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;

Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;

Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;

Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, or Trp;

Xaa at position 111 is Leu, Ile, Arg, Asp, or Met;

Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe;

Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn;

Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;

Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met;

Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile;

Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro;

Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;

Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;

Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gln;

Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;

Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;

Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; and wherein from 1 to 14 amino acids are optionally deleted from the N-terminus and/or from 1 to 15 amino acids are optionally deleted from the C-terminus of said modified human IL-3 amino acid sequence;

L1 is a linker capable of linking R1 to R2; and

said hematopoietic protein is optionally immediately preceded by (methionine-1), (alanine-1) or (methionine-2, alanine-1).

37. The hematopoietic protein as recited in claim 36 wherein in said modified human IL-3 sequence the amino acids which differ from the corresponding residue in native human interleukin-3 are selected from the group consisting of:

position 42 wherein Xaa is Gly, Asp, Ser, Ile, Leu, Met, Tyr, or Ala;

position 45 wherein Xaa is Gln, Val, Met or Asn;

position 46 wherein Xaa is Asp, Ser, Gln, His or Val;

position 50 wherein Xaa is Glu or Asp;

position 51 wherein Xaa is Asn, Pro or Thr;

position 62 wherein Xaa is Asn or Pro;

position 76 wherein Xaa is Ser, or Pro;

position 82 wherein Xaa is Leu, Trp, Asp, Asn Glu, His, Phe, Ser or Tyr;

position 95 wherein Xaa is His, Arg, Thr, Asn or Ser;

position 98 wherein Xaa is His, Ile, Leu, Ala, Gln, Lys, Met, Ser, Tyr or Val;

position 100 wherein Xaa is Lys or Arg;

position 101 wherein Xaa is Asp;

position 105 wherein Xaa is Asn, or Pro;

position 108 wherein Xaa is Arg, Ala, or Ser;

position 116 wherein Xaa is Lys;

position 121 wherein Xaa is Ala, or Ile;

position 122 wherein Xaa is Gln, or Ile;

position 123 wherein Xaa is Ala, Met or Glu.

38. A nucleic acid molecule encoding said hematopoietic protein of claim 37.

39. The hematopoietic protein as recited in claim 36 wherein said modified human IL-3 sequence is selected from the group consisting of SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, and SEQ ID NO: 228.

40. A nucleic acid molecule encoding said hematopoietic protein of claim 39.

41. The hematopoietic protein as recited in claim 36 wherein said modified human IL-3 sequence differs from native human IL-3 by substitution of Asp for Glu at position 50.

42. A nucleic acid molecule encoding said hematopoietic protein of claim 41.

43. A nucleic acid molecule encoding said hematopoietic protein of claim 36.

44. A hematopoietic protein comprising an amino acid sequence of the formula:

R1-L1-R2, R2-L1-R1, R1-R2, or R2-R1

wherein R1 is a biologically active human c-mpl ligand comprising a modified amino acid sequence of SEQ ID NO:256

wherein;

Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe, Trp, or Met;

Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met;

Xaa at position 114 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met;

Xaa at position 115 is deleted or Gln, Gly, Ser, Thr, Tyr, or Asn; and

wherein the N-terminus is joined to the C-terminus directly or through a linker (L2) capable of joining the N-terminus to the C-terminus wherein new C-termini and N-termini are created between the amino acid reside pairs of SEQ ID NO:256 selected from the group consisting of:

2- 27. 27-28, 28-29, 29-30, 30-31, 32-33, 33-34, 34-35, 36-37, 37-38, 38-39, 40-41, 41-42, 42-43, 43-44, 44-45, 46-47, 47-48, 48-49, 50-51, 51-52, 52-53, 53-54, 54-55, 55-56, 56-57, 57-58, 58-59, 59-60, 78-79, 79-80, 80-81, 81-82, 82-83, 83-84, 84-85, 85-86, 86-87, 87-88, 88-89, 108-109, 109-110, 110-111, 111-112, 112-113, 113-114, 114-115, 115-116, 116-117, 117-118, 118-119, 119-120, 120-121, 121-122, 122-123, 123-124, 124-125, 125-126, 126-127 or 127-128;

wherein R2 is G-CSF or G-CSF Ser17;

L1 is a linker capable of linking R1 to R2; and

said hematopoietic protein is optionally immediately preceded by (methionine-1), (alanine-1) or (methionine-2, alanine-1).

45. A nucleic acid molecule encoding said hematopoietic protein of claim 44.

46. The hematopoietic protein as recited in claim 1, 17, 36, 37, 39, 41, or 44 wherein said linker (L2) is selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247 and SEQ ID NO: 248.

47. A nucleic acid molecule encoding said hematopoietic protein of claim 46.

48. A method of producing a hematopoietic protein comprising: growing under suitable nutrient conditions, a host cell transformed or transfected with a replicable vector comprising a nucleic acid molecule of claim 47 under conditions which result in the expression of said hematopoietic protein and recovering said hematopoietic protein.

49. A pharmaceutical composition comprising; the hematopoietic protein according to claim 46 and a pharmaceutically acceptable carrier.

50. A method of stimulating the production of hematopoietic cells in a patient comprising the step of; administering to said patient an amount of the hematopoietic protein as recited in claim 46, effective to stimulate the production of hematopoietic cells.

51. A method for selective ex vivo expansion of hematopoietic cells, comprising the steps of;

(a) culturing hematopoietic cells with a culture medium comprising; an amount of the hematopoietic protein of claim 46, effective to expand said hematopoietic cells; and

(b) harvesting the cultured hematopoietic cells of step (a).

52. A method for selective ex vivo expansion of hematopoietic stem cells, comprising the steps of;

(a) separating hematopoietic stem cells from other cells;

(b) culturing the separated hematopoietic stem cells from step (a) with a selected culture, medium comprising; an amount of the hematopoietic protein of claim 46, effective to expand said hematopoietic stem cells; and

(c) harvesting the cultured hematopoietic cells of step (b).

53. A method for treatment of a patient having a hematopoietic disorder, comprising the steps of;

(a) removing hematopoietic cells from said patient;

(b) separating hematopoietic stem cells from other cells removed from said patient;

(c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 46 effective to expand and/or differentiate the hematopoietic stem cells;

(d) harvesting the cultured hematopoietic cells from step (c); and

(e) introducing the cultured hematopoietic cells from step (d) into said patient to increase the number of hematopoietic cells.

54. A method of expanding and transducing hematopoietic cells for use in gene therapy, comprising the steps of;

(a) removing hematopoietic cells from a patient;

(b) separating hematopoietic stem cells from other cells removed from the patient in step (a);

(c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 46 effective to expand the hematopoietic stem cells;

(d) transducing the cultured hematopoietic cells from step (c) by introducing DNA into said cultured hematopoietic cells; and

(e) harvesting said transduced hematopoietic cells.

55. A method of producing a hematopoietic protein comprising: growing under suitable nutrient conditions, a host cell transformed or transfected with a replicable vector comprising a nucleic acid molecule of claim 7, 18, 43, 38, 40, 42, 45, 3, 4, or 6 under conditions which result in the expression of said hematopoietic protein and recovering said hematopoietic protein.

56. A pharmaceutical composition comprising; the hematopoietic protein according to claim 1, 17, 36, 37, 39, 41, 44, 2, or 5 and a pharmaceutically acceptable carrier.

57. A method of stimulating the production of hematopoietic cells in a patient comprising the step of; administering to said patient an amount of the hematopoietic protein as recited in claim 1, 17, 36, 37, 39, 41, 44, 2, or 5, effective to stimulate the production of hematopoietic cells.

58. A method for selective ex vivo expansion of hematopoietic cells, comprising the steps of;

(a) culturing hematopoietic cells with a culture medium comprising; an amount of the hematopoietic protein of claim 1, 17, 36, 37, 39, 41, 44, 2, or 5, effective to expand said hematopoietic cells; and

(b) harvesting the cultured hematopoietic cells of step (a).